<html><head><meta content="text/html; charset=UTF-8" http-equiv="content-type"><style type="text/css">@import url('https://themes.googleusercontent.com/fonts/css?kit=Lx1xfUTR4qFjwg0Z_pb902yWOW57Glq29V3__n4AGA4U98cTH0AXYqBJCjdiQdfwhpnKj2Ls7ffS9ZklmqVqKOF0oDgc7LalnC18808k6hw');.lst-kix_kxcc4a1pk4g-8>li:before{content:"\0025a0  "}.lst-kix_txme4cepwvun-2>li:before{content:"\0025a0  "}.lst-kix_kxcc4a1pk4g-7>li:before{content:"\0025cb  "}.lst-kix_txme4cepwvun-1>li:before{content:"\0025cb  "}.lst-kix_txme4cepwvun-3>li:before{content:"\0025cf  "}.lst-kix_kxcc4a1pk4g-6>li:before{content:"\0025cf  "}.lst-kix_txme4cepwvun-0>li:before{content:"\0025cf  "}.lst-kix_txme4cepwvun-4>li:before{content:"\0025cb  "}.lst-kix_u1miwd4ifplz-0>li:before{content:"" counter(lst-ctn-kix_u1miwd4ifplz-0,decimal) ". "}.lst-kix_xtr5a4oh4bgi-1>li{counter-increment:lst-ctn-kix_xtr5a4oh4bgi-1}ol.lst-kix_x4qr3m7alqzt-1{list-style-type:none}.lst-kix_txme4cepwvun-6>li:before{content:"\0025cf  "}ol.lst-kix_x4qr3m7alqzt-2{list-style-type:none}.lst-kix_u1miwd4ifplz-1>li:before{content:"" counter(lst-ctn-kix_u1miwd4ifplz-1,lower-latin) ". "}.lst-kix_u1miwd4ifplz-2>li:before{content:"" counter(lst-ctn-kix_u1miwd4ifplz-2,lower-roman) ". "}ol.lst-kix_xftmuywemg5q-0.start{counter-reset:lst-ctn-kix_xftmuywemg5q-0 0}.lst-kix_txme4cepwvun-5>li:before{content:"\0025a0  "}.lst-kix_txme4cepwvun-7>li:before{content:"\0025cb  "}ol.lst-kix_x4qr3m7alqzt-0{list-style-type:none}ol.lst-kix_x4qr3m7alqzt-5{list-style-type:none}.lst-kix_xftmuywemg5q-2>li{counter-increment:lst-ctn-kix_xftmuywemg5q-2}ol.lst-kix_x4qr3m7alqzt-6{list-style-type:none}ol.lst-kix_x4qr3m7alqzt-3{list-style-type:none}ol.lst-kix_x4qr3m7alqzt-4{list-style-type:none}ul.lst-kix_y9bv39t2d2mx-3{list-style-type:none}.lst-kix_u1miwd4ifplz-5>li:before{content:"" counter(lst-ctn-kix_u1miwd4ifplz-5,lower-roman) ". "}.lst-kix_u1miwd4ifplz-6>li:before{content:"" counter(lst-ctn-kix_u1miwd4ifplz-6,decimal) ". "}ul.lst-kix_y9bv39t2d2mx-2{list-style-type:none}.lst-kix_kxcc4a1pk4g-1>li:before{content:"\0025cb  "}ul.lst-kix_y9bv39t2d2mx-1{list-style-type:none}ul.lst-kix_y9bv39t2d2mx-0{list-style-type:none}.lst-kix_kxcc4a1pk4g-2>li:before{content:"\0025a0  "}ul.lst-kix_y9bv39t2d2mx-7{list-style-type:none}.lst-kix_txme4cepwvun-8>li:before{content:"\0025a0  "}.lst-kix_u1miwd4ifplz-3>li:before{content:"" counter(lst-ctn-kix_u1miwd4ifplz-3,decimal) ". "}.lst-kix_u1miwd4ifplz-4>li:before{content:"" counter(lst-ctn-kix_u1miwd4ifplz-4,lower-latin) ". "}.lst-kix_u1miwd4ifplz-7>li:before{content:"" counter(lst-ctn-kix_u1miwd4ifplz-7,lower-latin) ". "}.lst-kix_u1miwd4ifplz-8>li:before{content:"" counter(lst-ctn-kix_u1miwd4ifplz-8,lower-roman) ". "}ul.lst-kix_y9bv39t2d2mx-6{list-style-type:none}ul.lst-kix_y9bv39t2d2mx-5{list-style-type:none}ul.lst-kix_y9bv39t2d2mx-4{list-style-type:none}.lst-kix_kxcc4a1pk4g-4>li:before{content:"\0025cb  "}ol.lst-kix_xtr5a4oh4bgi-4.start{counter-reset:lst-ctn-kix_xtr5a4oh4bgi-4 0}.lst-kix_kxcc4a1pk4g-3>li:before{content:"\0025cf  "}.lst-kix_kxcc4a1pk4g-5>li:before{content:"\0025a0  "}ul.lst-kix_y9bv39t2d2mx-8{list-style-type:none}.lst-kix_u1miwd4ifplz-4>li{counter-increment:lst-ctn-kix_u1miwd4ifplz-4}.lst-kix_reytss2l8ssc-8>li:before{content:"\0025a0  "}ol.lst-kix_x4qr3m7alqzt-7{list-style-type:none}ol.lst-kix_x4qr3m7alqzt-8{list-style-type:none}ol.lst-kix_fc2ykfigc51k-7.start{counter-reset:lst-ctn-kix_fc2ykfigc51k-7 0}ol.lst-kix_6rkpxax2xgx6-4.start{counter-reset:lst-ctn-kix_6rkpxax2xgx6-4 0}.lst-kix_reytss2l8ssc-0>li:before{content:"\0025cf  "}.lst-kix_reytss2l8ssc-2>li:before{content:"\0025a0  "}.lst-kix_reytss2l8ssc-1>li:before{content:"\0025cb  "}ul.lst-kix_xk7ya91ob6yn-4{list-style-type:none}.lst-kix_x4qr3m7alqzt-3>li{counter-increment:lst-ctn-kix_x4qr3m7alqzt-3}ul.lst-kix_xk7ya91ob6yn-3{list-style-type:none}ul.lst-kix_xk7ya91ob6yn-2{list-style-type:none}.lst-kix_reytss2l8ssc-4>li:before{content:"\0025cb  "}.lst-kix_reytss2l8ssc-6>li:before{content:"\0025cf  "}ul.lst-kix_xk7ya91ob6yn-1{list-style-type:none}ul.lst-kix_xk7ya91ob6yn-0{list-style-type:none}.lst-kix_reytss2l8ssc-3>li:before{content:"\0025cf  "}.lst-kix_reytss2l8ssc-7>li:before{content:"\0025cb  "}ul.lst-kix_xk7ya91ob6yn-8{list-style-type:none}ul.lst-kix_xk7ya91ob6yn-7{list-style-type:none}ul.lst-kix_xk7ya91ob6yn-6{list-style-type:none}.lst-kix_reytss2l8ssc-5>li:before{content:"\0025a0  "}ul.lst-kix_xk7ya91ob6yn-5{list-style-type:none}ul.lst-kix_igvphj22m9h3-1{list-style-type:none}ul.lst-kix_igvphj22m9h3-0{list-style-type:none}ul.lst-kix_igvphj22m9h3-3{list-style-type:none}ul.lst-kix_igvphj22m9h3-2{list-style-type:none}ul.lst-kix_igvphj22m9h3-5{list-style-type:none}ul.lst-kix_igvphj22m9h3-4{list-style-type:none}ul.lst-kix_igvphj22m9h3-7{list-style-type:none}ul.lst-kix_igvphj22m9h3-6{list-style-type:none}ul.lst-kix_igvphj22m9h3-8{list-style-type:none}.lst-kix_kxcc4a1pk4g-0>li:before{content:"\0025cf  "}ol.lst-kix_fc2ykfigc51k-2.start{counter-reset:lst-ctn-kix_fc2ykfigc51k-2 0}ol.lst-kix_xftmuywemg5q-5.start{counter-reset:lst-ctn-kix_xftmuywemg5q-5 0}ul.lst-kix_srd6nt24vl21-5{list-style-type:none}ul.lst-kix_srd6nt24vl21-6{list-style-type:none}ul.lst-kix_srd6nt24vl21-3{list-style-type:none}ul.lst-kix_srd6nt24vl21-4{list-style-type:none}ul.lst-kix_srd6nt24vl21-7{list-style-type:none}ul.lst-kix_srd6nt24vl21-8{list-style-type:none}ul.lst-kix_bo57k090qe1r-0{list-style-type:none}ul.lst-kix_srd6nt24vl21-1{list-style-type:none}.lst-kix_xtr5a4oh4bgi-8>li{counter-increment:lst-ctn-kix_xtr5a4oh4bgi-8}ul.lst-kix_srd6nt24vl21-2{list-style-type:none}ul.lst-kix_srd6nt24vl21-0{list-style-type:none}ul.lst-kix_u1ujgvuq2lk9-8{list-style-type:none}ul.lst-kix_u1ujgvuq2lk9-7{list-style-type:none}ul.lst-kix_u1ujgvuq2lk9-6{list-style-type:none}ul.lst-kix_u1ujgvuq2lk9-5{list-style-type:none}ul.lst-kix_ie0dqyb5ymnc-6{list-style-type:none}ul.lst-kix_ie0dqyb5ymnc-5{list-style-type:none}ul.lst-kix_ie0dqyb5ymnc-8{list-style-type:none}ul.lst-kix_ie0dqyb5ymnc-7{list-style-type:none}ul.lst-kix_u1ujgvuq2lk9-0{list-style-type:none}ul.lst-kix_ie0dqyb5ymnc-2{list-style-type:none}ul.lst-kix_ie0dqyb5ymnc-1{list-style-type:none}ul.lst-kix_ie0dqyb5ymnc-4{list-style-type:none}ul.lst-kix_ie0dqyb5ymnc-3{list-style-type:none}ul.lst-kix_u1ujgvuq2lk9-4{list-style-type:none}ul.lst-kix_u1ujgvuq2lk9-3{list-style-type:none}ul.lst-kix_u1ujgvuq2lk9-2{list-style-type:none}ul.lst-kix_ie0dqyb5ymnc-0{list-style-type:none}ul.lst-kix_u1ujgvuq2lk9-1{list-style-type:none}.lst-kix_6rkpxax2xgx6-2>li:before{content:"" counter(lst-ctn-kix_6rkpxax2xgx6-2,lower-roman) ". "}.lst-kix_x4qr3m7alqzt-2>li{counter-increment:lst-ctn-kix_x4qr3m7alqzt-2}.lst-kix_3qcga3w32puo-2>li:before{content:"\0025a0  "}.lst-kix_6rkpxax2xgx6-6>li:before{content:"" counter(lst-ctn-kix_6rkpxax2xgx6-6,decimal) ". "}.lst-kix_vm5eb5wj9btb-1>li:before{content:"\0025cb  "}.lst-kix_6rkpxax2xgx6-4>li:before{content:"" counter(lst-ctn-kix_6rkpxax2xgx6-4,lower-latin) ". "}.lst-kix_3qcga3w32puo-0>li:before{content:"\0025cf  "}.lst-kix_3qcga3w32puo-8>li:before{content:"\0025a0  "}.lst-kix_xtr5a4oh4bgi-6>li:before{content:"" counter(lst-ctn-kix_xtr5a4oh4bgi-6,decimal) ". "}.lst-kix_xtr5a4oh4bgi-8>li:before{content:"" counter(lst-ctn-kix_xtr5a4oh4bgi-8,lower-roman) ". "}.lst-kix_6rkpxax2xgx6-8>li:before{content:"" counter(lst-ctn-kix_6rkpxax2xgx6-8,lower-roman) ". "}ul.lst-kix_3qcga3w32puo-8{list-style-type:none}ul.lst-kix_3qcga3w32puo-7{list-style-type:none}ul.lst-kix_3qcga3w32puo-6{list-style-type:none}ul.lst-kix_3qcga3w32puo-5{list-style-type:none}ul.lst-kix_3qcga3w32puo-4{list-style-type:none}ul.lst-kix_3qcga3w32puo-3{list-style-type:none}ul.lst-kix_3qcga3w32puo-2{list-style-type:none}ul.lst-kix_3qcga3w32puo-1{list-style-type:none}ol.lst-kix_xftmuywemg5q-8{list-style-type:none}ul.lst-kix_3qcga3w32puo-0{list-style-type:none}.lst-kix_vm5eb5wj9btb-7>li:before{content:"\0025cb  "}ol.lst-kix_xftmuywemg5q-0{list-style-type:none}ol.lst-kix_xftmuywemg5q-1{list-style-type:none}ol.lst-kix_xftmuywemg5q-2{list-style-type:none}ol.lst-kix_xftmuywemg5q-3{list-style-type:none}.lst-kix_vm5eb5wj9btb-3>li:before{content:"\0025cf  "}.lst-kix_vm5eb5wj9btb-5>li:before{content:"\0025a0  "}ol.lst-kix_xftmuywemg5q-4{list-style-type:none}ol.lst-kix_xftmuywemg5q-5{list-style-type:none}ol.lst-kix_xftmuywemg5q-6{list-style-type:none}ol.lst-kix_xftmuywemg5q-7{list-style-type:none}.lst-kix_3qcga3w32puo-6>li:before{content:"\0025cf  "}.lst-kix_6rkpxax2xgx6-0>li:before{content:"" counter(lst-ctn-kix_6rkpxax2xgx6-0,decimal) ". "}.lst-kix_3qcga3w32puo-4>li:before{content:"\0025cb  "}.lst-kix_mnhl5qv63e85-1>li:before{content:"\0025cb  "}.lst-kix_mnhl5qv63e85-2>li:before{content:"\0025a0  "}.lst-kix_srd6nt24vl21-6>li:before{content:"\0025cf  "}.lst-kix_mnhl5qv63e85-5>li:before{content:"\0025a0  "}.lst-kix_mnhl5qv63e85-6>li:before{content:"\0025cf  "}.lst-kix_srd6nt24vl21-7>li:before{content:"\0025cb  "}.lst-kix_xtr5a4oh4bgi-0>li:before{content:"" counter(lst-ctn-kix_xtr5a4oh4bgi-0,decimal) ". "}ol.lst-kix_x4qr3m7alqzt-4.start{counter-reset:lst-ctn-kix_x4qr3m7alqzt-4 0}.lst-kix_xtr5a4oh4bgi-4>li:before{content:"" counter(lst-ctn-kix_xtr5a4oh4bgi-4,lower-latin) ". "}.lst-kix_xtr5a4oh4bgi-3>li:before{content:"" counter(lst-ctn-kix_xtr5a4oh4bgi-3,decimal) ". "}.lst-kix_srd6nt24vl21-2>li:before{content:"\0025a0  "}ul.lst-kix_251ao7edjvnc-0{list-style-type:none}ul.lst-kix_251ao7edjvnc-1{list-style-type:none}.lst-kix_srd6nt24vl21-3>li:before{content:"\0025cf  "}ul.lst-kix_251ao7edjvnc-2{list-style-type:none}ul.lst-kix_251ao7edjvnc-3{list-style-type:none}ul.lst-kix_251ao7edjvnc-4{list-style-type:none}ul.lst-kix_251ao7edjvnc-5{list-style-type:none}.lst-kix_u1ujgvuq2lk9-8>li:before{content:"\0025a0  "}ul.lst-kix_251ao7edjvnc-6{list-style-type:none}ul.lst-kix_251ao7edjvnc-7{list-style-type:none}ul.lst-kix_251ao7edjvnc-8{list-style-type:none}.lst-kix_9svm7rgqi3v0-6>li:before{content:"\0025cf  "}.lst-kix_u1ujgvuq2lk9-4>li:before{content:"\0025cb  "}.lst-kix_u1ujgvuq2lk9-5>li:before{content:"\0025a0  "}.lst-kix_9svm7rgqi3v0-2>li:before{content:"\0025a0  "}ol.lst-kix_6rkpxax2xgx6-0.start{counter-reset:lst-ctn-kix_6rkpxax2xgx6-0 0}ol.lst-kix_x4qr3m7alqzt-5.start{counter-reset:lst-ctn-kix_x4qr3m7alqzt-5 0}.lst-kix_9svm7rgqi3v0-1>li:before{content:"\0025cb  "}ul.lst-kix_w38yctfkyp2x-0{list-style-type:none}.lst-kix_u1ujgvuq2lk9-0>li:before{content:"\0025cf  "}ul.lst-kix_w38yctfkyp2x-1{list-style-type:none}ul.lst-kix_w38yctfkyp2x-2{list-style-type:none}.lst-kix_u1ujgvuq2lk9-1>li:before{content:"\0025cb  "}ul.lst-kix_w38yctfkyp2x-3{list-style-type:none}ul.lst-kix_w38yctfkyp2x-4{list-style-type:none}ul.lst-kix_w38yctfkyp2x-5{list-style-type:none}ul.lst-kix_w38yctfkyp2x-6{list-style-type:none}ul.lst-kix_w38yctfkyp2x-7{list-style-type:none}ul.lst-kix_w38yctfkyp2x-8{list-style-type:none}.lst-kix_9svm7rgqi3v0-5>li:before{content:"\0025a0  "}ol.lst-kix_xtr5a4oh4bgi-8{list-style-type:none}ol.lst-kix_xtr5a4oh4bgi-6{list-style-type:none}ol.lst-kix_xtr5a4oh4bgi-7{list-style-type:none}ol.lst-kix_xtr5a4oh4bgi-4{list-style-type:none}ol.lst-kix_xtr5a4oh4bgi-5{list-style-type:none}ol.lst-kix_xtr5a4oh4bgi-2{list-style-type:none}ol.lst-kix_xtr5a4oh4bgi-3{list-style-type:none}ol.lst-kix_xtr5a4oh4bgi-0{list-style-type:none}ol.lst-kix_xtr5a4oh4bgi-1{list-style-type:none}ol.lst-kix_6rkpxax2xgx6-5.start{counter-reset:lst-ctn-kix_6rkpxax2xgx6-5 0}ul.lst-kix_81uxck1pvydf-0{list-style-type:none}ul.lst-kix_h6pl6prycf0s-8{list-style-type:none}ol.lst-kix_6rkpxax2xgx6-8{list-style-type:none}ol.lst-kix_6rkpxax2xgx6-6{list-style-type:none}ol.lst-kix_6rkpxax2xgx6-7{list-style-type:none}ul.lst-kix_81uxck1pvydf-6{list-style-type:none}ul.lst-kix_h6pl6prycf0s-4{list-style-type:none}ul.lst-kix_81uxck1pvydf-5{list-style-type:none}ul.lst-kix_h6pl6prycf0s-5{list-style-type:none}ul.lst-kix_81uxck1pvydf-8{list-style-type:none}ul.lst-kix_h6pl6prycf0s-6{list-style-type:none}ul.lst-kix_81uxck1pvydf-7{list-style-type:none}ul.lst-kix_h6pl6prycf0s-7{list-style-type:none}ul.lst-kix_81uxck1pvydf-2{list-style-type:none}ul.lst-kix_h6pl6prycf0s-0{list-style-type:none}ul.lst-kix_81uxck1pvydf-1{list-style-type:none}ul.lst-kix_h6pl6prycf0s-1{list-style-type:none}.lst-kix_81uxck1pvydf-0>li:before{content:"\0025cf  "}ul.lst-kix_81uxck1pvydf-4{list-style-type:none}.lst-kix_81uxck1pvydf-8>li:before{content:"\0025a0  "}ul.lst-kix_h6pl6prycf0s-2{list-style-type:none}.lst-kix_6rkpxax2xgx6-2>li{counter-increment:lst-ctn-kix_6rkpxax2xgx6-2}ul.lst-kix_81uxck1pvydf-3{list-style-type:none}ul.lst-kix_h6pl6prycf0s-3{list-style-type:none}ol.lst-kix_x4qr3m7alqzt-0.start{counter-reset:lst-ctn-kix_x4qr3m7alqzt-0 0}ul.lst-kix_4m75w8hvs20i-0{list-style-type:none}ol.lst-kix_6rkpxax2xgx6-4{list-style-type:none}ol.lst-kix_6rkpxax2xgx6-5{list-style-type:none}ul.lst-kix_4m75w8hvs20i-2{list-style-type:none}ol.lst-kix_6rkpxax2xgx6-2{list-style-type:none}ul.lst-kix_4m75w8hvs20i-1{list-style-type:none}ol.lst-kix_6rkpxax2xgx6-3{list-style-type:none}ol.lst-kix_6rkpxax2xgx6-0{list-style-type:none}ol.lst-kix_6rkpxax2xgx6-1{list-style-type:none}.lst-kix_x4qr3m7alqzt-8>li:before{content:"" counter(lst-ctn-kix_x4qr3m7alqzt-8,lower-roman) ". "}ol.lst-kix_xtr5a4oh4bgi-3.start{counter-reset:lst-ctn-kix_xtr5a4oh4bgi-3 0}.lst-kix_x4qr3m7alqzt-4>li{counter-increment:lst-ctn-kix_x4qr3m7alqzt-4}.lst-kix_x4qr3m7alqzt-0>li:before{content:"" counter(lst-ctn-kix_x4qr3m7alqzt-0,decimal) ". "}ol.lst-kix_xtr5a4oh4bgi-0.start{counter-reset:lst-ctn-kix_xtr5a4oh4bgi-0 0}.lst-kix_x4qr3m7alqzt-4>li:before{content:"" counter(lst-ctn-kix_x4qr3m7alqzt-4,lower-latin) ". "}.lst-kix_81uxck1pvydf-4>li:before{content:"\0025cb  "}.lst-kix_6rkpxax2xgx6-3>li:before{content:"" counter(lst-ctn-kix_6rkpxax2xgx6-3,decimal) ". "}.lst-kix_vm5eb5wj9btb-0>li:before{content:"\0025cf  "}.lst-kix_xtr5a4oh4bgi-7>li:before{content:"" counter(lst-ctn-kix_xtr5a4oh4bgi-7,lower-latin) ". "}.lst-kix_qtag81809xxx-5>li:before{content:"\0025a0  "}.lst-kix_6rkpxax2xgx6-7>li:before{content:"" counter(lst-ctn-kix_6rkpxax2xgx6-7,lower-latin) ". "}.lst-kix_qtag81809xxx-1>li:before{content:"\0025cb  "}.lst-kix_fc2ykfigc51k-2>li{counter-increment:lst-ctn-kix_fc2ykfigc51k-2}ul.lst-kix_4m75w8hvs20i-8{list-style-type:none}ul.lst-kix_4m75w8hvs20i-7{list-style-type:none}ul.lst-kix_vm5eb5wj9btb-7{list-style-type:none}ul.lst-kix_4m75w8hvs20i-4{list-style-type:none}ul.lst-kix_vm5eb5wj9btb-8{list-style-type:none}ul.lst-kix_4m75w8hvs20i-3{list-style-type:none}ul.lst-kix_vm5eb5wj9btb-5{list-style-type:none}ul.lst-kix_4m75w8hvs20i-6{list-style-type:none}ul.lst-kix_vm5eb5wj9btb-6{list-style-type:none}ul.lst-kix_4m75w8hvs20i-5{list-style-type:none}ul.lst-kix_vm5eb5wj9btb-3{list-style-type:none}ul.lst-kix_vm5eb5wj9btb-4{list-style-type:none}ul.lst-kix_vm5eb5wj9btb-1{list-style-type:none}ul.lst-kix_vm5eb5wj9btb-2{list-style-type:none}ul.lst-kix_vm5eb5wj9btb-0{list-style-type:none}.lst-kix_vm5eb5wj9btb-8>li:before{content:"\0025a0  "}.lst-kix_3qcga3w32puo-7>li:before{content:"\0025cb  "}.lst-kix_3qcga3w32puo-3>li:before{content:"\0025cf  "}.lst-kix_vm5eb5wj9btb-4>li:before{content:"\0025cb  "}.lst-kix_h6pl6prycf0s-8>li:before{content:"\0025a0  "}.lst-kix_vc00w1t3u3x3-7>li:before{content:"\0025cb  "}.lst-kix_vc00w1t3u3x3-6>li:before{content:"\0025cf  "}.lst-kix_hwsfq798gxn5-2>li:before{content:"\0025a0  "}.lst-kix_hwsfq798gxn5-5>li:before{content:"\0025a0  "}ul.lst-kix_9svm7rgqi3v0-7{list-style-type:none}ul.lst-kix_9svm7rgqi3v0-8{list-style-type:none}.lst-kix_hwsfq798gxn5-4>li:before{content:"\0025cb  "}.lst-kix_vc00w1t3u3x3-1>li:before{content:"\0025cb  "}.lst-kix_y9bv39t2d2mx-0>li:before{content:"\0025cf  "}ol.lst-kix_u1miwd4ifplz-8.start{counter-reset:lst-ctn-kix_u1miwd4ifplz-8 0}.lst-kix_vc00w1t3u3x3-4>li:before{content:"\0025cb  "}.lst-kix_w38yctfkyp2x-0>li:before{content:"\0025cf  "}.lst-kix_y9bv39t2d2mx-2>li:before{content:"\0025a0  "}.lst-kix_57j7vjaq73pq-0>li:before{content:"\0025cf  "}.lst-kix_w38yctfkyp2x-2>li:before{content:"\0025a0  "}ol.lst-kix_6rkpxax2xgx6-3.start{counter-reset:lst-ctn-kix_6rkpxax2xgx6-3 0}.lst-kix_y9bv39t2d2mx-7>li:before{content:"\0025cb  "}.lst-kix_57j7vjaq73pq-2>li:before{content:"\0025a0  "}.lst-kix_w38yctfkyp2x-3>li:before{content:"\0025cf  "}.lst-kix_w38yctfkyp2x-5>li:before{content:"\0025a0  "}.lst-kix_57j7vjaq73pq-3>li:before{content:"\0025cf  "}.lst-kix_y9bv39t2d2mx-5>li:before{content:"\0025a0  "}ul.lst-kix_9svm7rgqi3v0-3{list-style-type:none}.lst-kix_w38yctfkyp2x-8>li:before{content:"\0025a0  "}ul.lst-kix_9svm7rgqi3v0-4{list-style-type:none}.lst-kix_h6pl6prycf0s-0>li:before{content:"\0025cf  "}ul.lst-kix_9svm7rgqi3v0-5{list-style-type:none}ul.lst-kix_9svm7rgqi3v0-6{list-style-type:none}.lst-kix_hwsfq798gxn5-7>li:before{content:"\0025cb  "}.lst-kix_57j7vjaq73pq-8>li:before{content:"\0025a0  "}ul.lst-kix_9svm7rgqi3v0-0{list-style-type:none}.lst-kix_h6pl6prycf0s-2>li:before{content:"\0025a0  "}ul.lst-kix_9svm7rgqi3v0-1{list-style-type:none}.lst-kix_57j7vjaq73pq-5>li:before{content:"\0025a0  "}ul.lst-kix_9svm7rgqi3v0-2{list-style-type:none}ul.lst-kix_qtag81809xxx-7{list-style-type:none}.lst-kix_xtr5a4oh4bgi-3>li{counter-increment:lst-ctn-kix_xtr5a4oh4bgi-3}.lst-kix_h6pl6prycf0s-5>li:before{content:"\0025a0  "}ul.lst-kix_qtag81809xxx-6{list-style-type:none}ul.lst-kix_qtag81809xxx-5{list-style-type:none}.lst-kix_y9bv39t2d2mx-8>li:before{content:"\0025a0  "}ul.lst-kix_qtag81809xxx-4{list-style-type:none}ul.lst-kix_qtag81809xxx-3{list-style-type:none}.lst-kix_ie0dqyb5ymnc-1>li:before{content:"\0025cb  "}.lst-kix_h6pl6prycf0s-3>li:before{content:"\0025cf  "}ul.lst-kix_qtag81809xxx-2{list-style-type:none}ul.lst-kix_qtag81809xxx-1{list-style-type:none}ul.lst-kix_qtag81809xxx-0{list-style-type:none}ul.lst-kix_77czq22cdr8e-8{list-style-type:none}ul.lst-kix_77czq22cdr8e-7{list-style-type:none}ul.lst-kix_77czq22cdr8e-6{list-style-type:none}ul.lst-kix_77czq22cdr8e-5{list-style-type:none}ul.lst-kix_77czq22cdr8e-4{list-style-type:none}ul.lst-kix_77czq22cdr8e-3{list-style-type:none}ul.lst-kix_77czq22cdr8e-2{list-style-type:none}ul.lst-kix_77czq22cdr8e-1{list-style-type:none}ul.lst-kix_77czq22cdr8e-0{list-style-type:none}ol.lst-kix_u1miwd4ifplz-3.start{counter-reset:lst-ctn-kix_u1miwd4ifplz-3 0}ol.lst-kix_xftmuywemg5q-6.start{counter-reset:lst-ctn-kix_xftmuywemg5q-6 0}ul.lst-kix_vc00w1t3u3x3-8{list-style-type:none}ul.lst-kix_vc00w1t3u3x3-7{list-style-type:none}ul.lst-kix_vc00w1t3u3x3-6{list-style-type:none}ul.lst-kix_vc00w1t3u3x3-5{list-style-type:none}ul.lst-kix_vc00w1t3u3x3-4{list-style-type:none}ul.lst-kix_vc00w1t3u3x3-3{list-style-type:none}ul.lst-kix_vc00w1t3u3x3-2{list-style-type:none}li.li-bullet-2:before{margin-left:-9pt;white-space:nowrap;display:inline-block;min-width:9pt}ol.lst-kix_xtr5a4oh4bgi-5.start{counter-reset:lst-ctn-kix_xtr5a4oh4bgi-5 0}.lst-kix_fc2ykfigc51k-0>li{counter-increment:lst-ctn-kix_fc2ykfigc51k-0}.lst-kix_1ladtov3yl5q-4>li:before{content:"\0025cb  "}.lst-kix_xtr5a4oh4bgi-7>li{counter-increment:lst-ctn-kix_xtr5a4oh4bgi-7}.lst-kix_1ladtov3yl5q-2>li:before{content:"\0025a0  "}ul.lst-kix_kxcc4a1pk4g-0{list-style-type:none}ul.lst-kix_kxcc4a1pk4g-1{list-style-type:none}.lst-kix_inlqfkxlm01z-7>li:before{content:"\0025cb  "}ol.lst-kix_xftmuywemg5q-4.start{counter-reset:lst-ctn-kix_xftmuywemg5q-4 0}ol.lst-kix_u1miwd4ifplz-1.start{counter-reset:lst-ctn-kix_u1miwd4ifplz-1 0}ul.lst-kix_kxcc4a1pk4g-2{list-style-type:none}ul.lst-kix_kxcc4a1pk4g-3{list-style-type:none}ul.lst-kix_kxcc4a1pk4g-4{list-style-type:none}ul.lst-kix_kxcc4a1pk4g-5{list-style-type:none}ul.lst-kix_kxcc4a1pk4g-6{list-style-type:none}ul.lst-kix_kxcc4a1pk4g-7{list-style-type:none}ul.lst-kix_kxcc4a1pk4g-8{list-style-type:none}.lst-kix_c0gqsl31o9rr-8>li:before{content:"\0025a0  "}.lst-kix_x4qr3m7alqzt-7>li:before{content:"" counter(lst-ctn-kix_x4qr3m7alqzt-7,lower-latin) ". "}ol.lst-kix_xftmuywemg5q-1.start{counter-reset:lst-ctn-kix_xftmuywemg5q-1 0}.lst-kix_x4qr3m7alqzt-5>li:before{content:"" counter(lst-ctn-kix_x4qr3m7alqzt-5,lower-roman) ". "}.lst-kix_c0gqsl31o9rr-0>li:before{content:"\0025cf  "}.lst-kix_igvphj22m9h3-1>li:before{content:"\0025cb  "}.lst-kix_81uxck1pvydf-7>li:before{content:"\0025cb  "}.lst-kix_81uxck1pvydf-5>li:before{content:"\0025a0  "}.lst-kix_inlqfkxlm01z-1>li:before{content:"\0025cb  "}.lst-kix_c0gqsl31o9rr-2>li:before{content:"\0025a0  "}.lst-kix_834gwign38o3-6>li:before{content:"\0025cf  "}.lst-kix_ie0dqyb5ymnc-7>li:before{content:"\0025cb  "}.lst-kix_834gwign38o3-8>li:before{content:"\0025a0  "}.lst-kix_igvphj22m9h3-7>li:before{content:"\0025cb  "}.lst-kix_u1miwd4ifplz-5>li{counter-increment:lst-ctn-kix_u1miwd4ifplz-5}.lst-kix_qtag81809xxx-0>li:before{content:"\0025cf  "}ol.lst-kix_6rkpxax2xgx6-8.start{counter-reset:lst-ctn-kix_6rkpxax2xgx6-8 0}.lst-kix_xftmuywemg5q-4>li{counter-increment:lst-ctn-kix_xftmuywemg5q-4}.lst-kix_qtag81809xxx-6>li:before{content:"\0025cf  "}.lst-kix_834gwign38o3-0>li:before{content:"\0025cf  "}.lst-kix_6rkpxax2xgx6-0>li{counter-increment:lst-ctn-kix_6rkpxax2xgx6-0}.lst-kix_qtag81809xxx-8>li:before{content:"\0025a0  "}ol.lst-kix_xtr5a4oh4bgi-8.start{counter-reset:lst-ctn-kix_xtr5a4oh4bgi-8 0}.lst-kix_srd6nt24vl21-5>li:before{content:"\0025a0  "}ul.lst-kix_pydpz6z6x5vm-0{list-style-type:none}ul.lst-kix_pydpz6z6x5vm-1{list-style-type:none}ul.lst-kix_pydpz6z6x5vm-2{list-style-type:none}ul.lst-kix_pydpz6z6x5vm-3{list-style-type:none}.lst-kix_77czq22cdr8e-5>li:before{content:"\0025a0  "}ul.lst-kix_pydpz6z6x5vm-4{list-style-type:none}.lst-kix_mnhl5qv63e85-3>li:before{content:"\0025cf  "}.lst-kix_77czq22cdr8e-2>li:before{content:"\0025a0  "}ul.lst-kix_pydpz6z6x5vm-5{list-style-type:none}ul.lst-kix_pydpz6z6x5vm-6{list-style-type:none}ul.lst-kix_pydpz6z6x5vm-7{list-style-type:none}ul.lst-kix_pydpz6z6x5vm-8{list-style-type:none}.lst-kix_srd6nt24vl21-0>li:before{content:"\0025cf  "}.lst-kix_srd6nt24vl21-8>li:before{content:"\0025a0  "}ul.lst-kix_834gwign38o3-0{list-style-type:none}ul.lst-kix_834gwign38o3-4{list-style-type:none}.lst-kix_x4qr3m7alqzt-0>li{counter-increment:lst-ctn-kix_x4qr3m7alqzt-0}ul.lst-kix_834gwign38o3-3{list-style-type:none}ul.lst-kix_834gwign38o3-2{list-style-type:none}ul.lst-kix_834gwign38o3-1{list-style-type:none}ul.lst-kix_834gwign38o3-8{list-style-type:none}ul.lst-kix_834gwign38o3-7{list-style-type:none}ul.lst-kix_834gwign38o3-6{list-style-type:none}ul.lst-kix_834gwign38o3-5{list-style-type:none}ol.lst-kix_u1miwd4ifplz-0.start{counter-reset:lst-ctn-kix_u1miwd4ifplz-0 0}.lst-kix_xftmuywemg5q-1>li{counter-increment:lst-ctn-kix_xftmuywemg5q-1}.lst-kix_mnhl5qv63e85-8>li:before{content:"\0025a0  "}.lst-kix_rx43k1prc8h0-6>li:before{content:"\0025cf  "}.lst-kix_u1miwd4ifplz-1>li{counter-increment:lst-ctn-kix_u1miwd4ifplz-1}.lst-kix_rx43k1prc8h0-3>li:before{content:"\0025cf  "}.lst-kix_xtr5a4oh4bgi-5>li:before{content:"" counter(lst-ctn-kix_xtr5a4oh4bgi-5,lower-roman) ". "}.lst-kix_xtr5a4oh4bgi-2>li:before{content:"" counter(lst-ctn-kix_xtr5a4oh4bgi-2,lower-roman) ". "}.lst-kix_xtr5a4oh4bgi-0>li{counter-increment:lst-ctn-kix_xtr5a4oh4bgi-0}.lst-kix_9ps8jprlmeqd-7>li:before{content:"\002022  "}.lst-kix_u1ujgvuq2lk9-7>li:before{content:"\0025cb  "}.lst-kix_9svm7rgqi3v0-4>li:before{content:"\0025cb  "}.lst-kix_9svm7rgqi3v0-7>li:before{content:"\0025cb  "}.lst-kix_fc2ykfigc51k-3>li{counter-increment:lst-ctn-kix_fc2ykfigc51k-3}ul.lst-kix_rx43k1prc8h0-7{list-style-type:none}ul.lst-kix_rx43k1prc8h0-8{list-style-type:none}ul.lst-kix_rx43k1prc8h0-5{list-style-type:none}ul.lst-kix_rx43k1prc8h0-6{list-style-type:none}ul.lst-kix_rx43k1prc8h0-3{list-style-type:none}ul.lst-kix_rx43k1prc8h0-4{list-style-type:none}.lst-kix_9ps8jprlmeqd-2>li:before{content:"\002022  "}ul.lst-kix_rx43k1prc8h0-1{list-style-type:none}ul.lst-kix_rx43k1prc8h0-2{list-style-type:none}ul.lst-kix_rx43k1prc8h0-0{list-style-type:none}.lst-kix_u1ujgvuq2lk9-2>li:before{content:"\0025a0  "}.lst-kix_bo57k090qe1r-3>li:before{content:"\0025cf  "}ul.lst-kix_bo57k090qe1r-2{list-style-type:none}ul.lst-kix_bo57k090qe1r-1{list-style-type:none}ul.lst-kix_bo57k090qe1r-4{list-style-type:none}ul.lst-kix_bo57k090qe1r-3{list-style-type:none}ul.lst-kix_bo57k090qe1r-6{list-style-type:none}ul.lst-kix_bo57k090qe1r-5{list-style-type:none}ul.lst-kix_bo57k090qe1r-8{list-style-type:none}ul.lst-kix_bo57k090qe1r-7{list-style-type:none}.lst-kix_mnhl5qv63e85-0>li:before{content:"\0025cf  "}.lst-kix_inlqfkxlm01z-4>li:before{content:"\0025cb  "}.lst-kix_xftmuywemg5q-8>li{counter-increment:lst-ctn-kix_xftmuywemg5q-8}ol.lst-kix_u1miwd4ifplz-4.start{counter-reset:lst-ctn-kix_u1miwd4ifplz-4 0}.lst-kix_81uxck1pvydf-2>li:before{content:"\0025a0  "}.lst-kix_u1miwd4ifplz-8>li{counter-increment:lst-ctn-kix_u1miwd4ifplz-8}.lst-kix_251ao7edjvnc-1>li:before{content:"\0025cb  "}.lst-kix_cdeuz8uxcywt-6>li:before{content:"\0025cf  "}.lst-kix_pydpz6z6x5vm-1>li:before{content:"\0025cb  "}.lst-kix_bo57k090qe1r-6>li:before{content:"\0025cf  "}ul.lst-kix_vc00w1t3u3x3-1{list-style-type:none}ul.lst-kix_vc00w1t3u3x3-0{list-style-type:none}.lst-kix_c0gqsl31o9rr-5>li:before{content:"\0025a0  "}.lst-kix_x4qr3m7alqzt-2>li:before{content:"" counter(lst-ctn-kix_x4qr3m7alqzt-2,lower-roman) ". "}ol.lst-kix_u1miwd4ifplz-7.start{counter-reset:lst-ctn-kix_u1miwd4ifplz-7 0}.lst-kix_fc2ykfigc51k-3>li:before{content:"" counter(lst-ctn-kix_fc2ykfigc51k-3,decimal) ". "}.lst-kix_igvphj22m9h3-4>li:before{content:"\0025cb  "}.lst-kix_1ladtov3yl5q-7>li:before{content:"\0025cb  "}.lst-kix_3qcga3w32puo-1>li:before{content:"\0025cb  "}ul.lst-kix_qtag81809xxx-8{list-style-type:none}ol.lst-kix_u1miwd4ifplz-6.start{counter-reset:lst-ctn-kix_u1miwd4ifplz-6 0}.lst-kix_ie0dqyb5ymnc-4>li:before{content:"\0025cb  "}.lst-kix_xk7ya91ob6yn-0>li:before{content:"\0025cf  "}ul.lst-kix_txme4cepwvun-0{list-style-type:none}.lst-kix_6rkpxax2xgx6-5>li:before{content:"" counter(lst-ctn-kix_6rkpxax2xgx6-5,lower-roman) ". "}ul.lst-kix_txme4cepwvun-2{list-style-type:none}ul.lst-kix_txme4cepwvun-1{list-style-type:none}ul.lst-kix_txme4cepwvun-4{list-style-type:none}ul.lst-kix_txme4cepwvun-3{list-style-type:none}ul.lst-kix_txme4cepwvun-6{list-style-type:none}ul.lst-kix_txme4cepwvun-5{list-style-type:none}ul.lst-kix_txme4cepwvun-8{list-style-type:none}.lst-kix_qtag81809xxx-3>li:before{content:"\0025cf  "}ul.lst-kix_txme4cepwvun-7{list-style-type:none}ol.lst-kix_u1miwd4ifplz-5.start{counter-reset:lst-ctn-kix_u1miwd4ifplz-5 0}.lst-kix_xk7ya91ob6yn-8>li:before{content:"\0025a0  "}li.li-bullet-0:before{margin-left:-18pt;white-space:nowrap;display:inline-block;min-width:18pt}.lst-kix_vm5eb5wj9btb-6>li:before{content:"\0025cf  "}.lst-kix_6rkpxax2xgx6-3>li{counter-increment:lst-ctn-kix_6rkpxax2xgx6-3}.lst-kix_834gwign38o3-3>li:before{content:"\0025cf  "}ul.lst-kix_9ps8jprlmeqd-8{list-style-type:none}ul.lst-kix_9ps8jprlmeqd-6{list-style-type:none}ul.lst-kix_9ps8jprlmeqd-7{list-style-type:none}ul.lst-kix_9ps8jprlmeqd-4{list-style-type:none}ul.lst-kix_9ps8jprlmeqd-5{list-style-type:none}ul.lst-kix_9ps8jprlmeqd-2{list-style-type:none}ul.lst-kix_9ps8jprlmeqd-3{list-style-type:none}ul.lst-kix_9ps8jprlmeqd-0{list-style-type:none}ul.lst-kix_9ps8jprlmeqd-1{list-style-type:none}.lst-kix_xftmuywemg5q-1>li:before{content:"" counter(lst-ctn-kix_xftmuywemg5q-1,lower-latin) ". "}.lst-kix_xftmuywemg5q-2>li:before{content:"" counter(lst-ctn-kix_xftmuywemg5q-2,lower-roman) ". "}.lst-kix_xftmuywemg5q-3>li:before{content:"" counter(lst-ctn-kix_xftmuywemg5q-3,decimal) ". "}.lst-kix_xftmuywemg5q-4>li:before{content:"" counter(lst-ctn-kix_xftmuywemg5q-4,lower-latin) ". "}.lst-kix_xftmuywemg5q-5>li:before{content:"" counter(lst-ctn-kix_xftmuywemg5q-5,lower-roman) ". "}.lst-kix_xftmuywemg5q-8>li:before{content:"" counter(lst-ctn-kix_xftmuywemg5q-8,lower-roman) ". "}.lst-kix_xftmuywemg5q-6>li:before{content:"" counter(lst-ctn-kix_xftmuywemg5q-6,decimal) ". "}.lst-kix_xftmuywemg5q-7>li:before{content:"" counter(lst-ctn-kix_xftmuywemg5q-7,lower-latin) ". "}ol.lst-kix_x4qr3m7alqzt-7.start{counter-reset:lst-ctn-kix_x4qr3m7alqzt-7 0}.lst-kix_3tteimmmx0yp-4>li:before{content:"\0025cb  "}.lst-kix_3tteimmmx0yp-5>li:before{content:"\0025a0  "}.lst-kix_4m75w8hvs20i-5>li:before{content:"\0025a0  "}.lst-kix_4m75w8hvs20i-6>li:before{content:"\0025cf  "}.lst-kix_3tteimmmx0yp-2>li:before{content:"\0025a0  "}.lst-kix_3tteimmmx0yp-6>li:before{content:"\0025cf  "}.lst-kix_u1miwd4ifplz-0>li{counter-increment:lst-ctn-kix_u1miwd4ifplz-0}.lst-kix_4m75w8hvs20i-1>li:before{content:"\0025cb  "}.lst-kix_3tteimmmx0yp-3>li:before{content:"\0025cf  "}.lst-kix_4m75w8hvs20i-0>li:before{content:"\0025cf  "}.lst-kix_4m75w8hvs20i-7>li:before{content:"\0025cb  "}.lst-kix_4m75w8hvs20i-8>li:before{content:"\0025a0  "}.lst-kix_fc2ykfigc51k-7>li:before{content:"" counter(lst-ctn-kix_fc2ykfigc51k-7,lower-latin) ". "}.lst-kix_fc2ykfigc51k-8>li:before{content:"" counter(lst-ctn-kix_fc2ykfigc51k-8,lower-roman) ". "}.lst-kix_3tteimmmx0yp-0>li:before{content:"\0025cf  "}.lst-kix_3tteimmmx0yp-1>li:before{content:"\0025cb  "}.lst-kix_4m75w8hvs20i-2>li:before{content:"\0025a0  "}.lst-kix_4m75w8hvs20i-3>li:before{content:"\0025cf  "}.lst-kix_4m75w8hvs20i-4>li:before{content:"\0025cb  "}ul.lst-kix_inlqfkxlm01z-3{list-style-type:none}ul.lst-kix_inlqfkxlm01z-2{list-style-type:none}ul.lst-kix_inlqfkxlm01z-5{list-style-type:none}ul.lst-kix_inlqfkxlm01z-4{list-style-type:none}ul.lst-kix_inlqfkxlm01z-7{list-style-type:none}ul.lst-kix_inlqfkxlm01z-6{list-style-type:none}ul.lst-kix_inlqfkxlm01z-8{list-style-type:none}ol.lst-kix_u1miwd4ifplz-2.start{counter-reset:lst-ctn-kix_u1miwd4ifplz-2 0}.lst-kix_3tteimmmx0yp-8>li:before{content:"\0025a0  "}.lst-kix_3tteimmmx0yp-7>li:before{content:"\0025cb  "}ul.lst-kix_inlqfkxlm01z-1{list-style-type:none}ul.lst-kix_inlqfkxlm01z-0{list-style-type:none}.lst-kix_251ao7edjvnc-4>li:before{content:"\0025cb  "}.lst-kix_cdeuz8uxcywt-7>li:before{content:"\0025cb  "}.lst-kix_251ao7edjvnc-2>li:before{content:"\0025a0  "}.lst-kix_251ao7edjvnc-6>li:before{content:"\0025cf  "}.lst-kix_cdeuz8uxcywt-5>li:before{content:"\0025a0  "}.lst-kix_251ao7edjvnc-8>li:before{content:"\0025a0  "}.lst-kix_251ao7edjvnc-0>li:before{content:"\0025cf  "}.lst-kix_fc2ykfigc51k-6>li{counter-increment:lst-ctn-kix_fc2ykfigc51k-6}ol.lst-kix_fc2ykfigc51k-0.start{counter-reset:lst-ctn-kix_fc2ykfigc51k-0 0}.lst-kix_pydpz6z6x5vm-0>li:before{content:"\0025cf  "}.lst-kix_cdeuz8uxcywt-1>li:before{content:"\0025cb  "}.lst-kix_cdeuz8uxcywt-3>li:before{content:"\0025cf  "}ul.lst-kix_hwsfq798gxn5-8{list-style-type:none}ul.lst-kix_hwsfq798gxn5-6{list-style-type:none}ul.lst-kix_hwsfq798gxn5-7{list-style-type:none}ul.lst-kix_hwsfq798gxn5-4{list-style-type:none}ul.lst-kix_hwsfq798gxn5-5{list-style-type:none}ul.lst-kix_hwsfq798gxn5-2{list-style-type:none}ul.lst-kix_hwsfq798gxn5-3{list-style-type:none}.lst-kix_x4qr3m7alqzt-7>li{counter-increment:lst-ctn-kix_x4qr3m7alqzt-7}ol.lst-kix_xtr5a4oh4bgi-6.start{counter-reset:lst-ctn-kix_xtr5a4oh4bgi-6 0}.lst-kix_fc2ykfigc51k-6>li:before{content:"" counter(lst-ctn-kix_fc2ykfigc51k-6,decimal) ". "}.lst-kix_fc2ykfigc51k-4>li:before{content:"" counter(lst-ctn-kix_fc2ykfigc51k-4,lower-latin) ". "}.lst-kix_fc2ykfigc51k-2>li:before{content:"" counter(lst-ctn-kix_fc2ykfigc51k-2,lower-roman) ". "}ol.lst-kix_6rkpxax2xgx6-7.start{counter-reset:lst-ctn-kix_6rkpxax2xgx6-7 0}.lst-kix_fc2ykfigc51k-0>li:before{content:"" counter(lst-ctn-kix_fc2ykfigc51k-0,decimal) ". "}.lst-kix_xk7ya91ob6yn-1>li:before{content:"\0025cb  "}.lst-kix_xk7ya91ob6yn-5>li:before{content:"\0025a0  "}.lst-kix_xk7ya91ob6yn-3>li:before{content:"\0025cf  "}.lst-kix_fc2ykfigc51k-5>li{counter-increment:lst-ctn-kix_fc2ykfigc51k-5}.lst-kix_pydpz6z6x5vm-8>li:before{content:"\0025a0  "}.lst-kix_xk7ya91ob6yn-7>li:before{content:"\0025cb  "}ol.lst-kix_fc2ykfigc51k-7{list-style-type:none}ol.lst-kix_fc2ykfigc51k-6{list-style-type:none}ol.lst-kix_fc2ykfigc51k-8{list-style-type:none}.lst-kix_pydpz6z6x5vm-2>li:before{content:"\0025a0  "}.lst-kix_pydpz6z6x5vm-4>li:before{content:"\0025cb  "}ol.lst-kix_fc2ykfigc51k-1{list-style-type:none}ol.lst-kix_fc2ykfigc51k-0{list-style-type:none}.lst-kix_pydpz6z6x5vm-6>li:before{content:"\0025cf  "}ol.lst-kix_xftmuywemg5q-2.start{counter-reset:lst-ctn-kix_xftmuywemg5q-2 0}ol.lst-kix_fc2ykfigc51k-3{list-style-type:none}ol.lst-kix_fc2ykfigc51k-2{list-style-type:none}ol.lst-kix_fc2ykfigc51k-5{list-style-type:none}.lst-kix_6rkpxax2xgx6-6>li{counter-increment:lst-ctn-kix_6rkpxax2xgx6-6}ol.lst-kix_fc2ykfigc51k-4{list-style-type:none}.lst-kix_77czq22cdr8e-3>li:before{content:"\0025cf  "}.lst-kix_77czq22cdr8e-4>li:before{content:"\0025cb  "}ol.lst-kix_xtr5a4oh4bgi-7.start{counter-reset:lst-ctn-kix_xtr5a4oh4bgi-7 0}.lst-kix_6rkpxax2xgx6-7>li{counter-increment:lst-ctn-kix_6rkpxax2xgx6-7}ol.lst-kix_6rkpxax2xgx6-6.start{counter-reset:lst-ctn-kix_6rkpxax2xgx6-6 0}ol.lst-kix_xftmuywemg5q-3.start{counter-reset:lst-ctn-kix_xftmuywemg5q-3 0}.lst-kix_77czq22cdr8e-0>li:before{content:"\0025cf  "}.lst-kix_rx43k1prc8h0-5>li:before{content:"\0025a0  "}.lst-kix_rx43k1prc8h0-4>li:before{content:"\0025cb  "}ol.lst-kix_6rkpxax2xgx6-1.start{counter-reset:lst-ctn-kix_6rkpxax2xgx6-1 0}.lst-kix_rx43k1prc8h0-1>li:before{content:"\0025cb  "}.lst-kix_rx43k1prc8h0-0>li:before{content:"\0025cf  "}.lst-kix_77czq22cdr8e-7>li:before{content:"\0025cb  "}.lst-kix_77czq22cdr8e-8>li:before{content:"\0025a0  "}.lst-kix_9ps8jprlmeqd-8>li:before{content:"\002022  "}.lst-kix_xftmuywemg5q-5>li{counter-increment:lst-ctn-kix_xftmuywemg5q-5}.lst-kix_9ps8jprlmeqd-4>li:before{content:"\002022  "}.lst-kix_9ps8jprlmeqd-5>li:before{content:"\002022  "}.lst-kix_xtr5a4oh4bgi-4>li{counter-increment:lst-ctn-kix_xtr5a4oh4bgi-4}.lst-kix_9ps8jprlmeqd-0>li:before{content:"\002022  "}.lst-kix_9ps8jprlmeqd-1>li:before{content:"\002022  "}.lst-kix_bo57k090qe1r-0>li:before{content:"\0025cf  "}.lst-kix_bo57k090qe1r-1>li:before{content:"\0025cb  "}.lst-kix_rx43k1prc8h0-8>li:before{content:"\0025a0  "}.lst-kix_bo57k090qe1r-4>li:before{content:"\0025cb  "}ol.lst-kix_x4qr3m7alqzt-3.start{counter-reset:lst-ctn-kix_x4qr3m7alqzt-3 0}ol.lst-kix_xftmuywemg5q-7.start{counter-reset:lst-ctn-kix_xftmuywemg5q-7 0}.lst-kix_251ao7edjvnc-3>li:before{content:"\0025cf  "}.lst-kix_cdeuz8uxcywt-8>li:before{content:"\0025a0  "}.lst-kix_1ladtov3yl5q-1>li:before{content:"\0025cb  "}.lst-kix_1ladtov3yl5q-5>li:before{content:"\0025a0  "}.lst-kix_251ao7edjvnc-7>li:before{content:"\0025cb  "}.lst-kix_c0gqsl31o9rr-7>li:before{content:"\0025cb  "}ul.lst-kix_57j7vjaq73pq-0{list-style-type:none}.lst-kix_inlqfkxlm01z-6>li:before{content:"\0025cf  "}ul.lst-kix_57j7vjaq73pq-3{list-style-type:none}ul.lst-kix_57j7vjaq73pq-4{list-style-type:none}ul.lst-kix_57j7vjaq73pq-1{list-style-type:none}.lst-kix_bo57k090qe1r-8>li:before{content:"\0025a0  "}ul.lst-kix_57j7vjaq73pq-2{list-style-type:none}ul.lst-kix_57j7vjaq73pq-7{list-style-type:none}ul.lst-kix_57j7vjaq73pq-8{list-style-type:none}.lst-kix_cdeuz8uxcywt-0>li:before{content:"\0025cf  "}.lst-kix_cdeuz8uxcywt-4>li:before{content:"\0025cb  "}.lst-kix_x4qr3m7alqzt-6>li{counter-increment:lst-ctn-kix_x4qr3m7alqzt-6}ul.lst-kix_57j7vjaq73pq-5{list-style-type:none}ul.lst-kix_57j7vjaq73pq-6{list-style-type:none}.lst-kix_u1miwd4ifplz-7>li{counter-increment:lst-ctn-kix_u1miwd4ifplz-7}.lst-kix_fc2ykfigc51k-7>li{counter-increment:lst-ctn-kix_fc2ykfigc51k-7}.lst-kix_fc2ykfigc51k-5>li:before{content:"" counter(lst-ctn-kix_fc2ykfigc51k-5,lower-roman) ". "}.lst-kix_igvphj22m9h3-2>li:before{content:"\0025a0  "}.lst-kix_xtr5a4oh4bgi-6>li{counter-increment:lst-ctn-kix_xtr5a4oh4bgi-6}.lst-kix_fc2ykfigc51k-1>li:before{content:"" counter(lst-ctn-kix_fc2ykfigc51k-1,lower-latin) ". "}.lst-kix_c0gqsl31o9rr-3>li:before{content:"\0025cf  "}.lst-kix_inlqfkxlm01z-2>li:before{content:"\0025a0  "}ol.lst-kix_xtr5a4oh4bgi-2.start{counter-reset:lst-ctn-kix_xtr5a4oh4bgi-2 0}.lst-kix_ie0dqyb5ymnc-6>li:before{content:"\0025cf  "}.lst-kix_igvphj22m9h3-6>li:before{content:"\0025cf  "}.lst-kix_834gwign38o3-5>li:before{content:"\0025a0  "}ol.lst-kix_x4qr3m7alqzt-1.start{counter-reset:lst-ctn-kix_x4qr3m7alqzt-1 0}ul.lst-kix_c0gqsl31o9rr-8{list-style-type:none}ul.lst-kix_c0gqsl31o9rr-7{list-style-type:none}ul.lst-kix_c0gqsl31o9rr-6{list-style-type:none}ul.lst-kix_c0gqsl31o9rr-5{list-style-type:none}.lst-kix_xk7ya91ob6yn-2>li:before{content:"\0025a0  "}ul.lst-kix_c0gqsl31o9rr-4{list-style-type:none}ul.lst-kix_c0gqsl31o9rr-3{list-style-type:none}ul.lst-kix_c0gqsl31o9rr-2{list-style-type:none}ul.lst-kix_c0gqsl31o9rr-1{list-style-type:none}ul.lst-kix_c0gqsl31o9rr-0{list-style-type:none}ol.lst-kix_xftmuywemg5q-8.start{counter-reset:lst-ctn-kix_xftmuywemg5q-8 0}ol.lst-kix_x4qr3m7alqzt-2.start{counter-reset:lst-ctn-kix_x4qr3m7alqzt-2 0}ol.lst-kix_xtr5a4oh4bgi-1.start{counter-reset:lst-ctn-kix_xtr5a4oh4bgi-1 0}.lst-kix_xk7ya91ob6yn-6>li:before{content:"\0025cf  "}.lst-kix_xftmuywemg5q-7>li{counter-increment:lst-ctn-kix_xftmuywemg5q-7}.lst-kix_xftmuywemg5q-0>li:before{content:"" counter(lst-ctn-kix_xftmuywemg5q-0,decimal) ". "}.lst-kix_834gwign38o3-1>li:before{content:"\0025cb  "}.lst-kix_pydpz6z6x5vm-3>li:before{content:"\0025cf  "}.lst-kix_pydpz6z6x5vm-7>li:before{content:"\0025cb  "}ol.lst-kix_6rkpxax2xgx6-2.start{counter-reset:lst-ctn-kix_6rkpxax2xgx6-2 0}.lst-kix_hwsfq798gxn5-1>li:before{content:"\0025cb  "}.lst-kix_h6pl6prycf0s-6>li:before{content:"\0025cf  "}.lst-kix_6rkpxax2xgx6-8>li{counter-increment:lst-ctn-kix_6rkpxax2xgx6-8}.lst-kix_hwsfq798gxn5-3>li:before{content:"\0025cf  "}.lst-kix_h6pl6prycf0s-7>li:before{content:"\0025cb  "}.lst-kix_vc00w1t3u3x3-0>li:before{content:"\0025cf  "}.lst-kix_vc00w1t3u3x3-8>li:before{content:"\0025a0  "}.lst-kix_vc00w1t3u3x3-2>li:before{content:"\0025a0  "}.lst-kix_vc00w1t3u3x3-3>li:before{content:"\0025cf  "}.lst-kix_vc00w1t3u3x3-5>li:before{content:"\0025a0  "}.lst-kix_u1miwd4ifplz-2>li{counter-increment:lst-ctn-kix_u1miwd4ifplz-2}.lst-kix_hwsfq798gxn5-0>li:before{content:"\0025cf  "}.lst-kix_y9bv39t2d2mx-1>li:before{content:"\0025cb  "}.lst-kix_w38yctfkyp2x-1>li:before{content:"\0025cb  "}.lst-kix_y9bv39t2d2mx-4>li:before{content:"\0025cb  "}.lst-kix_x4qr3m7alqzt-1>li{counter-increment:lst-ctn-kix_x4qr3m7alqzt-1}.lst-kix_57j7vjaq73pq-1>li:before{content:"\0025cb  "}.lst-kix_y9bv39t2d2mx-3>li:before{content:"\0025cf  "}.lst-kix_w38yctfkyp2x-4>li:before{content:"\0025cb  "}.lst-kix_y9bv39t2d2mx-6>li:before{content:"\0025cf  "}.lst-kix_57j7vjaq73pq-6>li:before{content:"\0025cf  "}.lst-kix_xftmuywemg5q-0>li{counter-increment:lst-ctn-kix_xftmuywemg5q-0}.lst-kix_h6pl6prycf0s-1>li:before{content:"\0025cb  "}.lst-kix_w38yctfkyp2x-7>li:before{content:"\0025cb  "}.lst-kix_ie0dqyb5ymnc-0>li:before{content:"\0025cf  "}.lst-kix_57j7vjaq73pq-4>li:before{content:"\0025cb  "}.lst-kix_w38yctfkyp2x-6>li:before{content:"\0025cf  "}.lst-kix_hwsfq798gxn5-6>li:before{content:"\0025cf  "}.lst-kix_ie0dqyb5ymnc-3>li:before{content:"\0025cf  "}.lst-kix_h6pl6prycf0s-4>li:before{content:"\0025cb  "}.lst-kix_ie0dqyb5ymnc-2>li:before{content:"\0025a0  "}.lst-kix_57j7vjaq73pq-7>li:before{content:"\0025cb  "}.lst-kix_hwsfq798gxn5-8>li:before{content:"\0025a0  "}.lst-kix_u1miwd4ifplz-6>li{counter-increment:lst-ctn-kix_u1miwd4ifplz-6}ol.lst-kix_fc2ykfigc51k-8.start{counter-reset:lst-ctn-kix_fc2ykfigc51k-8 0}ol.lst-kix_fc2ykfigc51k-1.start{counter-reset:lst-ctn-kix_fc2ykfigc51k-1 0}.lst-kix_6rkpxax2xgx6-4>li{counter-increment:lst-ctn-kix_6rkpxax2xgx6-4}.lst-kix_81uxck1pvydf-1>li:before{content:"\0025cb  "}.lst-kix_inlqfkxlm01z-5>li:before{content:"\0025a0  "}.lst-kix_1ladtov3yl5q-6>li:before{content:"\0025cf  "}.lst-kix_81uxck1pvydf-3>li:before{content:"\0025cf  "}.lst-kix_c0gqsl31o9rr-6>li:before{content:"\0025cf  "}ol.lst-kix_x4qr3m7alqzt-6.start{counter-reset:lst-ctn-kix_x4qr3m7alqzt-6 0}.lst-kix_6rkpxax2xgx6-1>li{counter-increment:lst-ctn-kix_6rkpxax2xgx6-1}.lst-kix_bo57k090qe1r-5>li:before{content:"\0025a0  "}.lst-kix_1ladtov3yl5q-0>li:before{content:"\0025cf  "}.lst-kix_bo57k090qe1r-7>li:before{content:"\0025cb  "}li.li-bullet-1:before{margin-left:-9pt;white-space:nowrap;display:inline-block;min-width:9pt}.lst-kix_x4qr3m7alqzt-1>li:before{content:"" counter(lst-ctn-kix_x4qr3m7alqzt-1,lower-latin) ". "}.lst-kix_c0gqsl31o9rr-4>li:before{content:"\0025cb  "}.lst-kix_fc2ykfigc51k-4>li{counter-increment:lst-ctn-kix_fc2ykfigc51k-4}.lst-kix_igvphj22m9h3-5>li:before{content:"\0025a0  "}.lst-kix_1ladtov3yl5q-8>li:before{content:"\0025a0  "}.lst-kix_x4qr3m7alqzt-3>li:before{content:"" counter(lst-ctn-kix_x4qr3m7alqzt-3,decimal) ". "}.lst-kix_igvphj22m9h3-3>li:before{content:"\0025cf  "}.lst-kix_inlqfkxlm01z-3>li:before{content:"\0025cf  "}ul.lst-kix_1ladtov3yl5q-2{list-style-type:none}ol.lst-kix_u1miwd4ifplz-7{list-style-type:none}.lst-kix_834gwign38o3-4>li:before{content:"\0025cb  "}ul.lst-kix_1ladtov3yl5q-3{list-style-type:none}ol.lst-kix_u1miwd4ifplz-8{list-style-type:none}ul.lst-kix_1ladtov3yl5q-0{list-style-type:none}ol.lst-kix_u1miwd4ifplz-5{list-style-type:none}ul.lst-kix_1ladtov3yl5q-1{list-style-type:none}ol.lst-kix_u1miwd4ifplz-6{list-style-type:none}ul.lst-kix_1ladtov3yl5q-6{list-style-type:none}ul.lst-kix_1ladtov3yl5q-7{list-style-type:none}ul.lst-kix_1ladtov3yl5q-4{list-style-type:none}ul.lst-kix_1ladtov3yl5q-5{list-style-type:none}.lst-kix_ie0dqyb5ymnc-5>li:before{content:"\0025a0  "}ul.lst-kix_1ladtov3yl5q-8{list-style-type:none}.lst-kix_qtag81809xxx-4>li:before{content:"\0025cb  "}ol.lst-kix_u1miwd4ifplz-3{list-style-type:none}ol.lst-kix_u1miwd4ifplz-4{list-style-type:none}ol.lst-kix_x4qr3m7alqzt-8.start{counter-reset:lst-ctn-kix_x4qr3m7alqzt-8 0}ol.lst-kix_u1miwd4ifplz-1{list-style-type:none}ol.lst-kix_u1miwd4ifplz-2{list-style-type:none}ol.lst-kix_u1miwd4ifplz-0{list-style-type:none}.lst-kix_qtag81809xxx-2>li:before{content:"\0025a0  "}ul.lst-kix_mnhl5qv63e85-8{list-style-type:none}ul.lst-kix_mnhl5qv63e85-7{list-style-type:none}ul.lst-kix_mnhl5qv63e85-6{list-style-type:none}ul.lst-kix_mnhl5qv63e85-5{list-style-type:none}ul.lst-kix_mnhl5qv63e85-4{list-style-type:none}ul.lst-kix_mnhl5qv63e85-3{list-style-type:none}ul.lst-kix_mnhl5qv63e85-2{list-style-type:none}ul.lst-kix_mnhl5qv63e85-1{list-style-type:none}ul.lst-kix_mnhl5qv63e85-0{list-style-type:none}.lst-kix_834gwign38o3-2>li:before{content:"\0025a0  "}.lst-kix_x4qr3m7alqzt-8>li{counter-increment:lst-ctn-kix_x4qr3m7alqzt-8}.lst-kix_srd6nt24vl21-4>li:before{content:"\0025cb  "}.lst-kix_77czq22cdr8e-1>li:before{content:"\0025cb  "}.lst-kix_srd6nt24vl21-1>li:before{content:"\0025cb  "}.lst-kix_u1miwd4ifplz-3>li{counter-increment:lst-ctn-kix_u1miwd4ifplz-3}.lst-kix_mnhl5qv63e85-4>li:before{content:"\0025cb  "}.lst-kix_xtr5a4oh4bgi-2>li{counter-increment:lst-ctn-kix_xtr5a4oh4bgi-2}.lst-kix_mnhl5qv63e85-7>li:before{content:"\0025cb  "}ul.lst-kix_reytss2l8ssc-8{list-style-type:none}ul.lst-kix_reytss2l8ssc-6{list-style-type:none}ul.lst-kix_reytss2l8ssc-7{list-style-type:none}ul.lst-kix_reytss2l8ssc-4{list-style-type:none}ul.lst-kix_reytss2l8ssc-5{list-style-type:none}ul.lst-kix_reytss2l8ssc-2{list-style-type:none}ul.lst-kix_reytss2l8ssc-3{list-style-type:none}ul.lst-kix_reytss2l8ssc-0{list-style-type:none}ol.lst-kix_fc2ykfigc51k-4.start{counter-reset:lst-ctn-kix_fc2ykfigc51k-4 0}ul.lst-kix_reytss2l8ssc-1{list-style-type:none}.lst-kix_rx43k1prc8h0-2>li:before{content:"\0025a0  "}.lst-kix_fc2ykfigc51k-1>li{counter-increment:lst-ctn-kix_fc2ykfigc51k-1}.lst-kix_77czq22cdr8e-6>li:before{content:"\0025cf  "}.lst-kix_xtr5a4oh4bgi-1>li:before{content:"" counter(lst-ctn-kix_xtr5a4oh4bgi-1,lower-latin) ". "}.lst-kix_xftmuywemg5q-3>li{counter-increment:lst-ctn-kix_xftmuywemg5q-3}ul.lst-kix_cdeuz8uxcywt-8{list-style-type:none}.lst-kix_9ps8jprlmeqd-6>li:before{content:"\002022  "}ul.lst-kix_cdeuz8uxcywt-5{list-style-type:none}.lst-kix_6rkpxax2xgx6-5>li{counter-increment:lst-ctn-kix_6rkpxax2xgx6-5}ul.lst-kix_cdeuz8uxcywt-4{list-style-type:none}ul.lst-kix_cdeuz8uxcywt-7{list-style-type:none}ul.lst-kix_cdeuz8uxcywt-6{list-style-type:none}.lst-kix_9svm7rgqi3v0-3>li:before{content:"\0025cf  "}ul.lst-kix_cdeuz8uxcywt-1{list-style-type:none}ul.lst-kix_cdeuz8uxcywt-0{list-style-type:none}.lst-kix_9ps8jprlmeqd-3>li:before{content:"\002022  "}ul.lst-kix_cdeuz8uxcywt-3{list-style-type:none}ul.lst-kix_cdeuz8uxcywt-2{list-style-type:none}.lst-kix_9svm7rgqi3v0-0>li:before{content:"\0025cf  "}.lst-kix_9svm7rgqi3v0-8>li:before{content:"\0025a0  "}.lst-kix_u1ujgvuq2lk9-6>li:before{content:"\0025cf  "}.lst-kix_u1ujgvuq2lk9-3>li:before{content:"\0025cf  "}ul.lst-kix_hwsfq798gxn5-0{list-style-type:none}ul.lst-kix_hwsfq798gxn5-1{list-style-type:none}.lst-kix_rx43k1prc8h0-7>li:before{content:"\0025cb  "}.lst-kix_bo57k090qe1r-2>li:before{content:"\0025a0  "}.lst-kix_251ao7edjvnc-5>li:before{content:"\0025a0  "}.lst-kix_x4qr3m7alqzt-5>li{counter-increment:lst-ctn-kix_x4qr3m7alqzt-5}ol.lst-kix_fc2ykfigc51k-3.start{counter-reset:lst-ctn-kix_fc2ykfigc51k-3 0}.lst-kix_inlqfkxlm01z-0>li:before{content:"\0025cf  "}.lst-kix_inlqfkxlm01z-8>li:before{content:"\0025a0  "}.lst-kix_1ladtov3yl5q-3>li:before{content:"\0025cf  "}ul.lst-kix_3tteimmmx0yp-0{list-style-type:none}ul.lst-kix_3tteimmmx0yp-1{list-style-type:none}ul.lst-kix_3tteimmmx0yp-2{list-style-type:none}ul.lst-kix_3tteimmmx0yp-3{list-style-type:none}ul.lst-kix_3tteimmmx0yp-8{list-style-type:none}ul.lst-kix_3tteimmmx0yp-4{list-style-type:none}ul.lst-kix_3tteimmmx0yp-5{list-style-type:none}.lst-kix_cdeuz8uxcywt-2>li:before{content:"\0025a0  "}ul.lst-kix_3tteimmmx0yp-6{list-style-type:none}ul.lst-kix_3tteimmmx0yp-7{list-style-type:none}ol.lst-kix_fc2ykfigc51k-6.start{counter-reset:lst-ctn-kix_fc2ykfigc51k-6 0}.lst-kix_x4qr3m7alqzt-6>li:before{content:"" counter(lst-ctn-kix_x4qr3m7alqzt-6,decimal) ". "}.lst-kix_igvphj22m9h3-0>li:before{content:"\0025cf  "}.lst-kix_81uxck1pvydf-6>li:before{content:"\0025cf  "}.lst-kix_c0gqsl31o9rr-1>li:before{content:"\0025cb  "}.lst-kix_xftmuywemg5q-6>li{counter-increment:lst-ctn-kix_xftmuywemg5q-6}.lst-kix_ie0dqyb5ymnc-8>li:before{content:"\0025a0  "}ol.lst-kix_fc2ykfigc51k-5.start{counter-reset:lst-ctn-kix_fc2ykfigc51k-5 0}.lst-kix_igvphj22m9h3-8>li:before{content:"\0025a0  "}.lst-kix_834gwign38o3-7>li:before{content:"\0025cb  "}.lst-kix_xtr5a4oh4bgi-5>li{counter-increment:lst-ctn-kix_xtr5a4oh4bgi-5}.lst-kix_xk7ya91ob6yn-4>li:before{content:"\0025cb  "}.lst-kix_fc2ykfigc51k-8>li{counter-increment:lst-ctn-kix_fc2ykfigc51k-8}.lst-kix_qtag81809xxx-7>li:before{content:"\0025cb  "}.lst-kix_vm5eb5wj9btb-2>li:before{content:"\0025a0  "}.lst-kix_3qcga3w32puo-5>li:before{content:"\0025a0  "}.lst-kix_6rkpxax2xgx6-1>li:before{content:"" counter(lst-ctn-kix_6rkpxax2xgx6-1,lower-latin) ". "}.lst-kix_pydpz6z6x5vm-5>li:before{content:"\0025a0  "}ol{margin:0;padding:0}table td,table th{padding:0}.c55{border-right-style:solid;padding:0pt 2pt 0pt 2pt;border-bottom-color:#000000;border-top-width:1pt;border-right-width:1pt;border-left-color:#000000;vertical-align:top;border-right-color:#000000;border-left-width:1pt;border-top-style:solid;background-color:#b7b7b7;border-left-style:solid;border-bottom-width:1pt;width:49.5pt;border-top-color:#000000;border-bottom-style:solid}.c60{border-right-style:solid;padding:0pt 2pt 0pt 2pt;border-bottom-color:#000000;border-top-width:1pt;border-right-width:1pt;border-left-color:#000000;vertical-align:top;border-right-color:#000000;border-left-width:1pt;border-top-style:solid;background-color:#ffffff;border-left-style:solid;border-bottom-width:1pt;width:31.4pt;border-top-color:#000000;border-bottom-style:solid}.c147{border-right-style:solid;padding:5pt 5pt 5pt 5pt;border-bottom-color:#000000;border-top-width:1pt;border-right-width:1pt;border-left-color:#000000;vertical-align:top;border-right-color:#000000;border-left-width:1pt;border-top-style:solid;border-left-style:solid;border-bottom-width:1pt;width:55.9pt;border-top-color:#000000;border-bottom-style:solid}.c173{border-right-style:solid;padding:5pt 5pt 5pt 5pt;border-bottom-color:#000000;border-top-width:0pt;border-right-width:0pt;border-left-color:#000000;vertical-align:top;border-right-color:#000000;border-left-width:1pt;border-top-style:solid;border-left-style:solid;border-bottom-width:1pt;width:31.4pt;border-top-color:#000000;border-bottom-style:solid}.c142{border-right-style:solid;padding:5pt 5pt 5pt 5pt;border-bottom-color:#000000;border-top-width:0pt;border-right-width:0pt;border-left-color:#000000;vertical-align:top;border-right-color:#000000;border-left-width:0pt;border-top-style:solid;border-left-style:solid;border-bottom-width:1pt;width:58.1pt;border-top-color:#000000;border-bottom-style:solid}.c56{border-right-style:solid;padding:5pt 5pt 5pt 5pt;border-bottom-color:#000000;border-top-width:1pt;border-right-width:1pt;border-left-color:#000000;vertical-align:top;border-right-color:#000000;border-left-width:1pt;border-top-style:solid;border-left-style:solid;border-bottom-width:1pt;width:147pt;border-top-color:#000000;border-bottom-style:solid}.c61{border-right-style:solid;padding:5pt 5pt 5pt 5pt;border-bottom-color:#000000;border-top-width:1pt;border-right-width:1pt;border-left-color:#000000;vertical-align:top;border-right-color:#000000;border-left-width:1pt;border-top-style:solid;border-left-style:solid;border-bottom-width:1pt;width:43.7pt;border-top-color:#000000;border-bottom-style:solid}.c176{border-right-style:solid;padding:3pt 3pt 3pt 3pt;border-bottom-color:#000000;border-top-width:1pt;border-right-width:1pt;border-left-color:#000000;vertical-align:middle;border-right-color:#000000;border-left-width:1pt;border-top-style:solid;border-left-style:solid;border-bottom-width:1pt;width:102.8pt;border-top-color:#000000;border-bottom-style:solid}.c8{border-right-style:solid;padding:5pt 5pt 5pt 5pt;border-bottom-color:#000000;border-top-width:1pt;border-right-width:1pt;border-left-color:#000000;vertical-align:top;border-right-color:#000000;border-left-width:1pt;border-top-style:solid;border-left-style:solid;border-bottom-width:1pt;width:48.8pt;border-top-color:#000000;border-bottom-style:solid}.c16{border-right-style:solid;padding:5pt 5pt 5pt 5pt;border-bottom-color:#000000;border-top-width:1pt;border-right-width:1pt;border-left-color:#000000;vertical-align:top;border-right-color:#000000;border-left-width:1pt;border-top-style:solid;border-left-style:solid;border-bottom-width:1pt;width:150.8pt;border-top-color:#000000;border-bottom-style:solid}.c101{border-right-style:solid;padding:5pt 5pt 5pt 5pt;border-bottom-color:#000000;border-top-width:0pt;border-right-width:0pt;border-left-color:#000000;vertical-align:top;border-right-color:#000000;border-left-width:0pt;border-top-style:solid;border-left-style:solid;border-bottom-width:1pt;width:33.6pt;border-top-color:#000000;border-bottom-style:solid}.c87{border-right-style:solid;padding:5pt 5pt 5pt 5pt;border-bottom-color:#000000;border-top-width:1pt;border-right-width:1pt;border-left-color:#000000;vertical-align:top;border-right-color:#000000;border-left-width:1pt;border-top-style:solid;border-left-style:solid;border-bottom-width:1pt;width:67.5pt;border-top-color:#000000;border-bottom-style:solid}.c157{border-right-style:solid;padding:3pt 3pt 3pt 3pt;border-bottom-color:#000000;border-top-width:1pt;border-right-width:1pt;border-left-color:#000000;vertical-align:middle;border-right-color:#000000;border-left-width:1pt;border-top-style:solid;border-left-style:solid;border-bottom-width:2.2pt;width:129pt;border-top-color:#000000;border-bottom-style:solid}.c52{border-right-style:solid;padding:5pt 5pt 5pt 5pt;border-bottom-color:#000000;border-top-width:1pt;border-right-width:1pt;border-left-color:#000000;vertical-align:top;border-right-color:#000000;border-left-width:1pt;border-top-style:solid;border-left-style:solid;border-bottom-width:1pt;width:58.5pt;border-top-color:#000000;border-bottom-style:solid}.c130{border-right-style:solid;padding:5pt 5pt 5pt 5pt;border-bottom-color:#000000;border-top-width:1pt;border-right-width:1pt;border-left-color:#000000;vertical-align:top;border-right-color:#000000;border-left-width:1pt;border-top-style:solid;border-left-style:solid;border-bottom-width:1pt;width:32.2pt;border-top-color:#000000;border-bottom-style:solid}.c179{border-right-style:solid;padding:5pt 5pt 5pt 5pt;border-bottom-color:#000000;border-top-width:1pt;border-right-width:1pt;border-left-color:#000000;vertical-align:top;border-right-color:#000000;border-left-width:1pt;border-top-style:solid;border-left-style:solid;border-bottom-width:1pt;width:62.2pt;border-top-color:#000000;border-bottom-style:solid}.c164{border-right-style:solid;padding:3pt 3pt 3pt 3pt;border-bottom-color:#000000;border-top-width:2.2pt;border-right-width:2.2pt;border-left-color:#000000;vertical-align:middle;border-right-color:#000000;border-left-width:1pt;border-top-style:solid;border-left-style:solid;border-bottom-width:1pt;width:129pt;border-top-color:#000000;border-bottom-style:solid}.c138{border-right-style:solid;padding:5pt 5pt 5pt 5pt;border-bottom-color:#000000;border-top-width:1pt;border-right-width:1pt;border-left-color:#000000;vertical-align:top;border-right-color:#000000;border-left-width:1pt;border-top-style:solid;border-left-style:solid;border-bottom-width:1pt;width:31.5pt;border-top-color:#000000;border-bottom-style:solid}.c63{border-right-style:solid;padding:0pt 2pt 0pt 2pt;border-bottom-color:#000000;border-top-width:1pt;border-right-width:1pt;border-left-color:#000000;vertical-align:top;border-right-color:#000000;border-left-width:1pt;border-top-style:solid;border-left-style:solid;border-bottom-width:1pt;width:31.4pt;border-top-color:#000000;border-bottom-style:solid}.c151{border-right-style:solid;padding:5pt 5pt 5pt 5pt;border-bottom-color:#000000;border-top-width:0pt;border-right-width:0pt;border-left-color:#000000;vertical-align:top;border-right-color:#000000;border-left-width:0pt;border-top-style:solid;border-left-style:solid;border-bottom-width:1pt;width:43.1pt;border-top-color:#000000;border-bottom-style:solid}.c45{border-right-style:solid;padding:5pt 5pt 5pt 5pt;border-bottom-color:#000000;border-top-width:1pt;border-right-width:1pt;border-left-color:#000000;vertical-align:top;border-right-color:#000000;border-left-width:1pt;border-top-style:solid;border-left-style:solid;border-bottom-width:1pt;width:75pt;border-top-color:#000000;border-bottom-style:solid}.c66{border-right-style:solid;padding:0pt 2pt 0pt 2pt;border-bottom-color:#000000;border-top-width:1pt;border-right-width:1pt;border-left-color:#000000;vertical-align:top;border-right-color:#000000;border-left-width:1pt;border-top-style:solid;border-left-style:solid;border-bottom-width:1pt;width:43.1pt;border-top-color:#000000;border-bottom-style:solid}.c163{border-right-style:solid;padding:3pt 3pt 3pt 3pt;border-bottom-color:#000000;border-top-width:1pt;border-right-width:1pt;border-left-color:#000000;vertical-align:middle;border-right-color:#000000;border-left-width:2.2pt;border-top-style:solid;border-left-style:solid;border-bottom-width:1pt;width:81pt;border-top-color:#000000;border-bottom-style:solid}.c136{border-right-style:solid;padding:5pt 5pt 5pt 5pt;border-bottom-color:#000000;border-top-width:0pt;border-right-width:1pt;border-left-color:#000000;vertical-align:top;border-right-color:#000000;border-left-width:0pt;border-top-style:solid;border-left-style:solid;border-bottom-width:1pt;width:31.4pt;border-top-color:#000000;border-bottom-style:solid}.c178{border-right-style:solid;padding:0pt 2pt 0pt 2pt;border-bottom-color:#000000;border-top-width:1pt;border-right-width:1pt;border-left-color:#000000;vertical-align:middle;border-right-color:#000000;border-left-width:1pt;border-top-style:solid;border-left-style:solid;border-bottom-width:1pt;width:468pt;border-top-color:#000000;border-bottom-style:solid}.c74{border-right-style:solid;padding:5pt 5pt 5pt 5pt;border-bottom-color:#000000;border-top-width:1pt;border-right-width:1pt;border-left-color:#000000;vertical-align:top;border-right-color:#000000;border-left-width:1pt;border-top-style:solid;border-left-style:solid;border-bottom-width:1pt;width:32.8pt;border-top-color:#000000;border-bottom-style:solid}.c118{border-right-style:solid;padding:5pt 5pt 5pt 5pt;border-bottom-color:#000000;border-top-width:1pt;border-right-width:1pt;border-left-color:#000000;vertical-align:top;border-right-color:#000000;border-left-width:1pt;border-top-style:solid;border-left-style:solid;border-bottom-width:1pt;width:37.5pt;border-top-color:#000000;border-bottom-style:solid}.c49{border-right-style:solid;padding:0pt 2pt 0pt 2pt;border-bottom-color:#000000;border-top-width:1pt;border-right-width:1pt;border-left-color:#000000;vertical-align:top;border-right-color:#000000;border-left-width:1pt;border-top-style:solid;border-left-style:solid;border-bottom-width:1pt;width:36.1pt;border-top-color:#000000;border-bottom-style:solid}.c46{border-right-style:solid;padding:0pt 2pt 0pt 2pt;border-bottom-color:#000000;border-top-width:1pt;border-right-width:1pt;border-left-color:#000000;vertical-align:top;border-right-color:#000000;border-left-width:1pt;border-top-style:solid;border-left-style:solid;border-bottom-width:1pt;width:58.1pt;border-top-color:#000000;border-bottom-style:solid}.c188{border-right-style:solid;padding:5pt 5pt 5pt 5pt;border-bottom-color:#000000;border-top-width:0pt;border-right-width:0pt;border-left-color:#000000;vertical-align:top;border-right-color:#000000;border-left-width:0pt;border-top-style:solid;border-left-style:solid;border-bottom-width:1pt;width:57pt;border-top-color:#000000;border-bottom-style:solid}.c37{border-right-style:solid;padding:5pt 5pt 5pt 5pt;border-bottom-color:#000000;border-top-width:1pt;border-right-width:1pt;border-left-color:#000000;vertical-align:top;border-right-color:#000000;border-left-width:1pt;border-top-style:solid;border-left-style:solid;border-bottom-width:1pt;width:72.8pt;border-top-color:#000000;border-bottom-style:solid}.c171{border-right-style:solid;padding:3pt 3pt 3pt 3pt;border-bottom-color:#000000;border-top-width:2.2pt;border-right-width:1pt;border-left-color:#000000;vertical-align:middle;border-right-color:#000000;border-left-width:2.2pt;border-top-style:solid;border-left-style:solid;border-bottom-width:1pt;width:81pt;border-top-color:#000000;border-bottom-style:solid}.c47{border-right-style:solid;padding:0pt 2pt 0pt 2pt;border-bottom-color:#000000;border-top-width:1pt;border-right-width:1pt;border-left-color:#000000;vertical-align:top;border-right-color:#000000;border-left-width:1pt;border-top-style:solid;border-left-style:solid;border-bottom-width:1pt;width:33.6pt;border-top-color:#000000;border-bottom-style:solid}.c91{border-right-style:solid;padding:5pt 5pt 5pt 5pt;border-bottom-color:#000000;border-top-width:1pt;border-right-width:1pt;border-left-color:#000000;vertical-align:top;border-right-color:#000000;border-left-width:1pt;border-top-style:solid;border-left-style:solid;border-bottom-width:1pt;width:33pt;border-top-color:#000000;border-bottom-style:solid}.c93{border-right-style:solid;padding:3pt 3pt 3pt 3pt;border-bottom-color:#000000;border-top-width:1pt;border-right-width:1pt;border-left-color:#000000;vertical-align:middle;border-right-color:#000000;border-left-width:1pt;border-top-style:solid;border-left-style:solid;border-bottom-width:2.2pt;width:102.8pt;border-top-color:#000000;border-bottom-style:solid}.c50{border-right-style:solid;padding:5pt 5pt 5pt 5pt;border-bottom-color:#000000;border-top-width:1pt;border-right-width:1pt;border-left-color:#000000;vertical-align:top;border-right-color:#000000;border-left-width:1pt;border-top-style:solid;border-left-style:solid;border-bottom-width:1pt;width:126pt;border-top-color:#000000;border-bottom-style:solid}.c3{border-right-style:solid;padding:5pt 5pt 5pt 5pt;border-bottom-color:#000000;border-top-width:1pt;border-right-width:1pt;border-left-color:#000000;vertical-align:top;border-right-color:#000000;border-left-width:1pt;border-top-style:solid;border-left-style:solid;border-bottom-width:1pt;width:58.8pt;border-top-color:#000000;border-bottom-style:solid}.c65{border-right-style:solid;padding:5pt 5pt 5pt 5pt;border-bottom-color:#000000;border-top-width:0pt;border-right-width:0pt;border-left-color:#000000;vertical-align:top;border-right-color:#000000;border-left-width:0pt;border-top-style:solid;border-left-style:solid;border-bottom-width:1pt;width:31.4pt;border-top-color:#000000;border-bottom-style:solid}.c134{border-right-style:solid;padding:5pt 5pt 5pt 5pt;border-bottom-color:#000000;border-top-width:0pt;border-right-width:0pt;border-left-color:#000000;vertical-align:top;border-right-color:#000000;border-left-width:0pt;border-top-style:solid;border-left-style:solid;border-bottom-width:1pt;width:36.1pt;border-top-color:#000000;border-bottom-style:solid}.c99{border-right-style:solid;padding:5pt 5pt 5pt 5pt;border-bottom-color:#000000;border-top-width:1pt;border-right-width:1pt;border-left-color:#000000;vertical-align:top;border-right-color:#000000;border-left-width:1pt;border-top-style:solid;border-left-style:solid;border-bottom-width:1pt;width:56.2pt;border-top-color:#000000;border-bottom-style:solid}.c109{border-right-style:solid;padding:5pt 5pt 5pt 5pt;border-bottom-color:#000000;border-top-width:1pt;border-right-width:1pt;border-left-color:#000000;vertical-align:top;border-right-color:#000000;border-left-width:1pt;border-top-style:solid;border-left-style:solid;border-bottom-width:1pt;width:35.2pt;border-top-color:#000000;border-bottom-style:solid}.c182{border-right-style:solid;padding:3pt 3pt 3pt 3pt;border-bottom-color:#000000;border-top-width:1pt;border-right-width:2.2pt;border-left-color:#000000;vertical-align:middle;border-right-color:#000000;border-left-width:1pt;border-top-style:solid;border-left-style:solid;border-bottom-width:1pt;width:129pt;border-top-color:#000000;border-bottom-style:solid}.c117{border-right-style:solid;padding:5pt 5pt 5pt 5pt;border-bottom-color:#000000;border-top-width:1pt;border-right-width:1pt;border-left-color:#000000;vertical-align:top;border-right-color:#000000;border-left-width:1pt;border-top-style:solid;border-left-style:solid;border-bottom-width:1pt;width:128.2pt;border-top-color:#000000;border-bottom-style:solid}.c159{border-right-style:solid;padding:5pt 5pt 5pt 5pt;border-bottom-color:#000000;border-top-width:1pt;border-right-width:1pt;border-left-color:#000000;vertical-align:top;border-right-color:#000000;border-left-width:1pt;border-top-style:solid;border-left-style:solid;border-bottom-width:1pt;width:110.2pt;border-top-color:#000000;border-bottom-style:solid}.c146{border-right-style:solid;padding:5pt 5pt 5pt 5pt;border-bottom-color:#000000;border-top-width:1pt;border-right-width:1pt;border-left-color:#000000;vertical-align:top;border-right-color:#000000;border-left-width:1pt;border-top-style:solid;border-left-style:solid;border-bottom-width:1pt;width:56.6pt;border-top-color:#000000;border-bottom-style:solid}.c189{border-right-style:solid;padding:3pt 3pt 3pt 3pt;border-bottom-color:#000000;border-top-width:2.2pt;border-right-width:1pt;border-left-color:#000000;vertical-align:middle;border-right-color:#000000;border-left-width:1pt;border-top-style:solid;border-left-style:solid;border-bottom-width:1pt;width:102.8pt;border-top-color:#000000;border-bottom-style:solid}.c69{border-right-style:solid;padding:5pt 5pt 5pt 5pt;border-bottom-color:#000000;border-top-width:1pt;border-right-width:1pt;border-left-color:#000000;vertical-align:top;border-right-color:#000000;border-left-width:1pt;border-top-style:solid;border-left-style:solid;border-bottom-width:1pt;width:42.8pt;border-top-color:#000000;border-bottom-style:solid}.c139{border-right-style:solid;padding:5pt 5pt 5pt 5pt;border-bottom-color:#000000;border-top-width:1pt;border-right-width:1pt;border-left-color:#000000;vertical-align:top;border-right-color:#000000;border-left-width:1pt;border-top-style:solid;border-left-style:solid;border-bottom-width:1pt;width:53.2pt;border-top-color:#000000;border-bottom-style:solid}.c183{border-right-style:solid;padding:3pt 3pt 3pt 3pt;border-bottom-color:#000000;border-top-width:1pt;border-right-width:1pt;border-left-color:#000000;vertical-align:middle;border-right-color:#000000;border-left-width:1pt;border-top-style:solid;border-left-style:solid;border-bottom-width:2.2pt;width:81pt;border-top-color:#000000;border-bottom-style:solid}.c29{border-right-style:solid;padding:0pt 2pt 0pt 2pt;border-bottom-color:#000000;border-top-width:1pt;border-right-width:1pt;border-left-color:#000000;vertical-align:top;border-right-color:#000000;border-left-width:1pt;border-top-style:solid;border-left-style:solid;border-bottom-width:1pt;width:57pt;border-top-color:#000000;border-bottom-style:solid}.c40{border-right-style:solid;padding:5pt 5pt 5pt 5pt;border-bottom-color:#000000;border-top-width:1pt;border-right-width:1pt;border-left-color:#000000;vertical-align:top;border-right-color:#000000;border-left-width:1pt;border-top-style:solid;border-left-style:solid;border-bottom-width:1pt;width:41.2pt;border-top-color:#000000;border-bottom-style:solid}.c44{border-right-style:solid;padding:5pt 5pt 5pt 5pt;border-bottom-color:#000000;border-top-width:1pt;border-right-width:1pt;border-left-color:#000000;vertical-align:top;border-right-color:#000000;border-left-width:1pt;border-top-style:solid;border-left-style:solid;border-bottom-width:1pt;width:141pt;border-top-color:#000000;border-bottom-style:solid}.c110{border-right-style:solid;padding:5pt 5pt 5pt 5pt;border-bottom-color:#000000;border-top-width:1pt;border-right-width:1pt;border-left-color:#000000;vertical-align:top;border-right-color:#000000;border-left-width:1pt;border-top-style:solid;border-left-style:solid;border-bottom-width:1pt;width:39.8pt;border-top-color:#000000;border-bottom-style:solid}.c75{padding-top:20pt;padding-bottom:6pt;line-height:1.15;page-break-after:avoid;orphans:2;widows:2;text-align:left;height:20pt}.c116{margin-left:72pt;padding-top:12pt;padding-left:0pt;padding-bottom:12pt;line-height:1.1500000000000001;orphans:2;widows:2;text-align:left}.c15{margin-left:36pt;padding-top:12pt;padding-left:0pt;padding-bottom:12pt;line-height:1.1500000000000001;orphans:2;widows:2;text-align:left}.c59{margin-left:36pt;padding-top:10pt;padding-left:0pt;padding-bottom:0pt;line-height:1.15;orphans:2;widows:2;text-align:left}.c104{padding-top:20pt;padding-bottom:6pt;line-height:1.0;page-break-after:avoid;orphans:2;widows:2;text-align:left;height:20pt}.c72{padding-top:18pt;padding-bottom:6pt;line-height:1.15;page-break-after:avoid;orphans:2;widows:2;text-align:left}.c89{padding-top:12pt;padding-bottom:4pt;line-height:1.15;page-break-after:avoid;orphans:2;widows:2;text-align:left}.c0{color:#000000;font-weight:400;text-decoration:none;vertical-align:baseline;font-size:11pt;font-family:"Helvetica Neue";font-style:normal}.c84{padding-top:20pt;padding-bottom:6pt;line-height:1.15;page-break-after:avoid;orphans:2;widows:2;text-align:left}.c1{padding-top:0pt;padding-bottom:0pt;line-height:1.15;orphans:2;widows:2;text-align:left;height:11pt}.c121{margin-left:90pt;padding-top:3pt;padding-bottom:0pt;line-height:1.0;orphans:2;widows:2;text-align:left}.c58{padding-top:16pt;padding-bottom:4pt;line-height:1.15;page-break-after:avoid;orphans:2;widows:2;text-align:left}.c54{padding-top:14pt;padding-bottom:4pt;line-height:1.15;page-break-after:avoid;orphans:2;widows:2;text-align:left}.c24{margin-left:36pt;padding-top:3pt;padding-bottom:0pt;line-height:1.0;orphans:2;widows:2;text-align:left}.c4{color:#000000;font-weight:700;text-decoration:none;vertical-align:baseline;font-size:14pt;font-family:"Helvetica Neue";font-style:normal}.c6{color:#000000;font-weight:400;text-decoration:none;vertical-align:baseline;font-size:8pt;font-family:"Helvetica Neue";font-style:normal}.c113{margin-left:72pt;padding-top:3pt;padding-bottom:0pt;line-height:1.0;orphans:2;widows:2;text-align:left}.c105{margin-left:54pt;padding-top:3pt;padding-bottom:0pt;line-height:1.0;orphans:2;widows:2;text-align:left}.c64{margin-left:18pt;padding-top:3pt;padding-bottom:0pt;line-height:1.0;orphans:2;widows:2;text-align:left}.c126{padding-top:12pt;padding-bottom:4pt;line-height:1.0;orphans:2;widows:2;text-align:left}.c166{padding-top:14pt;padding-bottom:4pt;line-height:1.0;orphans:2;widows:2;text-align:left}.c106{padding-top:11pt;padding-bottom:7pt;line-height:1.16;orphans:2;widows:2;text-align:left}.c168{padding-top:12pt;padding-bottom:12pt;line-height:1.1500000000000001;orphans:2;widows:2;text-align:left}.c53{padding-top:0pt;padding-bottom:12pt;line-height:1.0;orphans:2;widows:2;text-align:left}.c11{padding-top:12pt;padding-bottom:12pt;line-height:1.15;orphans:2;widows:2;text-align:center}.c68{color:#666666;font-weight:400;text-decoration:none;font-size:12pt;font-family:"Arial";font-style:normal}.c23{margin-left:13.2pt;padding-top:0pt;text-indent:-13.2pt;padding-bottom:0pt;line-height:2.0;text-align:left}.c28{color:#666666;font-weight:400;text-decoration:none;font-size:11pt;font-family:"Arial";font-style:normal}.c83{padding-top:0pt;padding-bottom:0pt;line-height:1.15;orphans:2;widows:2;text-align:center}.c14{color:#000000;font-weight:400;text-decoration:none;font-size:14pt;font-family:"Helvetica Neue";font-style:normal}.c177{padding-top:4pt;padding-bottom:0pt;line-height:1.0;orphans:2;widows:2;text-align:left}.c18{color:#000000;font-weight:400;text-decoration:none;font-size:7pt;font-family:"Arial";font-style:normal}.c153{padding-top:0pt;padding-bottom:0pt;line-height:1.6;orphans:2;widows:2;text-align:left}.c131{padding-top:18pt;padding-bottom:6pt;line-height:1.0;orphans:2;widows:2;text-align:left}.c94{color:#000000;font-weight:400;text-decoration:none;font-size:16pt;font-family:"Arial";font-style:normal}.c175{padding-top:18pt;padding-bottom:4pt;line-height:1.15;orphans:2;widows:2;text-align:left}.c115{padding-top:20pt;padding-bottom:6pt;line-height:1.0;orphans:2;widows:2;text-align:left}.c155{padding-top:0pt;padding-bottom:16pt;line-height:1.15;orphans:2;widows:2;text-align:left}.c81{padding-top:16pt;padding-bottom:4pt;line-height:1.15;orphans:2;widows:2;text-align:left}.c21{color:#000000;font-weight:400;text-decoration:none;font-size:8pt;font-family:"Arial";font-style:normal}.c80{padding-top:17pt;padding-bottom:11pt;line-height:1.16;orphans:2;widows:2;text-align:left}.c132{padding-top:0pt;padding-bottom:3pt;line-height:1.0;orphans:2;widows:2;text-align:left}.c34{color:#434343;font-weight:400;text-decoration:none;font-size:14pt;font-family:"Arial";font-style:normal}.c71{color:#000000;font-weight:400;text-decoration:none;font-size:10pt;font-family:"Arial";font-style:normal}.c76{padding-top:10pt;padding-bottom:0pt;line-height:1.0;orphans:2;widows:2;text-align:left}.c20{color:#000000;font-weight:400;text-decoration:none;font-size:11pt;font-family:"Arial";font-style:normal}.c7{padding-top:0pt;padding-bottom:0pt;line-height:1.15;orphans:2;widows:2;text-align:left}.c43{padding-top:12pt;padding-bottom:12pt;line-height:1.15;orphans:2;widows:2;text-align:left}.c172{padding-top:10pt;padding-bottom:4pt;line-height:1.0;orphans:2;widows:2;text-align:left}.c33{color:#000000;font-weight:400;text-decoration:none;font-size:20pt;font-family:"Arial";font-style:normal}.c103{padding-top:14pt;padding-bottom:4pt;line-height:1.15;orphans:2;widows:2;text-align:left}.c17{padding-top:0pt;padding-bottom:0pt;line-height:1.0;orphans:2;widows:2;text-align:left}.c51{color:#000000;font-weight:400;text-decoration:none;font-size:12pt;font-family:"Times";font-style:normal}.c124{padding-top:0pt;padding-bottom:0pt;line-height:1.1500000000000001;orphans:2;widows:2;text-align:left}.c30{padding-top:0pt;padding-bottom:0pt;line-height:1.15;orphans:2;widows:2;text-align:right}.c112{padding-top:16pt;padding-bottom:4pt;line-height:1.0;orphans:2;widows:2;text-align:left}.c13{color:#000000;font-weight:400;text-decoration:none;font-size:9pt;font-family:"Arial";font-style:normal}.c95{color:#434343;text-decoration:none;font-size:14pt;font-family:"Arial";font-style:normal}.c154{background-color:#fafafa;color:#333333;font-weight:400;font-size:15pt;font-family:"Times New Roman"}.c114{color:#404040;text-decoration:none;font-size:14.5pt;font-style:normal}.c119{padding-top:0pt;padding-bottom:0pt;line-height:1.15;text-align:left}.c97{text-decoration-skip-ink:none;-webkit-text-decoration-skip:none;color:#1155cc;text-decoration:underline}.c128{color:#666666;font-size:12pt;font-family:"Arial";font-style:normal}.c26{padding-top:0pt;padding-bottom:0pt;line-height:1.0;text-align:left}.c10{background-color:#ffffff;font-family:"Helvetica Neue";color:#1a1a1a;font-weight:400}.c67{color:#1d1c1d;text-decoration:none;font-size:11.5pt;font-style:normal}.c127{border-spacing:0;border-collapse:collapse;margin-right:auto}.c86{color:#000000;text-decoration:none;font-size:12pt;font-style:normal}.c19{vertical-align:super;font-family:"Helvetica Neue";font-weight:400}.c152{font-weight:400;font-size:13.5pt;font-family:"Times"}.c88{font-size:10.5pt;font-family:"Roboto";font-weight:400}.c9{background-color:#d9ead3;font-family:"Helvetica Neue";font-weight:400}.c79{text-decoration:none;font-size:11pt;font-style:normal}.c100{color:#000000;text-decoration:none;font-style:normal}.c92{font-size:11.5pt;color:#1d1c1d}.c123{color:#000000;font-size:11pt}.c31{padding:0;margin:0}.c122{margin-left:72pt;padding-left:0pt}.c140{font-weight:400;font-family:"Arial"}.c2{color:inherit;text-decoration:inherit}.c111{font-size:17pt;font-family:"Arial"}.c192{width:33%;height:1px}.c36{font-weight:400;font-family:"Helvetica Neue"}.c48{border:1px solid black;margin:5px}.c160{color:#434343;font-size:14pt}.c96{margin-left:27pt;padding-left:-9pt}.c165{max-width:468pt;padding:72pt 72pt 72pt 72pt}.c38{font-family:"Helvetica Neue";font-weight:700}.c167{font-weight:400;font-family:"Spectral"}.c102{font-size:11pt;font-style:normal}.c82{margin-left:36pt;padding-left:0pt}.c156{height:20.2pt}.c141{color:#000000}.c90{height:12pt}.c187{height:16pt}.c184{color:#cc2936}.c57{height:19.5pt}.c149{height:27pt}.c169{height:79.5pt}.c39{font-weight:700}.c42{font-size:9pt}.c145{font-size:11pt}.c41{vertical-align:super}.c62{background-color:#fff2cc}.c158{font-size:20pt}.c137{background-color:#f4cccc}.c12{vertical-align:baseline}.c186{font-size:15pt}.c148{color:#666666}.c108{height:22.4pt}.c70{background-color:#ffffff}.c78{height:16.8pt}.c129{margin-left:36pt}.c22{font-size:8pt}.c120{height:31.5pt}.c144{background-color:#dddddd}.c162{height:34.5pt}.c32{height:11pt}.c5{background-color:#fce5cd}.c143{height:45.8pt}.c25{height:0pt}.c135{font-style:normal}.c73{font-size:10pt}.c161{color:#404040}.c133{font-size:10.5pt}.c191{font-size:26pt}.c125{text-decoration:none}.c98{height:27.8pt}.c170{font-size:7pt}.c85{background-color:#bdc0bf}.c27{background-color:#d9ead3}.c35{font-style:italic}.c181{height:44.2pt}.c150{font-size:16pt}.c107{page-break-after:avoid}.c185{vertical-align:sub}.c77{height:23.2pt}.c190{height:24.8pt}.c180{background-color:#ffff00}.c174{font-family:"Arial"}.title{padding-top:0pt;color:#000000;font-size:26pt;padding-bottom:3pt;font-family:"Arial";line-height:1.15;page-break-after:avoid;orphans:2;widows:2;text-align:left}.subtitle{padding-top:0pt;color:#666666;font-size:15pt;padding-bottom:16pt;font-family:"Arial";line-height:1.15;page-break-after:avoid;orphans:2;widows:2;text-align:left}li{color:#000000;font-size:11pt;font-family:"Arial"}p{margin:0;color:#000000;font-size:11pt;font-family:"Arial"}h1{padding-top:20pt;color:#000000;font-size:20pt;padding-bottom:6pt;font-family:"Arial";line-height:1.15;page-break-after:avoid;orphans:2;widows:2;text-align:left}h2{padding-top:18pt;color:#000000;font-size:16pt;padding-bottom:6pt;font-family:"Arial";line-height:1.15;page-break-after:avoid;orphans:2;widows:2;text-align:left}h3{padding-top:16pt;color:#434343;font-size:14pt;padding-bottom:4pt;font-family:"Arial";line-height:1.15;page-break-after:avoid;orphans:2;widows:2;text-align:left}h4{padding-top:14pt;color:#666666;font-size:12pt;padding-bottom:4pt;font-family:"Arial";line-height:1.15;page-break-after:avoid;orphans:2;widows:2;text-align:left}h5{padding-top:12pt;color:#666666;font-size:11pt;padding-bottom:4pt;font-family:"Arial";line-height:1.15;page-break-after:avoid;orphans:2;widows:2;text-align:left}h6{padding-top:12pt;color:#666666;font-size:11pt;padding-bottom:4pt;font-family:"Arial";line-height:1.15;page-break-after:avoid;font-style:italic;orphans:2;widows:2;text-align:left}</style></head><body class="c70 c165 doc-content"><div><h1 class="c104" id="h.u5u0uydqa9t1"><span class="c33 c12"></span></h1><p class="c1"><span class="c33 c12"></span></p></div><h1 class="c84" id="h.wna4sjdcoewy"><span>A Technology Roadmap to Ubiquitous Clinical Sequencing</span></h1><p class="c107 c155 subtitle" id="h.u3a0qsdc5hd3"><span>Pathogen-agnostic sequencing of human samples</span><hr style="page-break-before:always;display:none;"></p><h1 class="c84" id="h.h8ioqblvmuxt"><span class="c33 c12">Contents</span></h1><p class="c119 c32"><span class="c20 c12"></span></p><p class="c177"><span class="c4"><a class="c2" href="#h.wna4sjdcoewy">A Technology Roadmap to Ubiquitous Clinical Sequencing</a></span><span class="c4">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c4"><a class="c2" href="#h.wna4sjdcoewy">1</a></span></p><p class="c76"><span class="c4"><a class="c2" href="#h.h8ioqblvmuxt">Contents</a></span><span class="c4">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c4"><a class="c2" href="#h.h8ioqblvmuxt">2</a></span></p><p class="c24"><span class="c14 c12"><a class="c2" href="#h.nf23mv1skohk">Background</a></span><span class="c14 c12">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c14 c12"><a class="c2" href="#h.nf23mv1skohk">7</a></span></p><p class="c24"><span class="c14 c12"><a class="c2" href="#h.b7ecarfyrv63">Outline of a point-of-care MGS platform</a></span><span class="c14 c12">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c14 c12"><a class="c2" href="#h.b7ecarfyrv63">8</a></span></p><p class="c76"><span class="c4"><a class="c2" href="#h.4mnpz8g9u130">Background</a></span><span class="c4">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c4"><a class="c2" href="#h.4mnpz8g9u130">9</a></span></p><p class="c64"><span class="c14 c12"><a class="c2" href="#h.30j0zll">Summary</a></span><span class="c14 c12">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c14 c12"><a class="c2" href="#h.30j0zll">9</a></span></p><p class="c64"><span class="c14 c12"><a class="c2" href="#h.1fob9te">Early detection and mass testing</a></span><span class="c14 c12">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c14 c12"><a class="c2" href="#h.1fob9te">10</a></span></p><p class="c24"><span class="c14 c12"><a class="c2" href="#h.3znysh7">Phase 1: Unknown and unmonitored - COVID-19</a></span><span class="c14 c12">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c14 c12"><a class="c2" href="#h.3znysh7">10</a></span></p><p class="c105"><span class="c14 c12"><a class="c2" href="#h.tyjcwt">Environmental monitoring</a></span><span class="c14 c12">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c14 c12"><a class="c2" href="#h.tyjcwt">11</a></span></p><p class="c105"><span class="c14 c12"><a class="c2" href="#h.3dy6vkm">Individual monitoring</a></span><span class="c14 c12">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c14 c12"><a class="c2" href="#h.3dy6vkm">11</a></span></p><p class="c24"><span class="c14 c12"><a class="c2" href="#h.1t3h5sf">Phases 2 &amp; 3: Known but unmonitored plus test development</a></span><span class="c14 c12">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c14 c12"><a class="c2" href="#h.1t3h5sf">12</a></span></p><p class="c64"><span class="c14 c12"><a class="c2" href="#h.2s8eyo1">Technical requirements and Bottlenecks in current approaches</a></span><span class="c14 c12">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c14 c12"><a class="c2" href="#h.2s8eyo1">13</a></span></p><p class="c24"><span class="c14 c12"><a class="c2" href="#h.dw4n2yi4n9c1">Cost</a></span><span class="c14 c12">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c14 c12"><a class="c2" href="#h.dw4n2yi4n9c1">14</a></span></p><p class="c24"><span class="c14 c12"><a class="c2" href="#h.pvkbd3mpbn12">Automation</a></span><span class="c14 c12">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c14 c12"><a class="c2" href="#h.pvkbd3mpbn12">15</a></span></p><p class="c24"><span class="c14 c12"><a class="c2" href="#h.jlumzuodtayd">Time to Answer</a></span><span class="c14 c12">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c14 c12"><a class="c2" href="#h.jlumzuodtayd">15</a></span></p><p class="c76"><span class="c4"><a class="c2" href="#h.3rdcrjn">Understanding the Sample</a></span><span class="c4">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c4"><a class="c2" href="#h.3rdcrjn">17</a></span></p><p class="c24"><span class="c14 c12"><a class="c2" href="#h.26in1rg">Summary</a></span><span class="c14 c12">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c14 c12"><a class="c2" href="#h.26in1rg">17</a></span></p><p class="c24"><span class="c14 c12"><a class="c2" href="#h.lnxbz9">Understanding COVID-19 Metagenomic samples</a></span><span class="c14 c12">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c14 c12"><a class="c2" href="#h.lnxbz9">18</a></span></p><p class="c24"><span class="c14 c12"><a class="c2" href="#h.fbcc5gkzr38j">Other Respiratory Viruses</a></span><span class="c14 c12">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c14 c12"><a class="c2" href="#h.fbcc5gkzr38j">18</a></span></p><p class="c24"><span class="c14 c12"><a class="c2" href="#h.c2urvf92wx9">Bacterial Pathogens</a></span><span class="c14 c12">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c14 c12"><a class="c2" href="#h.c2urvf92wx9">18</a></span></p><p class="c76"><span class="c4"><a class="c2" href="#h.z337ya">Building Hypothesis-free Pathogen Diagnostic Platforms</a></span><span class="c4">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c4"><a class="c2" href="#h.z337ya">19</a></span></p><p class="c76"><span class="c4"><a class="c2" href="#h.m6p2op3667yp">Sensitivity</a></span><span class="c4">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c4"><a class="c2" href="#h.m6p2op3667yp">21</a></span></p><p class="c64"><span class="c14 c12"><a class="c2" href="#h.2j2fgo3598d6">Sensitivity - qPCR and Sequencing</a></span><span class="c14 c12">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c14 c12"><a class="c2" href="#h.2j2fgo3598d6">21</a></span></p><p class="c64"><span class="c14 c12"><a class="c2" href="#h.jyil4u9jz0an">Metagenomic Sequencing Studies</a></span><span class="c14 c12">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c14 c12"><a class="c2" href="#h.jyil4u9jz0an">22</a></span></p><p class="c64"><span class="c14 c12"><a class="c2" href="#h.6ij61c715nd3">Contrasting qPCR and Sequencing</a></span><span class="c14 c12">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c14 c12"><a class="c2" href="#h.6ij61c715nd3">23</a></span></p><p class="c64"><span class="c14 c12"><a class="c2" href="#h.a3hi7bn2k67j">Modeling qPCR and Sequencing</a></span><span class="c14 c12">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c14 c12"><a class="c2" href="#h.a3hi7bn2k67j">23</a></span></p><p class="c76"><span class="c4"><a class="c2" href="#h.4i7ojhp">Sequencing Platforms</a></span><span class="c4">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c4"><a class="c2" href="#h.4i7ojhp">26</a></span></p><p class="c24"><span class="c14 c12"><a class="c2" href="#h.2xcytpi">Summary</a></span><span class="c14 c12">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c14 c12"><a class="c2" href="#h.2xcytpi">26</a></span></p><p class="c24"><span class="c14 c12"><a class="c2" href="#h.vqy5imk3t5js">Sequencing Landscape</a></span><span class="c14 c12">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c14 c12"><a class="c2" href="#h.vqy5imk3t5js">27</a></span></p><p class="c24"><span class="c14 c12"><a class="c2" href="#h.48osl2vi805o">Evolution of Existing Approaches</a></span><span class="c14 c12">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c14 c12"><a class="c2" href="#h.48osl2vi805o">29</a></span></p><p class="c105"><span class="c14 c12"><a class="c2" href="#h.nkjw7id33m7j">Colony based approaches</a></span><span class="c14 c12">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c14 c12"><a class="c2" href="#h.nkjw7id33m7j">29</a></span></p><p class="c105"><span class="c14 c12"><a class="c2" href="#h.a21yf5ffxp3z">Nanopore</a></span><span class="c14 c12">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c14 c12"><a class="c2" href="#h.a21yf5ffxp3z">30</a></span></p><p class="c105"><span class="c14 c12"><a class="c2" href="#h.i5bi7qtj282c">Single Molecule Optical</a></span><span class="c14 c12">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c14 c12"><a class="c2" href="#h.i5bi7qtj282c">31</a></span></p><p class="c24"><span class="c14 c12"><a class="c2" href="#h.mhazs4ebatd7">Blue-sky Technologies</a></span><span class="c14 c12">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c14 c12"><a class="c2" href="#h.mhazs4ebatd7">32</a></span></p><p class="c76"><span class="c4"><a class="c2" href="#h.c4gvr3cqcif8">Sample Acquisition and Preparation</a></span><span class="c4">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c4"><a class="c2" href="#h.c4gvr3cqcif8">34</a></span></p><p class="c64"><span class="c14 c12"><a class="c2" href="#h.ck96969578cz">Sample Acquisition</a></span><span class="c14 c12">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c14 c12"><a class="c2" href="#h.ck96969578cz">34</a></span></p><p class="c64"><span class="c14 c12"><a class="c2" href="#h.ftgjkg2hl1gc">Sample and Library Preparation</a></span><span class="c14 c12">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c14 c12"><a class="c2" href="#h.ftgjkg2hl1gc">34</a></span></p><p class="c24"><span class="c14 c12"><a class="c2" href="#h.787zd2hrxkar">Sample Preparation</a></span><span class="c14 c12">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c14 c12"><a class="c2" href="#h.787zd2hrxkar">35</a></span></p><p class="c24"><span class="c14 c12"><a class="c2" href="#h.q01mqmuai2bd">Library Preparation</a></span><span class="c14 c12">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c14 c12"><a class="c2" href="#h.q01mqmuai2bd">35</a></span></p><p class="c105"><span class="c14 c12"><a class="c2" href="#h.e5e4ydv9cwzz">High Complexity - Pacific Biosciences, MGI</a></span><span class="c14 c12">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c14 c12"><a class="c2" href="#h.e5e4ydv9cwzz">35</a></span></p><p class="c105"><span class="c14 c12"><a class="c2" href="#h.mu9zypp4pqod">Medium Complexity - Illumina, Ion Torrent, Oxford Nanopore</a></span><span class="c14 c12">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c14 c12"><a class="c2" href="#h.mu9zypp4pqod">35</a></span></p><p class="c105"><span class="c14 c12"><a class="c2" href="#h.vjb9d57vewon">Low Complexity - Helicos, Pacific Biosciences, Direct RNA</a></span><span class="c14 c12">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c14 c12"><a class="c2" href="#h.vjb9d57vewon">36</a></span></p><p class="c105"><span class="c14 c12"><a class="c2" href="#h.w0we1mwshrae">Library Preparation - Integrated Approaches</a></span><span class="c14 c12">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c14 c12"><a class="c2" href="#h.w0we1mwshrae">36</a></span></p><p class="c105"><span class="c14 c12"><a class="c2" href="#h.3ovb6015dq">Pre-sequencing Steps (Cluster and Colony Generation) - Platform Preparation</a></span><span class="c14 c12">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c14 c12"><a class="c2" href="#h.3ovb6015dq">37</a></span></p><p class="c24"><span class="c14 c12"><a class="c2" href="#h.6b54u5a0ik5">Selection</a></span><span class="c14 c12">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c14 c12"><a class="c2" href="#h.6b54u5a0ik5">37</a></span></p><p class="c24"><span class="c14 c12"><a class="c2" href="#h.4rh7z0hdaov8">Solutions - Automated and Integrated</a></span><span class="c14 c12">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c14 c12"><a class="c2" href="#h.4rh7z0hdaov8">38</a></span></p><p class="c105"><span class="c14 c12"><a class="c2" href="#h.mhw6jbi6d4ll">Current Solutions</a></span><span class="c14 c12">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c14 c12"><a class="c2" href="#h.mhw6jbi6d4ll">38</a></span></p><p class="c105"><span class="c14 c12"><a class="c2" href="#h.4lv1thp6g2sz">New Solutions</a></span><span class="c14 c12">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c14 c12"><a class="c2" href="#h.4lv1thp6g2sz">38</a></span></p><p class="c76"><span class="c4"><a class="c2" href="#h.fodn8mjl6y7m">Conclusions and Recommendations</a></span><span class="c4">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c4"><a class="c2" href="#h.fodn8mjl6y7m">41</a></span></p><p class="c64"><span class="c14 c12"><a class="c2" href="#h.rrtp42o71bdm">A Roadmap</a></span><span class="c14 c12">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c14 c12"><a class="c2" href="#h.rrtp42o71bdm">41</a></span></p><p class="c24"><span class="c14 c12"><a class="c2" href="#h.1ldo51emz09q">Where are we?</a></span><span class="c14 c12">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c14 c12"><a class="c2" href="#h.1ldo51emz09q">41</a></span></p><p class="c24"><span class="c14 c12"><a class="c2" href="#h.tc0c8v6jtuu1">Where are we going?</a></span><span class="c14 c12">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c14 c12"><a class="c2" href="#h.tc0c8v6jtuu1">41</a></span></p><p class="c24"><span class="c14 c12"><a class="c2" href="#h.fvp1k5i774e2">How do we get there?</a></span><span class="c14 c12">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c14 c12"><a class="c2" href="#h.fvp1k5i774e2">41</a></span></p><p class="c105"><span class="c14 c12"><a class="c2" href="#h.gnpy4l3hza6">Phase 0 - Building a better understanding</a></span><span class="c14 c12">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c14 c12"><a class="c2" href="#h.gnpy4l3hza6">42</a></span></p><p class="c105"><span class="c14 c12"><a class="c2" href="#h.wcsbr9mmj4oc">Phase 1 - Development of Novel Sample Preparation Tools For Use With Existing Sequencers</a></span><span class="c14 c12">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c14 c12"><a class="c2" href="#h.wcsbr9mmj4oc">43</a></span></p><p class="c105"><span class="c14 c12"><a class="c2" href="#h.vvccaruisbmk">Phase 2 - Development of Novel Sequencing Instrumentation</a></span><span class="c14 c12">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c14 c12"><a class="c2" href="#h.vvccaruisbmk">43</a></span></p><p class="c113"><span class="c14 c12"><a class="c2" href="#h.70c09eug8ye8">$1 to $10 - Low Technical Risk</a></span><span class="c14 c12">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c14 c12"><a class="c2" href="#h.70c09eug8ye8">44</a></span></p><p class="c113"><span class="c14 c12"><a class="c2" href="#h.p6dtnewwemij">$1 to $10 - High Technical Risk</a></span><span class="c14 c12">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c14 c12"><a class="c2" href="#h.p6dtnewwemij">45</a></span></p><p class="c113"><span class="c14 c12"><a class="c2" href="#h.60su3oqp9rhf">$1 to $10 - Very High Technical Risk</a></span><span class="c14 c12">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c14 c12"><a class="c2" href="#h.60su3oqp9rhf">45</a></span></p><p class="c113"><span class="c14 c12"><a class="c2" href="#h.s3moraed02h6">$50 to $100</a></span><span class="c14 c12">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c14 c12"><a class="c2" href="#h.s3moraed02h6">46</a></span></p><p class="c121"><span class="c14 c12"><a class="c2" href="#h.z7fpuvd3dbc7">Illumina-style SBS</a></span><span class="c14 c12">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c14 c12"><a class="c2" href="#h.z7fpuvd3dbc7">46</a></span></p><p class="c121"><span class="c14 c12"><a class="c2" href="#h.5oqubcmc212l">Nanopore</a></span><span class="c14 c12">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c14 c12"><a class="c2" href="#h.5oqubcmc212l">47</a></span></p><p class="c105"><span class="c14 c12"><a class="c2" href="#h.bwkztcjrhr0a">Phase 3 - Integration</a></span><span class="c14 c12">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c14 c12"><a class="c2" href="#h.bwkztcjrhr0a">47</a></span></p><p class="c64"><span class="c14 c12"><a class="c2" href="#h.lfk66pann063">Conclusion</a></span><span class="c14 c12">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c14 c12"><a class="c2" href="#h.lfk66pann063">48</a></span></p><p class="c76"><span class="c4"><a class="c2" href="#h.2x8k73bad8k2">Appendix A - Platform Requirements</a></span><span class="c4">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c4"><a class="c2" href="#h.2x8k73bad8k2">49</a></span></p><p class="c76"><span class="c4"><a class="c2" href="#h.z7yod4pc4rr">Appendix B - Ontology of Sequencing Approaches</a></span><span class="c4">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c4"><a class="c2" href="#h.z7yod4pc4rr">50</a></span></p><p class="c64"><span class="c14 c12"><a class="c2" href="#h.mfrsqmeci3jy">Single Molecule versus Ensemble</a></span><span class="c14 c12">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c14 c12"><a class="c2" href="#h.mfrsqmeci3jy">50</a></span></p><p class="c64"><span class="c14 c12"><a class="c2" href="#h.bvuwefny2o5h">Cluster/Colony Approaches</a></span><span class="c14 c12">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c14 c12"><a class="c2" href="#h.bvuwefny2o5h">51</a></span></p><p class="c24"><span class="c14 c12"><a class="c2" href="#h.4xpz5kje2fpk">Surface Amplification</a></span><span class="c14 c12">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c14 c12"><a class="c2" href="#h.4xpz5kje2fpk">51</a></span></p><p class="c24"><span class="c14 c12"><a class="c2" href="#h.pc4p5acwoajf">Sequencing-by-synthesis</a></span><span class="c14 c12">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c14 c12"><a class="c2" href="#h.pc4p5acwoajf">52</a></span></p><p class="c24"><span class="c14 c12"><a class="c2" href="#h.a3pklzwy7cxt">Other Colony/Cluster Approaches</a></span><span class="c14 c12">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c14 c12"><a class="c2" href="#h.a3pklzwy7cxt">53</a></span></p><p class="c24"><span class="c14 c12"><a class="c2" href="#h.13yw0x74v0dv">Summary and Further Thoughts</a></span><span class="c14 c12">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c14 c12"><a class="c2" href="#h.13yw0x74v0dv">54</a></span></p><p class="c64"><span class="c14 c12"><a class="c2" href="#h.c2gd49y0vam8">Single Molecule Approaches</a></span><span class="c14 c12">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c14 c12"><a class="c2" href="#h.c2gd49y0vam8">54</a></span></p><p class="c24"><span class="c12 c14"><a class="c2" href="#h.iw4fsljuy5of">Nanopore</a></span><span class="c14 c12">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c14 c12"><a class="c2" href="#h.iw4fsljuy5of">54</a></span></p><p class="c105"><span class="c14 c12"><a class="c2" href="#h.igbot3ypyq3n">Ionic Current Sensing using Biological Nanopores</a></span><span class="c14 c12">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c14 c12"><a class="c2" href="#h.igbot3ypyq3n">55</a></span></p><p class="c105"><span class="c14 c12"><a class="c2" href="#h.la6x6dxodr3q">Ionic Current Sensing using Solid-state Nanopores</a></span><span class="c14 c12">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c14 c12"><a class="c2" href="#h.la6x6dxodr3q">58</a></span></p><p class="c113"><span class="c14 c12"><a class="c2" href="#h.bbstr5jppxn0">Solid-state Nanopore, dimension requirements</a></span><span class="c14 c12">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c14 c12"><a class="c2" href="#h.bbstr5jppxn0">59</a></span></p><p class="c113"><span class="c14 c12"><a class="c2" href="#h.dpj54i53ny2f">Motion Control</a></span><span class="c14 c12">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c14 c12"><a class="c2" href="#h.dpj54i53ny2f">61</a></span></p><p class="c113"><span class="c14 c12"><a class="c2" href="#h.l6zx3iu0l7b4">Summary</a></span><span class="c14 c12">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c14 c12"><a class="c2" href="#h.l6zx3iu0l7b4">62</a></span></p><p class="c105"><span class="c14 c12"><a class="c2" href="#h.mflk6oq2wmoj">Tunneling Current Sensing</a></span><span class="c14 c12">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c14 c12"><a class="c2" href="#h.mflk6oq2wmoj">63</a></span></p><p class="c105"><span class="c14 c12"><a class="c2" href="#h.pyxzv2nvoaah">Back bone Conduction</a></span><span class="c14 c12">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c14 c12"><a class="c2" href="#h.pyxzv2nvoaah">63</a></span></p><p class="c105"><span class="c14 c12"><a class="c2" href="#h.q5arbxbbemt2">Optical Nanopore Sensing</a></span><span class="c14 c12">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c14 c12"><a class="c2" href="#h.q5arbxbbemt2">66</a></span></p><p class="c113"><span class="c14 c12"><a class="c2" href="#h.2uvwv0tb0b16">Potential Drawbacks</a></span><span class="c14 c12">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c14 c12"><a class="c2" href="#h.2uvwv0tb0b16">67</a></span></p><p class="c113"><span class="c14 c12"><a class="c2" href="#h.fgfmdeukw6aw">Advantages</a></span><span class="c14 c12">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c14 c12"><a class="c2" href="#h.fgfmdeukw6aw">68</a></span></p><p class="c113"><span class="c14 c12"><a class="c2" href="#h.cnt4328prvje">State of Development</a></span><span class="c14 c12">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c14 c12"><a class="c2" href="#h.cnt4328prvje">68</a></span></p><p class="c113"><span class="c14 c12"><a class="c2" href="#h.xsduwvkpni7z">Summary</a></span><span class="c14 c12">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c14 c12"><a class="c2" href="#h.xsduwvkpni7z">69</a></span></p><p class="c105"><span class="c14 c12"><a class="c2" href="#h.fmfrco1j7ald">FET Nanopores</a></span><span class="c14 c12">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c14 c12"><a class="c2" href="#h.fmfrco1j7ald">70</a></span></p><p class="c105"><span class="c14 c12"><a class="c2" href="#h.8oom81iredpd">Summary</a></span><span class="c14 c12">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c14 c12"><a class="c2" href="#h.8oom81iredpd">70</a></span></p><p class="c24"><span class="c14 c12"><a class="c2" href="#h.26zvcapt661d">Optical - Sequencing-by-Synthesis</a></span><span class="c14 c12">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c14 c12"><a class="c2" href="#h.26zvcapt661d">70</a></span></p><p class="c105"><span class="c14 c12"><a class="c2" href="#h.qgxz0pno0cfg">Real-time</a></span><span class="c14 c12">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c14 c12"><a class="c2" href="#h.qgxz0pno0cfg">70</a></span></p><p class="c105"><span class="c14 c12"><a class="c2" href="#h.ri62hc761p3n">Cyclic</a></span><span class="c14 c12">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c14 c12"><a class="c2" href="#h.ri62hc761p3n">73</a></span></p><p class="c24"><span class="c14 c12"><a class="c2" href="#h.u4r069r1u6wk">Other Single Molecule</a></span><span class="c14 c12">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c14 c12"><a class="c2" href="#h.u4r069r1u6wk">74</a></span></p><p class="c64"><span class="c14 c12"><a class="c2" href="#h.85at7ip1ysnj">Other Sequencing Companies and Approaches</a></span><span class="c14 c12">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c14 c12"><a class="c2" href="#h.85at7ip1ysnj">74</a></span></p><p class="c76"><span class="c4"><a class="c2" href="#h.oeifh5rta8qo">Appendix C - Global Sequencing Capacity</a></span><span class="c4">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c4"><a class="c2" href="#h.oeifh5rta8qo">75</a></span></p><p class="c76"><span class="c4"><a class="c2" href="#h.xqpcx9fauasn">Appendix D - Papers included in Metagenomic Sequencing Review</a></span><span class="c4">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c4"><a class="c2" href="#h.xqpcx9fauasn">78</a></span></p><p class="c76"><span class="c4"><a class="c2" href="#h.o9daiytw1vnk">Appendix E - Metagenomic Sequencing Literature Review</a></span><span class="c4">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c4"><a class="c2" href="#h.o9daiytw1vnk">81</a></span></p><p class="c64"><span class="c14 c12"><a class="c2" href="#h.pqu44e4zo4d">Sensitivity</a></span><span class="c14 c12">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c14 c12"><a class="c2" href="#h.pqu44e4zo4d">82</a></span></p><p class="c64"><span class="c14 c12"><a class="c2" href="#h.ukv84wvebv04">qPCR False Negatives</a></span><span class="c14 c12">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c14 c12"><a class="c2" href="#h.ukv84wvebv04">83</a></span></p><p class="c64"><span class="c14 c12"><a class="c2" href="#h.gk0sq5w66da5">Data availability</a></span><span class="c14 c12">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c14 c12"><a class="c2" href="#h.gk0sq5w66da5">83</a></span></p><p class="c76"><span class="c4"><a class="c2" href="#h.57blvqajq4y2">Appendix F - Viral Load Estimates</a></span><span class="c4">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c4"><a class="c2" href="#h.57blvqajq4y2">84</a></span></p><p class="c76"><span class="c4"><a class="c2" href="#h.iw3clw55vts">Appendix G - Sequencing Vendor Library Preparation Notes</a></span><span class="c4">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c4"><a class="c2" href="#h.iw3clw55vts">85</a></span></p><p class="c105"><span class="c14 c12"><a class="c2" href="#h.tmfcck7pnulm">Helicos - Direct RNA</a></span><span class="c14 c12">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c14 c12"><a class="c2" href="#h.tmfcck7pnulm">85</a></span></p><p class="c105"><span class="c14 c12"><a class="c2" href="#h.vn4cf8fcvsbw">Oxford Nanopore</a></span><span class="c14 c12">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c14 c12"><a class="c2" href="#h.vn4cf8fcvsbw">85</a></span></p><p class="c105"><span class="c14 c12"><a class="c2" href="#h.pecikmofxord">Illumina</a></span><span class="c14 c12">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c14 c12"><a class="c2" href="#h.pecikmofxord">85</a></span></p><p class="c105"><span class="c14 c12"><a class="c2" href="#h.82vkxijx2mvg">Ion Torrent</a></span><span class="c14 c12">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c14 c12"><a class="c2" href="#h.82vkxijx2mvg">85</a></span></p><p class="c105"><span class="c14 c12"><a class="c2" href="#h.9z22v79l425l">MGI</a></span><span class="c14 c12">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c14 c12"><a class="c2" href="#h.9z22v79l425l">86</a></span></p><p class="c105"><span class="c14 c12"><a class="c2" href="#h.jinoyyhnk5vd">Pacific Biosciences</a></span><span class="c14 c12">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c14 c12"><a class="c2" href="#h.jinoyyhnk5vd">86</a></span></p><p class="c76"><span class="c4"><a class="c2" href="#h.d98euvfdgdre">Appendix H - Amplification Issues for qPCR</a></span><span class="c4">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c4"><a class="c2" href="#h.d98euvfdgdre">86</a></span></p><p class="c24"><span class="c14 c12"><a class="c2" href="#h.5hmy89198ukk">Mutations</a></span><span class="c14 c12">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c14 c12"><a class="c2" href="#h.5hmy89198ukk">86</a></span></p><p class="c24"><span class="c14 c12"><a class="c2" href="#h.xqhginvi4lmg">Fragmentation - Handling</a></span><span class="c14 c12">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c14 c12"><a class="c2" href="#h.xqhginvi4lmg">87</a></span></p><p class="c24"><span class="c14 c12"><a class="c2" href="#h.ctd8tvpacg6f">Fragmentation - At Collection</a></span><span class="c14 c12">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c14 c12"><a class="c2" href="#h.ctd8tvpacg6f">87</a></span></p><p class="c24"><span class="c14 c12"><a class="c2" href="#h.w8mphloz7g69">Fragmentation - sgRNA</a></span><span class="c14 c12">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c14 c12"><a class="c2" href="#h.w8mphloz7g69">87</a></span></p><p class="c76"><span class="c4"><a class="c2" href="#h.sk9dbcetximj">References</a></span><span class="c4">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c4"><a class="c2" href="#h.sk9dbcetximj">89</a></span></p><p class="c32 c172"><span class="c14 c12"></span></p><hr style="page-break-before:always;display:none;"><p class="c17 c32"><span class="c0"></span></p><p class="c107 c132 title" id="h.e1p4jhf132en"><span>Report </span><span>Summary &nbsp; &nbsp;</span><span class="c100 c140 c12 c191">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</span></p><p class="c124" id="h.3znysh7"><span class="c123 c36 c12 c125 c35">This report discusses one route to limiting the impact of future pandemic-capable pathogens. This draft is provided to provoke discussion and we would welcome both positive and negative feedback. All comments are welcome!</span></p><p class="c124 c32" id="h.kwd1xcn3gy4v"><span class="c123 c36 c12 c35 c125"></span></p><h3 class="c107 c168" id="h.nf23mv1skohk"><span class="c95 c39 c12">Background</span></h3><ul class="c31 lst-kix_3qcga3w32puo-0 start"><li class="c15 li-bullet-0" id="h.b7ecarfyrv63"><span class="c36">The COVID-19 pandemic has shown that </span><span class="c38">current systems are ill-equipped to detect outbreaks of novel pathogens</span><span class="c0">&nbsp;before they evolve into pandemics.</span></li><li class="c15 li-bullet-0" id="h.ygsbgr1xxo7i"><span class="c36">There is a crucial unmet need for a layered system for early detection and response. An integral component of this system could be </span><span class="c38">pathogen-agnostic infectious disease diagnostics</span><span class="c0">.</span></li><li class="c15 li-bullet-0" id="h.w5cpk15p9rqv"><span class="c36">For years,</span><span class="c38">&nbsp;metagenomic sequencing (MGS) has</span><span class="c38">&nbsp;received widespread recognition for its pathogen-agnostic detection capabilities</span><span class="c0">. </span></li><li class="c15 li-bullet-0" id="h.w5cpk15p9rqv-1"><span class="c36">Metagenomic sequencing has the </span><span class="c38">proven ability to match or in some cases exceed the sensitivity and specificity of qPCR</span><span class="c0">, the current gold standard in pathogen diagnostics. </span></li><li class="c15 li-bullet-0" id="h.wcdnw86n7ekt"><span class="c36">However, despite its obvious advantages, MGS has failed to gain significant traction in </span><span class="c36">point of care settings,</span><span class="c36">&nbsp;primarily due to issues such as</span><span class="c36">&nbsp;high cost, slow time-to-result, the requirement for skilled labor, and a lack of cheap and portable platforms. </span></li><li class="c15 li-bullet-0" id="h.33xm5h1yrttc"><span class="c36">To achieve widespread adoption in a clinical setting, point-of-care MGS has provide </span><span class="c38">sensitivity and specificity similar to that of qPCR</span><span class="c36">&nbsp;(~Ct 35, &gt;99% ), </span><span class="c38">simple and fast (&lt;1hr) fully-integrated sample-to-answer</span><span class="c36">&nbsp;processing, in </span><span class="c38">cheap and deployable</span><span class="c36">&nbsp;portable sequencing platforms. &nbsp; </span></li><li class="c15 li-bullet-0" id="h.lrcxtpk1gkui"><span class="c36">We</span><span class="c38">&nbsp;</span><span class="c36">argue that metagenomic sequencing</span><span class="c36">&nbsp;and </span><span class="c36">supporting technologies</span><span class="c36">&nbsp;(sample preparation, bioinformatics, etc.) have reached a level of maturity where they</span><span class="c38">&nbsp;</span><span class="c36">can</span><span class="c36">, given wise development, achieve </span><span class="c38">widespread adoption in clinics</span><span class="c36">&nbsp;and integration into a layered early detection system, dramatically improving our capacity to detect and respond to novel outbreaks.</span></li><li class="c15 li-bullet-0" id="h.b7ecarfyrv63-2"><span class="c36">Although the </span><span class="c38">sequencing market </span><span class="c36">is thriving and seeing substantial investments in a wide range of platforms and supporting technologies, almost all of this activity is aimed at </span><span class="c38">use cases other than infectious disease detection</span><span class="c0">, such as human whole genome sequencing, cancer diagnostics, or primary research.</span></li><li class="c15 li-bullet-0" id="h.b7ecarfyrv63-3"><span class="c36">This suggests that the </span><span class="c38">low-hanging fruit </span><span class="c0">in developing instrumentation optimized for infectious disease detection has not yet been picked, and R&amp;D investments may yield substantial improvements.</span></li></ul><h3 class="c168 c107" id="h.b7ecarfyrv63-4"><span class="c39">Outline of a point-of-care MGS platform</span></h3><ul class="c31 lst-kix_4m75w8hvs20i-0 start"><li class="c15 li-bullet-0" id="h.b7ecarfyrv63-5"><span class="c36">We find that a device optimized for clinical settings would differ substantially from all sequencers currently available. In particular, </span><span class="c38">read-length and accuracy requirements are more modest than in traditional settings</span><span class="c36">, while pressures for </span><span class="c38">short runtime and easy integrated sample-to-answer</span><span class="c0">&nbsp;systems are substantially higher.</span></li><li class="c15 li-bullet-0" id="h.3uyhzr6mzeag"><span class="c0">We outline a single sample point-of-care MGS device, with fully-integrated sample processing and real-time bioinformatic analysis, that is capable of achieving widespread adoption, displacing qPCR, with the following characteristics:</span></li></ul><ul class="c31 lst-kix_4m75w8hvs20i-1 start"><li class="c116 li-bullet-0" id="h.b7ecarfyrv63-6"><span class="c0">Sensitivity and specificity competitive with qPCR.</span></li><li class="c116 li-bullet-0" id="h.b7ecarfyrv63-7"><span class="c36">Cost per </span><span class="c36">sample</span><sup><a href="#cmnt1" id="cmnt_ref1">[a]</a></sup><sup><a href="#cmnt2" id="cmnt_ref2">[b]</a></sup><span class="c0">&nbsp;$5-10.</span></li><li class="c116 li-bullet-0" id="h.b7ecarfyrv63-8"><span class="c0">Time to answer &lt;1 hour.</span></li></ul><ul class="c31 lst-kix_4m75w8hvs20i-0"><li class="c15 li-bullet-0" id="h.5xa3iprmct73"><span class="c36">Sequencing: single-molecule optical and nanopore sequencing technologies are capable of delivering the necessary </span><span class="c36">read-length, accuracy, throughput, and time requirements, and can also be </span><span class="c0">packaged in cheap deployable platforms (&lt;$1000). </span></li><li class="c15 li-bullet-0" id="h.3xfp8a2nhsvg"><span class="c0">Sample prep: leveraging similar sample preparation technologies that are driving the adoption of cheap point-of-care qPCR, pathogen-agnostic MGS can be implemented in cheap single-use point-of-care cartridges that can process clinical samples directly from collection without requiring skilled handling.</span></li><li class="c15 li-bullet-0" id="h.4qdttibf0nsn"><span class="c0">Data analysis: a number of companies have already developed automated bioinformatics pipelines applicable for a sample to answer platform (e.g., BugSeq and Pathogenomix) </span></li></ul><p class="c168" id="h.4qdttibf0nsn-9"><span class="c95 c39 c12">Findings</span></p><ul class="c31 lst-kix_57j7vjaq73pq-0 start"><li class="c15 li-bullet-0" id="h.ppqmd799urnq"><span class="c36">T</span><span class="c0">he lowest-hanging fruit lies in developing low-cost, easy-to-use sample preparation cartridges similar to those implemented in point-of-care qPCR systems.</span></li><li class="c15 li-bullet-0" id="h.fuwebw65g96a"><span class="c36">The most widespread sequencing platforms, based on </span><span class="c38">ensemble sequencing by synthesis</span><span class="c36">, are </span><span class="c38">unlikely to match</span><span class="c0">&nbsp;our cost, time-to-answer and performance goals.</span></li><li class="c15 li-bullet-0" id="h.fm8szrzih9rf"><span class="c0">Two candidate sequencing technologies that could meet our goals within the decade are:</span></li></ul><ul class="c31 lst-kix_57j7vjaq73pq-1 start"><li class="c116 li-bullet-0" id="h.b7ecarfyrv63-10"><span class="c0">Single-molecule optical sequencing</span></li><li class="c116 li-bullet-0" id="h.b7ecarfyrv63-11"><span class="c0">Cost-optimized biological nanopore sequencing</span></li></ul><ul class="c31 lst-kix_57j7vjaq73pq-0"><li class="c15 li-bullet-0" id="h.b7ecarfyrv63-12"><span class="c36">Other promising emerging sequencing technologies, such as solid-state nanopores, are unlikely to reach maturity by 2030.</span></li></ul><h1 class="c115 c107" id="h.4mnpz8g9u130"><span>Background</span><sup><a href="#cmnt3" id="cmnt_ref3">[c]</a></sup></h1><p class="c17 c32"><span class="c0"></span></p><p class="c17 c32"><span class="c0"></span></p><h2 class="c17 c107" id="h.30j0zll"><span class="c38">Summary</span></h2><p class="c17 c32"><span class="c0"></span></p><p class="c17"><span class="c36 c5">In this section we discuss the COVID-19 pandemic and build a framework for thinking about pandemics and pandemic response. There are several conclusions we can draw from this. Firstly, we can think of pandemics occurring in </span><span class="c36 c5">three phases</span><span class="c0 c5">:</span></p><p class="c17 c32"><span class="c0 c5"></span></p><p class="c17"><span class="c36 c5">Phase 1: Unknown and unmonitored<br>Phase 2: Known, but unmonitored.<br></span><span class="c0 c5">Phase 3: Pandemic response capability developed and deployed.</span></p><p class="c17 c32"><span class="c0 c5"></span></p><p class="c17"><span class="c0 c5">Secondly, while sequencing based diagnostics offer significant advantages over traditional approaches (e.g. qPCR), they have not gained traction during COVID-19 beyond use for tracking variants that give rise to new strains. There are two strong factors which have prevented adoption:</span></p><p class="c17 c32"><span class="c0 c5"></span></p><ul class="c31 lst-kix_9ps8jprlmeqd-1 start"><li class="c17 c96 li-bullet-1"><span class="c36 c5">Cost: qPCR costs ~$1 where</span><span class="c36 c5">&nbsp;</span><span class="c36 c5">sequencing costs $50 to $100 per sample/run.</span></li><li class="c17 c96 li-bullet-2"><span class="c0 c5">Market: the value of sequencing over qPCR is not well understood.</span></li></ul><p class="c17 c32"><span class="c0 c5"></span></p><p class="c17"><span class="c36 c5">Applying</span><span class="c36 c5">&nbsp;metagenomic sequencing</span><span class="c0 c5">&nbsp;in a pandemic preparedness program will face similar issues. The value to both the user and clinicians of metagenomic sequencing-based diagnostics needs to be made clear. The cost of such a diagnostic test needs to be low enough to allow it to be economically performed.</span></p><p class="c17 c32"><span class="c0 c5"></span></p><p class="c17"><span class="c0 c5">Our most likely route here is to provide a universal metagenomic sequencing-based diagnostic for respiratory (and other) conditions. In one such scenario, a symptomatic individual would visit a primary care physician to be evaluated. The physician could perform a metagenomic sequencing-based test to detect both known and unknown pathogens, which would provide a valuable diagnostic to guide care. For example, an anterior nasal swab test could determine if a patient had a viral, bacterial or fungal infection, determine the strain of pathogen, and ideally identify any anti-microbial resistance genes to guide treatment. Essentially this provides an enhanced full respiratory diagnostic panel for the cost of a Flu/RSV/COVID qPCR kit. </span></p><p class="c17 c32"><span class="c0 c5"></span></p><p class="c17"><span class="c36 c5">This is a clear value to both patients and clinicians and builds a more robust culture to detect and contain </span><span class="c36 c5">new viruses.</span><span class="c0 c5">&nbsp;And only by displacing qPCR as the first line diagnostic tool of choice, can we provide the robust pandemic preparedness technology we desire.</span></p><p class="c17 c32"><span class="c0 c5"></span></p><p class="c17"><span class="c0 c5">When unknown RNA or DNA is detected the information would be sent to a central (likely cloud-based) monitoring center. Providing a pandemic early warning system.</span></p><p class="c17 c32"><span class="c0 c5"></span></p><p class="c17"><span class="c36 c5">The most significant risk here is market and </span><span class="c36 c5">regulatory</span><span class="c0 c5">. But reports suggest there is demand from patients and clinicians.</span></p><p class="c17 c32"><span class="c0 c5"></span></p><p class="c17"><span class="c0 c5">The following sections will discuss the requirements of such a system.</span></p><p class="c17 c32"><span class="c0 c5"></span></p><h2 class="c17 c107" id="h.1fob9te"><span class="c100 c38 c12 c5 c150">Early detection and mass testing</span></h2><p class="c17 c32"><span class="c0 c5"></span></p><p class="c17"><span class="c36 c5">COVID-19 was the first worldwide pandemic to occur in modern times. And while we can draw some lessons from previous novel viral outbreaks (</span><span class="c36 c5">SARS, MERS, Ebola</span><span class="c0 c5">), we must principally look to COVID-19 when evaluating modern methods for pandemic response. </span></p><p class="c17 c32"><span class="c0 c5"></span></p><p class="c17"><span class="c0 c5">We can think of the global response to COVID-19 as occurring in 3 distinct phases. </span></p><p class="c17 c32"><span class="c0 c5"></span></p><p class="c17"><span class="c0 c5">Phase 1: Unknown and unmonitored<br>Phase 2: Known, but unmonitored.<br>Phase 3: Pandemic response capability developed and deployed. </span></p><p class="c32 c53"><span class="c12 c5 c51"></span></p><p class="c17"><span style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 642.51px; height: 127.88px;"><img alt="Group" src="images/image7.png" style="width: 642.51px; height: 127.88px; margin-left: 0.00px; margin-top: 0.00px; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px);" title=""></span></p><p class="c53 c32"><span class="c51 c12 c70"></span></p><h3 class="c17 c107" id="h.3znysh7-13"><span class="c27">Phase 1: Unknown and unmonitored - COVID-19 </span></h3><p class="c17 c32"><span class="c0 c27"></span></p><p class="c17"><span class="c9">In COVID-19 and prior viral outbreaks, it became clear that our methods for detecting a new viral outbreak are not up to the task. While the index case of SARS-CoV-2 has yet to be identified, it is clear that more than a month passed between the beginning of human-to-human transmission and its identification as the causative agent of respiratory disease cases in the Wuhan region</span><span class="c19 c27"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?OCagce&amp;sa=D&amp;source=editors&amp;ust=1679054519889474&amp;usg=AOvVaw2MmxWwUjhYhXMeytwo_Pew">1</a></span><span class="c0 c27">.</span></p><p class="c17 c32"><span class="c0 c27"></span></p><p class="c17"><span class="c9">Disease response centers monitor spikes in patients with novel symptoms, this monitoring relies largely on </span><span class="c9">self-reporting by </span><span class="c9">on the &ldquo;astute physician&rdquo; to notice unusual signs of an illness (a challenging task given the similarity of symptoms across a wide range of pathogens) and</span><span class="c9">&nbsp;on self-reporting by hospitals, with guidelines varying in countries across the world</span><span class="c19 c144"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?EzO1X2&amp;sa=D&amp;source=editors&amp;ust=1679054519890611&amp;usg=AOvVaw3BubUxty4V9bL3HxFNZA6n">1</a></span><span class="c9">.</span><span class="c19 c27">&nbsp;</span><span class="c0 c27">Therefore, we are likely to only notice an outbreak when a critical mass of infections has taken place. At this point of the exponential growth typically exhibited by pandemic-capable pathogens, an outbreak is substantially more difficult to contain than it is at earlier phases.</span></p><p class="c17 c32"><span class="c0"></span></p><p class="c17"><span class="c9">Once a suspected novel virus has been identified, it may be isolated and sequenced. In the case of SARS-CoV-2, </span><span class="c9">known viruses were first ruled out through antigen kits, then confirmed by qPCR</span><span class="c9">, prior to metagenomic sequencing which </span><span class="c9">identified a novel viral strain</span><span class="c9">.</span><span class="c19 c27"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?AQxYU8&amp;sa=D&amp;source=editors&amp;ust=1679054519891791&amp;usg=AOvVaw0PjLEH4AxhspzpraEeWTiE">2</a></span><span class="c0 c27">&nbsp;</span></p><p class="c17 c32"><span class="c0 c27"></span></p><p class="c17"><span class="c9">The availability of the viral genome is a critical milestone in pandemic response. Not only does it provide the foundation for the </span><span class="c9 c35">development of diagnostic </span><span class="c9 c35">kits</span><span class="c9">&nbsp;</span><span class="c9">(qPCR and other)</span><span class="c9">, but it also allows the first steps toward </span><span class="c9 c35">vaccine development</span><span class="c9">&nbsp;to begin. </span></p><p class="c17 c32"><span class="c0 c27"></span></p><p class="c17"><span class="c9">Our goal is to move from this slow, pathogen-targeted </span><span class="c9">status quo to a more rapid, pathogen- agnostic approach to outbreak detection and response.</span><span class="c9">&nbsp;</span><span class="c9">Two potentially complementary approaches have been proposed: </span><span class="c9 c35">environmental monitoring</span><span class="c9">&nbsp;and </span><span class="c9 c35">individual monitoring</span><span class="c9">.</span></p><h4 class="c54 c90" id="h.w9vcwht2arb4"><span class="c68 c12"></span></h4><h4 class="c54" id="h.tyjcwt"><span class="c27">Environmental monitoring </span></h4><p class="c17"><span class="c9">In an environmental monitoring approach, data is collected on pathogen genomic material shed into the environment. Example samples include wastewater or air filters at key locations. Pathogen-targeted environmental monitoring approaches have successfully been used during the </span><span class="c9">COVID-19 pandemic to </span><span class="c9">monitor variants circulating within a population</span><span class="c19 c27"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?WbaZB1&amp;sa=D&amp;source=editors&amp;ust=1679054519894637&amp;usg=AOvVaw3xOGETjz1yTW-3J020PbkQ">3</a></span><span class="c0 c27">. </span></p><p class="c17 c32"><span class="c0 c27"></span></p><p class="c17"><span class="c9">Metagenomics-based environmental monitoring approaches have the potential to perform pathogen-agnostic monitoring at the population level</span><span class="c19 c27"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?ivdYrO&amp;sa=D&amp;source=editors&amp;ust=1679054519895836&amp;usg=AOvVaw331uR80BYyTRpHiZ2IQLOP">4</a></span><span class="c0 c27">, but face distinct challenges in system sensitivity and cost. Additionally, they lack a commercial engine to drive their ubiquitous adoption. </span></p><p class="c17 c32"><span class="c0 c27"></span></p><p class="c17"><span class="c9">However, metagenomics-based environmental monitoring may eventually be worth the cost in a layered biodefense system (i.e. for detecting pathogens with a longer latency or subtle initial symptoms), especially if progress in high-throughput sequencing, sample preparation (e.g. depletion of known genomic material), and computational analysis is achieved in the coming years. These challenges are worthy of a separate roadmapping exercise. However, in this roadmap, we focus on an approach where we see a clearer path to pathogen-agnostic early outbreak detection within the coming 5-10 years, namely individual monitoring.</span></p><h4 class="c54" id="h.3dy6vkm"><span>Individual monitoring </span><sup><a href="#cmnt4" id="cmnt_ref4">[d]</a></sup></h4><p class="c17"><span class="c0 c5">In an individual monitoring approach, samples would be isolated from individuals for testing. This could be done either at the point of care or in a sentinel context. Below, we focus on the former.</span></p><p class="c17 c32"><span class="c0 c5"></span></p><p class="c17"><span class="c36 c5">In samples acquired from patients infected by SARS-CoV-2</span><span class="c36 c5">, the total RNA from nasopharyngeal samples contains viral</span><span class="c36 c5">&nbsp;</span><span class="c36 c5">RNA at up to 5% </span><span class="c36 c5">when ribosomal RNA (rRNA) is depleted</span><span class="c36 c5">.</span><span class="c19 c5"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?OU3DwX&amp;sa=D&amp;source=editors&amp;ust=1679054519897962&amp;usg=AOvVaw0lNX-3o1BldefXB19vg6f2">5</a></span><span class="c36 c5">&nbsp;At this level of abundance, direct sequencing of total RNA would almost certainly reveal the presence of a novel, SARS-CoV-2-like respiratory virus.</span><sup class="c36 c5"><a href="#ftnt1" id="ftnt_ref1">[1]</a></sup><span class="c0 c5">&nbsp;</span></p><p class="c17 c32"><span class="c0 c5"></span></p><p class="c17"><span class="c0 c5">In addition to this abundance of signals for pathogen detection, individuals showing symptoms (fever and or flu-like symptoms) may already be inclined to seek medical assistance. Reports suggest that patients increasingly want to receive a diagnosis rather than &ldquo;non-specific upper respiratory infection&rdquo;, the majority diagnosis in ambulatory care visits for respiratory issues.</span></p><p class="c17 c32"><span class="c0 c5"></span></p><p class="c17"><span class="c36 c5">For instance, </span><span class="c36 c5">Emily Volk</span><span class="c19 c5"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?qDxcPN&amp;sa=D&amp;source=editors&amp;ust=1679054519899408&amp;usg=AOvVaw0nIMouwazUlxkQOZ8d0FFF">6</a></span><span class="c36 c5">&nbsp;reports:</span></p><p class="c17 c32"><span class="c0 c5"></span></p><p class="c17 c129"><span class="c92 c36 c5 c35">&ldquo;Frankly, patient experience scores increase when patients leave our care and have a name for the thing that is bothering them even if there isn&rsquo;t a targeted antibiotic or antimicrobial that has been identified, that would work against the pathogen. It still is comforting to patients and their families to have a name for the illness that they have.&rdquo;</span></p><p class="c17 c32"><span class="c36 c12 c5 c67"></span></p><p class="c17"><span class="c36 c5 c92">Clinicians themselves are becoming more inclined to order broader panels. According to Emmanuel Andr&eacute;</span><span class="c19 c92 c5"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?DXh03H&amp;sa=D&amp;source=editors&amp;ust=1679054519900909&amp;usg=AOvVaw0jUSCyfIZOirDBbHx5hKn_">6</a></span><span class="c67 c36 c12 c5">:</span></p><p class="c17 c32"><span class="c67 c36 c12 c5"></span></p><p class="c17 c129"><span class="c92 c36 c5 c35">&ldquo;The single pathogenic approach will progressively disappear. Why? Because it&rsquo;s simply not efficient from a clinical perspective, from a lab perspective and care requires a more comprehensive approach. Where I think we&rsquo;re going is toward broader panels.&rdquo;</span></p><p class="c17 c32"><span class="c0 c5"></span></p><p class="c17"><span class="c0 c5">Metagenomic sequencing provides the broadest of all possible panels. As such, a metagenomic sequencing-based approach, if it can be as cheap as qPCR testing, may quickly gain widespread adoption even in the absence of planned pandemic prevention efforts.</span></p><p class="c17 c32"><span class="c0 c5"></span></p><p class="c17"><span class="c36 c5">A</span><span class="c0 c5">ny unknown pathogen sequence identified by these tests may be transmitted to pandemic monitoring centers, allowing novel human pathogen cases to be identified almost as soon as they occur.</span></p><p class="c17 c32"><span class="c86 c36 c12 c5"></span></p><h3 class="c17 c107" id="h.1t3h5sf"><span>Phases 2</span><span>&nbsp;&amp; 3: Known but unmonitored plus test development </span><sup><a href="#cmnt5" id="cmnt_ref5">[e]</a></sup></h3><p class="c17 c32"><span class="c86 c36 c12"></span></p><p class="c17"><span class="c0 c27">The SARS-CoV-2 genome was made publicly available in January 2020, more than two months after the first human transmission. For current diagnostic approaches, this is a significant issue. Each new virus requires a new test to be developed, approved, and deployed. When potentially hundreds of millions of tests are required, this is a huge logistical issue. </span></p><p class="c17 c32"><span class="c0 c27"></span></p><p class="c17"><span class="c9">In the case of COVID-19, </span><span class="c36 c62">it took more than 4 months for 1 million tests to be performed in the US and 9 months to deploy 100 million tests</span><span class="c19"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?s9uX3H&amp;sa=D&amp;source=editors&amp;ust=1679054519903462&amp;usg=AOvVaw0a9QfmqcQ5SVwk729SIrax">7</a></span><span class="c36 c62">.</span><span class="c0 c27">&nbsp;Logistical and regulatory issues, therefore, limit our ability to engage in &ldquo;track and trace&rdquo; operations allowing the pandemic to proceed largely unmonitored.</span></p><p class="c17 c32"><span class="c0 c27"></span></p><p class="c17"><span class="c0 c27">In order to remove the long ramp-up associated with kit deployment, we either need kits that can be more rapidly produced or that are pathogen-agnostic. The ability to stockpile tests without the need to predict the pathogen they will be used for is a distinct advantage.</span></p><p class="c17 c32"><span class="c0 c27"></span></p><p class="c17"><span class="c9">New approaches to DNA synthesis (enzymatic approaches) could potentially help ramp up and distribute the production of qPCR kits once a novel threat has been identified.</span></p><p class="c17 c32"><span class="c0 c27"></span></p><p class="c17"><span class="c0 c27">However, a more practical and versatile proposition is to design our diagnostic approach using the same techniques used to identify new viral outbreaks currently: metagenomic sequencing.</span></p><p class="c17 c32"><span class="c0 c27"></span></p><p class="c17"><span class="c9">In this approach, our diagnostic instruments are </span><span class="c9 c35">already </span><span class="c0 c27">deployed as part of our pandemic monitoring program and provide patients with valuable diagnostic information regarding their suspected infections, ideally building a culture where the majority of suspected respiratory infections receive a full metagenomic-based diagnostic test.</span></p><p class="c17 c32"><span class="c86 c36 c12"></span></p><h2 class="c17 c107" id="h.2s8eyo1"><span class="c94 c12 c27">Technical requirements and Bottlenecks in current approaches </span></h2><p class="c17 c32"><span class="c86 c9 c12"></span></p><p class="c17"><span style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 627.50px; height: 154.42px;"><img alt="Image" src="images/image9.png" style="width: 627.50px; height: 154.42px; margin-left: 0.00px; margin-top: 0.00px; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px);" title=""></span><span class="c0 c27">Our proposed future solution to pandemic monitoring is, therefore, to use metagenomic sequencing to address all phases of the pandemic. We will consider how such a system might be built using existing platforms, what the cost barriers to adoption are, and how we might address the deficiencies of these platforms. </span></p><hr style="page-break-before:always;display:none;"><p class="c17 c32"><span class="c0 c27"></span></p><p class="c17"><span class="c9">It is of note that a number of sequencing-based diagnostic approaches have been attempted during COVID-19. However, they have largely failed to gain </span><span class="c9">traction</span><span class="c9">&nbsp;and cumulatively represented &lt;1% of the testing used to detect and monitor COVID-19 infections</span><span class="c19 c27"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?mhRwMO&amp;sa=D&amp;source=editors&amp;ust=1679054519906561&amp;usg=AOvVaw0M6V-x50KjHobXgV_Pfcf6">8</a></span><span class="c0 c27">: </span></p><p class="c17 c32"><span class="c0 c27"></span></p><p class="c17"><span style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 222.50px; height: 217.77px;"><img alt="Group" src="images/image45.png" style="width: 222.50px; height: 217.77px; margin-left: 0.00px; margin-top: 0.00px; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px);" title=""></span></p><p class="c17"><span class="c0 c27">There are a number of reasons for this which we summarize in the table below:</span></p><p class="c17 c32"><span class="c0 c27"></span></p><a id="t.463b6f90492df98b76a9bd4a14c42aa07db6499d"></a><a id="t.0"></a><table class="c127"><tr class="c25"><td class="c56" colspan="1" rowspan="1"><p class="c26 c32"><span class="c0 c27"></span></p></td><td class="c159" colspan="1" rowspan="1"><p class="c26"><span class="c0 c27">qPCR</span></p></td><td class="c16" colspan="1" rowspan="1"><p class="c26"><span class="c0 c27">Metagenomic Sequencing</span></p></td></tr><tr class="c25"><td class="c56" colspan="1" rowspan="1"><p class="c26"><span class="c9">Cost-of-goods</span><span class="c0 c27">&nbsp;(COGs)</span></p></td><td class="c159" colspan="1" rowspan="1"><p class="c26"><span class="c0 c27">$1 to $5</span></p></td><td class="c16" colspan="1" rowspan="1"><p class="c26"><span class="c0 c27">$15 to $100</span></p></td></tr><tr class="c25"><td class="c56" colspan="1" rowspan="1"><p class="c26"><span class="c0 c27">Automation</span></p></td><td class="c159" colspan="1" rowspan="1"><p class="c26"><span class="c0 c27">Widely deployed</span></p></td><td class="c16" colspan="1" rowspan="1"><p class="c26"><span class="c0 c27">Limited</span></p></td></tr><tr class="c25"><td class="c56" colspan="1" rowspan="1"><p class="c26"><span class="c0 c27">Time to answer</span></p></td><td class="c159" colspan="1" rowspan="1"><p class="c26"><span class="c0 c27">&lt; 1 hour</span></p></td><td class="c16" colspan="1" rowspan="1"><p class="c26"><span class="c0 c27">Days to Weeks</span></p></td></tr></table><p class="c17 c32"><span class="c0 c27"></span></p><p class="c17"><span class="c0 c27">Unless these issues are addressed, metagenomic sequencing-based approaches are unlikely to gain widespread adoption.</span></p><p class="c17 c32"><span class="c36 c12 c86"></span></p><h3 class="c112 c107" id="h.dw4n2yi4n9c1"><span class="c27">Cos</span><span class="c34 c12 c27">t</span></h3><p class="c1"><span class="c20 c12 c27"></span></p><p class="c17"><span class="c9">Illumina&rsquo;s</span><span class="c9">&nbsp;(current market leader in sequencing) cheapest runs cost ~$300 to $500</span><span class="c19"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?NJMTcC&amp;sa=D&amp;source=editors&amp;ust=1679054519912931&amp;usg=AOvVaw2RZMXCnAhdvUKBeBkAc69t">9</a></span><span class="c36 c62">. </span><span class="c0 c27">As such, healthcare providers are unlikely to use these instruments for sequencing single samples. Batching and multiplexing multiple samples onto a single sequencing run can significantly reduce the cost per sample, but introduces a delay before sequencing can begin. The delay is dependent on the nature of the testing facility and the number of samples being received per day, but typically, this is on the order of a week. </span></p><p class="c17 c32"><span class="c0 c27"></span></p><p class="c17"><span class="c9">Other instruments (for example, Oxford Nanopore&rsquo;s Flongle) cost ~$100</span><span class="c19 c27"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?QpfDWf&amp;sa=D&amp;source=editors&amp;ust=1679054519914244&amp;usg=AOvVaw2HBCqZSUtQARhurbMHCg-8">10</a></span><span class="c0 c27">, which could enable fewer samples to be multiplexed, perhaps on a daily basis. </span></p><p class="c17 c32"><span class="c0 c27"></span></p><p class="c17"><span class="c0 c27">However, a delay of days to weeks is likely unacceptable in an infectious disease diagnostic context where we ideally want to provide results as rapidly as possible.</span></p><p class="c17 c32"><span class="c0 c27"></span></p><p class="c17"><span class="c9">Furthermore, and perhaps most problematically, multiplexing multiple samples onto a single chip significantly reduces the sensitivity of the test since the sequence coverage per sample reduces proportional to the number of samples.</span></p><p class="c17 c32"><span class="c0 c27"></span></p><p class="c17"><span class="c9">Therefore the high single-run cost for current instruments makes them a poor fit for diagnostic applications. This is the case even if we look at the COGS (Illumina $50 to $100s, Oxford Nanopore $50 to $450</span><span class="c9">&nbsp;based on stated margins</span><span class="c41 c144"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?uZfJ69&amp;sa=D&amp;source=editors&amp;ust=1679054519915955&amp;usg=AOvVaw2aq0JScvSFaSqE7J2V2A4c">1</a></span><span class="c41">&nbsp;</span><span class="c19"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?tljpmF&amp;sa=D&amp;source=editors&amp;ust=1679054519916498&amp;usg=AOvVaw0yFWpc2AVq439j6jAUusx-">12</a></span><span class="c0 c27">. Cheaper options could make running single-sample tests economically viable.</span></p><h3 class="c112 c107" id="h.pvkbd3mpbn12"><span class="c34 c12">Automation</span></h3><p class="c17 c32"><span class="c0"></span></p><p class="c17"><span class="c20 c12 c27">Sequencing-based assays are complex and typically require multiple hours of skilled labor to execute (both in the wet lab and data analysis).</span></p><p class="c17 c32"><span class="c20 c12 c27"></span></p><p class="c17"><span class="c27">A pushbutton &ldquo;sample-to-answer&rdquo; sequencing platform could allow minimally-trained personnel to load a sample and walk away from the device. Such a platform could have a major impact on the ease of implementation of sequencing-based diagnostics. Yet, </span><span class="c0 c27">no sample-to-answer sequencing platform currently exists. </span></p><p class="c17 c32"><span class="c0 c27"></span></p><p class="c17"><span class="c0 c27">Efforts have been made to automate parts of the sample preparation and library preparation process workflows, but these have largely addressed research applications or users who are comfortable investing effort in developing automation systems to process large numbers of samples in centralized labs. No low-cost fixed protocol suitable for use in a clinical context is available.</span></p><h3 class="c112 c107" id="h.jlumzuodtayd"><span class="c34 c12">Time to Answer</span></h3><p class="c1"><span class="c20 c12"></span></p><p class="c17"><span class="c9">We previously discussed how the requirement of multiplexing can increase diagnostic turnaround time by days to weeks. Sending samples to a centralized lab followed by the execution of complex workflows by trained personnel also adds significantly to the time to answer. Indeed, current metagenomic-based pathogen tests often have a 2-4 week turnaround time</span><span class="c19"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?7jVZxG&amp;sa=D&amp;source=editors&amp;ust=1679054519918226&amp;usg=AOvVaw2bcB814S2mweBhncc-HJZZ">13</a></span><span class="c0">.</span></p><p class="c17 c32"><span class="c86 c9 c12"></span></p><p class="c17"><span class="c9">On the sequencing technology front, </span><span class="c9">Illumina&rsquo;s fastest sequencing runs are </span><span class="c9">~4 hours</span><span class="c19 c27"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?RCkl9s&amp;sa=D&amp;source=editors&amp;ust=1679054519919061&amp;usg=AOvVaw1kLT522vpk-IcVvgSZLznD">14</a></span><span class="c9">, though their runs typically fall between 24-48 hours. In combination with the factors discussed above, we believe this</span><span class="c0 c27">&nbsp;is too slow to provide valuable clinical feedback to patients in many cases. However, nanopore and single-molecule approaches can currently provide sequencing data in a &lt;1-hour timeframe.</span></p><p class="c17 c32"><span class="c0 c27"></span></p><p class="c17"><span class="c9">Sample and library preparation are also significant bottlenecks here. This is strongly dependent on the sequencing technology being used. Standard protocols typically take &gt;2 hours. But rapid protocols are available which can provide sequencing-ready DNA in </span><span class="c9">~10 minutes</span><span class="c19 c27"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?gUoxVG&amp;sa=D&amp;source=editors&amp;ust=1679054519920194&amp;usg=AOvVaw0aaWKrL8NmAOHfwD3Tx_eU">15</a></span><span class="c0 c27">.</span></p><p class="c17 c32"><span class="c0"></span></p><p class="c17 c32"><span class="c0 c5"></span></p><hr style="page-break-before:always;display:none;"><p class="c17 c32"><span class="c0"></span></p><h1 class="c115 c107" id="h.3rdcrjn"><span>Understanding the </span><span>Sample</span></h1><h3 class="c17 c107" id="h.26in1rg"><span class="c34 c12">Summary</span></h3><p class="c1"><span class="c20 c12"></span></p><p class="c7"><span class="c36 c5">In order to understand the critical specifications for a sensitive MGS diagnostic, we first need to understand the nature of the sample.</span><span class="c0 c5">&nbsp;In this section we look primarily at SARS-CoV-2 to better understand how abundant and intact viral material in a metagenomic sample is likely to be. These factors ultimately determine the sensitivity and specificity of a diagnostic test. </span></p><p class="c1"><span class="c0 c5"></span></p><p class="c7"><span class="c0 c5">Existing tests (qPCR) only probe for specific targets. While this limits them to testing for a small number of pathogens, it also makes them largely unaffected by background material (human RNA and DNA). In contrast, any MGS diagnostic which is not targeted to a specific pathogen, or has not used exhaustive depletion strategies, will need to read through this background material. A more comprehensive understanding of the composition of samples is therefore critical.</span></p><p class="c1"><span class="c0 c5"></span></p><p class="c7"><span class="c0 c5">The total quantity of viral genetic material in a sample depends on sample type and disease stage. Given the scope of this roadmap, we will consider the sample characteristics for individuals with early-stage symptoms of a respiratory disease.</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c36 c137">In</span><sup><a href="#cmnt6" id="cmnt_ref6">[f]</a></sup><span class="c36 c137">&nbsp;a metagenomic sequencing experiment, for a SARS-CoV-2-like RNA respiratory virus, we can expect to see approximately 0.02% of reads coming from the viral genome of interest in symptomatic individuals. However, reported viral copy numbers vary significantly from </span><span class="c36 c137">100 to 100000s per uL</span><sup><a href="#cmnt7" id="cmnt_ref7">[g]</a></sup><span class="c0 c137">, and if we wish to match the sensitivity of qPCR we will need to detect viral fractions over a large dynamic range (see &ldquo;Sensitivity&rdquo; for a detailed analysis of this issue).</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c36 c137">The majority of this material appears to be fragmented, and &lt;1,000bp in size. Unfortunately, the majority of human material is of a similar size.</span><span class="c36 c137">&nbsp;Therefore, using size selection of nucleic acid fragments or of cells/capsids to remove non-targets may be ineffective</span><span class="c0 c137">.</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c0 c5">Nasal samples tend to have an order of magnitude higher abundance of viral copies than saliva making Anterior Nasal the sample type of choice for this and other reasons. Size selection of cells/capsids may be a viable approach to remove non-targets, however there is limited work exploring this in a research context.</span></p><p class="c1"><span class="c0 c5"></span></p><p class="c7"><span class="c0 c5">Across all samples, human material appears to dominate, forming &gt;90% of a metagenomic sample. In order to effectively sequence metagenomic samples for diagnostic purposes, we will need to deplete human RNA/DNA or compensate for this through higher sequencing depth. The factors that determine sequencing sensitivity are further explored in &ldquo;Sensitivity&rdquo;.</span></p><p class="c17 c32"><span class="c0"></span></p><h3 class="c17 c107" id="h.lnxbz9"><span>Understanding COVID-19 Metagenomic samples</span></h3><p class="c17 c32"><span class="c0"></span></p><p class="c17 c32"><span class="c0 c27"></span></p><p class="c17"><span class="c0 c27">SARS-CoV-2 diagnostics has largely focused on three sample types: anterior nasal swabs, nasopharyngeal swabs, and saliva. To a lesser extent, the presence of SAVS-CoV-2 in urine and blood has also been studied.</span></p><p class="c17 c32"><span class="c0 c27"></span></p><p class="c17"><span class="c0 c27">These sample types vary significantly in terms of viral copy numbers, viral fragmentation, and the quantity of background material present. This final metric is of limited importance in targeted diagnostics, but is an important factor for metagenomics-based diagnostics. That is because the sensitivity of metagenomics is determined by the relative abundance of the target genome.</span></p><p class="c17 c32"><span class="c0 c27"></span></p><p class="c17"><span class="c9">Studies suggest that anterior nasal swabs </span><span class="c9">yield about half the viral material of nasopharyngeal swabs</span><span class="c19 c27"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?wbZNpq&amp;sa=D&amp;source=editors&amp;ust=1679054519925296&amp;usg=AOvVaw2R2xWsXc3i6HHXx2Vn04TI">16</a></span><span class="c9">. Saliva samples are less well studied, but appear to yield roughly an order of magnitude less material</span><span class="c19 c27"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?gDEjMF&amp;sa=D&amp;source=editors&amp;ust=1679054519926041&amp;usg=AOvVaw0xFz_5oAsALN4kKhHjP1VX">17</a></span><span class="c0 c27">. A table summarizing viral load results is shown in Appendix F.</span></p><p class="c17 c32"><span class="c0 c27"></span></p><p class="c17"><span class="c9">Several studies have shown detection from blood, urine and stool samples</span><span class="c19 c27"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?66nqCY&amp;sa=D&amp;source=editors&amp;ust=1679054519927020&amp;usg=AOvVaw3PWO2CfrtNtBzlsuhABIyb">18,19</a></span><span class="c0 c27">. However, in many cases no viral material is detectable, and where present, viral loads in these samples typically are an order of magnitude lower or more than other sample types.</span></p><p class="c17 c32"><span class="c0 c27"></span></p><p class="c17"><span class="c9">The majority of new tests use anterior nasal collection, providing a balance between viral copies, and ease of collection. On this basis, we can broadly expect to use anterior nasal or saliva samples in a respiratory infectious disease testing platform, with anterior nasal being our sample of choice, due to the increased viral loads present.</span></p><p class="c1"><span class="c20 c12"></span></p><h3 class="c17 c107" id="h.fbcc5gkzr38j"><span class="c34 c12">Other Respiratory Viruses</span></h3><p class="c1"><span class="c20 c12"></span></p><p class="c7"><span class="c36 c5">Limited literature is available on the detection of other respiratory viruses through metagenomic sequencing. However, available studies show results broadly in line with SARS-CoV-2 studies</span><span class="c19"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?0nYoCS&amp;sa=D&amp;source=editors&amp;ust=1679054519928624&amp;usg=AOvVaw0zuygUZecf7Ongbt27c_gw">20,21</a></span><span class="c36 c5">. In particular one study showed the median viral fraction across multiple species was 0.01% (IQR, 0.002 to 0.07%) with read counts spanning &gt;5 orders of magnitude for respiratory infections</span><span class="c19"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?1oXM1S&amp;sa=D&amp;source=editors&amp;ust=1679054519929412&amp;usg=AOvVaw1qjSVpYVWy5P7irjcC4Lln">20</a></span><span class="c0 c5">.</span></p><h3 class="c58" id="h.c2urvf92wx9"><span>Bacterial</span><span class="c34 c12">&nbsp;Pathogens</span></h3><p class="c17 c32"><span class="c12 c135 c125 c154"></span></p><p class="c7"><span class="c36 c5">Studies suggest that bacterial transcripts in respiratory RNA-Seq samples are </span><span class="c36 c5">two orders of magnitude higher than viral fractions</span><span class="c19 c5"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?BYJrEx&amp;sa=D&amp;source=editors&amp;ust=1679054519930403&amp;usg=AOvVaw2i17qQs2ZR1HyREa3qvkGL">20</a></span><span class="c0 c5">. This bodes well for the use of RNA-Seq to detect both viral and bacterial pathogens.</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c0 c5">Large bacterial pathogen detection studies using metagenomic sequencing of DNA are somewhat absent from the literature however. Further studies in this area would provide a better understanding of the ability of a metagenomic sequencing based diagnostic platform to detect microbial pathogens through RNA alone.</span></p><p class="c1"><span class="c20 c12"></span></p><h1 class="c107 c115" id="h.z337ya"><span>Building Hypothesis-free Pathogen Diagnostic Platforms</span></h1><p class="c1"><span class="c20 c12"></span></p><p class="c7"><span class="c9">The remainder of this report discusses the </span><span class="c9">practicality of building hypothesis-free pathogen detection platforms</span><span class="c0 c27">&nbsp;based on our understanding of pathogenic targets in clinical samples (developed in the previous section and further built upon in &ldquo;Sensitivity&rdquo;) and the scenarios we believe such a platform will be deployed in (described in the background).</span></p><p class="c1"><span class="c0 c27"></span></p><p class="c7"><span class="c9">If we wish to deploy a hypothesis-free </span><span class="c9">pathogen </span><span class="c9">detection platform, current approaches face a number of challenges. Ideally, we would want our test to be used by all patients visiting a primary care facility for respiratory infections (</span><span class="c9">120M visits/year in the US, pre-COVID-19</span><span class="c19 c27"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?vUUGjW&amp;sa=D&amp;source=editors&amp;ust=1679054519932534&amp;usg=AOvVaw1JPNnfQkJ0InlhurjYVH5g">22</a></span><span class="c0 c27">). Such a test would need to compete with qPCR respiratory tests as a first-line diagnostic, so it should be low cost (similar to qPCR, COGS &lt;$25), have high sensitivity and specificity (~Ct 35, &gt;99%), and ideally provide results within the duration of an ambulatory care appointment (&lt;1 hour). </span></p><p class="c1"><span class="c0 c27"></span></p><p class="c7"><span class="c0 c27">To build this platform, we will need to address a number of interrelated technological challenges relating to the processing and analysis of samples:</span></p><p class="c1"><span class="c0 c27"></span></p><ol class="c31 lst-kix_xftmuywemg5q-0 start" start="1"><li class="c7 c122 li-bullet-0"><span class="c0 c27">Sample Acquisition</span></li><li class="c7 c122 li-bullet-0"><span class="c0 c27">Sample Preparation</span></li><li class="c7 c122 li-bullet-0"><span class="c0 c27">Library Preparation</span></li><li class="c7 c122 li-bullet-0"><span class="c0 c27">Sequencing</span></li><li class="c7 c122 li-bullet-0"><span class="c0 c27">Data Analysis and Reporting</span></li></ol><p class="c1"><span class="c0 c27"></span></p><p class="c7"><span class="c0 c27">Industry developed solutions to the above processes have focused on supporting large centralized facilities and research applications. Addressing these challenges in the context of point-of-care testing will, in many cases, require novel technological approaches.</span></p><hr style="page-break-before:always;display:none;"><h1 class="c104" id="h.xsc2xms1s040"><span class="c33 c12"></span></h1><h1 class="c115 c107" id="h.m6p2op3667yp"><span>Sensitivity</span><sup><a href="#cmnt8" id="cmnt_ref8">[h]</a></sup></h1><p class="c1"><span class="c20 c12"></span></p><p class="c7"><span class="c0 c137">In this section, we discuss the sensitivity of diagnostic tests, in particular contrasting sequencing and qPCR. We discuss fundamental differences in the nature of these approaches and their limitations. We present a literature review showing that sequencing can achieve comparable sensitivity to qPCR when correctly implemented. Finally, we present a theoretical framework for understanding the tradeoffs and platform requirements of a sequencing-based diagnostic compared to qPCR.</span></p><h2 class="c72" id="h.2j2fgo3598d6"><span class="c94 c12">Sensitivity - qPCR and Sequencing</span></h2><p class="c1"><span class="c20 c12"></span></p><p class="c7"><span class="c0 c27">qPCR is widely believed to be the &ldquo;gold standard&rdquo; in molecular diagnostic testing. qPCR has a very low LoD (limit of detection), in some cases, a handful of copies can be detected in a sample. This is generally assessed using synthetic material spiked into a sample to create standard curves like the following:</span></p><p class="c1"><span class="c20 c12 c27"></span></p><p class="c1"><span class="c20 c12 c27"></span></p><p class="c7"><span style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 624.00px; height: 232.00px;"><img alt="" src="images/image37.png" style="width: 624.00px; height: 232.00px; margin-left: 0.00px; margin-top: 0.00px; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px);" title=""></span></p><p class="c7"><span class="c9">Because qPCR targets a primer delimited region (the amplification region), it is insensitive to background material. A high fraction of human material (mostly rRNA in the case of RT-qPCR) or bacterial material will have only a minor effect on the sensitivity of qPCR. In other words, the LoD relies on the sample&#39;s </span><span class="c9 c35">absolute abundance</span><span class="c0 c27">&nbsp;of the target. </span></p><p class="c1"><span class="c0 c27"></span></p><p class="c7"><span class="c9">Metagenomic sequencing, however, is sensitive to background material. To ensure that your target(s) of interest is detected, you must also sequence through background fragments until your target is reached. Thus, metagenomic&rsquo;s LoD relies on the</span><span class="c9 c35">&nbsp;relative abundance </span><span class="c0 c27">of the target among the other nucleic acid in the sample</span></p><p class="c1"><span class="c0 c27"></span></p><p class="c7"><span class="c0 c27">At first glance, it seems like a foregone conclusion. qPCR will always be more sensitive than sequencing. In practice, however, it turns out that this may not be the case&hellip;</span></p><h2 class="c72" id="h.jyil4u9jz0an"><span class="c94 c12">Metagenomic Sequencing Studies</span></h2><p class="c7"><span class="c9">MGS literature demonstrates that not only does metagenomic sequencing have broader utility than qPCR, allowing the detection of known and unknown viruses</span><span class="c19 c125 c27 c184"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?broken%3DjUvyc2&amp;sa=D&amp;source=editors&amp;ust=1679054519937193&amp;usg=AOvVaw2XtTIyzfzuUbSJtnrtscCX">12</a></span><span class="c0 c27">, but that it also has at least comparable sensitivity when adequate read depth is used. Indeed, potential false negatives were detected by sequencing, indicating a greater test sensitivity in some cases. </span></p><p class="c1"><span class="c0 c27"></span></p><p class="c7"><span class="c0 c27">We reviewed 42 publications (Appendix D) where metagenomic sequencing was used on pathogenic samples. These were collected from literature searches, extracted from review papers, and received via a public call for relevant publications.</span></p><p class="c1"><span class="c0 c27"></span></p><p class="c7"><span class="c0 c27">We then selected publications that met the following criteria:</span></p><p class="c1"><span class="c0 c27"></span></p><ul class="c31 lst-kix_ie0dqyb5ymnc-0 start"><li class="c7 c82 li-bullet-0"><span class="c0 c27">More than 10 positive subjects.</span></li><li class="c7 c82 li-bullet-0"><span class="c0 c27">More than 10M average reads per sample.</span></li><li class="c7 c82 li-bullet-0"><span class="c0 c27">Did not use only contrived or pooled samples.</span></li><li class="c7 c82 li-bullet-0"><span class="c0 c27">Was not a targeted or semi-targeted study.</span></li></ul><p class="c1"><span class="c0 c27"></span></p><p class="c7"><span class="c0 c27">This ensures that studies have a sufficiently large size and number and that samples have sufficient reads to assess the sensitivity of sequencing. The result was the following 8 papers:</span></p><p class="c1"><span class="c20 c12 c27"></span></p><p class="c7"><span style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 624.00px; height: 144.00px;"><img alt="" src="images/image26.png" style="width: 624.00px; height: 144.00px; margin-left: 0.00px; margin-top: 0.00px; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px);" title=""></span></p><p class="c1"><span class="c20 c12"></span></p><p class="c7"><span class="c0 c62">Detailed comments on these publications can be found in Appendix E. Sensitivity was either calculated using data presented in the papers (based on agreement with qPCR, Panels, or Serology testing) or used explicit statements from these publications.</span></p><p class="c1"><span class="c0 c62"></span></p><p class="c7"><span class="c0 c62">Where a sensitivity estimate could be calculated against qPCR (5/8 papers), it was &gt;96%. This is the agreement we would expect to see between these tests, a sentiment broadly in agreement with the conclusions of these publications (see Appendix E).</span></p><p class="c1"><span class="c0 c62"></span></p><p class="c7"><span class="c0 c62">Moreover, 4 of the 8 papers have explicit statements on qPCR false negatives stating that sequencing was able to identify likely false negatives from qPCR using sequencing (see Appendix E) and therefore showed the potential for increased sensitivity relative to qPCR.</span></p><h2 class="c72" id="h.6ij61c715nd3"><span>Contrasting qPCR and Sequencing</span></h2><p class="c1"><span class="c20 c12"></span></p><p class="c7"><span class="c0 c62">As discussed above, the LoD for qPCR is very low, and the approach is insensitive to background material. However, qPCR is limited to a single region of our target pathogen. In the case of a viral target, this is typically in approximately 100 bp. For SARS-CoV-2, this is 0.3% of the genome. In sequencing, any location on the genome provides information that can enable detection.</span></p><p class="c1"><span class="c0 c62"></span></p><p class="c7"><span class="c0 c62">If all viral fragments are fully intact at the point of detection, this distinction is irrelevant. However, if the genome is fragmented, qPCR will only be able to detect that fraction of fragments that contain the amplification region. We show in Appendix H that studies suggest that SARS-CoV-2 (and other viral genomes) is likely fragmented either at collection or at point of analysis.</span></p><p class="c1"><span class="c0 c62"></span></p><p class="c7"><span class="c36 c62">Moreover, because qPCR uses primer sequences to enable detection, mutations in the primer region will cause issues for qPCR (see Appendix H). While this has not been a significant issue during COVID-19, it is worth noting.</span></p><h2 class="c72" id="h.a3hi7bn2k67j"><span class="c94 c12">Modeling qPCR and Sequencing</span></h2><p class="c7"><span class="c0">In order to more completely explore the specifications of a metagenomic sequencing based diagnostic we have created a simple model. In the first instance, we parameterize this model estimating our parameters from the JumpCode dataset mentioned in the review above: </span></p><p class="c1"><span class="c0"></span></p><ul class="c31 lst-kix_hwsfq798gxn5-0 start"><li class="c7 c82 li-bullet-0"><span class="c0">Total RNA: 10ng</span></li><li class="c7 c82 li-bullet-0"><span class="c0">Genome Size: 30Kb</span></li><li class="c7 c82 li-bullet-0"><span class="c0">rRNA fraction: 60%</span></li><li class="c7 c82 li-bullet-0"><span class="c0">qPCR Target Region: 90nt</span></li><li class="c7 c82 li-bullet-0"><span class="c0">Fragment Size: 1000nt</span></li><li class="c7 c82 li-bullet-0"><span class="c0">Read Count: 40M</span></li></ul><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c0">The model then calculated the number of reads generated, and &ldquo;on target fragments&rdquo; which can be used to estimate CT values from standard curves.</span></p><p class="c1"><span class="c0"></span></p><p class="c83"><span style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 624.00px; height: 132.00px;"><img alt="" src="images/image39.jpg" style="width: 624.00px; height: 132.00px; margin-left: 0.00px; margin-top: 0.00px; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px);" title=""></span></p><p class="c1"><span class="c20 c12"></span></p><p class="c7"><span class="c0">The model suggests that using the inputs above we expect to hit a sensitivity of ~CT 35 with sequencing, which is also roughly the conclusion the JumpCode paper comes to.</span></p><p class="c7"><span class="c0">With these parameters the model output is in reasonable agreement with the JumpCode dataset:</span></p><p class="c83"><span style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 416.50px; height: 310.74px;"><img alt="" src="images/image4.jpg" style="width: 416.50px; height: 310.74px; margin-left: 0.00px; margin-top: 0.00px; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px);" title=""></span></p><p class="c7"><span class="c0">While the model above shows the &ldquo;expected number of reads&rdquo; this is not the ideal metric for assessing a sequencing based diagnostic. As the distribution of read counts between samples will follow a Poisson distribution we are more interested in the probability of seeing &ldquo;at least one read&rdquo;. To maintain a &lt; 1 in 1000 false negative rate this should be 0.999.</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c0">The plot below shows how &ldquo;probability of signal read&rdquo; varies with read count and target fraction. </span></p><p class="c83"><span style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 385.71px; height: 288.91px;"><img alt="" src="images/image38.png" style="width: 385.71px; height: 288.91px; margin-left: 0.00px; margin-top: 0.00px; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px);" title=""></span></p><p class="c1"><span class="c20 c12"></span></p><p class="c7"><span class="c0">We can use this plot to determine the approximate number of reads required for a given target fraction. For example to have a probability of seeing at least one read &gt; 0.999 we will require &gt; 3.5M reads without rRNA depletion.</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c0">Below we see the same plot with target fraction used to calculate expected CT values from a qPCR test assuming 10ng of total material (and parameters others similar to the simulation shown above):</span></p><p class="c83 c32"><span class="c20 c12"></span></p><p class="c83"><span style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 514.50px; height: 385.88px;"><img alt="" src="images/image3.png" style="width: 514.50px; height: 385.88px; margin-left: 0.00px; margin-top: 0.00px; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px);" title=""></span></p><p class="c83 c32"><span class="c20 c12"></span></p><p class="c7"><span class="c0">We can see that 300K reads are sufficient to reach CT 30, 1M reads CT 33 etc.</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c0">Based on this analysis we believe that 1 to 10M reads is sufficient throughput for our metagenomic sequencing platform. It should be noted that this is not an average but a lower limit. As such platforms that exhibit significant sample to sample variability will be at a disadvantage.</span></p><h1 class="c104" id="h.52fmgbwzsb2w"><span class="c33 c12"></span></h1><h1 class="c115 c107" id="h.4i7ojhp"><span class="c33 c12">Sequencing Platforms</span></h1><p class="c17 c32"><span class="c0"></span></p><h3 class="c17 c107" id="h.2xcytpi"><span>Summary</span><sup><a href="#cmnt9" id="cmnt_ref9">[i]</a></sup></h3><p class="c1"><span class="c20 c12"></span></p><p class="c17"><span class="c0">In previous sections we have discussed the nature of metagenomic samples and the metrics we will need to meet in order to reach the sensitivity of qPCR. This allows us to evaluate sequencing approaches currently available or under development.</span></p><p class="c17 c32"><span class="c0"></span></p><p class="c17"><span class="c0">In this section we will summarize existing commercial approaches to sequencing, describing the limitations of these approaches with respect to the large-scale deployment of hypothesis-free infectious disease testing.</span></p><p class="c17 c32"><span class="c0"></span></p><p class="c17"><span class="c0">With this understanding of the current sequencing landscape in hand, we will propose methods which better address our requirements and the technical risks associated with different approaches.</span></p><p class="c17 c32"><span class="c0"></span></p><p class="c17"><span class="c0">In our evaluation of sequencing approaches we evaluate technologies based on the following requirements developed elsewhere in the report:</span></p><p class="c17 c32"><span class="c0"></span></p><ul class="c31 lst-kix_xk7ya91ob6yn-0 start"><li class="c17 c82 li-bullet-0"><span class="c0">Platforms should process single samples (Background).</span></li><li class="c17 c82 li-bullet-0"><span class="c0">Time to answer should be less than 1 hour (Background).</span></li><li class="c17 c82 li-bullet-0"><span class="c36">The COGS should be comparable</span><span class="c36">&nbsp;to qPCR (&lt;$5).</span></li><li class="c17 c82 li-bullet-0"><span class="c36">Single base accuracy should be higher than 95% (Appendix A).</span></li><li class="c17 c82 li-bullet-0"><span class="c36">Throughput should be sufficient to provide near equivalent sensitivity to qPCR (based on the analysis shown in &ldquo;Sensitivity&rdquo; this should be on the order of 1 to 10M reads.</span></li><li class="c17 c82 li-bullet-0"><span class="c36">Reads should be at least </span><span class="c36">18bp,</span><span class="c36">&nbsp;</span><span class="c36">but reads longer than ~1Kb provide limited utility (Understanding the target, and Appendix A).</span></li></ul><p class="c17 c129"><span class="c0">&nbsp;</span></p><p class="c17"><span class="c36">The final point may be surprising to those familiar with sequencing as applied to whole human genomes. However, as shown in Appendix A</span><span class="c36">,</span><span class="c36">&nbsp;</span><span class="c36">very short reads</span><span class="c36">&nbsp;can be effective</span><span class="c36">&nbsp;when sequencing</span><span class="c36">&nbsp;and assembling</span><span class="c36">&nbsp;small (SARS-CoV-2 30Kb) viral genomes and a diagnostic platform with </span><span class="c36">sensitivity and specificity superior to qPCR can be developed with these specifications.</span></p><p class="c17 c32"><span class="c0"></span></p><p class="c17"><span class="c0">Moreover, while we would ideally seek to exceed these specifications, building a platform which fits all our requirements requires compromise. In the next section we shall see that current instrumentation has been designed around the requirements of different applications (research, and whole human genome sequencing), and is a poor fit for point-of-care diagnostics.</span></p><h3 class="c112 c107" id="h.vqy5imk3t5js"><span class="c34 c12">Sequencing Landscape</span></h3><p class="c1"><span class="c20 c12"></span></p><p class="c7"><span class="c0">Next-generation sequencing platforms are currently offered by Illumina, MGI, Oxford Nanopore, Pacific Biosciences, SeqLL, GenoMind, Qitan Technology and Thermo (Ion Torrent).</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c36">A number of other players are also poised to enter the market (Element Biosciences, Singular Genomics, Ultima Genomics).</span><sup><a href="#cmnt10" id="cmnt_ref10">[j]</a></sup><span class="c0">&nbsp;For the most part however, these players use expired Illlumina intellectual property. They therefore in most cases have similar cost-of-goods-sold (COGS) and performance characteristics, and we will not address them here. They are however discussed in detail in Appendix B.</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c36">The relevant specifications of existing commercial platforms are summarized below:</span><sup><a href="#cmnt11" id="cmnt_ref11">[k]</a></sup></p><p class="c1"><span class="c13 c12"></span></p><a id="t.e9c23789359229c51a0ef06029d00cb29b588bbb"></a><a id="t.1"></a><table class="c127"><tr class="c25"><td class="c99" colspan="1" rowspan="1"><p class="c26"><span class="c13 c12">Platform</span></p></td><td class="c118" colspan="1" rowspan="1"><p class="c26"><span class="c13 c12">Reads per Run</span></p></td><td class="c130" colspan="1" rowspan="1"><p class="c26"><span class="c13 c12">Prep time.</span></p></td><td class="c138" colspan="1" rowspan="1"><p class="c26"><span class="c13 c12">Run time</span></p></td><td class="c91" colspan="1" rowspan="1"><p class="c26"><span class="c13 c12">Read Len</span></p></td><td class="c69" colspan="1" rowspan="1"><p class="c26"><span class="c13 c12">Error rate</span></p><p class="c26"><span class="c13 c12">Avg (%)</span></p></td><td class="c109" colspan="1" rowspan="1"><p class="c26"><span class="c13 c12">Direct RNA?</span></p></td><td class="c87" colspan="1" rowspan="1"><p class="c26"><span class="c13 c12">Input/Sample Concentration</span></p></td><td class="c40" colspan="1" rowspan="1"><p class="c26"><span class="c13 c12">Sample Volume</span></p></td><td class="c40" colspan="1" rowspan="1"><p class="c26"><span class="c13 c12">COGS</span></p></td><td class="c8" colspan="1" rowspan="1"><p class="c26"><span class="c13 c12">Refs</span></p><sup><a href="#cmnt12" id="cmnt_ref12">[l]</a></sup></td></tr><tr class="c25"><td class="c99" colspan="1" rowspan="1"><p class="c26"><span class="c13 c12">Illumina NovaSeq 6000</span></p></td><td class="c118" colspan="1" rowspan="1"><p class="c26"><span class="c13 c12">10B</span></p></td><td class="c130" colspan="1" rowspan="1"><p class="c26 c32"><span class="c13 c12"></span></p></td><td class="c138" colspan="1" rowspan="1"><p class="c26"><span class="c13 c12">14h</span></p><p class="c26"><span class="c13 c12">(min)</span></p></td><td class="c91" colspan="1" rowspan="1"><p class="c26"><span class="c13 c12">36 to 250</span></p></td><td class="c69" colspan="1" rowspan="1"><p class="c26"><span class="c13 c12">&lt;0.1</span></p></td><td class="c109" colspan="1" rowspan="1"><p class="c26"><span class="c13 c12">No</span></p></td><td class="c87" colspan="1" rowspan="1"><p class="c26"><span class="c42">1ng </span><span class="c13 c12">~200pM</span></p></td><td class="c40" colspan="1" rowspan="1"><p class="c26"><span class="c13 c12">~100uL</span></p></td><td class="c40" colspan="1" rowspan="1"><p class="c26"><span class="c13 c12">~$1000</span></p></td><td class="c8" colspan="1" rowspan="1"><p class="c26"><span class="c42 c41"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?BFTR6i&amp;sa=D&amp;source=editors&amp;ust=1679054519957192&amp;usg=AOvVaw1jH9l0rwPjWS5JRnvn6gbA">35</a></span><span class="c42">&nbsp;</span><span class="c42 c41"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?pcfzGc&amp;sa=D&amp;source=editors&amp;ust=1679054519957734&amp;usg=AOvVaw2dxBvIL5Jhm1UgDBLG_p2S">36</a></span><span class="c42">&nbsp; </span><span class="c42 c41"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?eM8gGS&amp;sa=D&amp;source=editors&amp;ust=1679054519958071&amp;usg=AOvVaw0-oc97QBkCUmz4GN-34UeQ">37</a></span><span class="c42">&nbsp;</span><span class="c42 c41"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?WiR7BU&amp;sa=D&amp;source=editors&amp;ust=1679054519958398&amp;usg=AOvVaw0nLvI7dcY4t-wV1VIsqsay">38</a></span></p></td></tr><tr class="c25"><td class="c99" colspan="1" rowspan="1"><p class="c26"><span class="c13 c12">Illumina</span></p><p class="c26"><span class="c13 c12">MiSeq</span></p></td><td class="c118" colspan="1" rowspan="1"><p class="c26"><span class="c13 c12">25M</span></p></td><td class="c130" colspan="1" rowspan="1"><p class="c26 c32"><span class="c13 c12"></span></p></td><td class="c138" colspan="1" rowspan="1"><p class="c26"><span class="c13 c12">4h</span></p><p class="c26"><span class="c13 c12">(min)</span></p></td><td class="c91" colspan="1" rowspan="1"><p class="c26"><span class="c13 c12">36 to 300</span></p></td><td class="c69" colspan="1" rowspan="1"><p class="c26"><span class="c13 c12">&lt;0.1</span></p></td><td class="c109" colspan="1" rowspan="1"><p class="c26"><span class="c13 c12">No</span></p></td><td class="c87" colspan="1" rowspan="1"><p class="c26"><span class="c13 c12">1ng ~10pM</span></p></td><td class="c40" colspan="1" rowspan="1"><p class="c26"><span class="c13 c12">~600uL</span></p></td><td class="c40" colspan="1" rowspan="1"><p class="c26"><span class="c13 c12">~$50</span></p></td><td class="c8" colspan="1" rowspan="1"><p class="c26"><span class="c42 c41"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?J2WwuF&amp;sa=D&amp;source=editors&amp;ust=1679054519962637&amp;usg=AOvVaw3CkDQHELUwsKE50AFUSWke">39</a></span><span class="c42">&nbsp;</span><span class="c42 c41"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?zK4rEC&amp;sa=D&amp;source=editors&amp;ust=1679054519963135&amp;usg=AOvVaw0aFShplAnmaDd_wa8AVJ9x">40</a></span><span class="c42">&nbsp;</span><span class="c42 c41"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?F2mnci&amp;sa=D&amp;source=editors&amp;ust=1679054519963503&amp;usg=AOvVaw0Gag58UJlZlXQ4v2c9Cz3z">14</a></span></p></td></tr><tr class="c25"><td class="c99" colspan="1" rowspan="1"><p class="c26"><span class="c13 c12">MGI</span></p><p class="c26"><span class="c13 c12">DNBSEQ-T7</span></p></td><td class="c118" colspan="1" rowspan="1"><p class="c26"><span class="c13 c12">5B</span></p></td><td class="c130" colspan="1" rowspan="1"><p class="c26 c32"><span class="c13 c12"></span></p></td><td class="c138" colspan="1" rowspan="1"><p class="c26"><span class="c13 c12">24h</span></p><p class="c26"><span class="c13 c12">(min)</span></p></td><td class="c91" colspan="1" rowspan="1"><p class="c26"><span class="c13 c12">100 to 150</span></p></td><td class="c69" colspan="1" rowspan="1"><p class="c26"><span class="c13 c12">&lt;0.1</span></p></td><td class="c109" colspan="1" rowspan="1"><p class="c26"><span class="c13 c12">No</span></p></td><td class="c87" colspan="1" rowspan="1"><p class="c26 c32"><span class="c13 c12"></span></p></td><td class="c40" colspan="1" rowspan="1"><p class="c26 c32"><span class="c13 c12"></span></p></td><td class="c40" colspan="1" rowspan="1"><p class="c26"><span class="c13 c12">~$1000</span></p></td><td class="c8" colspan="1" rowspan="1"><p class="c26"><span class="c41"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?2Rc5ZJ&amp;sa=D&amp;source=editors&amp;ust=1679054519966799&amp;usg=AOvVaw1lNY32kIDbStwd4iHMWlmT">41</a></span></p></td></tr><tr class="c25"><td class="c99" colspan="1" rowspan="1"><p class="c26"><span class="c13 c12">MGI</span></p><p class="c26"><span class="c13 c12">DNBSEQ-G50</span></p></td><td class="c118" colspan="1" rowspan="1"><p class="c26"><span class="c13 c12">500M</span></p></td><td class="c130" colspan="1" rowspan="1"><p class="c26 c32"><span class="c13 c12"></span></p></td><td class="c138" colspan="1" rowspan="1"><p class="c26"><span class="c13 c12">9h</span></p><p class="c26"><span class="c13 c12">(min)</span></p></td><td class="c91" colspan="1" rowspan="1"><p class="c26"><span class="c13 c12">50 to 150</span></p></td><td class="c69" colspan="1" rowspan="1"><p class="c26"><span class="c13 c12">&lt;0.1</span></p></td><td class="c109" colspan="1" rowspan="1"><p class="c26"><span class="c13 c12">No</span></p></td><td class="c87" colspan="1" rowspan="1"><p class="c26 c32"><span class="c13 c12"></span></p></td><td class="c40" colspan="1" rowspan="1"><p class="c26 c32"><span class="c13 c12"></span></p></td><td class="c40" colspan="1" rowspan="1"><p class="c26"><span class="c13 c12">~$50</span></p></td><td class="c8" colspan="1" rowspan="1"><p class="c26"><span class="c41"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?R1OEMY&amp;sa=D&amp;source=editors&amp;ust=1679054519970525&amp;usg=AOvVaw28eZsA_-TGyTyLsi4a1Vum">41</a></span></p></td></tr><tr class="c25"><td class="c99" colspan="1" rowspan="1"><p class="c26"><span class="c13 c12">ONT</span></p><p class="c26"><span class="c13 c12">Minion</span></p></td><td class="c118" colspan="1" rowspan="1"><p class="c26"><span class="c13 c12">3K to 2.4M</span></p><p class="c26"><span class="c13 c12">1M (RNA)</span></p></td><td class="c130" colspan="1" rowspan="1"><p class="c26"><span class="c13 c12">10m</span></p></td><td class="c138" colspan="1" rowspan="1"><p class="c26"><span class="c13 c12">1 to 72h</span></p></td><td class="c91" colspan="1" rowspan="1"><p class="c26"><span class="c13 c12">&gt;100Kb</span></p></td><td class="c69" colspan="1" rowspan="1"><p class="c26"><span class="c13 c12">&gt;1%</span></p><p class="c26"><span class="c13 c12">&lt;5%</span></p></td><td class="c109" colspan="1" rowspan="1"><p class="c26"><span class="c12 c13">Yes</span></p></td><td class="c87" colspan="1" rowspan="1"><p class="c26"><span class="c13 c12">1ng (DNA)</span></p><p class="c26"><span class="c42">500ng </span><span class="c42">(RNA)</span><sup><a href="#cmnt13" id="cmnt_ref13">[m]</a></sup></p></td><td class="c40" colspan="1" rowspan="1"><p class="c26 c32"><span class="c13 c12"></span></p></td><td class="c40" colspan="1" rowspan="1"><p class="c26"><span class="c13 c12">~$250</span></p></td><td class="c8" colspan="1" rowspan="1"><p class="c26"><span class="c41"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?KxiWtN&amp;sa=D&amp;source=editors&amp;ust=1679054519975306&amp;usg=AOvVaw0muNt_b8HAf7zzwz94Kv18">42</a></span></p></td></tr><tr class="c25"><td class="c99" colspan="1" rowspan="1"><p class="c26"><span class="c13 c12">Qitan Technology</span></p></td><td class="c118" colspan="1" rowspan="1"><p class="c26 c32"><span class="c13 c12"></span></p></td><td class="c130" colspan="1" rowspan="1"><p class="c26 c32"><span class="c13 c12"></span></p></td><td class="c138" colspan="1" rowspan="1"><p class="c26 c32"><span class="c13 c12"></span></p></td><td class="c91" colspan="1" rowspan="1"><p class="c26 c32"><span class="c13 c12"></span></p></td><td class="c69" colspan="1" rowspan="1"><p class="c26"><span class="c13 c12">&lt;10%</span></p></td><td class="c109" colspan="1" rowspan="1"><p class="c26 c32"><span class="c13 c12"></span></p></td><td class="c87" colspan="1" rowspan="1"><p class="c26 c32"><span class="c13 c12"></span></p></td><td class="c40" colspan="1" rowspan="1"><p class="c26 c32"><span class="c13 c12"></span></p></td><td class="c40" colspan="1" rowspan="1"><p class="c26"><span class="c13 c12">?</span></p></td><td class="c8" colspan="1" rowspan="1"><p class="c26 c32"><span class="c13 c12"></span></p></td></tr><tr class="c25"><td class="c99" colspan="1" rowspan="1"><p class="c26"><span class="c13 c12">Pacific Biosciences (Sequel II)</span></p></td><td class="c118" colspan="1" rowspan="1"><p class="c26 c32"><span class="c13 c12"></span></p></td><td class="c130" colspan="1" rowspan="1"><p class="c26 c32"><span class="c13 c12"></span></p></td><td class="c138" colspan="1" rowspan="1"><p class="c26"><span class="c13 c12">1 to 30h</span></p></td><td class="c91" colspan="1" rowspan="1"><p class="c26 c32"><span class="c13 c12"></span></p></td><td class="c69" colspan="1" rowspan="1"><p class="c26 c32"><span class="c13 c12"></span></p></td><td class="c109" colspan="1" rowspan="1"><p class="c26 c32"><span class="c13 c12"></span></p></td><td class="c87" colspan="1" rowspan="1"><p class="c26"><span class="c13 c12">500pg (DNA) </span></p></td><td class="c40" colspan="1" rowspan="1"><p class="c26 c32"><span class="c13 c12"></span></p></td><td class="c40" colspan="1" rowspan="1"><p class="c26 c32"><span class="c13 c12"></span></p></td><td class="c8" colspan="1" rowspan="1"><p class="c26"><span class="c42 c41"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?76yAF7&amp;sa=D&amp;source=editors&amp;ust=1679054519981156&amp;usg=AOvVaw3dqMElzthjipJZpqaQcH35">43</a></span><span class="c42">&nbsp;</span><span class="c42 c41"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?AKiwJD&amp;sa=D&amp;source=editors&amp;ust=1679054519981609&amp;usg=AOvVaw1Pu03x3yypvR809wIrtSpi">44</a></span></p></td></tr><tr class="c25"><td class="c99" colspan="1" rowspan="1"><p class="c26"><span class="c13 c12">SeqLL</span></p></td><td class="c118" colspan="1" rowspan="1"><p class="c26"><span class="c13 c12">1B</span></p></td><td class="c130" colspan="1" rowspan="1"><p class="c26"><span class="c13 c12">0m</span></p></td><td class="c138" colspan="1" rowspan="1"><p class="c26"><span class="c13 c12">7d</span></p></td><td class="c91" colspan="1" rowspan="1"><p class="c26"><span class="c13 c12">33</span></p></td><td class="c69" colspan="1" rowspan="1"><p class="c26"><span class="c13 c12">&lt;3%</span></p></td><td class="c109" colspan="1" rowspan="1"><p class="c26"><span class="c13 c12">Yes</span></p></td><td class="c87" colspan="1" rowspan="1"><p class="c26"><span class="c13 c12">2ng (2 - RNA)</span></p><p class="c26 c32"><span class="c13 c12"></span></p><p class="c26"><span class="c13 c12">100 to 250pg (3 - RNA)</span></p></td><td class="c40" colspan="1" rowspan="1"><p class="c26 c32"><span class="c13 c12"></span></p></td><td class="c40" colspan="1" rowspan="1"><p class="c26"><span class="c13 c12">?</span></p></td><td class="c8" colspan="1" rowspan="1"><p class="c26"><span class="c42 c41"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Ax2VFw&amp;sa=D&amp;source=editors&amp;ust=1679054519984861&amp;usg=AOvVaw29hxVQBmJ3xCbIOBsK5SSV">45</a></span><span class="c42">&nbsp;</span><span class="c41 c42"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?63ZRTR&amp;sa=D&amp;source=editors&amp;ust=1679054519985435&amp;usg=AOvVaw0C08ud-Vyag2QdZhLaEeuM">46</a></span><span class="c42">&nbsp;</span><span class="c42 c41"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?E3ENji&amp;sa=D&amp;source=editors&amp;ust=1679054519985841&amp;usg=AOvVaw3eENko4BTv5O6yFFpsAEQv">47</a></span></p></td></tr><tr class="c25"><td class="c99" colspan="1" rowspan="1"><p class="c26"><span class="c13 c12">GenoMind</span></p></td><td class="c118" colspan="1" rowspan="1"><p class="c26 c32"><span class="c13 c12"></span></p></td><td class="c130" colspan="1" rowspan="1"><p class="c26 c32"><span class="c13 c12"></span></p></td><td class="c138" colspan="1" rowspan="1"><p class="c26 c32"><span class="c13 c12"></span></p></td><td class="c91" colspan="1" rowspan="1"><p class="c26 c32"><span class="c13 c12"></span></p></td><td class="c69" colspan="1" rowspan="1"><p class="c26 c32"><span class="c13 c12"></span></p></td><td class="c109" colspan="1" rowspan="1"><p class="c26 c32"><span class="c13 c12"></span></p></td><td class="c87" colspan="1" rowspan="1"><p class="c26 c32"><span class="c13 c12"></span></p></td><td class="c40" colspan="1" rowspan="1"><p class="c26 c32"><span class="c13 c12"></span></p></td><td class="c40" colspan="1" rowspan="1"><p class="c26 c32"><span class="c13 c12"></span></p></td><td class="c8" colspan="1" rowspan="1"><p class="c26 c32"><span class="c13 c12"></span></p></td></tr><tr class="c25"><td class="c99" colspan="1" rowspan="1"><p class="c26"><span class="c13 c12">Ion Torrent (520)</span></p></td><td class="c118" colspan="1" rowspan="1"><p class="c26"><span class="c13 c12">5M</span></p></td><td class="c130" colspan="1" rowspan="1"><p class="c26 c32"><span class="c13 c12"></span></p></td><td class="c138" colspan="1" rowspan="1"><p class="c26"><span class="c13 c12">3h</span></p></td><td class="c91" colspan="1" rowspan="1"><p class="c26"><span class="c13 c12">200 to 600</span></p></td><td class="c69" colspan="1" rowspan="1"><p class="c26"><span class="c13 c12">&lt;2%</span></p></td><td class="c109" colspan="1" rowspan="1"><p class="c26"><span class="c13 c12">No</span></p></td><td class="c87" colspan="1" rowspan="1"><p class="c26 c32"><span class="c13 c12"></span></p></td><td class="c40" colspan="1" rowspan="1"><p class="c26 c32"><span class="c13 c12"></span></p></td><td class="c40" colspan="1" rowspan="1"><p class="c26 c32"><span class="c13 c12"></span></p></td><td class="c8" colspan="1" rowspan="1"><p class="c26"><span class="c41"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?DzNMET&amp;sa=D&amp;source=editors&amp;ust=1679054519991459&amp;usg=AOvVaw3mzTbLekyYDBB4jWeTC3qC">48</a></span></p></td></tr></table><p class="c1"><span class="c20 c12"></span></p><p class="c17"><span class="c36">As discussed in Understanding the Target, we can expect to have ~6ng/mL of total RNA. The majority of the above sequencing platforms can not directly sequence this sample type. Either they are unable to sequence RNA directly (Illumina, MGI, PacBio, Ion Torrent) or sample </span><span class="c36">input requirements are too high (ONT)</span><sup><a href="#cmnt14" id="cmnt_ref14">[n]</a></sup><span class="c0">.</span></p><p class="c17 c32"><span class="c0"></span></p><p class="c17"><span class="c0">Surprisingly the only platform capable of directly sequencing such samples is provided by SeqLL, likely the smallest player in the next-gen sequencing market. This company provides a platform previously developed by defunct sequencing startup Helicos.</span></p><p class="c17 c32"><span class="c0"></span></p><p class="c17"><span class="c36">In terms of run time, only Oxford Nanopore and Pacific Biosciences platforms provide results within an </span><span class="c36">h</span><span class="c0">our (required to provide results within an ambulatory care visit, and comparable to current qPCR platforms).</span></p><p class="c17 c32"><span class="c0"></span></p><h3 class="c112 c107" id="h.48osl2vi805o"><span class="c34 c12">Evolution of Existing Approaches</span></h3><p class="c17 c32"><span class="c0"></span></p><p class="c7"><span class="c0">Given that existing sequencing approaches have clear limitations, we have two routes forward. Either we can build on established methodologies to create platforms more fit for purpose, or we can develop entirely new sensing methodologies and approaches.</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c0">Sequencing technologies are complex and require significant investment; this is most recently apparent in the development of Nanopore sequencing. This effort took more than 25 years of active development, and billions of dollars of academic and commercial funding.</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c0">In this section we discuss lower risk approaches developing low cost, high speed sequencing platforms which build up existing sensing methodologies. It should be noted however, that while these approaches are lower risk, bringing any novel sequencing platform to commercial launch will likely require at least $100M, and that there is still significant market, regulatory and technical risk.</span></p><h4 class="c54" id="h.nkjw7id33m7j"><span class="c68 c12">Colony based approaches</span></h4><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c0">Current market leading approaches use amplified copies of a single template on a surface or bead. The most popular of these is provided by Illumina, using bridge amplification.</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c36">Illumina cluster generation time </span><span class="c36">is at its fastest 60 minutes</span><span class="c19"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?CvGnN2&amp;sa=D&amp;source=editors&amp;ust=1679054519995536&amp;usg=AOvVaw2cfAS-lS9c11iB4LhnHScC">49</a></span><span class="c36">. </span><span class="c36">This limitation alone suggests that colony based approaches will require significant development to meet our run time requirements (&lt;1 hour).</span><sup><a href="#cmnt15" id="cmnt_ref15">[o]</a></sup></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c36">Beyond colony generation, all current colony based approaches use a cyclic chemistry. In this approach template extension occurs sequentially. This may or may not occur in concert with detection, but it means that a fluidic system is required. This adds cost and complexity to the platform, and while we believe Illumina instruments may be able to achieve a COGS near $50 per run, </span><span class="c36">$5 or less seems like a challenging goal for a complex fluidic system and therefore reagent cartridge.</span><sup><a href="#cmnt16" id="cmnt_ref16">[p]</a></sup></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c36">One route to removing the complexity of a cyclic chemistry could be through the use of photo-cleavable terminators, such as the Lightning terminators </span><span class="c36">developed by LaserGen</span><span class="c19"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?kh7rF1&amp;sa=D&amp;source=editors&amp;ust=1679054519996975&amp;usg=AOvVaw1_tDDYpPFCvK2Aj1q7F5MT">50</a></span><span class="c0">. Using this approach, rather than using a cleavage reagent, terminators would be unblocked with a UV light source. This would dramatically simplify the platform and could help significantly reduce consumable costs.</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c0">Overall, we believe that there are significant challenges to using colony based approaches when developing low cost diagnostics consumables.</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c0">Beyond the issues stated above, the library preparation requirements are significant, requiring reverse transcription (in the case of RNA viral diagnostics) and ligation/addition of adapters. Automating and integrating these sample prep stages itself brings costs which we would rather avoid.</span></p><h4 class="c54" id="h.a21yf5ffxp3z"><span>Nanopore</span><sup><a href="#cmnt17" id="cmnt_ref17">[q]</a></sup></h4><p class="c17 c32"><span class="c0"></span></p><p class="c7"><span class="c36">Oxford Nanopore and Qitan Technology have been extremely successful in bringing to market the first single molecule direct electrical detection sequencing platforms. As noted above Nanopore platforms have several desirable characteristics. Firstly, runs can be extremely short (an hour long run on a Minion could provide nearly 1 million 1Kb reads). </span><span class="c36">This would be sufficient to identify novel viral RNA in a metagenomic sample.</span><sup><a href="#cmnt18" id="cmnt_ref18">[r]</a></sup><span class="c0">&nbsp;The platform can also potentially provide a direct readout from RNA. Enabling such experiments would require significant developments in sample preparation, but seems tractable.</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c0">However, a current key limitation for Nanopore sequencing is the COGS of the sequencing consumable. At present Oxford Nanopore accounts state that goods are sold at 50% margin. This suggests that Minion flow cells would cost ~$250, and the Flongle flow cell ~$45. &nbsp;As described elsewhere, for broad adoption we feel that we need a COGS nearer to the $5 range including all sample preparation reagents.</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c0">For a Nanopore based diagnostic platform we would therefore need to reduce the COGS by one to two orders of magnitude. This may be possible, but is extremely challenging. A reduction in feature size (from wells of ~150um currently) would help with this. Integration of the current amplification analog frontend onto the sensing substrate, or out of the consumable could also help reduce COGS.</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c0">Like Illumina sequencing, Oxford Nanopore sequencing also requires adapters to be added to templates. This process would also need to be integrated into the sample prep instrumentation.</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c36">Overall,</span><span class="c0">&nbsp;the most significant risks here are the relatively high cost of goods, and the lack of a clear path to low cost consumables.</span></p><p class="c17 c32"><span class="c0"></span></p><h4 class="c107 c166" id="h.i5bi7qtj282c"><span class="c68 c12">Single Molecule Optical</span></h4><p class="c17 c32"><span class="c0"></span></p><p class="c7"><span class="c0">Two single molecule optical approaches have been successfully brought to market: Helicos (SeqLL) and Pacific Biosciences.</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c36">The Pacific Biosciences approach uses zero mode waveguides in its current embodiment; these are integrated into a CMOS sensing platform. While the platform can potentially provide a sequencing output within an hour the instrumentation and consumables are costly. Therefore many of the cost-of-goods issues with Nanopore sequencing likely also exist here. The platform </span><span class="c36">however could potentially be adapted to sequence RNA directly</span><sup><a href="#cmnt19" id="cmnt_ref19">[s]</a></sup><span class="c0">.</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c36">An evolution of the Helicos approach seems more practical here, and we would suggest it is the most practical route based on known sensing methodologies. While as originally implemented in the 2000s Helios&rsquo; instrumentation cost &gt;$100000, advances in imaging technologies now allow single molecule imaging to be performed using $100 CMOS image sensors. The basic approach also</span><span class="c36">&nbsp;requires minimal sample preparation</span><span class="c36">. Sequencing </span><span class="c36">unmodified RNA directly on a flow cell has been demonstrated with no need for adapter ligation or other library preparation steps</span><span class="c36">.</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c36">The Helicos approach has two key limitations for application in diagnostic instrumentation. Firstly, Helicos data quality is significantly worse than any other current player in next generation sequencing. The platform generated short reads (&lt;50bp) and had a relatively high error rate (</span><span class="c36">~3% overall</span><span class="c36">). This was a significant issue when addressing whole genome sequencing. However, for use in diagnostics and with short viral genomes, </span><span class="c36">relatively high error rates can be tolerated</span><span class="c0">. Additional strategies may also be developed to reduce error rates and increase read lengths.</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c0">The second issue is that the Helicos approach retains the complexity of a cyclic chemistry associated with the colony based approaches described above.</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c0">There are however a number of strategies that would remove the requirement for a cyclic chemistry in a single molecule optical sequencing platform. One of these is the use of stochastic label removal as proposed by Reticula (disclosure, the founder of Reticula was involved in the development of this report). This, and related approaches would dramatically reduce the complexity of the reagent and fluidic system.</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c36">This approach has well characterized technical risks (</span><span class="c36">as the single molecule optical detection method has already been </span><span class="c36">demonstrated by Helicos) and free-running detection of labels has recently been shown to work well in DNA-PAINT and related approaches. It also requires a </span><span class="c36">very simple integrated sample preparation system</span><span class="c0">&nbsp;nearly identical to that used in qPCR.</span></p><h3 class="c112 c107" id="h.mhazs4ebatd7"><span class="c34 c12">Blue-sky Technologies</span></h3><p class="c1"><span class="c20 c12"></span></p><p class="c7"><span class="c20 c12">A number of other novel sequencing approaches have been proposed, these are documented in detail in Appendix B. </span></p><p class="c1"><span class="c20 c12"></span></p><p class="c7"><span class="c0">The most interesting of these for our application are solid state nanopore approaches. Solid state Nanopore approaches promise many of the advantages of Oxford Nanopore&rsquo;s protein nanopore platform but also offer the possibility of rectifying many of the problems. Specifically, solid state nanopore platforms promise to be higher accuracy, higher throughput, lower cost, and require simpler sample prep.</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c0">However solid state nanopore research has been underway for more than 20 years and to date no reproducible demonstration of near single base resolution sequencing has been shown.</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c0">Oxford Nanopore&rsquo;s protein nanopore sequencing platform uses ionic current blockages to detect nucleotides as they translocate through a biological nanopore. The Oxford Nanopore platform uses biological pores with single digit nanometer scale features (1.2 nm constriction in a 2nm barrel). The reliable fabrication of solid state nanopores with equivalent feature size would be extremely challenging.</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c36">If fabrication challenges were solved, it seems likely that Oxford Nanopore&rsquo;s enzymatic motion control strategy could be combined with a solid state sensing platform. Such a platform may unfortunately not have any compelling advantage over a protein nanopore sequencing platform. </span><span class="c36">Namely, the sequencing speed will likely be the same (</span><span class="c36">420bp/s</span><span class="c36">),</span><span class="c0">&nbsp;and potentially accuracy limitations associated with the limited ability to accurately control translocation of the strand through the pore. It could however be more easily washable in situ, allowing the sensing mechanism to be reused indefinitely for multiple samples.</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c0">The readout read of an ionic current detection nanopore is likely limited to &lt; 1000bp/s, based solely on the number of and mobility of charge carriers. Other approaches have been suggested that address nanopore sequencing accuracy and speed limitations.</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c0">One example of this is tunneling current sensing. Here transverse electrodes are used to register a tunneling current. As nucleotides translocate through the sensing region they interfere with this tunneling current. This signal is then used to determine the sequence of the template.</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c0">This approach has been pursued commercially (Quantum Biosystems, Genvida) and in a number of academic labs. While a number of groups have shown that DNA can be imaged using tunneling currents (STM) there have been no reproducible results showing sequencing data on strand. Tunneling current detection promises higher accuracy (as larger currents can be generated), and higher readout speeds. But remains at present a research activity which may take decades to fulfill its promise, that is if insurmountable physical limitations are not discovered.</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c36">Nanopore embedded field effect sensors have also been proposed. These would embed a FET inside a nanopore, where the dielectric changes produced by nucleosides as they pass in close contact to the sensor would be detected through changes in the electric field. This approach is being pursued by startup iNanoBio. iNanoBio was founded 14 years ago, and to date no sequencing results have been reported. iNanoBio suggests that they may be able to reach extremely high readout speeds (millions of bases/s). However, related techniques such as scanning capacitance microscopy (SCM) have </span><span class="c36">so far been </span><span class="c36">limited to a few kilohertz</span><span class="c19"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?OyaVmX&amp;sa=D&amp;source=editors&amp;ust=1679054520004681&amp;usg=AOvVaw2pFBVRqny3ucI4fnXeig56">51</a></span><span class="c0">, suggesting this might be challenging.</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c36">Various other novel nanopore platforms are also in development such as optical nanopore platforms (Quantapore) or SBS-Nanopore systems (Genia, AxBio). In many cases the advantages of these platforms, particularly for diagnostic applications, is unclear.</span><hr style="page-break-before:always;display:none;"></p><h1 class="c115 c107" id="h.c4gvr3cqcif8"><span class="c33 c12">Sample Acquisition and Preparation</span></h1><p class="c7"><span class="c0">A complete sample-to-answer metagenomic sequencing platform will require the development of a sample acquisition and preparation system. This will take samples from patients and prepare them for introduction to sequencing instrumentation. In clinically viable platform sample preparation will be integrated into sequencing instrumentation, such that a clinician need only add the sample to a pre-loaded cartridge and insert it into an instrument. This is much the same workflow that exists for sample-to-answer qPCR instrumentation (Cepheid GeneXpert). And we shall see that it may be possible to leverage much of this work in the development of tools for sample-to-answer metagenomic sequencing platforms.</span></p><p class="c1"><span class="c20 c12"></span></p><h2 class="c107 c131" id="h.ck96969578cz"><span>Sample Acquisition </span></h2><p class="c17"><span class="c36">For the purpose of a ubiquitous sequencing system, sample collection should be non-invasive and cheap. Sample types of </span><span class="c36">interest</span><span class="c36">&nbsp;are: nasopharyngeal swabs, anterior nasal swabs, breath condensate, urine, saliva and blood.</span><sup><a href="#cmnt20" id="cmnt_ref20">[t]</a></sup></p><p class="c17 c32"><span class="c0"></span></p><p class="c17"><span class="c0">Effective and non-invasive sample acquisition consumables have been developed for use during COVID-19. For respiratory conditions we would expect swab based anterior nasal collection systems to provide an effective solution.</span></p><p class="c17 c32"><span class="c20 c12"></span></p><h2 class="c131 c107" id="h.ftgjkg2hl1gc"><span>Sample</span><sup><a href="#cmnt21" id="cmnt_ref21">[u]</a></sup><span>&nbsp;and</span><span>&nbsp;Library</span><sup><a href="#cmnt22" id="cmnt_ref22">[v]</a></sup><span>&nbsp;</span><span>Preparation</span><sup><a href="#cmnt23" id="cmnt_ref23">[w]</a></sup><sup><a href="#cmnt24" id="cmnt_ref24">[x]</a></sup><span class="c94 c12">&nbsp;</span></h2><p class="c7"><span class="c0">Once a sample has been collected it needs to undergo a number of preparation steps prior to sequencing. Broadly we describe these as &ldquo;sample preparation&rdquo; and &ldquo;library preparation&rdquo;. Sample preparation describes the preparation of a sample such that it largely contains only the material of interest, absent of contaminants. Library preparation describes subsequent preparation steps required to prepare a sample for sequencing.</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c36">Both sample and library preparation requirements will vary significantly depending on the sequencing platform being used</span><span class="c36">. </span><span class="c36">And both these processes will contribute to the complexity of any integrated infectious disease testing device. In fact, for many approaches the sample and library preparation steps may be the most costly and time consuming parts of the sequencing process.</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c0">In this section we will discuss sample and library preparation requirements for RNA shotgun metagenomic sequencing of samples.</span></p><h3 class="c112 c107" id="h.787zd2hrxkar"><span>Sample Preparation</span><sup><a href="#cmnt25" id="cmnt_ref25">[y]</a></sup><sup><a href="#cmnt26" id="cmnt_ref26">[z]</a></sup><sup><a href="#cmnt27" id="cmnt_ref27">[aa]</a></sup></h3><p class="c17 c32"><span class="c0"></span></p><p class="c7"><span class="c0">Ideally, samples would require no preparation and raw samples could be loaded directly onto a sequencing instrument. However, this is not generally practical. Even in the most ambitious scenario we will likely at least need to dilute the sample in a loading buffer.</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c36">More realistically we will need to remove contaminants and inhibitors, and may wish to </span><span class="c36">remove material that is not of interest</span><sup><a href="#cmnt28" id="cmnt_ref28">[ab]</a></sup><span class="c0">&nbsp;(see Selection below).</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c36">Typically either silica beads, columns or surfaces are used here, these techniques have largely displaced conventional </span><span class="c36">phenol-chloroform based extraction</span><span class="c19"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?F2yEdb&amp;sa=D&amp;source=editors&amp;ust=1679054520009599&amp;usg=AOvVaw2BVxsNKeYp4Owab1fj4NGk">52</a></span><span class="c0">&nbsp;approaches.</span></p><p class="c17 c32"><span class="c0"></span></p><p class="c7"><span class="c36">For platforms only capable of sequencing DNA (Illumina, Ion Torrent) RNA samples will also need to be converted into cDNA prior to library preparation.</span><sup><a href="#cmnt29" id="cmnt_ref29">[ac]</a></sup></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c36">Fortunately, the isolation and cDNA conversion of RNA samples has been performed at low cost and scale during COVID-19. As such we do not expect this to pose a significant challenge.</span></p><h3 class="c112 c107" id="h.q01mqmuai2bd"><span class="c34 c12">Library Preparation</span></h3><p class="c1"><span class="c20 c12"></span></p><p class="c7"><span class="c36">In this section we&rsquo;ll review library preparation steps for current sequencing platforms. In Appendix </span><span class="c36 c180">G</span><span class="c0">&nbsp;we review these in detail, here we draw on this to broadly describe approaches in order of complexity.</span></p><h4 class="c54" id="h.e5e4ydv9cwzz"><span class="c68 c12">High Complexity - Pacific Biosciences, MGI</span></h4><p class="c7"><span class="c36">While current Pacific Biosciences instruments could potentially be </span><span class="c36">capable of direct RNA sequencing</span><sup><a href="#cmnt30" id="cmnt_ref30">[ad]</a></sup><sup><a href="#cmnt31" id="cmnt_ref31">[ae]</a></sup><span class="c36">&nbsp;no such kits are currently available. The current Pacific Biosciences approach therefore relies on cDNA conversion during sample preparation. </span><span class="c36">These DNA templates are further used to create &ldquo;Universal SMRTbell templates&rdquo; for sequencing.</span><span class="c0">&nbsp;This is a complex process which generates circularized DNA as the input to the sequencing process. Similarly MGI requires circularized material for nanoball generation. </span></p><p class="c1"><span class="c20 c12"></span></p><h4 class="c54" id="h.mu9zypp4pqod"><span class="c68 c12">Medium Complexity - Illumina, Ion Torrent, Oxford Nanopore</span></h4><p class="c1"><span class="c20 c12"></span></p><p class="c7"><span class="c36">Oxford Nanopore, Illumina and Ion Torrent all require adaptor sequences to be added to templates to enable the sequencing process. This is usually performed using either ligation or </span><span class="c36">transposon/</span><span class="c36 c70 c133">topoisomerase</span><span class="c36">&nbsp;</span><span class="c0">based techniques.</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c36">While Oxford Nanopore </span><span class="c36">have a direct RNA sequencing kit</span><span class="c36">, sample preparation takes ~2 hours. Similarly Illumina and Ion Torrent kits also require ~2 hours of lab time. The fastest sample preparation route here is likely the transposon based approach used as used in Oxford </span><span class="c36">Nanopore&rsquo;s Rapid DNA sequencing kit, this process takes </span><span class="c36">~10 minutes</span><span class="c36">.</span><sup><a href="#cmnt32" id="cmnt_ref32">[af]</a></sup></p><h4 class="c54" id="h.vjb9d57vewon"><span class="c68 c12">Low Complexity - Helicos, Pacific Biosciences, Direct RNA</span></h4><p class="c1"><span class="c20 c12"></span></p><p class="c7"><span class="c36">In the case of </span><span class="c36">Helicos direct RNA sequencing</span><span class="c19"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?rYncGj&amp;sa=D&amp;source=editors&amp;ust=1679054520013360&amp;usg=AOvVaw2VtBZuiczVWDxRfGGdAwIu">46</a></span><span class="c36">&nbsp;where input RNA already has a naturally </span><span class="c36">pre-existing p</span><span class="c36">olyA tail</span><span class="c36">&nbsp;in other contexts </span><span class="c36">random hexamer primer single molecule sequencing has been demonstrated</span><span class="c19"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?TDYCwr&amp;sa=D&amp;source=editors&amp;ust=1679054520014272&amp;usg=AOvVaw3RgVxKetSEwhyjo34l7Als">53</a></span><span class="c36">. As such</span><span class="c36">&nbsp;no library preparation steps are required</span><span class="c0">&nbsp;in these cases.</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c0">Similarly, Pacific Biosciences could adapt their platform for use with single templates (rather than SMRTbell constructs) sacrificing accuracy for simplified library prep, a configuration that was previously supported on older instruments.</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c36">Failing this, a PolyA tail may be added using readily available polyA tailing kits</span><span class="c19"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?cpcxLU&amp;sa=D&amp;source=editors&amp;ust=1679054520015111&amp;usg=AOvVaw3uLilqnTHhm3XZRDsCZLl9">54</a></span><span class="c36">. This protocol takes ~1 hour.</span></p><h4 class="c54" id="h.w0we1mwshrae"><span class="c68 c12">Library Preparation - Integrated Approaches</span></h4><p class="c1"><span class="c20 c12"></span></p><p class="c7"><span class="c0">This section has discussed existing library preparation approaches. It&rsquo;s important to note that current platforms have been designed to be versatile and serve a number of applications using the same reagent kits and flowcells. However, we can further simplify the library preparation process if we sacrifice this versatility. For example, as discussed above, for Helicos direct RNA sequencing where naturally pre-existing polyA tails are present, no additional sample preparation is required. This is because the Helicos/SeqLL flow cells are coated with poly(dT) oligonucleotides to capture these polyA tailed templates.</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c36">We can imagine an approach where flow cells are coated with different oligonucleotides enabling other templates to be captured.</span><span class="c36">&nbsp;For example, the surface could be coated with random hexamer oligonucleotides allowing a material to be directly captured on the flowcell.</span><span class="c0">&nbsp;This would allow material to be captured on the flow cell without additional library preparation steps. A targeted approach could also be employed where oligonucleotides target specific known sequences (for example known viral sequence).</span></p><p class="c1"><span class="c100 c36 c12 c73"></span></p><h4 class="c54" id="h.3ovb6015dq"><span>Pre-sequencing Steps (Cluster and Colony Generation) - Platform </span><span>Preparation</span><sup><a href="#cmnt33" id="cmnt_ref33">[ag]</a></sup><span class="c68 c12">&nbsp;</span></h4><p class="c1"><span class="c20 c12"></span></p><p class="c7"><span class="c0">While we&rsquo;ve discussed sample and library preparation above there is a third set of processing steps that material often undergoes prior to sequencing. These are often hidden from the user and integrated into the sequencing process itself. However, if we are to build a complete integrated solution they must be considered.</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c0">Most significantly these &ldquo;pre-sequencing&rdquo; steps include the localized amplification of a single template: Clusters (Illumina - Bridge Amplification), DNA amplified beads (Ion Torrent, Genapsys, Ultima Genomics), or DNB (DNA Nanoballs - MGI).</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c0">DNA amplified beads in particular often require dedicated instrumentation (for example the Ion Torrent OneTouch). Adding significant complexity to a complete sequencing solution.</span></p><h3 class="c58" id="h.6b54u5a0ik5"><span>Selection</span><sup><a href="#cmnt34" id="cmnt_ref34">[ah]</a></sup></h3><p class="c1"><span class="c20 c12"></span></p><p class="c7"><span class="c36">W</span><span class="c36">e may want to remove unwanted material prior to sequencing.</span><sup><a href="#cmnt35" id="cmnt_ref35">[ai]</a></sup><span class="c36">&nbsp;This is material that would otherwise appear as background sequence reads, or otherwise interfere with the sequencing process. In other cases background human genomic material may contribute </span><span class="c36">personally identifiable information (PII) and for regulatory reasons may require removal prior to sequencing</span><span class="c0">.</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c0">Removal of unwanted material also allows us to reduce the number of reads we need to generate to reach equivalent sensitivity (see &ldquo;Sensitivity&rdquo;).</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c36">Typically at least the nucleic acid of interest will be selected for. This will involve the use of a DNase or RNase to digest either DNA or RNA. Which could otherwise form part of the sequencing library.</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c36">In RNA sequencing experiments ribosomal RNA (rRNA) is a significant contaminant. </span><span class="c36">Kits are available</span><span class="c19"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?dWnu4m&amp;sa=D&amp;source=editors&amp;ust=1679054520019038&amp;usg=AOvVaw2JelPSueeX5FKTyZB4DDuf">55</a></span><span class="c0">&nbsp;which will target and degrade rRNA, or other genomic RNA contaminants. However these approaches add complexity, for example the kit linked here requires nearly 2 hours of lab time (8mins hands on).</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c36">Beyond this other selection methods may be of interest. Most typically size selection and selection of material contained within viral envelopes.</span><span class="c36">&nbsp;Unfortunately, as noted in Understanding the Target, the majority of viral material may be degraded in our samples, suggesting that it exists outside of the viral envelope.</span><sup><a href="#cmnt36" id="cmnt_ref36">[aj]</a></sup><sup><a href="#cmnt37" id="cmnt_ref37">[ak]</a></sup><span class="c36">&nbsp;This material also appears to be similar in fragment size to background human derived RNA. As such particle, and RNA size selection methods may be of limited utility.</span></p><h3 class="c112 c107" id="h.4rh7z0hdaov8"><span>Solutions - </span><span>Automated and Integrated</span></h3><p class="c1"><span class="c20 c12"></span></p><p class="c7"><span class="c0">To build an effective sample-to-answer platform we will need to automate the steps described above in a low cost platform. Such an automation system is currently unavailable for use on a single sample basis. This is largely because there is no current market for a fixed protocol metagenomic sample preparation system. However as we shall see, viable approaches have already been demonstrated for use in qPCR sample-to-answer systems. We therefore view the development of automated sample preparations systems as a low technical risk problem.</span></p><h4 class="c54" id="h.mhw6jbi6d4ll"><span class="c68 c12">Current Solutions</span></h4><p class="c1"><span class="c20 c12"></span></p><p class="c7"><span class="c36">A number of integrated sample and library preparation devices are available or under development. Existing commercial approaches are largely built around pipette robots, and a number of turnkey platforms are available for </span><span class="c36">use with Illumina sequencers</span><span class="c19"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?tgNg6l&amp;sa=D&amp;source=editors&amp;ust=1679054520021309&amp;usg=AOvVaw1FACHLPyi6Nh16iNAhds7p">56</a></span><span class="c0">. These almost exclusively are designed to process &gt;8 samples, to support larger labs, require skilled personnel, and are not suitable for use in a point of care context.</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c36">Digital fluidic platforms (</span><span class="c36">Voltrax</span><span class="c19"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?1gEuyQ&amp;sa=D&amp;source=editors&amp;ust=1679054520022037&amp;usg=AOvVaw1LnOcqUHg5EqmMu_NuHQps">57</a></span><span class="c36">, Volta</span><span class="c19"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?fx2Y8I&amp;sa=D&amp;source=editors&amp;ust=1679054520022415&amp;usg=AOvVaw29NwFNeICmotTtUcTHs1K7">58</a></span><span class="c36">, Illumina Neoprep</span><span class="c19"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?sInpeV&amp;sa=D&amp;source=editors&amp;ust=1679054520022719&amp;usg=AOvVaw1tV_CElnvJmRtMs2evE7qz">59</a></span><span class="c0">) are also available, to date these have largely been used in a research context. Potentially these instruments can automate complex workflows in a small footprint. But they are generally designed to address research requirements at relatively high cost, and are not integrated into the sequencing platform itself.</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c36">One company (DNAe) is currently developing a </span><span class="c36">sample-to-answer sequencing platform</span><span class="c19"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?ZK4aFk&amp;sa=D&amp;source=editors&amp;ust=1679054520023427&amp;usg=AOvVaw0qhXI9_GTIkmsfaeognIZA">60</a></span><span class="c0">. However, it&rsquo;s unclear if this platform will be applicable for hypothesis-free infectious disease testing.</span></p><p class="c1"><span class="c0"></span></p><h4 class="c54" id="h.4lv1thp6g2sz"><span class="c68 c12">New Solutions</span></h4><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c36">The deployment of a viral metagenomics sequencing based diagnostic platform would require a new generation of automated sample and library preparation instrumentation. Outside of sequencing, fully integrated </span><span class="c36">qPCR sample-to-answer platforms</span><span class="c19"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?tsg7sb&amp;sa=D&amp;source=editors&amp;ust=1679054520024522&amp;usg=AOvVaw33abhT0FicueQYMQMiwucv">61</a></span><span class="c0">&nbsp;are available. Notable examples are the Cepheid Genexpert, GenMark ePlex and Abbott ID NOW. More recently, sample-to-answer platforms specifically targeting SARS-CoV-2 have also been developed. For example the DNANudge developed by TTP.</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c0">These tools integrate both sample preparation and molecular diagnostics platforms into single instruments and consumables. We see three main approaches here, those which use traditional cartridge integrated fluidic systems (Cepheid, DNANudge), novel fluidic approaches (Digital fluidics, GenMark), and approaches which seek to simplify the chemistry, removing the fluidic system entirely (Abbott ID NOW).</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c36">Digital fluidic platforms tend to be more expensive, with the </span><span class="c36">Genmark test sold at $157</span><span class="c19"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Zs1EnC&amp;sa=D&amp;source=editors&amp;ust=1679054520025574&amp;usg=AOvVaw2FHzlT2Y7pfiXJiRhwcJCr">62</a></span><span class="c0">, and aimed at a larger number of targets.</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c36">Traditional fluidic approaches (Cepheid Genexpert, DNANudge) have an estimated manufacturing cost of $3</span><span class="c19"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?nqu5ni&amp;sa=D&amp;source=editors&amp;ust=1679054520026109&amp;usg=AOvVaw1uTAqle5Ua7zTZnp38KGxy">63</a></span><span class="c36">, and are typically sold for ~$20.</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c0">These platforms incorporate the necessary reagents to lyse and extract RNA from a sample. As noted above, for some single molecule platforms (Helicos-like single molecule direct RNA sequencing) this provides sufficient sample preparation to proceed to sequencing.</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c0">In the DNANudge post-clean up cDNA is eluted into an imaging region. This could be replaced with a single molecule imaging region using a non-cyclic chemistry (Reticula). Alternatively, additional reagents could be added to enable adapter ligation or transposon based adapter addition. In this case the imaging window could be replaced with a nanopore array.</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c0">Both these approaches could be implemented without unduly increasing the complexity beyond that of the DNANudge device (manufactured and developed by TTP). As such we can expect such an integrated sample prep and sequencing instrument to have a COGS comparable to the DNANudge and other sample-to-answer platforms such as the Genexpert (~$3).</span></p><p class="c1"><span class="c0"></span></p><p class="c83"><span style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 223.55px; height: 230.13px;"><img alt="" src="images/image32.png" style="width: 223.55px; height: 230.13px; margin-left: 0.00px; margin-top: 0.00px; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px);" title=""></span><span style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 307.91px; height: 225.86px;"><img alt="" src="images/image25.png" style="width: 307.91px; height: 225.86px; margin-left: 0.00px; margin-top: 0.00px; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px);" title=""></span></p><p class="c83"><span class="c0">DNANudge and Cepheid sample-to-answer cartridges. Cepheid ship ~36 million units a year.</span></p><p class="c83 c32"><span class="c0"></span></p><p class="c7"><span class="c0">Beyond this, it&rsquo;s possible that surface amplification (Illumina - bridge amplification) and cyclic sequencing could be integrated into the sequencing cartridge (as in the iSeq) however as discussed in &ldquo;Sequencing Platforms&rdquo; this may result in a platform that no longer meeting our requirements.</span></p><p class="c1"><span class="c0"></span></p><hr style="page-break-before:always;display:none;"><h1 class="c75" id="h.m2k4qug7hy82"><span class="c33 c12"></span></h1><h1 class="c84" id="h.fodn8mjl6y7m"><span class="c33 c12">Conclusions and Recommendations</span></h1><p class="c1"><span class="c20 c12"></span></p><h2 class="c72" id="h.rrtp42o71bdm"><span class="c94 c12 c27">A Roadmap</span></h2><p class="c1"><span class="c20 c12 c27"></span></p><p class="c7"><span class="c20 c12 c27">Our report seeks to provide a roadmap to ubiquitous metagenomic diagnostics. Key to this has been identifying where we are now, and where we are going.</span></p><p class="c1"><span class="c20 c12 c27"></span></p><h3 class="c58" id="h.1ldo51emz09q"><span class="c34 c12 c27">Where are we?</span></h3><p class="c1"><span class="c20 c12 c27"></span></p><p class="c7"><span class="c27">In our discussions of the nature of metagenomic samples in &ldquo;</span><span class="c97 c27"><a class="c2" href="#h.3rdcrjn">Understanding the Sample</a></span><span class="c27">&rdquo; and &ldquo;</span><span class="c27 c97"><a class="c2" href="#h.m6p2op3667yp">Sensitivity</a></span><span class="c20 c12 c27">&rdquo;, we have tried to use our existing studies to estimate the requirements for a metagenomic sequencing platform. Many of these studies are incomplete and limited to a small number of pathogens and tissue types. Sufficient evidence has been collected to estimate the requirements of a metagenomic sequencing platform, but uncertainty remains.</span></p><p class="c1"><span class="c20 c12"></span></p><p class="c7"><span class="c20 c12 c27">We have also reviewed existing sequencing platforms, and how well they fulfill the requirements of metagenomic diagnostics and progress toward new technologies that might address the requirements of this application.</span></p><p class="c1"><span class="c20 c12 c27"></span></p><p class="c7"><span class="c20 c12 c27">What we find is that while certain promising technologies exist, the market has largely failed to create platforms with the characteristics required to address pandemic monitoring and prevention using MGS-based diagnostics.</span></p><p class="c1"><span class="c20 c12"></span></p><h3 class="c58" id="h.tc0c8v6jtuu1"><span class="c34 c12 c27">Where are we going?</span></h3><p class="c7"><span class="c27">Our goal is clearer. We want a simple, effective platform for MGS-based diagnostics. We discuss the technical requirements of such a platform based on our current understanding in &ldquo;</span><span class="c97 c27"><a class="c2" href="#h.2s8eyo1">Technical Requirements and Bottlenecks in Current Approaches</a></span><span class="c27">&rdquo; and &ldquo;</span><span class="c97 c27"><a class="c2" href="#h.a3hi7bn2k67j">Modelling qPCR and Sequencing</a></span><span class="c20 c12 c27">&rdquo;, where we compare sequencing to the current diagnostic gold standard (qPCR).</span></p><h3 class="c58" id="h.fvp1k5i774e2"><span class="c34 c12 c27">How do we get there? </span></h3><p class="c7"><span class="c20 c12 c27">For a roadmapping project, it is not enough to define our start and end points. We should also provide some guidance on how to achieve our goal. In our case, there are likely a number of relatively independent projects that could, however, be advanced in a coordinated manner. These projects will successively move us closer to the goal of fully-automated sample-to-answer diagnostic platforms that can be used in the clinic to detect and contain new potentially pandemic causing pathogens.</span></p><p class="c1"><span class="c20 c12"></span></p><p class="c83"><span style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 529.50px; height: 407.92px;"><img alt="" src="images/image2.png" style="width: 529.50px; height: 407.92px; margin-left: 0.00px; margin-top: 0.00px; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px);" title=""></span></p><h4 class="c54" id="h.gnpy4l3hza6"><span class="c39 c12 c125 c27 c128">Phase 0 - Building a better understanding</span></h4><p class="c1"><span class="c20 c12 c27"></span></p><p class="c7"><span class="c27">In order to set specifications from sample preparation and sequencing platforms, we need a broad understanding of the metagenomic landscape of our samples. Most existing studies (discussed in &ldquo;</span><span class="c97 c27"><a class="c2" href="#h.jyil4u9jz0an">Metagenomic Sequencing Studies</a></span><span class="c20 c12 c27">&rdquo;) have focused on particular targets to answer specific questions and have been relatively small. Consequently, we recommend a range of metagenomic sequencing studies are carried out to aid in the development of metagenomic pathogen detection and diagnostic platforms these would include:</span></p><p class="c1"><span class="c20 c12 c27"></span></p><ul class="c31 lst-kix_bo57k090qe1r-0 start"><li class="c7 c82 li-bullet-0"><span class="c27">Metagenomic </span><span class="c39 c27">baseline</span><span class="c27">&nbsp;studies on </span><span class="c79 c141 c39 c12 c27 c174">healthy individuals</span></li><li class="c7 c82 li-bullet-0"><span class="c27">Metagenomic </span><span class="c39 c27">longitudinal</span><span class="c27">&nbsp;studies of </span><span class="c79 c141 c39 c12 c27 c174">infected individuals</span></li><li class="c7 c82 li-bullet-0"><span class="c27">Metagenomic studies of </span><span class="c39 c27">environmental material</span><span class="c20 c12 c27">.</span></li></ul><p class="c1"><span class="c20 c12 c27"></span></p><p class="c7"><span class="c20 c12 c27">The focus should be on the first two study types. In a baseline study, we seek to gain an understanding of the background material that we would likely see in a sample. Particular open questions to be addressed by these studies are:</span></p><p class="c1"><span class="c20 c12 c27"></span></p><ul class="c31 lst-kix_834gwign38o3-0 start"><li class="c7 c82 li-bullet-0"><span class="c27">What is the extent, and nature of, </span><span class="c39 c27">novel DNA and RNA</span><span class="c20 c12 c27">&nbsp;present in metagenomic samples? Can this be easily classified as non-pathogenic?</span></li><li class="c7 c82 li-bullet-0"><span class="c27">How </span><span class="c39 c27">fragmented</span><span class="c27">&nbsp;is </span><span class="c39 c27">human</span><span class="c27">&nbsp;DNA and RNA in a sample? To what extent is </span><span class="c39 c27">pathogenic</span><span class="c20 c12 c27">&nbsp;DNA and RNA fragmented?</span></li><li class="c7 c82 li-bullet-0"><span class="c27">Is human DNA and RNA in a sample largely </span><span class="c39 c27">cell-free</span><span class="c20 c12 c27">?</span></li><li class="c7 c82 li-bullet-0"><span class="c27">Is pathogenic DNA and RNA in a sample largely </span><span class="c39 c27">active</span><span class="c20 c12 c27">?</span></li></ul><p class="c1"><span class="c20 c12 c27"></span></p><p class="c7"><span class="c20 c12 c27">Such projects would likely use a combination of short- and long-read sequencing approaches. In particular, long-read approaches and sample preparation techniques that keep long fragments intact would be an advantage. These projects would give us a baseline understanding of the pathogenic fraction and how intact pathogenic material is in a sample. As such they would be useful for the parallel development of pathogen detection informatics platforms. They would also allow us to course correct during the development of sample-to-answer diagnostic instrumentation, as studies help clarify platform requirements.</span></p><p class="c1"><span class="c20 c12"></span></p><h4 class="c54" id="h.wcsbr9mmj4oc"><span class="c68 c12">Phase 1 - Development of Novel Sample Preparation Tools For Use With Existing Sequencers</span></h4><p class="c7"><span class="c12 c20">In &ldquo;Automated and Integrated Preparation&rdquo; we discussed approaches to automating fixed sample preparation protocols for metagenomic sequencing. Low cost fixed protocols are practical today, however have not been developed for a number of commercial reasons.</span></p><p class="c1"><span class="c20 c12"></span></p><p class="c7"><span class="c20 c12">As such, in phase 1 we would seek to develop a low cost, automated sample preparation platform which could be coupled with existing sequencing instrumentation. Such a platform would not meet our overall technical requirements in terms of time-to-answer or cost-per-sample.</span></p><p class="c1"><span class="c20 c12"></span></p><p class="c7"><span class="c20 c12">However it would allow us to independently develop and re-disk sample preparation tools. Such a platform would allow us to more easily perform studies giving us a deeper understanding of metagenomic samples (phase 0) and allow us to address real applications where time-to-answer and cost-per-sample is not a barrier (for example track-and-trace applications).</span></p><p class="c1"><span class="c20 c12"></span></p><h4 class="c54" id="h.vvccaruisbmk"><span class="c68 c12">Phase 2 - Development of Novel Sequencing Instrumentation</span></h4><p class="c1"><span class="c20 c12"></span></p><p class="c7"><span class="c20 c12">Current sequencing instrumentation is a poor fit for metagenomic sequencing based diagnostics (see &ldquo;Technical requirements and bottlenecks in current approaches&rdquo;). The largest barriers to broad adoption likely being the lack of sample-to-answer platforms, relatively long time-to-answer and high cost-per-sample.</span></p><p class="c1"><span class="c20 c12"></span></p><p class="c7"><span class="c20 c12">Exactly how low cost our sequencing platform needs to be depends on how sensitive to cost you believe large scale deployments of metagenomic sequencing based diagnostics is. </span></p><p class="c1"><span class="c20 c12"></span></p><p class="c7"><span class="c70 c88">In &ldquo;Background&rdquo; we discuss our motivation for hitting the same price point with sequencing, as is currently provided by qPCR. To summarize, to create a cultural shift away from hypnosis driven testing which will make us robust to future pandemics we need to test a large fraction of the 120M individuals </span><span class="c0">seeking respiratory care every year in the US (and more broadly worldwide). COVID19 has shown that clinicians are willing to perform diagnostic tests on mass for respiratory conditions. And tools such as the GenXpert are widely deployed in a clinical context.</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c0">However, without a tool that provides essentially a full respiratory panel (and metagenomic testing as bonus) at the same cost as qPCR, clinicians are likely to use a metagenomic test as a second or third stage diagnostic. We therefore seek to provide a tool that deplaces qPCR and builds robust pandemic prevention into our diagnostic culture.</span></p><p class="c1"><span class="c88 c100 c12 c70"></span></p><p class="c7"><span class="c88 c100 c12 c70">A test costing $50+ (likely billing at $500 to $1000) is unlikely to create this cultural shift. However, we address both cost brackets here, to support projects where (for example) philanthropic funding of diagnostic testing may be obtained.</span></p><p class="c1"><span class="c20 c12"></span></p><p class="c7"><span>We also discuss approaches in terms of technical risk which would allow approaches to be matched to funding sources with an appropriate risk profile.</span></p><h5 class="c89" id="h.70c09eug8ye8"><span>$</span><span>1 to $10 </span><span class="c28 c12">- Low Technical Risk</span></h5><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c36">As discussed in the report, we believe that an evolution of single molecule optical approaches developed by Helicos could be a good fit for low-cost sequencing instrumentation (this approach is currently being pursued by Reticula). The approach uses well-validated techniques and takes advantage of advances in image sensors in recent years. Of all existing approaches, this approach has the simplest sample preparation (can sequence </span><span class="c36">native RNA without adapters</span><span class="c0">) and does not require on-device amplification.</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c36">The basic technique is 20 years old,</span><span class="c0">&nbsp;and while new techniques and IP will need to be developed, there is broad FTO on the fundamental approach. Significant technical innovation is required to develop effective real time sequencing on this platform without introducing additional complexity. However single molecule detection platforms using transient binding are now well established (DNA-PAINT) and we believe technically feasible.</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c36">The main disadvantage of this approach</span><sup><a href="#cmnt38" id="cmnt_ref38">[al]</a></sup><sup><a href="#cmnt39" id="cmnt_ref39">[am]</a></sup><sup><a href="#cmnt40" id="cmnt_ref40">[an]</a></sup><span class="c36">&nbsp;is the relatively low data quality and throughput which made the technique a poor fit for whole genome sequencing. However, given that it meets all our other requirements and</span><span class="c36">&nbsp;specifications are sufficient for viral diagnostics </span><span class="c0">we believe this is a good fit here (disclosure: one of the authors of this report is the founder of Reticula, a company pursuing this approach).</span></p><p class="c1"><span class="c0"></span></p><h5 class="c89" id="h.p6dtnewwemij"><span class="c135">$</span><span class="c135">1 to $10 </span><span class="c135">- </span><span class="c28 c12">High Technical Risk</span></h5><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c36">Nanopore sequencing platforms from Oxford Nanopore Technologies and Qitan currently have sufficient data quality, speed and throughput for the applications under discussion in this report. By integrating protein nanopore sensors into low cost sample preparation systems a sample-to-answer platform could be created. Sample preparation is more complex than that used for single molecule optical approaches, </span><span class="c36">requiring conversion to cDNA</span><sup><a href="#cmnt41" id="cmnt_ref41">[ao]</a></sup><sup><a href="#cmnt42" id="cmnt_ref42">[ap]</a></sup><sup><a href="#cmnt43" id="cmnt_ref43">[aq]</a></sup><sup><a href="#cmnt44" id="cmnt_ref44">[ar]</a></sup><span class="c0">&nbsp;and adapter addition (using ligation or transposon based approaches).</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c0">A key limitation here is the relatively high cost of goods of these platforms are present, which is likely at least $50. As such significant innovation would be required to reduce the cost of these platforms by one or two orders of magnitude (either through directly reducing manufacturing costs, or integrating washing into the instrument to reduce the cost-per-run).</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c0">Discussions with potential fabrication partners have suggested that a low cost of goods (~$1 per 100 channel device) may be possible with significant investment in manufacturing ($100M to $1B). As such, lowever technical risk may be achieved, if significant investment is available.</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c0">Broad FTO is also not available here, the development of a new platform would require either buy-in from Oxford Nanopore (who may be hesitant to develop a lower-cost platform competing with their current instruments) or the development of new IP avoiding current approaches. FTO however may be available on the basic sequencing approach, and it may be possible to obtain FTO through the development of novel motion control strategies.</span></p><p class="c1"><span class="c0"></span></p><h5 class="c89" id="h.60su3oqp9rhf"><span class="c135">$</span><span class="c135">1 to $10 </span><span class="c135">- </span><span class="c28 c12">Very High Technical Risk</span></h5><p class="c1"><span class="c0"></span></p><p class="c7"><span>Novel sequencing approaches can potentially meet and exceed all our requirements, however they have the significant disadvantage that their practical feasibility has not been demonstrated. The approaches most likely to be of interest here are novel solid-state nanopore approaches. This could potentially allow reusable sequencing instrumentation resulting in a lower cost of goods than biological nanopore sequencing. The lowest risk approach here may be a combination of enzymatic motion control (as used by Oxford Nanopore) and solid-state sensing, or using </span><span>hybrid nanopores</span><span class="c41"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?rP5s7l&amp;sa=D&amp;source=editors&amp;ust=1679054520037862&amp;usg=AOvVaw3jW899LcJlJwrO6ZUABoi9">64</a></span><span class="c20 c12">. Oxford Nanopore has given us a clearer understanding of the feature sizes and performance characteristics of ionic current detection sequencing systems and we would seek to build on this work. However, such a platform would require significant advances in fabrication approaches and likely does not have FTO (requiring enzymatic motion control, currently used by ONT, or the development of novel motion control approaches). Such a project therefore retains significant risk, but may just be within practical feasibility within a 10 year timeline.</span></p><p class="c1"><span class="c20 c12"></span></p><p class="c7"><span class="c20 c12">Other solid-state nanopore approaches will require the development of new sensing methodologies. We have discussed these in previous sections, but overall they remain research projects. It may be prudent to fund research in this area, but given the 20 year history of solid-state nanopore sequencing, such projects may not yield commercial results with a 10 year timeline.</span></p><p class="c1"><span class="c20 c12"></span></p><p class="c7"><span class="c20 c12">However, there is potential to fund the development of such projects either with an academic or commercial context.</span></p><p class="c1"><span class="c0"></span></p><h5 class="c89" id="h.s3moraed02h6"><span class="c28 c12">$50 to $100</span></h5><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c36">A COGS of $50 to $100 puts our platform </span><span class="c36">out of reach for routine diagnostic use</span><sup><a href="#cmnt45" id="cmnt_ref45">[as]</a></sup><sup><a href="#cmnt46" id="cmnt_ref46">[at]</a></sup><sup><a href="#cmnt47" id="cmnt_ref47">[au]</a></sup><span class="c36">. </span><span class="c36">At this price point tests are only likely to be ordered when the most common infections have been tested for using other approaches.</span><span class="c0">&nbsp;Current sample-to-answer panel platforms currently sit in this space and provide diagnostics covering a panel of ~20 targets.</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c36">However, this COGS is practical using approaches currently commercially deployed, and as such technical risk is low.</span></p><p class="c1"><span class="c0"></span></p><h6 class="c89" id="h.z7fpuvd3dbc7"><span class="c140 c145 c12 c125 c35 c148">Illumina-style SBS</span></h6><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c0">Current Illumina sequencing runs likely have a COGS in this range. As discussed in the report elsewhere, the required sample preparation can be automated at low cost. As such the technical approaches for single sample-to-answer metagenomic sequencing already exist.</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c36">Using the Illumina SBS sequencing approach we can likely easily obtain a run time of ~2 hours. This is longer than we&rsquo;d ideally like and longer than existing panel platforms (BioFire FilmArray). Cluster generation may fundamentally limit run time here (Illumina&rsquo;s shortest cluster generation times are </span><span class="c36">60 minutes</span><span class="c19"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?3lbxGA&amp;sa=D&amp;source=editors&amp;ust=1679054520040673&amp;usg=AOvVaw29F4JFBRCFvvQ726q3C2Zg">49</a></span><span class="c0">).</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c0">All required techniques are now off-patent, and it should be possible to pursue this approach with full freedom to operate. A number of companies have now developed &ldquo;Illumina-style&rdquo; platforms and it may be possible to sub-contract the development of a full sample-to-answer metagenomic sequencing platform relatively easily.</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c0">Further innovation here could provide effective sample-to-answer solutions as well. For example the development of a cartridge which isolates the fluidic system (such as is used in the iSeq) or one that simplifies the cartridge and fluidic system using novel sequences approaches.</span></p><p class="c1"><span class="c0"></span></p><h6 class="c89" id="h.5oqubcmc212l"><span class="c140 c145 c12 c148 c125 c35">Nanopore</span></h6><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c36">Nanopore sequencing can likely currently be performed at a COGS in this range as well. The principal advantage of using this approach is that a run time of less than 1 hour should be easily achievable here. In addition to this, </span><span class="c36">the longer read length may be an advantage for certain use cases.</span><sup><a href="#cmnt48" id="cmnt_ref48">[av]</a></sup></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c0">The principal disadvantage here is a lower accuracy as nanopore sequencing currently has an overall high error rate and significant systematic errors. For our application, these are unlikely to be significant issues. </span></p><p class="c1"><span class="c0"></span></p><h4 class="c54" id="h.bwkztcjrhr0a"><span class="c68 c12">Phase 3 - Integration</span></h4><p class="c1"><span class="c20 c12"></span></p><p class="c7"><span class="c20 c12">With appropriate sample preparation and sequencing systems available platforms we can begin addressing point-of-care applications. However to provide a full sample-to-answer platform we will need to integrate our validated sample preparation and sequencing approach.</span></p><p class="c1"><span class="c20 c12"></span></p><p class="c7"><span class="c20 c12">In this phase we would take our selected sequencing approach and validated sample preparation system and integrate them into a final platform which can be used by low skilled users. It is likely that much of this integration work will occur in parallel with the development of the sample preparation and sequencing platform developed in phases 2 and 3. Phase 3 itself therefore would take lessons learned from initial deployments of these independent systems to create a refined commercially viable platform.</span></p><p class="c1"><span class="c20 c12"></span></p><h2 class="c72" id="h.lfk66pann063"><span class="c94 c12">Conclusion </span></h2><p class="c7"><span class="c20 c12">In this report we have tried to provide a realistic roadmap to a clinical metagenomic sequencing platform which can provide robust pandemic preparedness. We have argued that to do this we believe it is necessary to displace qPCR as the gold standard in infectious disease testing. And we have provided a roadmap to enable the development of sample-to-answer sequencing platforms capable of displacing qPCR.</span></p><p class="c1"><span class="c20 c12"></span></p><p class="c7"><span class="c20 c12">While much technical and market risk remains, we believe these approaches give us the best chance at building diagnostic tools capable of addressing the challenges posed by future pandemic capable pathogens.</span></p><p class="c1"><span class="c20 c12"></span></p><p class="c1"><span class="c20 c12"></span></p><hr style="page-break-before:always;display:none;"><h1 class="c75" id="h.tus5owxgbml0"><span class="c33 c12"></span></h1><h1 class="c84" id="h.2x8k73bad8k2"><span>Appendix A - </span><span>Platform Requirements</span></h1><p class="c7"><span class="c20 c12">The metagenomic sequencing approach described in this document relies in the direct or in-direct sequencing of viral material. Acquired sequence data may be processed in a number of ways. As a baseline we will need to be able to detect existing, known, viruses. This is most commonly performed through alignment of reads to a reference of known viruses.</span></p><p class="c1"><span class="c20 c12"></span></p><p class="c7"><span>In order to assess the read length and accuracy requirements of our sequencing platform we simulated SARS-CoV-2 reads of varying lengths and accuracy. </span><span>These reads were then aligned to the complete human genome, all NCBI Viruses, and the SARS-CoV-2 reference.</span></p><p class="c1"><span class="c20 c12"></span></p><p class="c7"><span>The figure below shows the percentage of reads that correctly aligned to the SARS-CoV-2 reference.</span></p><p class="c1"><span class="c20 c12"></span></p><p class="c7"><span>This plot suggests that the majority of simulated reads are alignable at 20 bp, with an error rate as high at 5%.</span></p><p class="c1"><span class="c20 c12"></span></p><p class="c7"><span style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 420.50px; height: 227.17px;"><img alt="" src="images/image10.png" style="width: 420.50px; height: 227.17px; margin-left: 0.00px; margin-top: 0.00px; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px);" title=""></span></p><p class="c1"><span class="c20 c12"></span></p><p class="c7"><span>We can also simulate human reads of this length and error rate, then align them back to the human genome and SARS-CoV-2. If errored human material were to align to the SARS-CoV-2 reference this could result in a false positive. In simulation however, </span><span>we have </span><span class="c20 c12">been able to generate any such reads (after generating 100,000 reads).</span></p><p class="c1"><span class="c20 c12"></span></p><p class="c7"><span class="c20 c12">Using this data, we can calculate the false negative and positive rates from these simulated reads. These compare favorably to known rates for qPCR:</span></p><p class="c1"><span class="c20 c12"></span></p><p class="c1"><span class="c20 c12"></span></p><p class="c1"><span class="c20 c12"></span></p><p class="c1"><span class="c20 c12"></span></p><a id="t.29ac8dfb0a86e9587bd5db351cd501c176e733c9"></a><a id="t.2"></a><table class="c127"><tr class="c78"><td class="c157" colspan="1" rowspan="1"><p class="c1"><span class="c20 c12"></span></p></td><td class="c183" colspan="1" rowspan="1"><p class="c83"><span class="c20 c12">qPCR</span></p></td><td class="c93" colspan="1" rowspan="1"><p class="c83"><span class="c20 c12">20bp, 5% error</span></p></td></tr><tr class="c187"><td class="c164" colspan="1" rowspan="1"><p class="c83"><span class="c20 c12">False Negative Rate</span></p></td><td class="c171" colspan="1" rowspan="1"><p class="c83"><span class="c20 c12">1%</span></p></td><td class="c189" colspan="1" rowspan="1"><p class="c83"><span class="c20 c12">0.01%</span></p></td></tr><tr class="c78"><td class="c182" colspan="1" rowspan="1"><p class="c83"><span class="c20 c12">False Positive Rate</span></p></td><td class="c163" colspan="1" rowspan="1"><p class="c83"><span class="c20 c12">1.1%</span></p></td><td class="c176" colspan="1" rowspan="1"><p class="c83"><span class="c20 c12">0%</span></p></td></tr></table><h1 class="c84" id="h.z7yod4pc4rr"><span class="c33 c12">Appendix B - Ontology of Sequencing Approaches</span></h1><p class="c43"><span class="c0">By defining an overall ontology of DNA sequencing approaches we can address the limitations of approaches to sequencing with shared characteristics. We should be careful to note that many ontologies are possible, and that some approaches are not easily classifiable. Nevertheless, such an approach may help us assess technological approaches at a high level, before addressing edge cases.</span></p><p class="c43"><span class="c0">In this appendix we seek to enumerate current and proposed approaches to massively parallel sequencing (platforms which generate &gt;100,000 reads). We will also touch upon the relative merits of these approaches with respect to metagenomic sequencing.</span></p><h2 class="c175" id="h.mfrsqmeci3jy"><span class="c100 c111 c39 c12">Single Molecule versus Ensemble</span></h2><p class="c43"><span class="c0">Broadly DNA sequencing approaches may be classified as single molecule or ensemble. As the name suggests, single molecule approaches seek to identify the individual nucleotides on &nbsp;individual strands. </span></p><p class="c43"><span class="c0">In contrast to this, market dominating approaches have used ensemble methods. In these approaches amplified DNA is used as the input to the sequencing process. A typical example of this is Illumina sequencing-by-synthesis, where a single strand of DNA is used to grow a cluster of identical strands using bridge amplification.</span></p><p class="c43"><span class="c0">The most significant advantages of ensemble approaches are:</span></p><ol class="c31 lst-kix_u1miwd4ifplz-0 start" start="1"><li class="c43 c82 li-bullet-0"><span class="c36">Detecting signal from multiple copies simultaneously is technically easier.</span></li><li class="c43 c82 li-bullet-0"><span class="c0">Amplified clusters are more robust to damage.</span></li></ol><p class="c43"><span class="c0">By aggregating signal from multiple copies, ensemble approaches have been able to achieve higher accuracy than single molecule approaches. </span></p><p class="c43"><span class="c36">However the use of amplified material brings its own disadvantages. In particular by using a polymerase to amplify DNA we limit the overall accuracy of the </span><span class="c36">system to the accuracy of polymerase</span><span class="c0">. The amplification process also increases the overall complexity and cost of a sequencing approach.</span></p><h2 class="c72" id="h.bvuwefny2o5h"><span class="c94 c12">Cluster/Colony Approaches</span></h2><p class="c43"><span class="c0">Ensemble approaches currently dominate the DNA sequencing market. Specifically Illumina is the market leader in DNA sequencing with an ~80% market share (source DeciBio report).</span></p><p class="c43"><span class="c0">We will therefore discuss the approach used by Illumina in some detail and use this as a comparison point for other approaches.</span></p><h3 class="c43 c107" id="h.4xpz5kje2fpk"><span class="c34 c12">Surface Amplification</span></h3><p class="c43"><span class="c36">As the name suggests, colony approaches use spatially confined duplicates created from a single template. A number of approaches have been used to enable this, the most successful deployment is the bridge amplification process used in Illumina sequencing (originally developed by </span><span class="c36">Manteia Predictive Medicine</span><span class="c19"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?3aT2cI&amp;sa=D&amp;source=editors&amp;ust=1679054520050462&amp;usg=AOvVaw2EreEgcU6kstKWHsKPsLJK">65</a></span><span class="c0">.</span></p><p class="c43"><span class="c0">In this approach single molecules are first attached to a surface. The surface is first coated with oligonucleotides. DNA templates to be sequenced is prepared to which adapter sequences have been attached (either through ligation or other processes). These adapter are then used to attach the templates to the flowcell at both ends creating a &ldquo;bridge&rdquo; like structure.</span></p><p class="c43"><span class="c0">A polymerase is used to synthesize a complementary strand, creating a double stranded bridge. This is then melted, resulting in two copies of the original template (one complementary to the first). The process then repeats, with the two templates creating bridges performing further amplification cycles. After several iterations a colony or &ldquo;cluster&rdquo; of spatially localized molecules is created. Approximately half of which is identical to the original template and half to the complementary sequence.</span></p><p class="c43"><span>&#8203;</span><span style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 624.00px; height: 133.33px;"><img alt="" src="images/image34.png" style="width: 624.00px; height: 133.33px; margin-left: 0.00px; margin-top: 0.00px; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px);" title=""></span></p><p class="c11"><span class="c36">Bridge Amplification from </span><span class="c36">Illumina</span><span class="c19"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?oB24fm&amp;sa=D&amp;source=editors&amp;ust=1679054520051577&amp;usg=AOvVaw0JGYcemmtqutTsgkioc4N5">66</a></span><span class="c0">.</span></p><p class="c11 c32"><span class="c0"></span></p><p class="c43"><span class="c0">Illumina have further developed the basic bridge amplification approach, allowing for isothermal amplification (heating to melt the double stranded molecules is no longer required) and introducing patterned flowcells, creating dense ordered arrays of clusters.</span></p><p class="c43"><span class="c0">Other vendors have also pursued alternative colony generation approaches. In particular 454 and Ion Torrent (emulsion PCR) and Complete Genomics (now part of MGI) through the use of rolling circle amplification (RCA).</span></p><h3 class="c43 c107" id="h.pc4p5acwoajf"><span class="c34 c12">Sequencing-by-synthesis</span></h3><p class="c43"><span class="c0">With amplified colonies in place we can proceed to sequencing. Sequencing-by-synthesis is an approach where the incorporation of complementary nucleotides by a polymerase enables the sequencing process. Most typically this is through the incorporation of a detectable label. The diagram below shows how successive labels are incorporated (detected) and then removed:</span></p><p class="c43"><span style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 624.00px; height: 126.67px;"><img alt="" src="images/image28.png" style="width: 624.00px; height: 126.67px; margin-left: 0.00px; margin-top: 0.00px; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px);" title=""></span></p><p class="c43"><span class="c0">While sequencing-by-synthesis can be used for sequencing single molecules, in colony approaches there are a number of unique issues and advantages to consider.</span></p><p class="c43"><span class="c0">In the colony approach, multiple strands in a colony will be incorporating labels. This means that significantly more signal will be available during the detection process. However it also means that the multiple strands within a colony will need to be kept synchronized.</span></p><p class="c43"><span class="c0">In Illumina sequencing this synchronization is accomplished through the use of reversible terminators. These terminators ensure that only a single nucleotide can be incorporated into a strand prior to detection.</span></p><p class="c43"><span class="c0">As such the use of reversible terminators means that the sequencing process must occur cyclically. Reversible terminators are flowed into the flowcell and incorporated. Un-incorporated labels are then removed, and the flowcell is imaged to determine the incorporate base type. The terminator and labels are then removed (cleaved) prior to another round of incorporation.</span></p><p class="c43"><span class="c0">This cyclic sequencing process is dependent on a complex fluidic and reagent system. It brings complexity (increasing consumable cost) and the time to flow in reagents, incorporate, and image flowcells ultimately puts a limit on the time taken to sequence.</span></p><p class="c43"><span class="c0">Other colony based approaches (Ion Torrent, 454) use a so called &ldquo;single channel&rdquo; sequencing approach. These systems only incorporate a single nucleotide type in a cycle. They therefore do not require reversible terminators, simplifying the chemical approach. However, as runs of identical nucleotides (homopolymers) will result in multiple incorporation, these platforms can have issues determining the sequence of longer homoploymer runs (e.g. a run of 5 As compared to 6).</span></p><h3 class="c81" id="h.a3pklzwy7cxt"><span class="c34 c12">Other Colony/Cluster Approaches</span></h3><p class="c43"><span class="c0">In the above discussion we&rsquo;ve largely focused on Illumina&rsquo;s sequencing approach. A number of other colony based sequencing platforms are available or in development. These platforms are also similarly limited, but for completeness we mention them here.</span></p><p class="c43"><span class="c0">The most notable non-optical SBS platform is that provided by Ion Torrent (Thermo Fisher). This platform uses an ISFET (Ion Sensitive FET) chip to detect the incorporation of nucleotides. Ions are generated during the incorporation of wildtype nucleotides, leading to a simpler chemical process.</span></p><p class="c43"><span class="c36">However the ISFET chips are not small, and the COGS here is likely quite significant. Runs </span><span class="c36">cost in the region of $1000 to $2000</span><span class="c19"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?wVFLHC&amp;sa=D&amp;source=editors&amp;ust=1679054520054343&amp;usg=AOvVaw3MdX1M4N9qYUy6dcJCld6C">67</a></span><span class="c36">. Ion Torrent&rsquo;s market share is small (DeciBio) and their margins are likely low. COGS alone makes them a poor fit for the applications we are evaluating. Run time is also longer than desirable (</span><span class="c36">2.5h minimum</span><span class="c19"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?ioZdSn&amp;sa=D&amp;source=editors&amp;ust=1679054520054841&amp;usg=AOvVaw3pi_YYgKqmfhaAcCI2dHuN">68</a></span><span class="c0">&nbsp;+ prep).</span></p><p class="c43"><span class="c36">Companies have also looked at on-chip colony based optical platforms. The most successful of these is probably the Illumina iSeq, which images clusters directly coupled to an imaging sensor. But others have also investigated novel on-chip optical colony based sequencing. For example Personal Genomics (</span><span class="c36">Triple-junction photodiodes</span><span class="c19"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?cBXhtv&amp;sa=D&amp;source=editors&amp;ust=1679054520055353&amp;usg=AOvVaw2UJRpZx2OZksTePSqewmYc">69</a></span><span class="c36">) and inSilixa (</span><span class="c36">integrated platform</span><span class="c19"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?qmajN5&amp;sa=D&amp;source=editors&amp;ust=1679054520055887&amp;usg=AOvVaw2F85EnxCMKjrsG0jxeyCTK">70</a></span><span class="c0">). Due to the fundamental limitations of a chip-based colony sequencing platform, these are unlikely to be compelling for our application (high run cost, and long run time).</span></p><h3 class="c43 c107" id="h.13yw0x74v0dv"><span class="c34 c12">Summary and Further Thoughts</span></h3><p class="c43"><span class="c0">With the expiration of Illumina&rsquo;s basic sequencing-by-synthesis IP, a number of other players have entered the market. In particular Element Bio, Omniome (PacBio), and Singular Genomics have announced new instruments and MGI have instruments on the market, which they are now able to launch globally. </span></p><p class="c43"><span class="c0">All these players have proposed novel implementations of the colony sequencing-by-synthesis approach. With some (Element, Omniome) suggesting they can reach higher accuracy or lower cost (Ultima).</span></p><p class="c43"><span class="c0">For our purposes, these companies largely play into the same market as Illumina, and for the most part have similar limitations in terms of COGS and run time.</span></p><p class="c43"><span class="c0">They will most likely put pressure on Illumina to reduce their high (70%+ margins). Even with this dramatic reduction in cost, single runs will be too expensive to use for individual patient samples at point of care (likely COGS &gt;$50 as discussed elsewhere). As such we do not expect them to be disruptive.</span></p><h2 class="c175" id="h.c2gd49y0vam8"><span class="c100 c39 c12 c111">Single Molecule Approaches</span></h2><p class="c43"><span class="c0">While ensemble methods dominate the market, single molecule approaches are also potentially attractive if certain technical barriers can be overcome. By avoiding amplification we can remove errors introduced during the amplification process, and with some methods significantly increase read length.</span></p><p class="c43"><span class="c0">Using single molecule approaches we may also avoid cost and complexity associated with the amplification process required in ensemble approaches.</span></p><p class="c43"><span class="c0">However, single molecule detection requires more sensitive detectors and generally a lower signal to noise ratio is observed. As such, while amplification errors are avoided, the single read error rate is generally higher in single molecule sequencing.</span></p><p class="c43"><span class="c0">Single molecule approaches have to date largely focused on two main approaches. Nanopore sequencing and optical sequencing.</span></p><h3 class="c81" id="h.iw4fsljuy5of"><span class="c34 c12">Nanopore</span></h3><p class="c43"><span class="c0">Broadly, nanopore approaches sense DNA (or RNA) as it translocates (goes through) a small aperture (hole). DNA is nanoscale polymer, as such the aperture needs to be on the same scale to allow detection to take place. That is, approximately 1 nanometer (1millionth of a millimeter).</span></p><p class="c11"><span style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 290.46px; height: 378.19px;"><img alt="" src="images/image22.png" style="width: 290.46px; height: 378.19px; margin-left: 0.00px; margin-top: 0.00px; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px);" title=""></span></p><p class="c43"><span class="c0">Nanopore approaches vary in terms of the sensing approach used, and the methods used to construct the pore. To date only two companies have commercially released nanopore sequencers: Oxford Nanopore and Qitan Technology.</span></p><p class="c43"><span class="c0">Both these companies use the same basic biological ionic current sensing approach. As such, we&rsquo;ll begin by reviewing this approach before other nanopore approaches under development.</span></p><h4 class="c103" id="h.igbot3ypyq3n"><span class="c68 c12">Ionic Current Sensing using Biological Nanopores</span></h4><p class="c1"><span class="c20 c12"></span></p><p class="c7"><span class="c0">Ionic current sensing detects analytes through the blockage of an ionic current through a nanopore. Schematically this is shown below:</span></p><p class="c1"><span class="c0"></span></p><p class="c83"><span style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 369.68px; height: 261.39px;"><img alt="" src="images/image1.png" style="width: 369.68px; height: 261.39px; margin-left: 0.00px; margin-top: 0.00px; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px);" title=""></span></p><p class="c43"><span class="c36">In this approach a ionic buffer solution is placed either side of an aperture under a bias voltage. Current flows between the electrodes transported by the flow of charged atoms (ions) through the aperture. In a nanopore, this current is on the order of picoamps (in </span><span class="c36">practice a few hundred picoamps</span><span class="c19"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?hA19QJ&amp;sa=D&amp;source=editors&amp;ust=1679054520059413&amp;usg=AOvVaw0WXsilew4Gcg4-VeS3mXSp">71</a></span><span class="c0">). We can get some sense of the magnitude of a picoamp by comparing it to the number of electrons required to carry this much current. This is roughly 6 million electrons per second.</span></p><p class="c43"><span class="c0">This seems like a large number, until we consider a number of other factors. In addition to this, the best current sense amplifiers have a noise level of 0.145pA RMS at 10Khz bandwidth.</span></p><p class="c43"><span class="c0">As DNA moves (translocates) through the pore it blocks the ionic current, each nucleotide blocks the pore and restricts current flow to a different degree. The difference between the highest and lowest blockage currents tends to be ~15pA.</span></p><p class="c43"><span class="c36">Current biological nanopore sequencing platforms sense DNA translocation at </span><span class="c36">&lt;1000 bases/s</span><span class="c19"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?29ugdR&amp;sa=D&amp;source=editors&amp;ust=1679054520060530&amp;usg=AOvVaw3aPN3jqnohh-IjOKOiFyxh">72</a></span><span class="c0">. Due to the fundamental sensing limitations described above, it&rsquo;s unlikely that this approach will be able to significantly exceed this.</span></p><p class="c43"><span class="c0">Natively, DNA will translocate through a biological nanopore at millions of bases per second. In order to slow down translocation, biological nanopore sequencing approaches have incorporated enzymatic motion control strategies to slow translocation and therefore enable sequencing:</span></p><p class="c11"><span style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 560.50px; height: 354.80px;"><img alt="" src="images/image8.png" style="width: 560.50px; height: 354.80px; margin-left: 0.00px; margin-top: 0.00px; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px);" title=""></span></p><p class="c11"><span class="c36">The </span><span class="c36">stranded Nanopore sequencing approach</span><span class="c19"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?PqSNPK&amp;sa=D&amp;source=editors&amp;ust=1679054520061407&amp;usg=AOvVaw10Yn0h8fRD5BM2sg3Z4CuF">73</a></span><span class="c0">.</span></p><p class="c43"><span class="c36">In order to enable this platform, a number of bilayers need to be constructed on an array. Nanopores then self insert into these bilayer membranes stochastically. Some bilayers will therefore have no pore, some one and other multiple. However, only those bilayers with a single pore can produce usable sequence data. </span><span class="c36">This process is Poisson limited to </span><span class="c36">~36% of pore</span><span class="c19"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?iuQJNU&amp;sa=D&amp;source=editors&amp;ust=1679054520062056&amp;usg=AOvVaw2qAz6d2sCyekeayEut_9EM">74</a></span><span class="c36">&nbsp;providing usable data</span><span class="c36">. To compensate for this, Oxford Nanopore arrays have 4 wells multiplexed to a single sensing channel so that multiple and unoccupied wells do not use an acquisition channel.</span><sup><a href="#cmnt49" id="cmnt_ref49">[aw]</a></sup><sup><a href="#cmnt50" id="cmnt_ref50">[ax]</a></sup><sup><a href="#cmnt51" id="cmnt_ref51">[ay]</a></sup></p><p class="c43"><span class="c0">A minion sensor array contains 2048 sensing regions. The total sensing area is ~5x13mm (ref analysis). This is bonded directly to a sensing ASIC in a disposable flowcell and suggests wells are currently on the order of 150 micron. </span></p><p class="c43"><span class="c36">The bilayers are fabricated on a silicon substrate, and this cost is likely a significant fraction of the Minion flowcell COGS. At volume, we would expect these dies, on a standard </span><span class="c36">process to cost $5 to $18</span><span class="c19"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?RWnCUe&amp;sa=D&amp;source=editors&amp;ust=1679054520062872&amp;usg=AOvVaw2pzlzU6Fq6Q63A2DTFDOS3">75</a></span><span class="c0">.</span></p><p class="c43"><span class="c36">Oxford Nanopore have suggested that they can decrease well size to </span><span class="c36">40 microns</span><span class="c19"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?fZzaG6&amp;sa=D&amp;source=editors&amp;ust=1679054520063379&amp;usg=AOvVaw0A-btPDGw5wfjpgMEw9Trj">76</a></span><span class="c0">, and that this would enable ~100,000 nanopores on a piece of silicon 16x30mm.</span></p><p class="c43"><span class="c0">Our central thesis is that in order to provide a robust, global metagenomic sequencing based diagnostic platform that can be responsive to future threats single runs need to be near cost competitive with qPCR. Without major innovation, it&rsquo;s difficult to see how nanopore sequencing can address this requirement.</span></p><p class="c43"><span class="c36">The Oxford Nanopore platform also requires sample preparation to enable the enzymatic motion control process</span><span class="c19"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?4wvmtt&amp;sa=D&amp;source=editors&amp;ust=1679054520063930&amp;usg=AOvVaw3Ceis-_EKi9vSd08D_QIbd">77</a></span><span class="c0">. While this may be less arduous than the library preparation required for other sequencing platforms, it has a higher burden than other analytical approaches like qPCR.</span></p><p class="c43"><span class="c36">Oxford nanopore&rsquo;s motion control IP is set to expire in 2030</span><span class="c19"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?COG7Wp&amp;sa=D&amp;source=editors&amp;ust=1679054520064405&amp;usg=AOvVaw0BbiuayXQWo2QGSN-XJH9A">78</a></span><span class="c0">. However, our initial investigation suggests that the general motion control strategy IP has expired, and developing novel enzymatic motion control strategies is feasible.</span></p><p class="c43"><span class="c36">Outside of Oxford Nanopore, a number of companies have attempted to apply the basic biological nanopore sensing mechanism in different ways. For example Genia (acquired by Roche) uses an approach termed nanopore-SBS which combines nanopore sensing with single molecule sequencing by synthesis. AxBio</span><span class="c19"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?rrSNzI&amp;sa=D&amp;source=editors&amp;ust=1679054520064883&amp;usg=AOvVaw0pdPEbU6tc_XqMbIFwP8hH">79</a></span><span class="c36">&nbsp;also appear to be developing a related approach. Startup Qitan Technology has also been developing a biological nanopore platform, which reports</span><span class="c19"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?5CBVly&amp;sa=D&amp;source=editors&amp;ust=1679054520065333&amp;usg=AOvVaw1O1thDs3CeKHNnGJzj1uA0">80</a></span><span class="c0">&nbsp;suggest is very similar to Oxford&rsquo;s.</span></p><h4 class="c103" id="h.la6x6dxodr3q"><span class="c68 c12">Ionic Current Sensing using Solid-state Nanopores</span></h4><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c0">Our experimental setup here is similar to that used for biological pores, we&rsquo;re just replacing the biological pore with a manufactured one.</span></p><p class="c7"><span class="c0">As with biological ionic current sensing we have a conductive buffer solution, bias voltage, and current sense amplifier. Particles are detected as they move through a nanoscale hole (nanopore) blocking current flow.</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c36">This general principle is well established, and works for particles both large and small. The approach was first used in the </span><span class="c36">1940s</span><span class="c19"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?9OdmSr&amp;sa=D&amp;source=editors&amp;ust=1679054520066285&amp;usg=AOvVaw15h3sK9XvpD-xeUKYGoG2s">81</a></span><span class="c36">&nbsp;for counting white blood </span><span class="c36">in Coulter counters</span><span class="c36">. Here, whole cells pass through micron scale apertures. The principal even works for much larger particles up to </span><span class="c36">millimeters in size</span><span class="c19"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Wtjx6z&amp;sa=D&amp;source=editors&amp;ust=1679054520066713&amp;usg=AOvVaw1CpKbko3BoR9N5BXZyoG7c">82</a></span><span class="c0">&nbsp;and can be used for measuring particle sizes in paints and for other industrial applications.</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c36">In general, the particles used with Coulter counters need to be forced through the &ldquo;micropores&rdquo; under pressure driven flow. Some effort needs to be made to keep the flow consistent, and </span><span class="c36">novel pumping methods are often used</span><span class="c19"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?SjxydS&amp;sa=D&amp;source=editors&amp;ust=1679054520067283&amp;usg=AOvVaw2tx_YUM29LJfWP_LNaDmJq">83</a></span><span class="c0">.</span></p><p class="c7"><span class="c0">This isn&rsquo;t the case with DNA. Here the charge on the polymer is large enough that strands will move through the pore under a bias voltage.</span></p><p class="c1"><span class="c0"></span></p><h5 class="c89" id="h.bbstr5jppxn0"><span class="c28 c12">Solid-state Nanopore, dimension requirements</span></h5><p class="c7"><span class="c0">Clearly, Coulter counter sized pores (microns) will be too large to detect single molecules of DNA. We need a pore that is small enough that the background current doesn&rsquo;t overwhelm any current blockage, and where the DNA strand is somewhat confined in terms of its conformation and orientation as it passes through the pore.</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c0">Before we discuss experimental results, we can get some idea of the feature sizes required by looking at protein nanopore sequencing, for example with MspA:</span></p><p class="c1"><span class="c0"></span></p><p class="c83"><span style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 173.79px; height: 225.02px;"><img alt="" src="images/image27.jpg" style="width: 173.79px; height: 225.02px; margin-left: 0.00px; margin-top: 0.00px; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px);" title=""></span></p><p class="c83"><span class="c36">The MspA nanopore</span><span class="c19"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?ZwZomB&amp;sa=D&amp;source=editors&amp;ust=1679054520068971&amp;usg=AOvVaw2EdRXI9O3HR8z1nvhvvjVT">84</a></span><span class="c0">.</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c0">The construction here is 1.3nm (nanometers), and it&rsquo;s in a relatively high aspect ratio surface (literature suggests the sensing region is ~0.5nm). Even so, with MspA we see contributions from ~5 basepairs.</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c0">This can somewhat motivate us in terms of the feature sizes we&rsquo;d like to see in a solid-state nanopore, certainly we should be looking at single digit nanometer feature sizes.</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c0">Features in modern semiconductors are on the order of 30nm. Standard semiconductor fabrication is therefore almost 2 orders of magnitude larger than what has been shown to work for sequencing in biological nanopores.</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c0">As such, researchers have been developing novel fabrication processes for these applications. Using a variety of approaches they&rsquo;ve achieved pore sizes of ~2nm:</span></p><p class="c83"><span style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 418.67px; height: 334.67px;"><img alt="" src="images/image33.jpg" style="width: 418.67px; height: 334.67px; margin-left: 0.00px; margin-top: 0.00px; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px);" title=""></span></p><p class="c83"><span class="c36">Approaches to solid state nanopore fabrication</span><span class="c19"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?f0rgIq&amp;sa=D&amp;source=editors&amp;ust=1679054520071042&amp;usg=AOvVaw0kdgm334HuaZTEfMaoUHrL">85</a></span><span class="c0">.</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c0">Marija Drndi&#263;s lab does perhaps some of the more interesting work in solid state nanopore fabrication. The ~2nm pore in part (a) above comes from her lab and has feature sizes approaching those of MspA:</span></p><p class="c1"><span class="c0"></span></p><p class="c83"><span style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 352.00px; height: 161.33px;"><img alt="" src="images/image30.jpg" style="width: 352.00px; height: 161.33px; margin-left: 0.00px; margin-top: 0.00px; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px);" title=""></span></p><p class="c83"><span class="c36">A s</span><span class="c36">olid state nanopore compared to MspA</span><span class="c19"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?voE5rv&amp;sa=D&amp;source=editors&amp;ust=1679054520072576&amp;usg=AOvVaw2UrWAdv0JedmSvSo8PVgBX">86</a></span><span class="c0">.</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c0">This publication shows traces from homopolymer single stranded DNA:</span></p><p class="c83"><span style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 546.67px; height: 201.33px;"><img alt="" src="images/image13.jpg" style="width: 546.67px; height: 201.33px; margin-left: 0.00px; margin-top: 0.00px; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px);" title=""></span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c0">You can see that not only are the strands detected, but different homopolymers result in different current blockages. This is a great result, but has so far not resulted in a functional sequencing platform.</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c36">The strands are unfortunately translocating far too quickly to be able to determine even coarse features of the sequence. Others have taken this work in a different direction adding labels to the strands. In particular Ulrich Keyser&rsquo;s group has a bunch of interesting work using nanopipette for </span><span class="c36">applications including DNA data storage</span><span class="c19"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?7NKJ3g&amp;sa=D&amp;source=editors&amp;ust=1679054520074402&amp;usg=AOvVaw3TPZtnvcVbQUOT6rj9U8pN">87</a></span><span class="c0">.</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c36">But as far as I&rsquo;m aware, no-one has shown anything approaching single base resolution on an ionic current solid-state nanopore and Marija Drndi&#263;s work seems to be moving toward a </span><span class="c36">different sensing methodology</span><span class="c19"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?P4Wkt4&amp;sa=D&amp;source=editors&amp;ust=1679054520075073&amp;usg=AOvVaw3iFFqiQiA2WVoE_COenshh">88</a></span><span class="c0">.</span></p><p class="c1"><span class="c20 c12"></span></p><h5 class="c89" id="h.dpj54i53ny2f"><span class="c28 c12">Motion Control</span></h5><p class="c1"><span class="c20 c12"></span></p><p class="c7"><span class="c0">If we can&rsquo;t sense DNA at its native translocation rate it seems obvious that we would want to slow it down. And if we&rsquo;re going to slow it down, it seems obvious to use the same method used with biological nanopores, enzymatic motion control.</span></p><p class="c7"><span class="c36">Unfortunately as far as I can tell, there&rsquo;s not much work on combining enzymatic motion control and solid-state pores. In </span><span class="c36">one recent publication</span><span class="c19"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?hlP92y&amp;sa=D&amp;source=editors&amp;ust=1679054520076168&amp;usg=AOvVaw3K8hjWGXAxV7mshlyLBEve">89</a></span><span class="c0">&nbsp;a group showed that the Phi29 polymerase was active when confined to a solid-state pore, has potentially a prelude to using this mechanism for motion control:</span></p><p class="c83"><span style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 244.00px; height: 264.00px;"><img alt="" src="images/image6.jpg" style="width: 244.00px; height: 264.00px; margin-left: 0.00px; margin-top: 0.00px; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px);" title=""></span></p><p class="c7"><span class="c0">But it&rsquo;s not clear to me why more effort hasn&rsquo;t been made in this direction. Perhaps the work required to build this system isn&rsquo;t considered worth it. One potential criticism is that the result would be a platform very similar to a biological nanopore sequencing platform, likely with poorer fidelity due to the pores larger feature sizes.</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c36">Other solid state motion control strategies have been investigated as well, for example Armonia with their use of </span><span class="c36">Tortuous nanopores</span><span class="c19"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?HioOdE&amp;sa=D&amp;source=editors&amp;ust=1679054520077991&amp;usg=AOvVaw2SitK___JwezFnV8WmkVRb">90</a></span><span class="c36">, Nooma with their </span><span class="c36">dual nanopore</span><span class="c19"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?nC1bfW&amp;sa=D&amp;source=editors&amp;ust=1679054520078578&amp;usg=AOvVaw31PpWsP0CeI-69kWhI0Zt2">91</a></span><span class="c36">&nbsp;</span><span class="c36">approach, or </span><span class="c36">mechanical</span><span class="c36">&nbsp;</span><span class="c36">approaches</span><span class="c36">&nbsp;</span><span class="c19"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?hZu5y1&amp;sa=D&amp;source=editors&amp;ust=1679054520079210&amp;usg=AOvVaw1M2DBp5MP70ovbqlyksFQ-">92,93</a></span><span class="c36">. Buffer viscosity has also </span><span class="c36">slowed translocation</span><span class="c19"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?8nGpnJ&amp;sa=D&amp;source=editors&amp;ust=1679054520079716&amp;usg=AOvVaw0kQulR-yugqo_sZye40BQL">94</a></span><span class="c36">&nbsp;</span><span class="c36">by ~2 orders of magnitude, but unfortunately this is still a few orders of magnitude faster than enzymatic motion control. </span><span class="c36">RH Genetech</span><span class="c19"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?G0T3BE&amp;sa=D&amp;source=editors&amp;ust=1679054520080135&amp;usg=AOvVaw3F5wrhJbTRGE5ihupojQpK">95</a></span><span class="c0">&nbsp;also appear to be pursuing the development of a solid state ionic nanopore platform.</span></p><p class="c1"><span class="c0"></span></p><h5 class="c89" id="h.l6zx3iu0l7b4"><span class="c12 c28">Summary</span></h5><p class="c7"><span class="c36">Ionic current solid-state nanopore sequencing has been pursued in both the academic and commercial space. Notable commercial efforts include: </span><span class="c36">Northshore</span><span class="c19"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?uveCRl&amp;sa=D&amp;source=editors&amp;ust=1679054520080980&amp;usg=AOvVaw2XT5ecmySGMyN8dfiZPSLe">96</a></span><span class="c36">, </span><span class="c36">Nooma</span><span class="c19"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?3ElntR&amp;sa=D&amp;source=editors&amp;ust=1679054520081505&amp;usg=AOvVaw31wtIdQTf9tUNokaVXH23C">91</a></span><span class="c0">, and Nabsys.</span></p><p class="c7"><span class="c0">However no-one has demonstrated a platform that approaches anything close to sequencing to my knowledge. And with biological nanopore sequencing on the market, the big question is would a solid-state ionic approach be any better?</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c0">Throughput is likely to be similar, but could we see an improvement in terms of either cost of accuracy? Unfortunately improvements here are also likely hard to sell.</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c0">While semiconductor nanopore arrays are not cheap, I suspect at least the manufacturing process uses standard substrates and largely established fabrication processes. Currently, solid-state nanopores don&rsquo;t have this advantage. A low unit cost might be possible, but this is a difficult proposition if it means building a 100 million or billion dollar fabrication facility.</span></p><p class="c7"><span class="c36">In terms of accuracy, it seems unlikely that you&rsquo;d see much of an improvement unless much smaller feature sizes can be achieved. It&rsquo;s possible however that the </span><span class="c36">lower noise</span><span class="c19"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?ndgZJ3&amp;sa=D&amp;source=editors&amp;ust=1679054520082466&amp;usg=AOvVaw3-BnrLMsL44JdzlB9vXWJs">97</a></span><span class="c36">&nbsp;</span><span class="c0">associated with solid-state pores could eventually give them a slight edge.</span></p><p class="c1"><span class="c20 c12"></span></p><h4 class="c103" id="h.mflk6oq2wmoj"><span class="c68 c12">Tunneling Current Sensing</span></h4><p class="c43"><span class="c0">A number of companies and research groups have proposed DNA sequencing through tunneling current sensing. In this approach two electrodes are placed in close proximity to each other, creating a nanoscale gap. Due to electron tunneling, electrons can jump this gap creating a small current flow (nanoamps). DNA strands are translocated through the gap. As nucleotides pass through the gap they interfere with the tunneling current, allowing nucleotides to be detected.</span></p><p class="c43"><span class="c36">While a number of companies (</span><span class="c36 c70">Genvida</span><span class="c19"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?fW4J3g&amp;sa=D&amp;source=editors&amp;ust=1679054520083685&amp;usg=AOvVaw1S1E4UJqPLkKr1vK3Azv0K">98</a></span><span class="c10 c12 c79">, Quantum Biosystems) have engaged in the development of tunneling current sequencing platforms, no commercial platform has been released.</span></p><p class="c43"><span class="c10">The basic sensing approach has been proved out, for example through the </span><span class="c10">identification of single nucleotides when imaging static DNA strands embedded in a surface</span><span class="c10">&nbsp;using an STM</span><span class="c10 c41"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?b1lMJe&amp;sa=D&amp;source=editors&amp;ust=1679054520084433&amp;usg=AOvVaw3TBHuQ8iBWDvGeVdk5tnh4">99</a></span><span class="c10 c79 c12">&nbsp;(scanning tunneling microscope). However, even here imaging has not shown clear differentiation between all nucleotides.</span></p><p class="c43"><span class="c10">Tunneling current detection potentially provide much higher deflection currents than ionic current sensing. Here, currents are generally in the nanoamp, rather than picoamp range. But with significant research and commercial development having taken place over the </span><span class="c10">past 10 years</span><span class="c10 c41"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?jvmDXK&amp;sa=D&amp;source=editors&amp;ust=1679054520085023&amp;usg=AOvVaw0axvPynCirUs7IULd_zkik">100</a></span><span class="c10">&nbsp;without a clear proof-of-concept</span><span class="c10 c79 c12">, it is likely that commercial realization of the technology will take at least another 10 years if insurmountable physical limitations are not discovered.</span></p><h4 class="c80" id="h.pyxzv2nvoaah"><span class="c68 c12">Back bone Conduction</span></h4><p class="c7"><span class="c0">Others have proposed &ldquo;nanopore-like&rdquo; structures where changes in conductance are used to sequence nucleic acids. In particular, this approach has been pursued by Roswell Biotechnologies.</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c0">In the Roswell approach, there is indeed a nano gap, over which a &ldquo;self assembling&rdquo; double stranded DNA is built to form a &ldquo;bridge&rdquo;. With the bridge inserted, a small increase in current is detected:</span></p><p class="c83"><span style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 295.50px; height: 237.44px;"><img alt="" src="images/image23.jpg" style="width: 295.50px; height: 237.44px; margin-left: 0.00px; margin-top: 0.00px; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px);" title=""></span></p><p class="c7"><span class="c0">Roswell propose using this bridge as a scaffold on which to build a number of molecular sensors. I&rsquo;d previously assumed that the dominant source of current across the gap was due to tunneling. And it does seem that there is some small residual current, when no bridge is present. The dominant conduction mechanism here is likely conduction across the backbone. </span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c36">There does indeed seem to be academic support for this, with </span><span class="c36">one publication</span><span class="c19"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?lTC2I6&amp;sa=D&amp;source=editors&amp;ust=1679054520087062&amp;usg=AOvVaw2LxhV4kk087VSalD2HN_P5">101</a></span><span class="c0">&nbsp;showing currents of up to 5nA that vary across the backbone:</span></p><p class="c1"><span class="c0"></span></p><p class="c83"><span style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 238.84px; height: 256.91px;"><img alt="" src="images/image35.jpg" style="width: 238.84px; height: 256.91px; margin-left: 0.00px; margin-top: 0.00px; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px);" title=""></span></p><p class="c83"><span class="c36 c161">Current varies across the DNA backbone, suggesting conduction along the backbone</span><span class="c19 c161"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?zT7Wy1&amp;sa=D&amp;source=editors&amp;ust=1679054520088515&amp;usg=AOvVaw0_j3aV_dgBmyThmFI6ESbZ">101</a></span><span class="c79 c36 c12 c161">.</span></p><p class="c1"><span class="c79 c36 c12 c161"></span></p><p class="c7"><span class="c0">In Roswell&rsquo;s approach the bridge is used as a scaffold on which to build other sensing technologies. For example they&rsquo;ve shown data from a hybridization based assay:</span></p><p class="c83"><span style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 374.50px; height: 164.61px;"><img alt="" src="images/image21.jpg" style="width: 374.50px; height: 164.61px; margin-left: 0.00px; margin-top: 0.00px; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px);" title=""></span></p><p class="c7"><span class="c0">In this case a second single stranded fragment is attached to the DNA bridge. Target complmentary strands hybridize and an increase in current is registered.</span></p><p class="c153 c32"><span class="c0"></span></p><p class="c7"><span class="c36">Similarly, in their </span><span class="c36">proposed sequencing approach</span><span class="c19"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?tpgmEW&amp;sa=D&amp;source=editors&amp;ust=1679054520090001&amp;usg=AOvVaw38JkQU46uEkduMobH04p9p">102</a></span><span class="c0">, a polymerase is attached to the DNA bridge and again, here I&rsquo;m unclear how conformational changes in the polymerase would result in a change in the backbone conductance of the bridge.</span></p><p class="c83"><span style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 300.10px; height: 252.95px;"><img alt="" src="images/image18.jpg" style="width: 300.10px; height: 252.95px; margin-left: 0.00px; margin-top: 0.00px; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px);" title=""></span></p><p class="c7"><span class="c0">The polymerase (or hybridized oligo) could be affecting the conformation of the bridge changing its ability to conduct.. though how this results in increased, rather than decreased conductance is also unclear to me.</span></p><p class="c7"><span class="c0">I suspect a number of conduction paths may be present, in what is after all a relatively complex structure.</span></p><p class="c7"><span class="c0">In any case, Roswell seem to have shifted away from DNA sequencing. This indicates that the approach is probably challenging.</span></p><h4 class="c103 c90" id="h.f2god5yb5sf7"><span class="c68 c12"></span></h4><h4 class="c103 c90" id="h.37nvpyi5p1nn"><span class="c68 c12"></span></h4><h4 class="c103 c90" id="h.pdbroy8l0aw6"><span class="c68 c12"></span></h4><h4 class="c103" id="h.q5arbxbbemt2"><span class="c68 c12">Optical Nanopore Sensing</span></h4><p class="c7"><span class="c0">Optical Nanopore sensing has also been proposed, in this approach a nanopore is used to confine and control the translocation of a nucleic acid, but detection is performed optically. Quantapore is the only company that we are aware of that is developing this approach.</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c0">The essential idea behind Quantapore is the development of an optical Nanopore DNA sequencing platform. In this approach, strands are driven through a Nanopore (much like in Oxford Nanopore devices) but they are detected optically using fluorophores labels.</span></p><p class="c1"><span class="c0"></span></p><p class="c83"><span style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 200.00px; height: 248.00px;"><img alt="" src="images/image12.jpg" style="width: 200.00px; height: 248.00px; margin-left: 0.00px; margin-top: 0.00px; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px);" title=""></span></p><p class="c7"><span class="c0">A template (input DNA) is used to synthesize a complementary strand where all the nucleotides have a fluorescent label (one for each base type). This strand is translocated through a pore. Why do you need a pore at all if you&rsquo;re labeling the strand anyway? Well, the pore serves a few different purposes.</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c36">Firstly the nanopore has a </span><span class="c36">FRET</span><span class="c19"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?IwNj8O&amp;sa=D&amp;source=editors&amp;ust=1679054520094610&amp;usg=AOvVaw3UXVrBAgXC3zi1cV8nooZD">103</a></span><span class="c0">&nbsp;donor attached to it. FRET is an approach where two fluorophores are used. The first &ldquo;donor&rdquo; is excited, which then excites a second fluorophore (the acceptor). You therefore only get emission from the acceptor when the two fluorophores are in close proximity.</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c0">In this case, FRET is used to confine emissions to only those nucleotides near the nanopore. The donor, attached to the pore, excites the labeled nucleotides as they exit the pore. While the labeled nucleotides are in the pore, they are also squeezed into an orientation where they will not be excited by the FRET field.</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c0">An issue not yet addressed is motion control, that is to say, strands of DNA generally pass through nanopores too quickly to sense (millions of bases/s). So, you need some method of slowing the strand down. Oxford Nanopore do this enzymatically, but what about Quantapore?</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c0">They suggest that fluorescent modified nucleotides just translocate slower:</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c123 c36 c12 c125 c35">&ldquo;The resulting [fluorescently] labeled nucleic acid has an increased nominal diameter which results in a decreased translocation velocity when pulled through a nanopore&hellip; a most preferred translocation rate of 200-600 nucleotides per second.&rdquo;</span></p><p class="c1"><span class="c123 c36 c12 c125 c35"></span></p><p class="c7"><span class="c0">This may or may not be viable, but no data has been released by the company to date.</span></p><h5 class="c80" id="h.2uvwv0tb0b16"><span>Potential Drawbacks</span></h5><p class="c7"><span class="c0">The approach has a few clear disadvantages over Ionic current nanopore sequencing (Oxford Nanopore). The first is that you&rsquo;re not sequencing native material, this means no direct RNA sequencing or detection of base modifications. You also need to have a complete single molecule optical imaging system (they use Hamamatsu sCMOS cameras, these cost $20000 to $100000 and you need 4 of them, so the instrument isn&rsquo;t likely to be cheap).</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c0">The pores themselves likely need to be well stabilized. Protein nanopores in Bilayers are free to move around, but is a huge problem if you&rsquo;re imaging them. In the patent they drill nanopores (probably ~5nm) into TEM windows and then insert alpha hemolysin protein nanopores into those solid state pores.</span></p><p class="c83"><span style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 369.00px; height: 178.96px;"><img alt="" src="images/image15.jpg" style="width: 369.00px; height: 178.96px; margin-left: 0.00px; margin-top: 0.00px; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px);" title=""></span></p><p class="c7"><span class="c0">This is a pretty complex hybrid solid-state/protein nanopore system. It&rsquo;s challenging to fabricate in a research, let alone production environment (and certainly doesn&#39;t seem like it would be compatible with any kind of standard CMOS process).</span></p><p class="c32 c153"><span class="c114 c36 c12"></span></p><p class="c7"><span class="c36">The number of addressable pores in this system is also limited by the camera. As sequencing occurs in realtime you need to be observing the nanopores constantly (much like PacBio). Due to the relatively fast translocation times, this also needs to be a pretty fancy sCMOS camera, they mention frame rates of &gt;500Hz. Some quick googling around suggests this is &ldquo;very fast&rdquo; but not unheard of, with some recent papers showing </span><span class="c36">single molecule imaging at 200Hz</span><span class="c19"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Ls0oRV&amp;sa=D&amp;source=editors&amp;ust=1679054520098591&amp;usg=AOvVaw17JzgZ98nThEH8qkKr7d6w">104</a></span><span class="c0">.</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c0">So, the bandwidth is likely lower than ionic current nanopores (where you can sense at 5Khz+ relatively easily).</span></p><h5 class="c80" id="h.fgfmdeukw6aw"><span class="c28 c12">Advantages</span></h5><p class="c7"><span class="c0">If we assume that the FRET is really confined to a single position then it&rsquo;s potentially possible that the approach may be able to achieve be higher accuracy than ionic current approaches (we&rsquo;ll talk more about this below). They may also have more options of increasing the signal to noise ratio using an optical approach.</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c0">An ASIC also isn&rsquo;t required for sensing, and this could make the flow cell construction slightly simpler and cheaper (particularly if there&rsquo;s a solution to those fabrication issues).</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c0">Most likely the key advantage of an optical approach is scaling. They could potentially scale to say 4M pores, if each one was precisely aligned to a single pixel on a Hamamatsu sCMOS camera. This is clearly an order of magnitude higher than currently achievable using ionic current nanopore detection (where we&rsquo;re looking at ~2000 pores).</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c0">It also seems likely that only a single nanopore would insert at each site, so wouldn&rsquo;t have issues with multiple pore insertion that limit the number of active wells in protein nanopore systems.</span></p><h5 class="c80" id="h.cnt4328prvje"><span class="c28 c12">State of Development</span></h5><p class="c7"><span class="c0">The whole platform seems technically ambitious. Just getting protein nanopores to reliably insert into a solid state Nanopore itself seems like it would be a challenging project. But a couple of the figures in the paper suggest they have some experimental data. </span></p><p class="c83"><span style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 326.50px; height: 204.70px;"><img alt="" src="images/image17.jpg" style="width: 326.50px; height: 204.70px; margin-left: 0.00px; margin-top: 0.00px; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px);" title=""></span></p><p class="c7"><span class="c0">In the figure above they&#39;ve labeled Cs and Ts with different acceptor fluorophores. Cs labeled with Cy5 (solid line) and Ts with Atto700 (dashed line). It&rsquo;s always hard to draw conclusions from single traces, but the data certainly doesn&rsquo;t seem to be very clean.</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c0">In particular, looking at the C at 1052 on the trace, we can see that the fluorescent emission seems to continue for some time overlapping the adjacent T. That suggests that the FRET excitation isn&rsquo;t well confined to a single nucleotide and that you may see multiple labels emitting simultaneously.</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c0">Based on this data quality, I would suspect that a final system would have relatively high error rates (say in the 1 to 10% range, as is common with many single molecule approaches).</span></p><h5 class="c80" id="h.xsduwvkpni7z"><span class="c28 c12">Summary</span></h5><p class="c7"><span class="c0">If we assume that you can image say 400,000 nanopores simultaneously at 100bp/s we&rsquo;d be looking at 144Gb an hour. This is clearly faster than Illumina (at ~33Gb/h? on their high throughput instruments). And if we assume the platform is also producing long reads, this could be attractive for certain applications.</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c0">But, it seems likely that the accuracy will be far lower than Illumina.</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c0">Being able to produce huge amounts of (likely low accuracy) long reads seems like a fun platform though, and I&rsquo;m sure would be interesting for many research applications. For example, getting 1000x coverage of even highly errored reads on a de novo genome sequencing project in a few hours would likely be a great route to a first draft reference genome.</span></p><p class="c1"><span class="c20 c12"></span></p><h4 class="c54" id="h.fmfrco1j7ald"><span class="c68 c12">FET Nanopores</span></h4><p class="c7"><span class="c0">Others (notably iNanoBio) have suggested that so called &ldquo;FET nanopores&rdquo; could be used for DNA sequencing. This remains speculative with no proof-of-concept of the approach available after more than 8 years of development. In this approach a FET (Field Effect) sensor is embedded in a nanopore, as DNA translocates through the pore it alters the dielectric properties of the volume around the sensor.</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c0">The approach has significant challenges, and it&rsquo;s difficult to see how single DNA molecules can cause a large enough change to be registered by a FET sensor. At native speeds, translocation will also occur extremely quickly (at millions of nucleotides per second). Scanning Capacitive Microscopy, which use a related sensing approach typically operate 1000 times slower than this.</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c0">For our purposes, a FET nanopore platform promising extremely high throughput, could have advantages over Illumina&rsquo;s and Oxford Nanopore&rsquo;s platforms. However the sensing consumables are likely disposable and require nano-fabricated semiconductors. The cost-per-sample is therefore unlikely to be lower than Oxford Nanopore.</span></p><h4 class="c103" id="h.8oom81iredpd"><span class="c68 c12">Summary</span></h4><p class="c43"><span class="c0">Table showing fundamental limitations of ionic current, optical, charge and tunneling approaches. Area of silicon required for each pore type. Reflect on cost of silicon. etc. List of companies in this area (and any notable research).</span></p><h3 class="c81" id="h.26zvcapt661d"><span class="c34 c12">Optical - Sequencing-by-Synthesis</span></h3><p class="c43"><span class="c0">A number of companies have developed single molecule, optical, sequencing-by-synthesis platforms. These can broadly be classified as real time (Pacific Biosciences) and cyclic (Helicos, SeqLL, GeneMind).</span></p><h4 class="c43 c107" id="h.qgxz0pno0cfg"><span class="c68 c12">Real-time</span></h4><p class="c7"><span class="c0">In Pacific Bioscience&rsquo;s platform, labeled nucleotides are incorporated and excitation observed in real time and show in the diagram below:</span></p><p class="c83"><span style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 574.43px; height: 172.91px;"><img alt="" src="images/image43.jpg" style="width: 574.43px; height: 172.91px; margin-left: 0.00px; margin-top: 0.00px; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px);" title=""></span></p><p class="c83"><span class="c36">Pacific Biosciences sequencing approach</span><span class="c19"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?p7ntuG&amp;sa=D&amp;source=editors&amp;ust=1679054520105792&amp;usg=AOvVaw2d9nCBdlDrpFgsohqVV4XR">105</a></span><span class="c0">.</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c0">Nucleotides are incorporated by a polymerase, briefly emit, and are cleaved in a free running process. By recording the pattern of differing emissions, the sequence of a strand undergoing synthesis may be determined. As nucleotides are continuously incorporated, the strand must be continuously monitored (in &ldquo;real-time&rdquo;). A single sensor can not be multiplex across multiple reads (as in Illumina sequencing for example).</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c0">This realtime approach therefore introduces fundamental throughput limitations. So far, this has led to limited adoption. However, the platform also has significant read length advantages over colony based approaches (reaching read length of 30Kb as opposed to 300bp).</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c0">For our purposes, the direct coupling of sensing electronics into a disposable also leads to a high per-run/sample cost-of-goods. In Pacific Biosciences current instruments, disposable flowcells incorporate a complex opto-electrical chip:</span></p><p class="c83"><span style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 298.50px; height: 228.91px;"><img alt="" src="images/image31.png" style="width: 298.50px; height: 228.91px; margin-left: 0.00px; margin-top: 0.00px; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px);" title=""></span></p><p class="c83"><span class="c36">Pacific Biosciences chip structure from </span><span class="c36">one of their patents</span><span class="c19"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?KqFIXQ&amp;sa=D&amp;source=editors&amp;ust=1679054520107858&amp;usg=AOvVaw1oIZHNdr_dV2qpyhIuNhzE">106</a></span><span class="c0">.</span></p><p class="c7"><span class="c36">For our purposes, this high per-sample/run cost-of-goods likely makes the Pacific Biosciences approach prohibitively expensive. With </span><span class="c36">individual runs costing ~$2000</span><span class="c19"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?w80yOV&amp;sa=D&amp;source=editors&amp;ust=1679054520108722&amp;usg=AOvVaw2rAhfkeuITepTBJPg_YO-g">107</a></span><span class="c0">.</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c0">Others have proposed lower cost implementations of real-time sequencing (Reticula - founded by one of the co-authors of this report). This approach builds on the foundational work of Helicos (see below) to build a real-time single molecule sequencing platform using a cheap optical system. Reticula proposes using prism or waveguide style TIRF rather than Pacific Biosciences-style ZMWs. Moving the imaging system off chip reduces flowcell cost. Unlike both Pacific Biosciences and cyclic approaches Reticula suggests that multiple labels may be incorporated simultaneously:</span></p><p class="c1"><span class="c0"></span></p><p class="c83"><span style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 575.50px; height: 229.65px;"><img alt="" src="images/image19.png" style="width: 575.50px; height: 229.65px; margin-left: 0.00px; margin-top: 0.00px; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px);" title=""></span><span class="c0">&nbsp;</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c0">This will result in a convolved signal, where multiple dyes will be incorporated, emit and stochastically removed (though photo-bleaching or other mechanisms). This will result in a convolved signal which will require algorithmic deconvolution. Using hidden markov models (HMMs) or more advanced machine learning algorithms:</span></p><p class="c83"><span style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 507.18px; height: 240.34px;"><img alt="" src="images/image24.png" style="width: 507.18px; height: 240.34px; margin-left: 0.00px; margin-top: 0.00px; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px);" title=""></span></p><p class="c7"><span class="c0">Unlike Pacific Biosciences, such a platform is unlikely to generate long reads. Accuracy is also more likely to be in a similar ballpark to Helicos initially rather than Illumina (&lt;0.1% error rate) or Pacific Biosciences (&lt;0.001% CCS error rate). However the platform has been designed to compromise on these aspects to enable the lowest cost of goods and compete directly with qPCR on run cost.</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c0">It also retains the advantages of other single molecule approaches such as Helicos (see below) which require minimal sample preparation and can work will very small volumes. While also removing the need for any fluidics components (though the use of real-time sequencing).</span></p><h4 class="c54" id="h.ri62hc761p3n"><span class="c68 c12">Cyclic</span></h4><p class="c43"><span class="c0">Helicos was the first single molecule optical sequencing company and the approach has since been developed by SeqLL and GeneMind, but has always had a vanishingly small market share. The platform is capable of both direct DNA and RNA sequencing. As in Solexa/Illumina sequencing nucleotides are incorporated cyclically (see Cluster/Colony - Sequencing-by-synthesis). However, here no colonies of molecules are present. As such only a single emitter is available to allow an incorporated label to be detected. This means that individual templates (reads) are susceptible to photo-damage. During the imaging process, strands are illuminated with an excitation laser. Any such illumination will result in stochastic photo-damage, and the likelihood that any individual strand will be damaged increases with read length. Read length on these platforms therefore tend to be short (&lt;100bp).</span></p><p class="c43"><span class="c0">Pacific Biosciences have faced a number of these challenges and overcome them, but they have not yet been satisfactorily addressed in single molecule cyclic platforms.</span></p><p class="c43"><span class="c0">With no clear read length, accuracy or cost advantage over Illumina-style SBS sequencing. Single molecule cyclic approaches have failed to gain adoption.</span></p><p class="c43"><span class="c0">For our purposes however these approaches have two compelling potential advantages over Illumina-style sequencing. The approach requires almost no sample preparation and has been implemented to allow the sequencing of native DNA and RNA with no adapter addition. The approach is also somewhat similar to Illumina sequencing, removing the need for colony generation chemistry; this may also help reduce costs.</span></p><h3 class="c81" id="h.u4r069r1u6wk"><span class="c34 c12">Other Single Molecule</span></h3><p class="c43"><span class="c0">A number of other single molecule sequencing approaches are under development, however these are yet to yield commercial results and are mostly in early stages of development.</span></p><p class="c43"><span class="c0">In particular Depixus (Unzipping force), Halycon (TEM imaging), Geneseque (ligation, bead reporter), and XGenomes (undisclosed optical super-resolution) have all persued novel technological approaches. These approaches have largely targeted perceived weaknesses in Illumina&rsquo;s sequencing platform, attempting to generate much longer reads, or detect base modifications. For our purposes, these unique selling points do not address the &ldquo;cost-per-sample&rdquo; and workflow requirements of a point-of-care meta-genomic sequencing platform.</span></p><p class="c43 c32"><span class="c20 c12"></span></p><h2 class="c43 c107" id="h.85at7ip1ysnj"><span class="c94 c12">Other Sequencing Companies and Approaches</span></h2><p class="c7"><span class="c36">Beyond those companies mentioned above, a few other sequencing companies with very little publication exist, notably 4Catalyzer company </span><span class="c36">454.bio</span><span class="c19"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?jl6kPz&amp;sa=D&amp;source=editors&amp;ust=1679054520112042&amp;usg=AOvVaw0bnUO8saQrNkdmbb38-96M">108</a></span><span class="c36">&nbsp;and </span><span class="c36">Sequlite</span><span class="c19"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?fpl41w&amp;sa=D&amp;source=editors&amp;ust=1679054520112566&amp;usg=AOvVaw2x7ZgseOijB9-YF-qaQCMT">109</a></span><span class="c0">. With very little public information to go on it&rsquo;s difficult to exactly determine how relevant their approaches are for our purposes.</span></p><hr style="page-break-before:always;display:none;"><h1 class="c75" id="h.83t0i9fr0a5o"><span class="c33 c12"></span></h1><h1 class="c84" id="h.oeifh5rta8qo"><span class="c33 c12">Appendix C - Global Sequencing Capacity</span></h1><p class="c1"><span class="c20 c12"></span></p><a id="t.bddbb1875c2a33f7e93d8feb0da8df19c89b46cc"></a><a id="t.3"></a><table class="c127"><tr class="c25"><td class="c44" colspan="1" rowspan="1"><p class="c26"><span class="c20 c12">Platform</span></p></td><td class="c117" colspan="1" rowspan="1"><p class="c26"><span class="c20 c12">Estimated Instruments</span></p></td><td class="c50" colspan="1" rowspan="1"><p class="c26"><span class="c20 c12">Total Sequencing Capacity/year (Tb)</span></p></td><td class="c37" colspan="1" rowspan="1"><p class="c26"><span class="c20 c12">References</span></p></td></tr><tr class="c25"><td class="c44" colspan="1" rowspan="1"><p class="c26"><span class="c20 c12">ONT MinION</span></p></td><td class="c117" colspan="1" rowspan="1"><p class="c26"><span class="c20 c12">5501</span></p></td><td class="c50" colspan="1" rowspan="1"><p class="c26"><span class="c71 c12">5501*52*3*0.05=</span></p><p class="c119"><span class="c71 c12">42907.8Tb</span></p></td><td class="c37" colspan="1" rowspan="1"><p class="c26"><span class="c41"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?bpOF7W&amp;sa=D&amp;source=editors&amp;ust=1679054520116662&amp;usg=AOvVaw3y4VBI1P-KWlI3zeB_c8ie">12</a></span></p></td></tr><tr class="c25"><td class="c44" colspan="1" rowspan="1"><p class="c26"><span class="c20 c12">ONT GridION</span></p></td><td class="c117" colspan="1" rowspan="1"><p class="c26"><span class="c20 c12">782</span></p></td><td class="c50" colspan="1" rowspan="1"><p class="c26"><span class="c71 c12">782*52*3*0.25=</span></p><p class="c26"><span class="c71 c12">30498Tb</span></p></td><td class="c37" colspan="1" rowspan="1"><p class="c26"><span class="c41"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?2OrqET&amp;sa=D&amp;source=editors&amp;ust=1679054520118839&amp;usg=AOvVaw31TlYXdonV_h6B8rIzE6xM">12</a></span></p></td></tr><tr class="c25"><td class="c44" colspan="1" rowspan="1"><p class="c26"><span class="c20 c12">ONT PromethION 48</span></p></td><td class="c117" colspan="1" rowspan="1"><p class="c26"><span class="c20 c12">67</span></p></td><td class="c50" colspan="1" rowspan="1"><p class="c119"><span class="c71 c12">67*52*2*14=</span></p><p class="c119"><span class="c73">97552Tb</span></p></td><td class="c37" colspan="1" rowspan="1"><p class="c26"><span class="c41"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?ZlZn2F&amp;sa=D&amp;source=editors&amp;ust=1679054520121496&amp;usg=AOvVaw1JNy6fK9W-fsk7I4e7tRou">12</a></span><span>&nbsp;</span><span class="c41"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?5EzRk4&amp;sa=D&amp;source=editors&amp;ust=1679054520122262&amp;usg=AOvVaw0OgQnP8VHMDGqHXUEI5bwm">42</a></span></p></td></tr><tr class="c25"><td class="c44" colspan="1" rowspan="1"><p class="c26"><span class="c20 c12">Ilm Novaseq 6000</span></p></td><td class="c117" colspan="1" rowspan="1"><p class="c26"><span class="c20 c12">2340</span></p></td><td class="c50" colspan="1" rowspan="1"><p class="c26"><span class="c71 c12">2340*52*3*6=</span></p><p class="c119"><span class="c71 c12">2190240Tb</span></p></td><td class="c37" colspan="1" rowspan="1"><p class="c26"><span class="c41"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?kmmP8A&amp;sa=D&amp;source=editors&amp;ust=1679054520124851&amp;usg=AOvVaw26cnKixikcz_F5KySSIMDZ">110</a></span><span>&nbsp;</span><span class="c41"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?cfkhH9&amp;sa=D&amp;source=editors&amp;ust=1679054520125516&amp;usg=AOvVaw3DuFVwBWJXgB4Zm-x12zSV">37</a></span></p></td></tr><tr class="c108"><td class="c44" colspan="1" rowspan="1"><p class="c26"><span class="c20 c12">Ilm NextSeq</span></p></td><td class="c117" colspan="1" rowspan="1"><p class="c26"><span class="c20 c12">7260</span></p></td><td class="c50" colspan="1" rowspan="1"><p class="c26"><span class="c71 c12">7260*52*3*0.36=</span></p><p class="c26"><span class="c42">407721.6Tb</span></p></td><td class="c37" colspan="1" rowspan="1"><p class="c26"><span class="c41"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?bHJY7B&amp;sa=D&amp;source=editors&amp;ust=1679054520127101&amp;usg=AOvVaw10MDJ6xEYPesLVOgF9rhjQ">110</a></span></p></td></tr><tr class="c108"><td class="c44" colspan="1" rowspan="1"><p class="c26"><span class="c20 c12">Ilm Miseq/Mini/iSeq</span></p></td><td class="c117" colspan="1" rowspan="1"><p class="c26"><span class="c20 c12">10380</span></p></td><td class="c50" colspan="1" rowspan="1"><p class="c26"><span class="c71 c12">10380*52*3*0.015=</span></p><p class="c26"><span class="c71 c12">24289.2Tb</span></p></td><td class="c37" colspan="1" rowspan="1"><p class="c26"><span class="c41"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?NnP4b1&amp;sa=D&amp;source=editors&amp;ust=1679054520128959&amp;usg=AOvVaw2VdKd3fITjoZiEjWnqi_rU">110</a></span><span>&nbsp;</span><span class="c41"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?gK3BoM&amp;sa=D&amp;source=editors&amp;ust=1679054520129504&amp;usg=AOvVaw2bzAC1TdkvLnwtnQYoPODu">14</a></span></p></td></tr><tr class="c108"><td class="c44" colspan="1" rowspan="1"><p class="c26"><span class="c20 c12">Ion Torrent (est.)</span></p></td><td class="c117" colspan="1" rowspan="1"><p class="c26"><span class="c20 c12">2220</span></p></td><td class="c50" colspan="1" rowspan="1"><p class="c26"><span class="c71 c12">2220*52*14*0.05=</span></p><p class="c119"><span class="c12 c71">80808Tb</span></p></td><td class="c37" colspan="1" rowspan="1"><p class="c26"><span class="c20 c12">DeciBio</span></p></td></tr><tr class="c108"><td class="c44" colspan="1" rowspan="1"><p class="c26"><span class="c20 c12">PacBio</span></p></td><td class="c117" colspan="1" rowspan="1"><p class="c26"><span class="c20 c12">577</span></p></td><td class="c50" colspan="1" rowspan="1"><p class="c119"><span class="c71 c12">577*52*5*0.03=</span></p><p class="c119"><span class="c71 c12">4500.6Tb</span></p></td><td class="c37" colspan="1" rowspan="1"><p class="c26"><span class="c41"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?uZYjcv&amp;sa=D&amp;source=editors&amp;ust=1679054520133809&amp;usg=AOvVaw2pEqBAc11POB4ZBVQeKd0C">111</a></span></p></td></tr><tr class="c108"><td class="c44" colspan="1" rowspan="1"><p class="c26"><span class="c20 c12">MGI</span></p></td><td class="c117" colspan="1" rowspan="1"><p class="c26"><span class="c20 c12">2000</span></p></td><td class="c50" colspan="1" rowspan="1"><p class="c119"><span class="c71 c12">2000*3*52*0.720=</span></p><p class="c119"><span class="c73">224640Tb</span></p></td><td class="c37" colspan="1" rowspan="1"><p class="c26"><span class="c41"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?7h6rAn&amp;sa=D&amp;source=editors&amp;ust=1679054520135787&amp;usg=AOvVaw2sUFWgk7KZ1XZu9aJsq1cq">112</a></span></p></td></tr><tr class="c108"><td class="c44" colspan="1" rowspan="1"><p class="c26"><span class="c20 c12">Total</span></p></td><td class="c117" colspan="1" rowspan="1"><p class="c26"><span class="c20 c12">31127</span></p></td><td class="c50" colspan="1" rowspan="1"><p class="c119"><span class="c71 c12">3103157.2Tb (~98Gb/s)</span></p></td><td class="c37" colspan="1" rowspan="1"><p class="c26 c32"><span class="c20 c12"></span></p></td></tr></table><p class="c1"><span class="c20 c12"></span></p><p class="c1"><span class="c71 c12"></span></p><p class="c7"><span class="c36">Other genomic sequencing capacity estimates are also available</span><span class="c19"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?S4Bx2g&amp;sa=D&amp;source=editors&amp;ust=1679054520138340&amp;usg=AOvVaw0IE1W-MQtBJFnDpndzYTz7">113</a></span><span class="c0">.</span></p><p class="c1"><span class="c20 c12"></span></p><p class="c7"><span class="c20 c12">MinION Estimates:</span></p><p class="c1"><span class="c20 c12"></span></p><p class="c26"><span class="c0">Oxford Nanopore 2021 financial reports state that there are 5501 active customers using MinIONs. They also state that the MinION is designed as a first instrument, before users move to higher throughput platforms. It therefore seems likely that the majority of customers only have one MinION that they actively use, before progressing to higher throughput instruments. As such we have set the estimate here as the number of active customers (5501).</span></p><p class="c1"><span class="c20 c12"></span></p><p class="c7"><span class="c20 c12">GridION Estimates:</span></p><p class="c1"><span class="c20 c12"></span></p><p class="c7"><span class="c0">Similar to the MinION, the GridION is a lower throughput instrument, as such it likely does not make sense for a user to have multiple GridIONs, if they exceed instrument capacity a PromethION would be a more logical choice. As such we have set the instrument estimate as the number of active customers presented in the 2021 financials (782).</span></p><p class="c1"><span class="c20 c12"></span></p><p class="c7"><span class="c20 c12">PromethION Estimates:</span></p><p class="c1"><span class="c20 c12"></span></p><p class="c7"><span class="c36">G42 are likely the largest user of the promethION. The </span><span class="c36">image</span><span class="c36">&nbsp;in a &nbsp;</span><span class="c36">news report</span><span class="c19"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?zHZ4P8&amp;sa=D&amp;source=editors&amp;ust=1679054520140334&amp;usg=AOvVaw0Gt_Ktvm8Cca0a1bNpQZ0t">114</a></span><span class="c36">&nbsp;</span><span class="c36">shows ~12 instruments all of which are promethION 48s. Other sites</span><span class="c19"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?qQ2uq4&amp;sa=D&amp;source=editors&amp;ust=1679054520140912&amp;usg=AOvVaw22PK3_NfNDRAqfolD2DG95">115&ndash;119</a></span><span class="c36">&nbsp;</span><span class="c0">appear to use the PromethION 24, with little advantage to owning 2 PromethION 24s over a single 48, it is likely that these site have a single instrument. With 56 total customers, we can guess that G42 have 12 instruments, and other users have single instruments, giving a total of 67. For simplicity and to compensate for any under-estimation here, we will assume these are all PromethION 48s. </span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c0">Illumina Estimates:</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c0">Illumina presentations state their 2021 shipments as follows:</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c0">NovaSeq: 380, NextSeq: 1175, MiSeq/Mini/iSeq: 1680</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c0">Using 2021 shipments we can estimate the product mix breakdown as follows:</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c0">NovaSeq: 11.7%, NextSeq: 36.3%, MiSeq/Mini/iSeq: 51.9%</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c36">Illumina also state there are &gt;20000 total instruments installed</span><span class="c19"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Bia97i&amp;sa=D&amp;source=editors&amp;ust=1679054520142340&amp;usg=AOvVaw04V7MXAxostUGx9zTXJiiV">120</a></span><span class="c0">. Using these percentages suggests:</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c0">2340 NovaSeqs, 7260 NextSeqs, 10380 MiSeq/Mini/iSeqs</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c0">Ion Torrent Estimates:</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c0">Ion Torrent have an estimated 10% market share, Illumina almost completely dominates the rest of the market. Using this we would estimate that Ion Torrent have at most 10% of the Illumina total install base or 2220 instruments.</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c0">Pacific Biosciences Estimates:</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c36">PacBio shipped 374 instruments in 2021. Their total install base was 203 as of December 2020</span><span class="c19"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?DJVul1&amp;sa=D&amp;source=editors&amp;ust=1679054520143635&amp;usg=AOvVaw0idj1TWEDiB7kJJjvZJOCg">121</a></span><span class="c0">. As such, they have a total of 577 instruments placed as of December 31st 2022.</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c0">MGI Estimates:</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c36">MGI is the hardest to estimate as they may have significant market share in China, where we don&rsquo;t have good data. A press release from January 2019</span><span class="c19"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?PHWZaK&amp;sa=D&amp;source=editors&amp;ust=1679054520144512&amp;usg=AOvVaw3zkWPPCyJSY_XGbllpKnY9">112</a></span><span class="c36">&nbsp;states that they have installed 1000 instruments. A press release from July 2022</span><span class="c19"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?xpNeqV&amp;sa=D&amp;source=editors&amp;ust=1679054520144952&amp;usg=AOvVaw2Q-aYsMLJXdymjYk3tAUcn">122</a></span><span class="c36">&nbsp;simply states &ldquo;thousands&rdquo; </span><span class="c19"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?W1b2jR&amp;sa=D&amp;source=editors&amp;ust=1679054520145409&amp;usg=AOvVaw00170hadvwkkYQtyYXWY4w">122</a></span><span class="c36">. MGI have been restricted from selling instruments in many countries, which may have limited their growth. We&rsquo;d therefore estimate that there are likely only a few thousand instruments installed, 2000 seems like a reasonable estimate. We use their mid-range instrument</span><span class="c19"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?wNQ1h0&amp;sa=D&amp;source=editors&amp;ust=1679054520145778&amp;usg=AOvVaw21MHah_QF3ydofhy1OXL8D">41</a></span><span class="c0">&nbsp;as representative of their range, as we have no accurate breakdown of instrument deployments.</span></p><hr style="page-break-before:always;display:none;"><h1 class="c75" id="h.e80yc9s864c"><span class="c100 c36 c12 c158"></span></h1><h1 class="c84" id="h.xqpcx9fauasn"><span class="c33 c12">Appendix D - Papers included in Metagenomic Sequencing Review</span></h1><p class="c7"><span class="c36">Refer to </span><span class="c97 c36"><a class="c2" href="https://www.google.com/url?q=https://docs.google.com/spreadsheets/d/1fmwR63GJnPTcW7AMw191Y83B3hmSgyDRClGlZelKGUs/edit?usp%3Dsharing&amp;sa=D&amp;source=editors&amp;ust=1679054520146634&amp;usg=AOvVaw1uLy9GXtPCTlyzMERMOfIy">this google doc</a></span><span class="c0">&nbsp;for source of table.</span></p><p class="c1"><span class="c20 c12"></span></p><p class="c1"><span class="c20 c12"></span></p><p class="c1"><span class="c20 c12"></span></p><a id="t.d1333737985cd38a4dd5141b8d94e807f5b2d53a"></a><a id="t.4"></a><table class="c127"><tr class="c149"><td class="c178" colspan="12" rowspan="1"><p class="c83 c32"><span class="c6"></span></p></td></tr><tr class="c181"><td class="c55" colspan="1" rowspan="1"><p class="c7"><span class="c6">Paper</span></p></td><td class="c63 c85" colspan="1" rowspan="1"><p class="c7"><span class="c38 c22">Sample Type</span></p></td><td class="c63 c85" colspan="1" rowspan="1"><p class="c7"><span class="c38 c22">Target(s)</span></p></td><td class="c63 c85" colspan="1" rowspan="1"><p class="c7"><span class="c38 c22">Read Average</span></p></td><td class="c46 c85" colspan="1" rowspan="1"><p class="c7"><span class="c38 c22">Total RNA </span></p></td><td class="c63 c85" colspan="1" rowspan="1"><p class="c7"><span class="c38 c22">rRNA Depletion?</span></p></td><td class="c66 c85" colspan="1" rowspan="1"><p class="c30"><span class="c38 c22">Subjects (Pos/Neg Case/Control)</span></p></td><td class="c47 c85" colspan="1" rowspan="1"><p class="c7"><span class="c22 c38">Sensitivity/Agreement with qPCR</span></p></td><td class="c47 c85" colspan="1" rowspan="1"><p class="c7"><span class="c38 c22">rRNA/Human fraction</span></p></td><td class="c29 c85" colspan="1" rowspan="1"><p class="c7"><span class="c38 c22">qPCR (potential) False Negatives</span></p></td><td class="c49 c85" colspan="1" rowspan="1"><p class="c7"><span class="c38 c22">Average/Median Viral</span></p></td><td class="c63 c85" colspan="1" rowspan="1"><p class="c7"><span class="c38 c22">Data Availability</span></p></td></tr><tr class="c156"><td class="c55" colspan="1" rowspan="1"><p class="c7"><span class="c36 c22">Saravia-Butler et al. 2022</span><span class="c19 c22"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Kx3p3f&amp;sa=D&amp;source=editors&amp;ust=1679054520154946&amp;usg=AOvVaw05y7Qv5BhL_U37wQ2Ac_2f">123</a></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">Nasal Swab</span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">SARS-CoV-2</span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">63.2M</span></p></td><td class="c46" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c66" colspan="1" rowspan="1"><p class="c30"><span class="c6">317</span></p></td><td class="c47" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c47" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c29" colspan="1" rowspan="1"><p class="c30"><span class="c6">42</span></p></td><td class="c49" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">On Request</span></p></td></tr><tr class="c57"><td class="c55" colspan="1" rowspan="1"><p class="c7"><span class="c36 c22">Rajagopala et al. 2021</span><span class="c19 c22"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?mg5sk8&amp;sa=D&amp;source=editors&amp;ust=1679054520159619&amp;usg=AOvVaw1_q9A2-HqeRBXvd9Toun7_">124</a></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">Nasal Swab</span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">RSV CoV</span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">46.7M</span></p></td><td class="c46" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c66" colspan="1" rowspan="1"><p class="c30"><span class="c6">19 39</span></p></td><td class="c47" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c47" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c29" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c49" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">PRJNA671738</span></p></td></tr><tr class="c57"><td class="c55" colspan="1" rowspan="1"><p class="c7"><span class="c36 c22">Graf et al. 2016</span><span class="c19 c22"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?x2yL2x&amp;sa=D&amp;source=editors&amp;ust=1679054520164361&amp;usg=AOvVaw34ZYg9cWPGsfbShn1sN3Do">20</a></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">NP</span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">Panel</span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">15M</span></p></td><td class="c46" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">No</span></p></td><td class="c66" colspan="1" rowspan="1"><p class="c30"><span class="c6">35 67</span></p></td><td class="c47" colspan="1" rowspan="1"><p class="c7"><span class="c6">&gt;90%</span></p></td><td class="c47" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c29" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c49" colspan="1" rowspan="1"><p class="c30"><span class="c6">0.01%</span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">Not Listed</span></p></td></tr><tr class="c120"><td class="c55" colspan="1" rowspan="1"><p class="c7"><span class="c36 c22">Chan et al. 2022</span><span class="c19 c22"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?0bs9H2&amp;sa=D&amp;source=editors&amp;ust=1679054520167952&amp;usg=AOvVaw1cvqOaA9TvWsiQC-n9QfxK">125</a></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">Nasal Swab</span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">SARS-CoV-2</span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">40M</span></p></td><td class="c46" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">Yes</span></p></td><td class="c66" colspan="1" rowspan="1"><p class="c30"><span class="c6">56 16</span></p></td><td class="c47" colspan="1" rowspan="1"><p class="c30"><span class="c6">98.4%</span></p></td><td class="c47" colspan="1" rowspan="1"><p class="c7"><span class="c6">rRNA (non-depleted) 63%</span></p></td><td class="c29" colspan="1" rowspan="1"><p class="c30"><span class="c6">0</span></p></td><td class="c49" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">On Request</span></p></td></tr><tr class="c120"><td class="c55" colspan="1" rowspan="1"><p class="c7"><span class="c36 c22">Chen et al. 2020</span><span class="c19 c22"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?lD43U3&amp;sa=D&amp;source=editors&amp;ust=1679054520171718&amp;usg=AOvVaw380wWysEhKqE7ICGKD4Z0f">5</a></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">NP</span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">SARS-CoV-2</span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">1M (Miseq) 20M (NextSeq)</span></p></td><td class="c46" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">Both</span></p></td><td class="c66" colspan="1" rowspan="1"><p class="c30"><span class="c6">56 (7 protocols)</span></p></td><td class="c47" colspan="1" rowspan="1"><p class="c7"><span class="c6">100% (P2)</span></p></td><td class="c47" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c29" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c49" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">PRJNA638938</span></p></td></tr><tr class="c120"><td class="c55" colspan="1" rowspan="1"><p class="c7"><span class="c36 c22">Nakamura et al. 2009</span><span class="c19 c22"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?ajJ56R&amp;sa=D&amp;source=editors&amp;ust=1679054520175277&amp;usg=AOvVaw3FstFb-XJNd-Y8NJQHxG0C">126</a></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">NP and Fecal</span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">24K</span></p></td><td class="c46" colspan="1" rowspan="1"><p class="c7"><span class="c6">&lt;4ng (not measurable with Nanodrop)</span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">No</span></p></td><td class="c66" colspan="1" rowspan="1"><p class="c30"><span class="c6">8</span></p></td><td class="c47" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c47" colspan="1" rowspan="1"><p class="c7"><span class="c6">rRNA 54.7% to 69.9%</span></p></td><td class="c29" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c49" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">Not Listed</span></p></td></tr><tr class="c57"><td class="c55" colspan="1" rowspan="1"><p class="c7"><span class="c36 c22">Piralla et al. 2021</span><span class="c19 c22"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?iUebpJ&amp;sa=D&amp;source=editors&amp;ust=1679054520178477&amp;usg=AOvVaw27ZT6yoW06IBE0V0FeMsH7">32</a></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">Nasal Swab</span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">SARS-CoV-2</span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c46" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c66" colspan="1" rowspan="1"><p class="c30"><span class="c6">5</span></p></td><td class="c47" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c47" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c29" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c49" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">Not Listed</span></p></td></tr><tr class="c57"><td class="c55" colspan="1" rowspan="1"><p class="c7"><span class="c36 c22">Mostafa et al. 2020</span><span class="c19 c22"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?naOGwS&amp;sa=D&amp;source=editors&amp;ust=1679054520181930&amp;usg=AOvVaw0ciCcMx748jf86vsyDRRZt">127</a></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">NP</span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">SARS-CoV-2</span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">300K</span></p></td><td class="c46" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">No</span></p></td><td class="c66" colspan="1" rowspan="1"><p class="c30"><span class="c6">50</span></p></td><td class="c47" colspan="1" rowspan="1"><p class="c30"><span class="c6">77.5%</span></p></td><td class="c47" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c29" colspan="1" rowspan="1"><p class="c30"><span class="c6">0</span></p></td><td class="c49" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">Not Listed</span></p></td></tr><tr class="c57"><td class="c55" colspan="1" rowspan="1"><p class="c7"><span class="c36 c22">Faridl et al. 2022</span><span class="c19 c22"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?ZfBTLV&amp;sa=D&amp;source=editors&amp;ust=1679054520185841&amp;usg=AOvVaw0eSjQn-omyIl8R2Iqz4E4q">128</a></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">NP</span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">SARS-CoV-2</span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">~10M</span></p></td><td class="c46" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">Yes</span></p></td><td class="c66" colspan="1" rowspan="1"><p class="c30"><span class="c6">4</span></p></td><td class="c47" colspan="1" rowspan="1"><p class="c30"><span class="c6">100%</span></p></td><td class="c47" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c29" colspan="1" rowspan="1"><p class="c7"><span class="c6">NA</span></p></td><td class="c49" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">SRP343394</span></p></td></tr><tr class="c57"><td class="c55" colspan="1" rowspan="1"><p class="c7"><span class="c36 c22">Rodriguez et al. 2021</span><span class="c19 c22"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?S0eB1w&amp;sa=D&amp;source=editors&amp;ust=1679054520189855&amp;usg=AOvVaw2n4ofUKzyuB81LGaSv3G9K">129</a></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">NP</span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">SARS-CoV-2</span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">34M</span></p></td><td class="c46" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">No</span></p></td><td class="c66" colspan="1" rowspan="1"><p class="c30"><span class="c6">104</span></p></td><td class="c47" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c47" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c29" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c49" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">On Request</span></p></td></tr><tr class="c169"><td class="c55" colspan="1" rowspan="1"><p class="c7"><span class="c36 c22">Schlaberg et al. 2017</span><span class="c19 c22"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?vuvqUm&amp;sa=D&amp;source=editors&amp;ust=1679054520194602&amp;usg=AOvVaw3xdkReQA3n4Plp_cRxrH4i">130</a></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">NP/OP</span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">Panel</span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">17M</span></p></td><td class="c46" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">No</span></p></td><td class="c66" colspan="1" rowspan="1"><p class="c30"><span class="c6">70 90</span></p></td><td class="c47" colspan="1" rowspan="1"><p class="c7"><span class="c6">Near 99%? In positive group 1 sample was seq negative but PCR positive for one virus (ADV)</span></p></td><td class="c47" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c29" colspan="1" rowspan="1"><p class="c7"><span class="c6">34% (unknown detected by seq)</span></p></td><td class="c49" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">Not Listed</span></p></td></tr><tr class="c190"><td class="c55" colspan="1" rowspan="1"><p class="c7"><span class="c36 c22">Huang et al. 2019</span><span class="c19 c22"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?C9K8JO&amp;sa=D&amp;source=editors&amp;ust=1679054520199655&amp;usg=AOvVaw1fwKxBkm3JpyZvdtRrNmaQ">131</a></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">&ldquo;respiratory swabs&rdquo;</span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">InFlu A</span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">10.4M</span></p></td><td class="c46" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">Viral Amp</span></p></td><td class="c66" colspan="1" rowspan="1"><p class="c30"><span class="c6">5</span></p></td><td class="c47" colspan="1" rowspan="1"><p class="c7"><span class="c6">100%?</span></p></td><td class="c47" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c29" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c49" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">No</span></p></td></tr><tr class="c57"><td class="c55" colspan="1" rowspan="1"><p class="c7"><span class="c36 c22">Babiker et al. 2020</span><span class="c19 c22"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?wWBh8c&amp;sa=D&amp;source=editors&amp;ust=1679054520203533&amp;usg=AOvVaw1ihkWlApG5WNyOBZdMmOPi">132</a></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">NP</span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">SARS-CoV-2</span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">42M</span></p></td><td class="c46" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c66" colspan="1" rowspan="1"><p class="c30"><span class="c6">45 30</span></p></td><td class="c47" colspan="1" rowspan="1"><p class="c30"><span class="c6">97.8%</span></p></td><td class="c47" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c29" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c49" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">PRJNA634356</span></p></td></tr><tr class="c57"><td class="c55" colspan="1" rowspan="1"><p class="c7"><span class="c36 c22">Aljabr et al. 2019</span><span class="c19 c22"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?CtziS0&amp;sa=D&amp;source=editors&amp;ust=1679054520207353&amp;usg=AOvVaw2e-4LvyHhmkGnRrvPfoe6o">133</a></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">NPA</span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">HRSV</span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">not stated</span></p></td><td class="c46" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">PolyA selection</span></p></td><td class="c66" colspan="1" rowspan="1"><p class="c30"><span class="c6">12</span></p></td><td class="c47" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c47" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c29" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c49" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">Not Listed</span></p></td></tr><tr class="c57"><td class="c55" colspan="1" rowspan="1"><p class="c7"><span class="c36 c22">Bal et al. 2018</span><span class="c19 c22"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?8aJWFO&amp;sa=D&amp;source=editors&amp;ust=1679054520211289&amp;usg=AOvVaw3UcbUnD7PEoqVaWoZHK0Fm">134</a></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">NPA</span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">Panel</span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">5.1M</span></p></td><td class="c46" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c66" colspan="1" rowspan="1"><p class="c30"><span class="c6">37</span></p></td><td class="c47" colspan="1" rowspan="1"><p class="c30"><span class="c6">100%</span></p></td><td class="c47" colspan="1" rowspan="1"><p class="c7"><span class="c6">61.3% Human</span></p></td><td class="c29" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c49" colspan="1" rowspan="1"><p class="c30"><span class="c6">7.4%</span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">PRJNA494633</span></p></td></tr><tr class="c57"><td class="c55" colspan="1" rowspan="1"><p class="c7"><span class="c36 c22">Thorburn et al. 2015</span><span class="c19 c22"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?rapQgg&amp;sa=D&amp;source=editors&amp;ust=1679054520217683&amp;usg=AOvVaw0ZMkvhBBe4eYk8S49Z9mfz">135</a></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">NP</span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">Panel</span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">660K (30K-1.2M)</span></p></td><td class="c46" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c66" colspan="1" rowspan="1"><p class="c30"><span class="c6">89</span></p></td><td class="c47" colspan="1" rowspan="1"><p class="c30"><span class="c6">77.55%</span></p></td><td class="c47" colspan="1" rowspan="1"><p class="c7"><span class="c6">78.4% Human</span></p></td><td class="c29" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c49" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">Not Listed</span></p></td></tr><tr class="c98"><td class="c55" colspan="1" rowspan="1"><p class="c7"><span class="c36 c22">Prachayangprecha et al. 2014</span><span class="c19 c22"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?cP4yj1&amp;sa=D&amp;source=editors&amp;ust=1679054520223624&amp;usg=AOvVaw0z9R18FUqAtxXyVlR-tQr3">136</a></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">NPA</span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">Panel</span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">10K</span></p></td><td class="c46" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c66" colspan="1" rowspan="1"><p class="c30"><span class="c6">81</span></p></td><td class="c47" colspan="1" rowspan="1"><p class="c7"><span class="c6">~68%</span></p></td><td class="c47" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c29" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c49" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">Not Listed</span></p></td></tr><tr class="c120"><td class="c55" colspan="1" rowspan="1"><p class="c7"><span class="c36 c22">Carbo et al. 2020</span><span class="c19 c22"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?yWuZjb&amp;sa=D&amp;source=editors&amp;ust=1679054520228677&amp;usg=AOvVaw0mvKJwYbqpdpDrZUCYn1Hx">137</a></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">NP</span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">SARS-CoV-2</span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">10M</span></p></td><td class="c46" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">With/Without Viral Capture</span></p></td><td class="c66" colspan="1" rowspan="1"><p class="c30"><span class="c6">2</span></p></td><td class="c47" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c47" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c29" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c49" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">Not Listed</span></p></td></tr><tr class="c162"><td class="c55" colspan="1" rowspan="1"><p class="c7"><span class="c36 c22">Lewandowski el al. 2019</span><span class="c19 c22"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?dGQHSL&amp;sa=D&amp;source=editors&amp;ust=1679054520234675&amp;usg=AOvVaw2jvLbJP33JVHDBAEOSimYp">138</a></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">Contrived Spike ins - throat and nose swabs</span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">InFluA, Hazara</span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">&lt;1M</span></p></td><td class="c46" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c66" colspan="1" rowspan="1"><p class="c30"><span class="c6">15</span></p></td><td class="c47" colspan="1" rowspan="1"><p class="c7"><span class="c6">detection limit 1000/ml, 83%</span></p></td><td class="c47" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c29" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c49" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">PRJEB32861</span></p></td></tr><tr class="c149"><td class="c55" colspan="1" rowspan="1"><p class="c7"><span class="c36 c22">Madi et al. 2017</span><span class="c19 c22"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?OyrA5W&amp;sa=D&amp;source=editors&amp;ust=1679054520239123&amp;usg=AOvVaw3IK9ECiUKPyo6QPtlVoOJX">139</a></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">Various</span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">145K (3&#8208;439 927)</span></p></td><td class="c46" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">No</span></p></td><td class="c66" colspan="1" rowspan="1"><p class="c30"><span class="c6">86</span></p></td><td class="c47" colspan="1" rowspan="1"><p class="c7"><span class="c6">Poor Agreement</span></p></td><td class="c47" colspan="1" rowspan="1"><p class="c7"><span class="c6">64% Human</span></p></td><td class="c29" colspan="1" rowspan="1"><p class="c7"><span class="c6">Poor Agreement</span></p></td><td class="c49" colspan="1" rowspan="1"><p class="c7"><span class="c6">2% (0.04% to 7.87%)</span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">Not Listed</span></p></td></tr><tr class="c57"><td class="c55" colspan="1" rowspan="1"><p class="c7"><span class="c36 c22">O&rsquo;Flaherty et al. 2018</span><span class="c19 c22"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?afiGpF&amp;sa=D&amp;source=editors&amp;ust=1679054520242858&amp;usg=AOvVaw2uZIskF0Nt0TIJrDGBQuOG">140</a></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">NPS OPS</span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">Mostly targeted</span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">~300K</span></p></td><td class="c46" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">Mostly targeted</span></p></td><td class="c66" colspan="1" rowspan="1"><p class="c30 c32"><span class="c6"></span></p></td><td class="c47" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c47" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c29" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c49" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">PRJNA448596</span></p></td></tr><tr class="c57"><td class="c55" colspan="1" rowspan="1"><p class="c7"><span class="c36 c22">Parker et al. 2017</span><span class="c19 c22"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?6mnPQH&amp;sa=D&amp;source=editors&amp;ust=1679054520247083&amp;usg=AOvVaw1tcpiL5OwdeNiHW5K5I99n">141</a></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">NP, Nasal Swab</span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">ADV, HSV, HEP</span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">~3M</span></p></td><td class="c46" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c66" colspan="1" rowspan="1"><p class="c30"><span class="c6">9</span></p></td><td class="c47" colspan="1" rowspan="1"><p class="c30"><span class="c6">100%</span></p></td><td class="c47" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c29" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c49" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">Not Listed</span></p></td></tr><tr class="c57"><td class="c55" colspan="1" rowspan="1"><p class="c7"><span class="c36 c22">Ren et al. 2014</span><span class="c19 c22"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LN9Ipz&amp;sa=D&amp;source=editors&amp;ust=1679054520250726&amp;usg=AOvVaw2UdRY5-0ExG_x9iRdUrpHC">142</a></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">sputum</span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">InfuA</span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">30M and 60M</span></p></td><td class="c46" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c66" colspan="1" rowspan="1"><p class="c30"><span class="c6">2</span></p></td><td class="c47" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c47" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c29" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c49" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">Not Listed</span></p></td></tr><tr class="c120"><td class="c55" colspan="1" rowspan="1"><p class="c7"><span class="c36 c22">Shah et al. 2020</span><span class="c19 c22"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?2ADUCQ&amp;sa=D&amp;source=editors&amp;ust=1679054520255361&amp;usg=AOvVaw0MMGtWcxn84Y5WafIfF5JP">143</a></span><span class="c6">&nbsp;</span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">NPS</span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">Not stated?</span></p></td><td class="c46" colspan="1" rowspan="1"><p class="c7"><span class="c6">10 samples &lt;25 pg. So this is lower range?</span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">Yes</span></p></td><td class="c66" colspan="1" rowspan="1"><p class="c30"><span class="c6">107</span></p></td><td class="c47" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c47" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c29" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c49" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">On Request</span></p></td></tr><tr class="c57"><td class="c55" colspan="1" rowspan="1"><p class="c7"><span class="c36 c22">Tu et al. 2020</span><span class="c19 c22"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Ekumpk&amp;sa=D&amp;source=editors&amp;ust=1679054520259088&amp;usg=AOvVaw0UZMjDa7lnzKOZXlM-mCYW">144</a></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">Panel</span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">342K</span></p></td><td class="c46" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c66" colspan="1" rowspan="1"><p class="c30"><span class="c6">15 76</span></p></td><td class="c47" colspan="1" rowspan="1"><p class="c30"><span class="c6">86.70%</span></p></td><td class="c47" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c29" colspan="1" rowspan="1"><p class="c30"><span class="c6">21.10%</span></p></td><td class="c49" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">Not Listed</span></p></td></tr><tr class="c57"><td class="c55" colspan="1" rowspan="1"><p class="c7"><span class="c36 c22">Yang et al. 2011</span><span class="c19 c22"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?5w3p2C&amp;sa=D&amp;source=editors&amp;ust=1679054520262899&amp;usg=AOvVaw1RFi5ZG3YyYL2AQEiluzAM">145</a></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">NP</span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">DNA + RNA</span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">2.9M</span></p></td><td class="c46" colspan="1" rowspan="1"><p class="c7"><span class="c6">300ng?</span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">No</span></p></td><td class="c66" colspan="1" rowspan="1"><p class="c30"><span class="c6">15</span></p></td><td class="c47" colspan="1" rowspan="1"><p class="c30"><span class="c6">100%</span></p></td><td class="c47" colspan="1" rowspan="1"><p class="c7"><span class="c6">91.6% (DNA/RNA?)</span></p></td><td class="c29" colspan="1" rowspan="1"><p class="c7"><span class="c6">1 additional coinfection</span></p></td><td class="c49" colspan="1" rowspan="1"><p class="c30"><span class="c6">0.05%</span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">Not Listed</span></p></td></tr><tr class="c77"><td class="c55" colspan="1" rowspan="1"><p class="c7"><span class="c36 c22">Zoll et al. 2015</span><span class="c19 c22"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?ViXVr3&amp;sa=D&amp;source=editors&amp;ust=1679054520266364&amp;usg=AOvVaw29DL82ENKOk0FU6kRvOKrb">146</a></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">sputum, NP</span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">DNA + RNA</span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">525K (DNA) 170K (RNA)</span></p></td><td class="c46" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">Yes</span></p></td><td class="c66" colspan="1" rowspan="1"><p class="c30"><span class="c6">8 2</span></p></td><td class="c47" colspan="1" rowspan="1"><p class="c30"><span class="c6">100%</span></p></td><td class="c47" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c29" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c49" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">Not Listed</span></p></td></tr><tr class="c77"><td class="c55" colspan="1" rowspan="1"><p class="c7"><span class="c36 c22">Charalampous et al. 2019</span><span class="c19 c22"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?CaDxpr&amp;sa=D&amp;source=editors&amp;ust=1679054520269593&amp;usg=AOvVaw3T1LMyzUPWk0e59T7_Jjwd">147</a></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">sputum</span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">bacterial LRI (DNA)</span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">&lt;100000?</span></p></td><td class="c46" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">Host DNA Depletion</span></p></td><td class="c66" colspan="1" rowspan="1"><p class="c30"><span class="c6">81</span></p></td><td class="c47" colspan="1" rowspan="1"><p class="c7"><span class="c6">91.2% and 96.6% (LoD &gt;1000 cells)</span></p></td><td class="c47" colspan="1" rowspan="1"><p class="c7"><span class="c6">99.9% host material removed</span></p></td><td class="c29" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c49" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">PRJEB30781</span></p></td></tr><tr class="c77"><td class="c55" colspan="1" rowspan="1"><p class="c7"><span class="c36 c22">Manning et al. 2020</span><span class="c19 c22"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?hqPI4S&amp;sa=D&amp;source=editors&amp;ust=1679054520273117&amp;usg=AOvVaw1dV5T3O_SvBLAqHIYdQlsJ">148</a></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">NP and OP Swabs</span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">SARS-CoV-2</span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c46" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c66" colspan="1" rowspan="1"><p class="c30"><span class="c6">1</span></p></td><td class="c47" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c47" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c29" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c49" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td></tr><tr class="c162"><td class="c55" colspan="1" rowspan="1"><p class="c7"><span class="c36 c22">Tulloch et al. 2022</span><span class="c19 c22"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?roexEN&amp;sa=D&amp;source=editors&amp;ust=1679054520276628&amp;usg=AOvVaw1eyAc9zDXAqExC7r24W5K3">149</a></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">NP Swab and NPA, Culture, Vomitus </span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">At least 4M paired</span></p></td><td class="c46" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">Yes</span></p></td><td class="c66" colspan="1" rowspan="1"><p class="c30"><span class="c6">39</span></p></td><td class="c47" colspan="1" rowspan="1"><p class="c30"><span class="c6">100%</span></p></td><td class="c47" colspan="1" rowspan="1"><p class="c7"><span class="c6">70.8%(human)</span></p></td><td class="c29" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c49" colspan="1" rowspan="1"><p class="c7"><span class="c6">Lowest Fraction .0001. Mean 0.1, 0.01, 0.1 </span></p></td><td class="c60" colspan="1" rowspan="1"><p class="c7"><span class="c22">SRR22726217 - SRR22726256</span></p></td></tr><tr class="c77"><td class="c55" colspan="1" rowspan="1"><p class="c7"><span class="c36 c22">Willner et al. 2009</span><span class="c19 c22"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?5X6rJ0&amp;sa=D&amp;source=editors&amp;ust=1679054520280216&amp;usg=AOvVaw3Az4WhKLQOkwN9WhQCqWj2">150</a></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">Viral Communities in Cystic Fibrosis</span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c46" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c66" colspan="1" rowspan="1"><p class="c30"><span class="c6">5,5</span></p></td><td class="c47" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c47" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c29" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c49" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td></tr><tr class="c57"><td class="c55" colspan="1" rowspan="1"><p class="c7"><span class="c36 c22">Ogunbayo et al. 2023</span><span class="c19 c22"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?8sKyuU&amp;sa=D&amp;source=editors&amp;ust=1679054520283563&amp;usg=AOvVaw1Mk5ZGbQ74Wh7ieXryDlbW">151</a></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">NPS</span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">spikeins</span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c30"><span class="c6">71496</span></p></td><td class="c46" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c66" colspan="1" rowspan="1"><p class="c30"><span class="c6">1</span></p></td><td class="c47" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c47" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c29" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c49" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td></tr><tr class="c57"><td class="c55" colspan="1" rowspan="1"><p class="c7"><span class="c36 c22">Liu et al. 2020</span><span class="c19 c22"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?G6gVfg&amp;sa=D&amp;source=editors&amp;ust=1679054520287121&amp;usg=AOvVaw1AwVqAVYRosy_cJTxt4nsy">152</a></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">NPS</span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c46" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c66" colspan="1" rowspan="1"><p class="c30"><span class="c6">4</span></p></td><td class="c47" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c47" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c29" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c49" colspan="1" rowspan="1"><p class="c7"><span class="c6">lowest 0.05%</span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">PRJNA631867</span></p></td></tr><tr class="c57"><td class="c55" colspan="1" rowspan="1"><p class="c7"><span class="c36 c22">Ogunbayo et al. 2022</span><span class="c19 c22"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?KIRBfO&amp;sa=D&amp;source=editors&amp;ust=1679054520291099&amp;usg=AOvVaw2YRDA5P1aZB5khKwKN1mom">153</a></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">NP Swab</span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">SARI Pool</span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c46" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c66" colspan="1" rowspan="1"><p class="c30"><span class="c6">149 , 139 Pooled</span></p></td><td class="c47" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c47" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c29" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c49" colspan="1" rowspan="1"><p class="c7"><span class="c6">Min of 2% in a pool</span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td></tr><tr class="c57"><td class="c55" colspan="1" rowspan="1"><p class="c7"><span class="c36 c22">Li et al. 2020</span><span class="c19 c22"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?pVqsRB&amp;sa=D&amp;source=editors&amp;ust=1679054520297157&amp;usg=AOvVaw3P0BXnJNTwoRVS4qT4weAd">21</a></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">Throat swabs</span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">Resp. Inf.</span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">13M to 98M</span></p></td><td class="c46" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c66" colspan="1" rowspan="1"><p class="c30"><span class="c6">48,7</span></p></td><td class="c47" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c47" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c29" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c49" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">PRJNA540900</span></p></td></tr><tr class="c57"><td class="c55" colspan="1" rowspan="1"><p class="c7"><span class="c36 c22">Cheemarla et al. 2023</span><span class="c19 c22"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?HGRhCL&amp;sa=D&amp;source=editors&amp;ust=1679054520303159&amp;usg=AOvVaw38J5Lg5vkTDqcCqukf7_GF">154</a></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">NP Swab</span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c46" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">CXCL10</span></p></td><td class="c66" colspan="1" rowspan="1"><p class="c30"><span class="c6">32</span></p></td><td class="c47" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c47" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c29" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c49" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td></tr><tr class="c57"><td class="c55" colspan="1" rowspan="1"><p class="c7"><span class="c36 c22">Deng et al. 2020</span><span class="c19 c22"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?oYJqpY&amp;sa=D&amp;source=editors&amp;ust=1679054520308990&amp;usg=AOvVaw0yo_DuWAve4e-0kd6uB0Li">155</a></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c46" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">MSSPE</span></p></td><td class="c66" colspan="1" rowspan="1"><p class="c30"><span class="c6">54</span></p></td><td class="c47" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c47" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c29" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c49" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td></tr><tr class="c77"><td class="c55" colspan="1" rowspan="1"><p class="c7"><span class="c36 c22">Saha et al. 2020</span><span class="c19 c22"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?S1VU5H&amp;sa=D&amp;source=editors&amp;ust=1679054520314959&amp;usg=AOvVaw2fSqQdFxeGDaUXMXjQzJRx">156</a></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">NP Swab</span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c30"><span class="c6">11,747,398</span></p></td><td class="c46" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">Mixed random+target</span></p></td><td class="c66" colspan="1" rowspan="1"><p class="c30"><span class="c6">1</span></p></td><td class="c47" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c47" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c29" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c49" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">SRR11801823</span></p></td></tr><tr class="c143"><td class="c55" colspan="1" rowspan="1"><p class="c7"><span class="c36 c22">Bacci, G. et al. 2020</span><span class="c19 c22"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?6AHbev&amp;sa=D&amp;source=editors&amp;ust=1679054520320822&amp;usg=AOvVaw0vwLce4ptAxMtkiG6b8l0I">157</a></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">sputum</span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">Airway Microbiome of Cystic Fibrosis</span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">Table S2, some samples with &lt;10000. Average looks &lt;10M</span></p></td><td class="c46" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c66" colspan="1" rowspan="1"><p class="c30"><span class="c6">22</span></p></td><td class="c47" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c47" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c29" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c49" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">PRJNA516870</span></p></td></tr><tr class="c77"><td class="c55" colspan="1" rowspan="1"><p class="c7"><span class="c36 c22">Deschamps et al. 2019</span><span class="c19 c22"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?8kR38M&amp;sa=D&amp;source=editors&amp;ust=1679054520325077&amp;usg=AOvVaw3xa1oSWETFY6_VeplA5HN4">158</a></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">blood and skin</span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">Acute exanthemas, viral</span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">Not stated?</span></p></td><td class="c46" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c66" colspan="1" rowspan="1"><p class="c30"><span class="c6">10</span></p></td><td class="c47" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c47" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c29" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c49" colspan="1" rowspan="1"><p class="c1"><span class="c6"></span></p></td><td class="c63" colspan="1" rowspan="1"><p class="c7"><span class="c6">Not Listed</span></p></td></tr></table><p class="c1"><span class="c13 c12"></span></p><p class="c1"><span class="c20 c12"></span></p><h1 class="c84" id="h.o9daiytw1vnk"><span class="c33 c12">Appendix E - Metagenomic Sequencing Literature Review</span></h1><p class="c7"><span class="c0">Papers from the previous appendix were filtered to remove those papers meeting the following criteria:</span></p><p class="c1"><span class="c0"></span></p><ul class="c31 lst-kix_vm5eb5wj9btb-0 start"><li class="c7 c82 li-bullet-0"><span class="c0">Less than 10 positive subjects.</span></li><li class="c7 c82 li-bullet-0"><span class="c36">Less than 10M reads average per sample or read count unstated.</span><sup><a href="#cmnt52" id="cmnt_ref52">[az]</a></sup><sup><a href="#cmnt53" id="cmnt_ref53">[ba]</a></sup></li><li class="c7 c82 li-bullet-0"><span class="c0">Only contrived or pooled samples.</span></li><li class="c7 c82 li-bullet-0"><span class="c0">Targeted or semi-targeted studies.</span></li></ul><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c36">Eight papers remained after applying this criteria. These were carefully examined with respect to sensitivity and the potential for qPCR false positives. The following sections present the result of this analysis, a summary is provided in the main text.</span></p><h2 class="c72" id="h.pqu44e4zo4d"><span class="c94 c12">Sensitivity</span></h2><p class="c7"><span class="c0">Three of the papers have a clear statements on sensitivity these state sensitivities (assessed via qPCR/Panels) for sequencing of 97% (Saravia-Butler et al. 2022) &gt;90% (Graf et al. 2016) and 97.6% (Chan et al. 2022).</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c0">In three others, we calculated sensitivity/qPCR agreement from the data shown in the papers. These values were 97.4% (Rajagopala et al. 2021), 83.1% (Schlaberg et al. 2017), and 97.8% (Babiker et al. 2020). </span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c0">Schlaberg et al. 2017 is the least favorable paper. They break down sensitivity by virus as follows (combining control and patient groups): IAV 0/1 (0% RNA), ADV 0/8 (0% DNA). IBV 0/1 (0% RNA), HMPV 7/12 (58.3% RNA), HPIV 5/6 (83.3% RNA), RSV 23/29 (79% RNA), HCoV 4/5 (80% RNA), HRV 46/50 (92% DNA), M. pneumoniae 7/7 (100% DNA). In total 99/119 giving an overall sensitivity of 83.1%. Not great! Evaluating these results is complicated by several factors. Firstly they were looking at both DNA and RNA targets, but only capturing DNA through transcripts. Surprisingly, both their best and worst sensitivity is on DNA targets. They also state that viruses &ldquo;were detected by PCR of NP/OP swabs or serology&rdquo; so this is not a clean comparison against qPCR, and it seems at least possible that we are seeing some false positives. The RSV results are particularly odd, showing 96% sensitivity in the patient group, but 0% in the control. If I had to guess, I&rsquo;d say the control group used serology, and contained false positives from resolved infections&hellip; If we restrict ourselves to RNA viruses in the patient group we have an overall sensitivity of 92.1% which seems more inline with other results.</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c0">I also estimated sensitivity for Rodriguez et al. 2021, but the only data we have to go from here is a graph of Ct versus genomes copies/ng. Assuming a threshold of 1, it looks like at most 4 could be false negatives. This would give a lower bound sensitivity of 96%.</span></p><p class="c7"><span class="c0">Graf et al. 2016 compared sequencing to a panel (GenMarkDx) which I believe uses a hybridization assay. Positive results agreed in 34 out of 37 samples. But then they tried to confirm the 3 potential false positives using qPCR. Unfortunately, they only had enough material for 2 of the samples, both of which came back qPCR negative. To me, this puts a lower bound of 97.1% on the concordance of sequencing and qPCR positives. Their claim is that &ldquo;untargeted metagenomics has a sensitivity at least comparable to those of the RVP and qPCR&rdquo;.</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c0">These papers all show that metagenomic sequencing is at least as good as qPCR in my view. Where a sensitivity estimate could be calculated against PCR/Panels (5/8 papers) it was &gt;96%. In many cases it seems likely that slight threshold tweak would be enough for qPCR and sequencing to have 100% agreement, often affecting only single samples at high Ct in relatively small studies. </span></p><h2 class="c72" id="h.ukv84wvebv04"><span class="c94 c12">qPCR False Negatives</span></h2><p class="c7"><span class="c0">The sensitivity of sequencing is further supported by the number of potential false negatives we see in qPCR results.</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c0">Graf et al. 2016 states that &quot;There were several samples that were positive by both the RVP and untargeted metagenomics but negative by qPCR&rdquo;.</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c0">Saravia-Butler et al. 2022 states that &ldquo;42 out of 317 (13%) PCR-negative samples had detectable SARS-CoV-2 genomic material, suggesting they were false negatives&rdquo;.</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c0">And Schlaberg et al. 2017 states &ldquo;RNA-seq/PVG PCR detected previously missed, putative pathogens in 34% of patients&rdquo;.</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c36">In </span><span class="c36">Chan et al. 2022</span><span class="c19"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?whjmEX&amp;sa=D&amp;source=editors&amp;ust=1679054520333336&amp;usg=AOvVaw1ZWxCjyrUCt2mu0p-W6cDo">159</a></span><span class="c0">&nbsp;we suspect that threshold tweaks might reveal qPCR false negative results, as evidenced by low but detectable read counts shown for some qPCR negatives in the supplementary information of this paper.</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c0">In Rajagopala et al. 2022 they &ldquo;were able to identify OC43 in a sample and recover 100% of the genome with over 23&times; average read coverage, which the panel did not detect&rdquo;. The panel in question being an (I think end-point) PCR panel.</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c0">Overall, 4 of the 8 papers have explicit statements on qPCR false negatives.</span></p><h2 class="c72" id="h.gk0sq5w66da5"><span class="c94 c12">Data availability</span></h2><p class="c7"><span class="c0">One of the papers didn&rsquo;t provide enough information (PCR results) to estimate sensitivity or false negative rates (Li et al. 2020), but the data set is public. In total, 13 of the original 42 papers have public datasets available. A meta-analysis of these datasets seems like a worthwhile exercise!</span></p><h1 class="c84" id="h.57blvqajq4y2"><span class="c33 c12">Appendix F - Viral Load Estimates</span></h1><p class="c1"><span class="c20 c12"></span></p><p class="c17"><span class="c0">The table below summarizes the available literature on these sample types and the associated relevant metrics. Viral copy number varies significantly with host and disease progression. As such the results below only provide a broad guide:</span></p><p class="c17 c32"><span class="c20 c12"></span></p><a id="t.f22e766dd764e06c0aecf3685265ade33ca827c8"></a><a id="t.5"></a><table class="c127"><tr class="c25"><td class="c37" colspan="1" rowspan="1"><p class="c26"><span class="c21 c12">Sample Type</span></p></td><td class="c110" colspan="1" rowspan="1"><p class="c26"><span class="c21 c12">Sample Volume</span></p></td><td class="c74" colspan="1" rowspan="1"><p class="c26"><span class="c21 c12">Yield</span></p></td><td class="c74" colspan="1" rowspan="1"><p class="c26"><span class="c21 c12">Concentration</span></p></td><td class="c45" colspan="1" rowspan="1"><p class="c26"><span class="c21 c12">Viral Copy Number (per/uL)</span></p></td><td class="c52" colspan="1" rowspan="1"><p class="c26"><span class="c22">Fragmentation (average length)</span><sup><a href="#cmnt54" id="cmnt_ref54">[bb]</a></sup><sup><a href="#cmnt55" id="cmnt_ref55">[bc]</a></sup></p></td><td class="c61" colspan="1" rowspan="1"><p class="c26"><span class="c21 c12">Host Copy Number (per/uL)</span></p></td><td class="c146" colspan="1" rowspan="1"><p class="c26"><span class="c21 c12">Viral Fraction</span></p></td><td class="c147" colspan="1" rowspan="1"><p class="c26"><span class="c21 c12">References</span></p></td></tr><tr class="c25"><td class="c37" colspan="1" rowspan="1"><p class="c26"><span class="c21 c12">Anterior Nasal</span></p></td><td class="c110" colspan="1" rowspan="1"><p class="c26"><span class="c21 c12">~3mL</span></p></td><td class="c74" colspan="1" rowspan="1"><p class="c26 c32"><span class="c21 c12"></span></p></td><td class="c74" colspan="1" rowspan="1"><p class="c26 c32"><span class="c21 c12"></span></p></td><td class="c45" colspan="1" rowspan="1"><p class="c26"><span class="c21 c12">~10000</span></p><p class="c26"><span class="c12 c21">~100000</span></p></td><td class="c52" colspan="1" rowspan="1"><p class="c26 c32"><span class="c21 c12"></span></p></td><td class="c61" colspan="1" rowspan="1"><p class="c26 c32"><span class="c21 c12"></span></p></td><td class="c146" colspan="1" rowspan="1"><p class="c26 c32"><span class="c21 c12"></span></p></td><td class="c147" colspan="1" rowspan="1"><p class="c26"><span class="c41 c22"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?s5U9PL&amp;sa=D&amp;source=editors&amp;ust=1679054520340884&amp;usg=AOvVaw1tM5q-XxGuQ4rcz7rg3f80">160</a></span><span class="c22">&nbsp;</span><span class="c41 c22"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?HtTc3V&amp;sa=D&amp;source=editors&amp;ust=1679054520341381&amp;usg=AOvVaw0wGDTdOPg5mqyM7VW8TZu8">161</a></span></p></td></tr><tr class="c25"><td class="c37" colspan="1" rowspan="1"><p class="c26"><span class="c21 c12">Nasopharyngeal</span></p></td><td class="c110" colspan="1" rowspan="1"><p class="c26"><span class="c21 c12">~3mL</span></p></td><td class="c74" colspan="1" rowspan="1"><p class="c26 c32"><span class="c21 c12"></span></p></td><td class="c74" colspan="1" rowspan="1"><p class="c26 c32"><span class="c21 c12"></span></p></td><td class="c45" colspan="1" rowspan="1"><p class="c26"><span class="c21 c12">120226 (Delta)</span></p><p class="c26"><span class="c21 c12">36307 (Omicron)</span></p><p class="c26"><span class="c21 c12">~500000</span></p><p class="c26"><span class="c21 c12">23988 (child)</span></p></td><td class="c52" colspan="1" rowspan="1"><p class="c26"><span class="c21 c12">83% of samples &gt; 50% fragmented (8)</span></p><p class="c26 c32"><span class="c21 c12"></span></p><p class="c26"><span class="c21 c12">~350 SISPA (10)</span></p></td><td class="c61" colspan="1" rowspan="1"><p class="c26 c32"><span class="c21 c12"></span></p></td><td class="c146" colspan="1" rowspan="1"><p class="c26"><span class="c21 c12">0.02% (2) , 1% (rRNA depl.)</span></p><p class="c119"><span class="c21 c12">0.01 and 0.0001 (3)</span></p><p class="c119 c32"><span class="c21 c12"></span></p><p class="c119"><span class="c21 c12">0.002% (7 - untargeted)</span></p><p class="c119"><span class="c21 c12">35% (7 - viral enrich)</span></p><p class="c119"><span class="c21 c12">0.001% (9)</span></p><p class="c119 c32"><span class="c21 c12"></span></p></td><td class="c147" colspan="1" rowspan="1"><p class="c26"><span class="c41 c22"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Ik5qCC&amp;sa=D&amp;source=editors&amp;ust=1679054520345277&amp;usg=AOvVaw3q1NcWyI2G4tpiAlv2QDnC">5</a></span><span class="c22">&nbsp;</span><span class="c41 c22"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?mul1dU&amp;sa=D&amp;source=editors&amp;ust=1679054520345836&amp;usg=AOvVaw3o9ye_nmK7xbnU64jl0AaS">162</a></span><span class="c22">&nbsp;</span><span class="c41 c22"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?xhedB9&amp;sa=D&amp;source=editors&amp;ust=1679054520346247&amp;usg=AOvVaw1w5rhtF1o_VtPpALunhn8U">132</a></span><span class="c22">&nbsp;</span><span class="c41 c22"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?duwSI7&amp;sa=D&amp;source=editors&amp;ust=1679054520346690&amp;usg=AOvVaw03Nw1NsHsqICQOzAbELYEO">163</a></span><span class="c22">&nbsp;</span><span class="c41 c22"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?l3328v&amp;sa=D&amp;source=editors&amp;ust=1679054520347056&amp;usg=AOvVaw3tq2a6zz0G-jhhS1XFHL2p">160</a></span><span class="c22">&nbsp;</span><span class="c41 c22"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?URk0Yy&amp;sa=D&amp;source=editors&amp;ust=1679054520347416&amp;usg=AOvVaw3WLrlW3-UHHZfh5Q8FNnZD">164</a></span><span class="c22">&nbsp;</span><span class="c41 c22"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?8njSC5&amp;sa=D&amp;source=editors&amp;ust=1679054520347735&amp;usg=AOvVaw2CcXQK50O060Sid5mcGW1t">137</a></span><span class="c22">&nbsp;</span><span class="c41 c22"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?IhI5zz&amp;sa=D&amp;source=editors&amp;ust=1679054520348072&amp;usg=AOvVaw1ZmxDtzPblcyUanIJftg2k">165</a></span><span class="c22">&nbsp;</span><span class="c41 c22"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?mCfR7O&amp;sa=D&amp;source=editors&amp;ust=1679054520348402&amp;usg=AOvVaw2bt3ow8mg5rbE61xiXfyZS">127</a></span><span class="c21 c12">&nbsp;</span></p></td></tr><tr class="c25"><td class="c37" colspan="1" rowspan="1"><p class="c26"><span class="c21 c12">Nasal Mid-turbinate</span></p></td><td class="c110" colspan="1" rowspan="1"><p class="c26"><span class="c21 c12">~3mL</span></p></td><td class="c74" colspan="1" rowspan="1"><p class="c26 c32"><span class="c21 c12"></span></p></td><td class="c74" colspan="1" rowspan="1"><p class="c26 c32"><span class="c21 c12"></span></p></td><td class="c45" colspan="1" rowspan="1"><p class="c26 c32"><span class="c21 c12"></span></p></td><td class="c52" colspan="1" rowspan="1"><p class="c26 c32"><span class="c21 c12"></span></p></td><td class="c61" colspan="1" rowspan="1"><p class="c26 c32"><span class="c21 c12"></span></p></td><td class="c146" colspan="1" rowspan="1"><p class="c26 c32"><span class="c21 c12"></span></p></td><td class="c147" colspan="1" rowspan="1"><p class="c26 c32"><span class="c21 c12"></span></p></td></tr><tr class="c25"><td class="c37" colspan="1" rowspan="1"><p class="c26"><span class="c21 c12">Oropharyngeal</span></p></td><td class="c110" colspan="1" rowspan="1"><p class="c26 c32"><span class="c21 c12"></span></p></td><td class="c74" colspan="1" rowspan="1"><p class="c26 c32"><span class="c21 c12"></span></p></td><td class="c74" colspan="1" rowspan="1"><p class="c26 c32"><span class="c21 c12"></span></p></td><td class="c45" colspan="1" rowspan="1"><p class="c26"><span class="c21 c12">79.9</span></p><p class="c26"><span class="c21 c12">676 (&lt;day 5)</span></p></td><td class="c52" colspan="1" rowspan="1"><p class="c26"><span class="c21 c12">~700bp SISPA &nbsp;(4)</span></p></td><td class="c61" colspan="1" rowspan="1"><p class="c26 c32"><span class="c21 c12"></span></p></td><td class="c146" colspan="1" rowspan="1"><p class="c26"><span class="c21 c12">0.02%</span></p></td><td class="c147" colspan="1" rowspan="1"><p class="c26"><span class="c41 c22"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?ylzqHy&amp;sa=D&amp;source=editors&amp;ust=1679054520353886&amp;usg=AOvVaw3bqZAM0gmNH7xb3Sfneh0I">166</a></span><span class="c22">&nbsp;</span><span class="c41 c22"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?hsE1er&amp;sa=D&amp;source=editors&amp;ust=1679054520354334&amp;usg=AOvVaw2gLMP9-QepYN3rNEGHZPrY">162</a></span><span class="c22">&nbsp;</span><span class="c41 c22"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?QO15zW&amp;sa=D&amp;source=editors&amp;ust=1679054520354645&amp;usg=AOvVaw2WAI7ArLHZUkBaQj7Zlr5v">168</a></span><span class="c22">&nbsp;</span><span class="c41 c22"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?gaXsZN&amp;sa=D&amp;source=editors&amp;ust=1679054520355047&amp;usg=AOvVaw1XIdrfmBnHyGri3L_qrhcZ">169</a></span></p></td></tr><tr class="c25"><td class="c37" colspan="1" rowspan="1"><p class="c26"><span class="c21 c12">Sputum</span></p></td><td class="c110" colspan="1" rowspan="1"><p class="c26 c32"><span class="c21 c12"></span></p></td><td class="c74" colspan="1" rowspan="1"><p class="c26 c32"><span class="c21 c12"></span></p></td><td class="c74" colspan="1" rowspan="1"><p class="c26 c32"><span class="c21 c12"></span></p></td><td class="c45" colspan="1" rowspan="1"><p class="c26"><span class="c21 c12">752</span></p><p class="c26"><span class="c21 c12">1200</span></p></td><td class="c52" colspan="1" rowspan="1"><p class="c26 c32"><span class="c21 c12"></span></p></td><td class="c61" colspan="1" rowspan="1"><p class="c26 c32"><span class="c21 c12"></span></p></td><td class="c146" colspan="1" rowspan="1"><p class="c26 c32"><span class="c21 c12"></span></p></td><td class="c147" colspan="1" rowspan="1"><p class="c26"><span class="c41 c22"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?8qKk9p&amp;sa=D&amp;source=editors&amp;ust=1679054520357888&amp;usg=AOvVaw0p3fryKqUs7iaVSXsEALwR">167</a></span><span class="c22">&nbsp;</span><span class="c41 c22"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?lFGqTS&amp;sa=D&amp;source=editors&amp;ust=1679054520358466&amp;usg=AOvVaw0qf1Vd4TKyuQP_Xy8SVSYM">170</a></span></p></td></tr><tr class="c25"><td class="c37" colspan="1" rowspan="1"><p class="c26"><span class="c21 c12">Saliva</span></p></td><td class="c110" colspan="1" rowspan="1"><p class="c26"><span class="c21 c12">~1mL</span></p></td><td class="c74" colspan="1" rowspan="1"><p class="c26 c32"><span class="c21 c12"></span></p></td><td class="c74" colspan="1" rowspan="1"><p class="c26 c32"><span class="c21 c12"></span></p></td><td class="c45" colspan="1" rowspan="1"><p class="c26"><span class="c21 c12">1000</span></p><p class="c26"><span class="c21 c12">~100 (day 2 asymp)</span></p><p class="c26"><span class="c21 c12">7079 (D), 1819 (O)</span></p><p class="c26"><span class="c21 c12">549 (child)</span></p><p class="c26"><span class="c21 c12">~1000</span></p><p class="c26"><span class="c21 c12">3000 (7)</span></p><p class="c26"><span class="c21 c12">1 to 100 (8 - early infections)</span></p></td><td class="c52" colspan="1" rowspan="1"><p class="c26"><span class="c21 c12">74% of samples &gt; 50% fragmented (6)</span></p><sup><a href="#cmnt56" id="cmnt_ref56">[bd]</a></sup></td><td class="c61" colspan="1" rowspan="1"><p class="c26 c32"><span class="c21 c12"></span></p></td><td class="c146" colspan="1" rowspan="1"><p class="c26 c32"><span class="c21 c12"></span></p></td><td class="c147" colspan="1" rowspan="1"><p class="c26"><span class="c41 c22"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?NigDZ1&amp;sa=D&amp;source=editors&amp;ust=1679054520361949&amp;usg=AOvVaw07dKDQin8RWNYiEjMuwS3-">171</a></span><span class="c22">&nbsp;</span><span class="c41 c22"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?1PkZmw&amp;sa=D&amp;source=editors&amp;ust=1679054520362386&amp;usg=AOvVaw0zBbYaM1euVg7OpnqB5-tB">172</a></span><span class="c22">&nbsp;</span><span class="c41 c22"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?6HWYZM&amp;sa=D&amp;source=editors&amp;ust=1679054520362723&amp;usg=AOvVaw0Wu0-2FkCvLNJDI2gFBZMQ">164</a></span><span class="c22">&nbsp;</span><span class="c41 c22"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?tFLOtN&amp;sa=D&amp;source=editors&amp;ust=1679054520363045&amp;usg=AOvVaw3Ug-DDDB1_YsBh1W8-diJ7">165</a></span><span class="c22">&nbsp;</span><span class="c41 c22"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?bvPPVQ&amp;sa=D&amp;source=editors&amp;ust=1679054520363379&amp;usg=AOvVaw1SaLOkNBZb6goPEHMKqePW">162</a></span><span class="c22">&nbsp;</span><span class="c41 c22"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?asKAQI&amp;sa=D&amp;source=editors&amp;ust=1679054520363719&amp;usg=AOvVaw03wIzcfFZOovG0zkTKK29t">166</a></span><span class="c22">&nbsp;</span><span class="c41 c22"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?xt1Grj&amp;sa=D&amp;source=editors&amp;ust=1679054520364054&amp;usg=AOvVaw0XBqWoUrwqKgb70YKxAV-7">173</a></span><span class="c22">&nbsp;</span><span class="c41 c22"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?n1r2uu&amp;sa=D&amp;source=editors&amp;ust=1679054520364362&amp;usg=AOvVaw2yjcdTEQ9D_FB-GelcBNVY">174</a></span></p></td></tr><tr class="c25"><td class="c37" colspan="1" rowspan="1"><p class="c26"><span class="c21 c12">Blood (Serum)</span></p></td><td class="c110" colspan="1" rowspan="1"><p class="c26 c32"><span class="c21 c12"></span></p></td><td class="c74" colspan="1" rowspan="1"><p class="c26 c32"><span class="c21 c12"></span></p></td><td class="c74" colspan="1" rowspan="1"><p class="c26 c32"><span class="c21 c12"></span></p></td><td class="c45" colspan="1" rowspan="1"><p class="c26"><span class="c21 c12">127</span></p><p class="c26"><span class="c21 c12">2030</span></p></td><td class="c52" colspan="1" rowspan="1"><p class="c26 c32"><span class="c21 c12"></span></p></td><td class="c61" colspan="1" rowspan="1"><p class="c26 c32"><span class="c21 c12"></span></p></td><td class="c146" colspan="1" rowspan="1"><p class="c26 c32"><span class="c21 c12"></span></p></td><td class="c147" colspan="1" rowspan="1"><p class="c26"><span class="c41 c22"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?B1oI8t&amp;sa=D&amp;source=editors&amp;ust=1679054520368237&amp;usg=AOvVaw0IFa1F428A6bx7wJBsWbjP">19</a></span><span class="c22">&nbsp;</span><span class="c41 c22"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?muyKmH&amp;sa=D&amp;source=editors&amp;ust=1679054520368798&amp;usg=AOvVaw2uDVN0_PAAKWnjVvW3c5Fr">164</a></span></p></td></tr><tr class="c25"><td class="c37" colspan="1" rowspan="1"><p class="c26"><span class="c21 c12">Urine</span></p></td><td class="c110" colspan="1" rowspan="1"><p class="c26 c32"><span class="c21 c12"></span></p></td><td class="c74" colspan="1" rowspan="1"><p class="c26 c32"><span class="c21 c12"></span></p></td><td class="c74" colspan="1" rowspan="1"><p class="c26 c32"><span class="c21 c12"></span></p></td><td class="c45" colspan="1" rowspan="1"><p class="c26"><span class="c21 c12">109</span></p><p class="c26"><span class="c21 c12">136</span></p></td><td class="c52" colspan="1" rowspan="1"><p class="c26 c32"><span class="c21 c12"></span></p></td><td class="c61" colspan="1" rowspan="1"><p class="c26 c32"><span class="c21 c12"></span></p></td><td class="c146" colspan="1" rowspan="1"><p class="c26 c32"><span class="c21 c12"></span></p></td><td class="c147" colspan="1" rowspan="1"><p class="c26"><span class="c41 c22"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?aPk1AH&amp;sa=D&amp;source=editors&amp;ust=1679054520371368&amp;usg=AOvVaw0lkyufFvhx6_nblfTkUwnR">19</a></span><span class="c22">&nbsp;</span><span class="c41 c22"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?9pXehj&amp;sa=D&amp;source=editors&amp;ust=1679054520371783&amp;usg=AOvVaw1Oel2fVkDTrvYb9g-X9V_l">164</a></span></p></td></tr><tr class="c25"><td class="c37" colspan="1" rowspan="1"><p class="c26"><span class="c21 c12">Stool</span></p></td><td class="c110" colspan="1" rowspan="1"><p class="c26 c32"><span class="c21 c12"></span></p></td><td class="c74" colspan="1" rowspan="1"><p class="c26 c32"><span class="c21 c12"></span></p></td><td class="c74" colspan="1" rowspan="1"><p class="c26 c32"><span class="c21 c12"></span></p></td><td class="c45" colspan="1" rowspan="1"><p class="c26"><span class="c21 c12">100, 310, 8010</span></p><p class="c26"><span class="c21 c12">93325 (child)</span></p><p class="c26"><span class="c21 c12">43 </span></p></td><td class="c52" colspan="1" rowspan="1"><p class="c26 c32"><span class="c21 c12"></span></p></td><td class="c61" colspan="1" rowspan="1"><p class="c26 c32"><span class="c21 c12"></span></p></td><td class="c146" colspan="1" rowspan="1"><p class="c26 c32"><span class="c21 c12"></span></p></td><td class="c147" colspan="1" rowspan="1"><p class="c26"><span class="c41 c22"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?rA08TC&amp;sa=D&amp;source=editors&amp;ust=1679054520374710&amp;usg=AOvVaw1_vND0u-tvwovTKiaQAbov">19</a></span><span class="c22">&nbsp;</span><span class="c41 c22"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?5zybrV&amp;sa=D&amp;source=editors&amp;ust=1679054520375238&amp;usg=AOvVaw2qq9RpdfLznLlpk-EHWGZw">164</a></span><span class="c22">&nbsp;</span><span class="c41 c22"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?D0QiVF&amp;sa=D&amp;source=editors&amp;ust=1679054520375619&amp;usg=AOvVaw1ijcY4ZaNEjjeSV0h1ijd-">156</a></span><span class="c22">&nbsp;</span><span class="c41 c22"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?43U3eZ&amp;sa=D&amp;source=editors&amp;ust=1679054520375942&amp;usg=AOvVaw3_CAnBf8WTqK0sgwaH0VJI">154</a></span><span class="c22">&nbsp;</span><span class="c41 c22"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?jxAsoh&amp;sa=D&amp;source=editors&amp;ust=1679054520376291&amp;usg=AOvVaw3-oXsOKu2wSboJAG0W5BG8">159</a></span></p></td></tr></table><p class="c17 c32"><span class="c13 c12"></span></p><p class="c1"><span class="c20 c12"></span></p><h1 class="c115 c107" id="h.iw3clw55vts"><span class="c33 c12">Appendix G - Sequencing Vendor Library Preparation Notes</span></h1><p class="c17 c32"><span class="c0"></span></p><h4 class="c54" id="h.tmfcck7pnulm"><span class="c68 c12">Helicos - Direct RNA</span></h4><p class="c1"><span class="c100 c36 c12 c73"></span></p><p class="c7"><span class="c36">In the case of Helicos direct RNA sequencing</span><span class="c19"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?VijBlB&amp;sa=D&amp;source=editors&amp;ust=1679054520377840&amp;usg=AOvVaw2szB9iYIbCecJ9vZ8bIWDq">35</a></span><span class="c36">&nbsp;where input RNA already has a naturally pre-existing polyA tail, no additional library preparation steps are required. For other samples, a PolyA tail may be added using readily available polyA tailing kits</span><span class="c19"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?iLAm4x&amp;sa=D&amp;source=editors&amp;ust=1679054520378214&amp;usg=AOvVaw3Xoca-fCMPoEZxRXscfm23">43</a></span><span class="c0">. This protocol takes ~1 hour.</span></p><p class="c1"><span class="c100 c36 c12 c73"></span></p><h4 class="c54" id="h.vn4cf8fcvsbw"><span class="c68 c12">Oxford Nanopore</span></h4><p class="c1"><span class="c20 c12"></span></p><p class="c7"><span class="c36">Oxford Nanopore have a number of library preparation kits available for their platform. For direct RNA sequencing</span><span class="c19"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?aLYwnK&amp;sa=D&amp;source=editors&amp;ust=1679054520378884&amp;usg=AOvVaw3GT1h1-DctTL5RMuaIMuQH">165</a></span><span class="c36">&nbsp;</span><span class="c0">the protocol takes ~2 hours. While the process sequences RNA directly, it still requires reverse transcription (cDNA) and adapter ligation.</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c0">Oxford Nanopore also have a Rapid DNA sequencing kit, this protocol takes 10 minutes, however longer (30kb) DNA is recommended.</span></p><h4 class="c54" id="h.pecikmofxord"><span class="c12 c68">Illumina</span></h4><p class="c1"><span class="c20 c12"></span></p><p class="c7"><span class="c36">Nextera DNA Flex Library Preparation Kit</span><span class="c19"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?TXAPUt&amp;sa=D&amp;source=editors&amp;ust=1679054520379861&amp;usg=AOvVaw1sz4KqhPvVQOuEWseNWZXx">166</a></span><span class="c36">,</span><span class="c0">&nbsp;prep time is 3 to 4 hours.</span></p><h4 class="c54" id="h.82vkxijx2mvg"><span class="c68 c12">Ion Torrent</span></h4><p class="c1"><span class="c20 c12"></span></p><p class="c7"><span class="c36">Similar to Illumina sequencing, Ion Torrent also requires adapter ligation as part of the library preparation process. While Thermo previously offered a transposon based kit (80min of lab time), this is no longer available, the </span><span class="c36">standard Ion Torrent library preparation process</span><span class="c36">&nbsp;takes ~2 hours</span><span class="c19"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?gH6fPs&amp;sa=D&amp;source=editors&amp;ust=1679054520380606&amp;usg=AOvVaw3DHmySE3HRbP4icNODbKam">167</a></span><span class="c0">.</span></p><p class="c1"><span class="c20 c12"></span></p><h4 class="c54" id="h.9z22v79l425l"><span class="c68 c12">MGI</span></h4><p class="c1"><span class="c20 c12"></span></p><p class="c7"><span class="c36">MGIEasy Fast FS DNA Library Prep Set prep takes ~2.5 hours</span><span class="c19"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?19fn9y&amp;sa=D&amp;source=editors&amp;ust=1679054520381555&amp;usg=AOvVaw1KWh-B3gc1n4GsOmYbyHj4">168</a></span><span class="c0">.</span></p><h4 class="c54" id="h.jinoyyhnk5vd"><span class="c68 c12">Pacific Biosciences</span></h4><p class="c1"><span class="c100 c36 c12 c73"></span></p><p class="c7"><span class="c36">While Pacific Biosciences&rsquo; instruments should be capable of direct RNA sequencing, no such kits are currently available</span><span class="c19"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?buu8sx&amp;sa=D&amp;source=editors&amp;ust=1679054520382528&amp;usg=AOvVaw0qiJOwApg59dhZStdAqRkQ">169</a></span><span class="c36">. The current Pacific Biosciences approach therefore relies on cDNA conversion during sample preparation. These are further used to create &ldquo;Universal SMRTbell templates&rdquo; for sequencing. This is a complex process which generates circularized DNA as the input to the sequencing process, consisting of the</span><span class="c36">&nbsp;following steps</span><span class="c19"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?tYYGPJ&amp;sa=D&amp;source=editors&amp;ust=1679054520383072&amp;usg=AOvVaw17kNoKc0W-zycNiKVpqRg8">170</a></span><span class="c36">&nbsp;</span><span class="c19"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?pEv4Kf&amp;sa=D&amp;source=editors&amp;ust=1679054520383482&amp;usg=AOvVaw17C2LGHn7qztCStJOirL_Y">171</a></span><span class="c36">:</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c0">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;* DNA Damage Repair</span></p><p class="c7"><span class="c0">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;* End Repair</span></p><p class="c7"><span class="c0">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;* Adapter Ligation</span></p><p class="c7"><span class="c0">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;* Purification (clean up)</span></p><p class="c7"><span class="c0">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;* Primer Annealing</span></p><p class="c1"><span class="c0"></span></p><p class="c7"><span class="c36">In total this process takes 3 to 6 hours</span><span class="c19"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?7fo7td&amp;sa=D&amp;source=editors&amp;ust=1679054520384538&amp;usg=AOvVaw0AIKIiYt2q2mVLtyAaHSqX">172</a></span><span class="c0">.</span></p><p class="c1"><span class="c20 c12"></span></p><h1 class="c84" id="h.d98euvfdgdre"><span class="c33 c12">Appendix H - Amplification Issues for qPCR</span></h1><p class="c1"><span class="c20 c12"></span></p><p class="c7"><span class="c0 c62">In this appendix we discuss issues which may cause loss of amplification in qPCR.</span></p><h3 class="c106" id="h.5hmy89198ukk"><span>Mutations</span></h3><p class="c7"><span class="c36 c62">Single mutations in primer sites</span><span class="c19 c62"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?MkD7Mb&amp;sa=D&amp;source=editors&amp;ust=1679054520385485&amp;usg=AOvVaw3vVmAImzc-KqcFyfxh9_8q">173</a></span><span class="c36 c62">&nbsp;can result in PCR failure (no amplification)</span><span class="c19 c62"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?7XDGqi&amp;sa=D&amp;source=editors&amp;ust=1679054520385838&amp;usg=AOvVaw1YmEPJQpNuzLfasy8sV5GM">173,174</a></span><span class="c0 c62">. Such mutations would have no effect on sequencing, where reads are in general sufficiently long to align with multiple mutations.</span></p><p class="c1"><span class="c0 c62"></span></p><p class="c7"><span class="c36 c62">We suspect mutations are not the most significant issue in the majority of cases, but it is an issue worth considering as viral genomes evolve and potentially evade detection</span><span class="c19 c62"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?ppaRmD&amp;sa=D&amp;source=editors&amp;ust=1679054520386453&amp;usg=AOvVaw3yug3Yq4cssLsIUWm9eawk">174</a></span><span class="c36 c62">.</span></p><h3 class="c106" id="h.xqhginvi4lmg"><span class="c34 c12">Fragmentation - Handling</span></h3><p class="c7"><span class="c36 c62">The CDC SARS-CoV-2 Multiplex assay primers</span><span class="c19 c62"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?cxZVfq&amp;sa=D&amp;source=editors&amp;ust=1679054520387126&amp;usg=AOvVaw176r7A5b7sFaRkzLI5bpLU">175</a></span><span class="c36 c62">&nbsp;are about 90 nucleotides apart. qPCR is therefore able to detect SARS-CoV-2 if this 90 nucleotide region is present in the sample. SARS-CoV-2 is a 30 Kb genome. And as we&rsquo;ve seen with long-read sequencing platforms, keeping 30 Kb + fragments fully intact often requires special handling.</span><span class="c19 c62"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?SBUSIl&amp;sa=D&amp;source=editors&amp;ust=1679054520387551&amp;usg=AOvVaw1XeXl4-4JCjhLGpKXOji_4">176</a></span><span class="c0 c62">&nbsp;If during sample prep a SARS-CoV-2 genome is fragmented anywhere in that 90nt region, amplification of that molecule will fail. This is unlikely to be significant at a high viral load, but when single-digit copies are present in a sample, it could cause issues.</span></p><h3 class="c106" id="h.ctd8tvpacg6f"><span class="c34 c12">Fragmentation - At Collection</span></h3><p class="c7"><span class="c36 c62">Beyond this, evidence suggests that SARS-CoV-2 is fragmented in the sample at collection. Results discussing how long SARS-CoV-2 is viable in a sample</span><span class="c19 c62"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?aazqPD&amp;sa=D&amp;source=editors&amp;ust=1679054520388201&amp;usg=AOvVaw0Ym8ClS33X-R-q9IYzovCk">177</a></span><span class="c0 c62">&nbsp;suggest that SARS-CoV-2 degrades relatively quickly, and samples may therefore contain significant quantities of fragmented cell-free SARS-CoV-2 RNA.</span></p><p class="c1"><span class="c0 c62"></span></p><p class="c7"><span class="c36 c62">Other reports suggest that CT values of SARS-CoV-2 in viral transport medium increase by 3 points over a 14-day period</span><span class="c19 c62"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?TATQZJ&amp;sa=D&amp;source=editors&amp;ust=1679054520388735&amp;usg=AOvVaw1xcWCtOWNwIT1HWiLTVFD7">178</a></span><span class="c36 c62">, an approximately 10-fold reduction</span><span class="c19 c62"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?DSUckd&amp;sa=D&amp;source=editors&amp;ust=1679054520389072&amp;usg=AOvVaw2BnzTTFctErQPfG08fK_XV">179</a></span><span class="c0 c62">. This also suggests that it&rsquo;s likely the live virus is constantly degrading in the body and after collection. Therefore, a significant fraction of the nucleic acid material used by qPCR and sequencing may be fragmented.</span></p><p class="c1"><span class="c0 c62"></span></p><p class="c7"><span class="c36 c62">Yet other reports</span><span class="c19 c62"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?GQPgyg&amp;sa=D&amp;source=editors&amp;ust=1679054520389744&amp;usg=AOvVaw1iH7lINTJlMQD9NFlUAOru">180</a></span><span class="c36 c62">&nbsp;suggest that samples from high CT &ldquo;disease resolved&rdquo; patients are likely &ldquo;residual noninfectious fragmented viral RNA being released as a result of immune clearance&rdquo;. Samples taken 8 days after symptoms onset often fail to culture</span><span class="c19 c62"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?viegIK&amp;sa=D&amp;source=editors&amp;ust=1679054520390149&amp;usg=AOvVaw3berg8PKhbfOJh8PNjIexG">181</a></span><span class="c0 c62">, indicating live virus is not present. Again, this all suggests to me that fragmented viral RNA is generated during the course of an infection and remains present for some time.</span></p><p class="c1"><span class="c0 c62"></span></p><p class="c7"><span class="c36 c62">Elsewhere, sequencing was used to confirm this</span><span class="c19 c62"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?krjJRy&amp;sa=D&amp;source=editors&amp;ust=1679054520390781&amp;usg=AOvVaw3e2IUqpn50ffLlic2u3Jb3">116</a></span><span class="c0 c62">&nbsp;and suggested that in high CT patients, viral RNA was fragmented and non-viable:</span></p><p class="c1"><span class="c0 c62"></span></p><p class="c7"><span class="c123 c36 c62 c12 c125 c35">&ldquo;Bioinformatic reconstruction of sequenced RNA showed how samples did not have the whole viral genome, but only a few and very short gene fragments (&lt;600 nucleotides). This finding indicates that the residual RNA detected by molecular testing was not functional and represented only pieces of the degraded viral genome.&rdquo;</span></p><h3 class="c106" id="h.w8mphloz7g69"><span class="c34 c12">Fragmentation - sgRNA</span></h3><p class="c7"><span class="c36 c62">During the SARS-CoV-2 replication cycle, sgRNA is created. This sgRNA is also available to meta-genomic sequencing-based diagnostics, giving us an edge over qPCR. The presence of sgRNA (which is cleared relatively quickly</span><span class="c19 c62"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?RVErpF&amp;sa=D&amp;source=editors&amp;ust=1679054520391948&amp;usg=AOvVaw1qImebxh43BtJx4-vWvLfY">182</a></span><span class="c0 c62">) also indicates that replication is actively taking place.</span></p><p class="c1"><span class="c0 c62"></span></p><p class="c7"><span class="c36 c62">One study looked at 2 sgRNA regions and found that they represented about 20% of the ORF1ab counts. There are 10 canonical RNAs in SARS-CoV-2</span><span class="c19 c62"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?8Ly9oC&amp;sa=D&amp;source=editors&amp;ust=1679054520392868&amp;usg=AOvVaw2ccYrUeKbKr2rBvkU0yd6y">183</a></span><span class="c0 c62">. It, therefore, seems possible that the total quantity of sgRNA could be significant in infectious individuals. </span></p><hr style="page-break-before:always;display:none;"><p class="c1"><span class="c20 c12"></span></p><h1 class="c84" id="h.sk9dbcetximj"><span class="c33 c12">References</span></h1><p class="c1"><span class="c20 c12"></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520394136&amp;usg=AOvVaw2bF569hsgI5z_af_MVkumh">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Timing the SARS-CoV-2 index case in Hubei province | Science. https://www.science.org/doi/10.1126/science.abf8003.</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520394814&amp;usg=AOvVaw0VBUxxfaa8a4GPBty2upnI">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Investigating Unexplained Respiratory Outbreaks (URDO) | CDC. https://www.cdc.gov/urdo/outbreak.html (2022).</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520395430&amp;usg=AOvVaw1rL9oDJEgmqkR27WJRU6PM">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Wu, F. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520395856&amp;usg=AOvVaw3OyvInQmzuoBvMDngejZ8v">et al.</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520396245&amp;usg=AOvVaw0yg6iyWbTA3TjOjk7Sr6zF">&nbsp;A new coronavirus associated with human respiratory disease in China. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520396666&amp;usg=AOvVaw0KX35rrDCPGuFr1gGpPdJE">Nature </a></span><span class="c39 c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520397102&amp;usg=AOvVaw2NMcccDat8YnRJs9YzmmMR">579</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520397532&amp;usg=AOvVaw3iKzUWbHy8rVDEwR3SzLk6">, 265&ndash;269 (2020).</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520398159&amp;usg=AOvVaw3aPu7GhcHPHnsriXJsf1mA">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Li, L. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520398557&amp;usg=AOvVaw2Wz3szOYLdS0oGxfxEdAB-">et al.</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520398964&amp;usg=AOvVaw2ofIleNOOzHb28FEoZbUD4">&nbsp;Detecting SARS-CoV-2 variants in wastewater and their correlation with circulating variants in the communities. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520399386&amp;usg=AOvVaw1Ifa35hIcwANvVLtLhd_WJ">Sci. Rep. </a></span><span class="c39 c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520399796&amp;usg=AOvVaw2NWYggFSDUOGgMxY1hqMEj">12</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520400214&amp;usg=AOvVaw1qPDpupG7xy0YV1N7NCGPB">, 16141 (2022).</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520400883&amp;usg=AOvVaw0io7lDRvL6UJIN8pYaZRSY">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Consortium, T. N. A. O. A Global Nucleic Acid Observatory for Biodefense and Planetary Health. Preprint at https://doi.org/10.48550/arXiv.2108.02678 (2021).</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520401463&amp;usg=AOvVaw3SQ694oV81KxFjh4PXFbv4">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Liu, T. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520401863&amp;usg=AOvVaw1Mw37yBQ2HeecrilelkT4F">et al.</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520402312&amp;usg=AOvVaw2NGOTZeYtW4K5Z7VCtFG_7">&nbsp;A benchmarking study of SARS-CoV-2 whole-genome sequencing protocols using COVID-19 patient samples. 2020.11.10.375022 Preprint at https://doi.org/10.1101/2020.11.10.375022 (2020).</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520402973&amp;usg=AOvVaw1gInjSr-AFkf5qdHj4sHC6">7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Respiratory Testing in the COVID-19 Era: Implementation and its Challenges. https://event.on24.com/wcc/r/3733481/EFB2A2A7B11C45A4E54B9C4296D87CB1?mode=login&amp;email=new@sgenomics.org.</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520403595&amp;usg=AOvVaw1cYB0Uz2LbQED2IcUwKRmV">8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total COVID-19 tests. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520404048&amp;usg=AOvVaw379NNbNZfyKSdk62_6JWeG">Our World in Data </a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520404481&amp;usg=AOvVaw3LoZTFnJdnBBZISco5yOf2">https://ourworldindata.org/grapher/full-list-total-tests-for-covid-19.</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520405121&amp;usg=AOvVaw04wo2eh-xqk0nzhiygyhPs">9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;COVID-19 Diagnostics Market Size Report, 2030. https://www.grandviewresearch.com/industry-analysis/covid-19-diagnostics-market.</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520405745&amp;usg=AOvVaw1UtDMhBBA3vGsRRfuNUy93">10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;MiSeq (Illumina) sequencing | Cornell Institute of Biotechnology | Cornell University. https://www.biotech.cornell.edu/core-facilities-brc/services/miseq-illumina-sequencing.</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520406375&amp;usg=AOvVaw1pLV3xyMaXuhZfoF0EJSrE">11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Flongle Flow Cell (R9.4.1). https://store.nanoporetech.com/flongle-flow-cell-pack.html.</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520407006&amp;usg=AOvVaw2MXK3rYEhukI2JV67FDpyV">12.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Illumina, Inc. - Financial Information. https://investor.illumina.com/financials/default.aspx.</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520407569&amp;usg=AOvVaw3De_NPVTKNcU2ZKI73pLbZ">13.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Oxford Nanopore Annual Report 2021.</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520408153&amp;usg=AOvVaw26_MnLPMkkwM5Cx6-DS12-">14.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Metagenomics Pathogen Detection - Great Ormond Street Hospital Laboratory Medicine. http://www.labs.gosh.nhs.uk/laboratory-services/microbiology-virology-and-infection-control/metagenomics-pathogen-detection.</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520408722&amp;usg=AOvVaw1JzpaixSoJNL0FGO1ltoAG">15.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;MiSeq Specifications | Key performance parameters. https://www.illumina.com/systems/sequencing-platforms/miseq/specifications.html.</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520409276&amp;usg=AOvVaw00U7IhE5uqOb3WqA4e8BDj">16.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Rapid Sequencing Kit. https://store.nanoporetech.com/rapid-sequencing-kit.html.</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520409765&amp;usg=AOvVaw32G6vptUOcNhF4Z0EfC2_7">17.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;blog, L. B. P. Comparison of SARS-CoV-2 Specimen Types: Nasal Swabs, Nasopharyngeal Swabs and Beyond. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520410116&amp;usg=AOvVaw3ejb4UvGt-mb4Hkh2blY1A">lab-best-practice </a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520410442&amp;usg=AOvVaw1TTj_Rf7YBNDCG1TucgL1P">https://health.ucdavis.edu/blog/lab-best-practice/comparison-of-sars-cov-2-specimen-types-nasal-swabs-nasopharyngeal-swabs-and-beyond/2021/09.</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520410860&amp;usg=AOvVaw13ILfBM_wsMLq6JRhy_FC_">18.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Justo, A. F. O. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520411191&amp;usg=AOvVaw3w06XymF3lxA_OVYF4Rvlv">et al.</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520411534&amp;usg=AOvVaw3wDnuLlqxoNfDGx-s0qzMb">&nbsp;Comparison of viral load between saliva and nasopharyngeal swabs for SARS-CoV2: the role of days of symptoms onset on diagnosis. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520411859&amp;usg=AOvVaw377s3W5j7kpBNazDOIR_Sj">Mem. Inst. Oswaldo Cruz </a></span><span class="c39 c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520412160&amp;usg=AOvVaw1mHpFKHrBUj7--iI1P3Bab">116</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520412443&amp;usg=AOvVaw1sPkr9nejgDbaXgdDr1Fy8">, e210018 (2021).</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520412863&amp;usg=AOvVaw3v-ZjwbH2dPLv9IvXfX5XJ">19.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Kim, J.-M. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520413283&amp;usg=AOvVaw1gXf405QagQjcievK5RTwI">et al.</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520413632&amp;usg=AOvVaw3v2zcldQejcF3m3ztv1uvH">&nbsp;Detection and Isolation of SARS-CoV-2 in Serum, Urine, and Stool Specimens of COVID-19 Patients from the Republic of Korea. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520413975&amp;usg=AOvVaw17ZFJuDJhL255jEOvZDAIt">Osong Public Health Res. Perspect. </a></span><span class="c39 c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520414250&amp;usg=AOvVaw2_dLqKm-OMo2yhkdP0B_Y8">11</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520414545&amp;usg=AOvVaw0_Xvd8A5FMzcsYTuUTXwam">, 112&ndash;117 (2020).</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520415051&amp;usg=AOvVaw3nK7K2M1H_Yii2n3erf7h5">20.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A diagnostic host response biosignature for COVID-19 from RNA profiling of nasal swabs and blood | Science Advances. https://www.science.org/doi/10.1126/sciadv.abe5984.</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520415520&amp;usg=AOvVaw1pnxlFB41RdOg94v5tKs7d">21.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Graf, E. H. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520415796&amp;usg=AOvVaw03F6c32y09L3xkOyLz_SzE">et al.</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520416142&amp;usg=AOvVaw135xuyWUXhSO_8DKouEk_a">&nbsp;Unbiased Detection of Respiratory Viruses by Use of RNA Sequencing-Based Metagenomics: a Systematic Comparison to a Commercial PCR Panel. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520416557&amp;usg=AOvVaw2CmJhfCdSJM1ZDxXD1H1wj">J. Clin. Microbiol. </a></span><span class="c39 c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520416958&amp;usg=AOvVaw0sOwCLd8C5NJz0l6BUPN-3">54</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520417402&amp;usg=AOvVaw1jWZvQZvSgquC6D117YPe0">, 1000&ndash;1007 (2016).</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520417894&amp;usg=AOvVaw0NUynutQfVwIAv-LHqYLHy">22.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Li, C.-X. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520418250&amp;usg=AOvVaw2Lp0MBy5uY7WtPVEvo8Dcf">et al.</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520418645&amp;usg=AOvVaw39M_T83CEUAOFJyHXiNZPx">&nbsp;High resolution metagenomic characterization of complex infectomes in paediatric acute respiratory infection. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520418980&amp;usg=AOvVaw2K2GzCRmKWMERIIeViKAy9">Sci. Rep. </a></span><span class="c39 c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520419264&amp;usg=AOvVaw29oum4P8UwBzEPkWAPaUOi">10</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520419597&amp;usg=AOvVaw2zVAKE2l9yMiJ26Rvw0zN6">, 3963 (2020).</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520420055&amp;usg=AOvVaw0d994_4qgrr0p0q5zsM5TS">23.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Renati, S. &amp; Linder, J. A. Necessity of office visits for acute respiratory infections in primary care. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520420494&amp;usg=AOvVaw3q9YVbUikqf689NDA8nxG1">Fam. Pract. </a></span><span class="c39 c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520420787&amp;usg=AOvVaw3Da334kUkQhn-sXbJeRB_J">33</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520421051&amp;usg=AOvVaw3a6zcvc3fZfpZrhRsNN-xM">, 312&ndash;317 (2016).</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520421455&amp;usg=AOvVaw2Fe88yv9PTgpPVPfAeWCPI">24.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Illumina DNA PCR-Free Library Prep Reference Guide (1000000086922).</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520422039&amp;usg=AOvVaw0sHRymyaRjoo4MJl15Pz3S">25.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NovaSeq 6000 System Guide. https://jp.support.illumina.com/content/dam/illumina-support/documents/documentation/system_documentation/novaseq/1000000019358_17_novaseq-6000-system-guide.pdf.</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520422792&amp;usg=AOvVaw15RtK1rybe7ktlIkNXHxkz">26.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NovaSeq 6000 System Specifications | Output, run time, and more. https://emea.illumina.com/systems/sequencing-platforms/novaseq/specifications.html.</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520423512&amp;usg=AOvVaw3g_PvzNsaFr0kavkoyQ39J">27.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Illumina FAQ. https://support-docs.illumina.com/TS/FAQ/Content/FAQ.htm?fc=Instrument-NovaSeq_6000-.</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520424240&amp;usg=AOvVaw2cY4syAae1Uwa63m3QM-7L">28.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;MiSeq System Denature and Dilute Libraries Guide (15039740).</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520424961&amp;usg=AOvVaw3mGSPwmifM20yHcgfRNwFk">29.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;MiSeq System User Guide.</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520425511&amp;usg=AOvVaw1zrWIlxTv1cgOmOYMoWlNw">30.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;MGI sequencing platforms: High-throughput gene sequencers, DNBSEQ</a></span><span class="c41"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520425804&amp;usg=AOvVaw1xxT-p72VKXhuN9rdJCA-h">TM</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520426090&amp;usg=AOvVaw0ZElPQck-HOexQ28JZA09e">&nbsp;sequencing technology-MGI-Leading Life Science Innovation. https://en.mgi-tech.com/products/.</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520426473&amp;usg=AOvVaw3gtw9p37J0bpknIrFZBoUR">31.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Product specifications. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520426724&amp;usg=AOvVaw2Q7PLxCCEqmq8dgbI3kpiY">Oxford Nanopore Technologies </a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520426963&amp;usg=AOvVaw09UrqLMKdc7thq-37Tmwl9">https://nanoporetech.com/products/specifications.</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520427321&amp;usg=AOvVaw3-Z-ZGXarooS9sRVaPnfHT">32.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sequel systems - PacBio. https://www.pacb.com/technology/hifi-sequencing/sequel-system/.</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520427781&amp;usg=AOvVaw0BVTj4A3mX7MZ6tELmc10i">33.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Raley, C. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520428214&amp;usg=AOvVaw2jxT5Jvg_cWhGew3BdC5XV">et al.</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520428631&amp;usg=AOvVaw1Z43rrrRP5J6HM6imWO-qz">&nbsp;Preparation of next-generation DNA sequencing libraries from ultra-low amounts of input DNA: Application to single-molecule, real-time (SMRT) sequencing on the Pacific Biosciences RS II. 003566 Preprint at https://doi.org/10.1101/003566 (2014).</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520429190&amp;usg=AOvVaw0GlZ781GbmKZd6dppL-IO7">34.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SeqLL Sequencing Brochure. http://seqll.com/wp-content/uploads/2017/02/seqll-sequence-brochure2_2017.pdf.</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520429720&amp;usg=AOvVaw38KquHGk1zIEyMaoERAwms">35.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ozsolak, F. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520430118&amp;usg=AOvVaw2Cw_XZtIfzGhGrtlQBLM6L">et al.</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520430509&amp;usg=AOvVaw2WrkV9Cge7drKE5BB-JfOM">&nbsp;Direct RNA sequencing. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520430882&amp;usg=AOvVaw1g_F-DflRLxETRep5ye4rQ">Nature </a></span><span class="c39 c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520431236&amp;usg=AOvVaw3VNaK4kSOTpqwMbpeKqVN3">461</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520431598&amp;usg=AOvVaw2aFl89LGch2FODAbzYN4kS">, 814&ndash;818 (2009).</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520432153&amp;usg=AOvVaw16m5OLyMjW7hUS8Srgm8RP">36.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ozsolak, F. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520432532&amp;usg=AOvVaw1iwWDlBsLwOLoY-sBKD0tR">et al.</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520432963&amp;usg=AOvVaw3YOJatNLr0nW0p8drmqcXC">&nbsp;Digital transcriptome profiling from attomole-level RNA samples. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520433358&amp;usg=AOvVaw3aLbFyuGX1NK9hb0vIecgA">Genome Res. </a></span><span class="c39 c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520433728&amp;usg=AOvVaw1JkmBdcVTLbirOgTLytKTQ">20</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520434105&amp;usg=AOvVaw29pBIeZzwlxGz_isIzR6NU">, 519&ndash;525 (2010).</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520434603&amp;usg=AOvVaw3pC_nZntPi_BdotMLdcfMt">37.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#12471;&#12473;&#12486;&#12512;&#20181;&#27096; - JP. https://www.thermofisher.com/jp/ja/home/life-science/sequencing/next-generation-sequencing/ion-torrent-next-generation-sequencing-workflow/ion-torrent-next-generation-sequencing-run-sequence/ion-s5-ngs-targeted-sequencing/ion-s5-specifications.html.</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520435020&amp;usg=AOvVaw0-k5MGMofyEzYoCFt5Xjne">38.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Run time estimates for each sequencing step on Illumina sequencing platforms. https://jp.support.illumina.com/bulletins/2017/02/run-time-estimates-for-each-sequencing-step-on-illumina-sequenci.html.</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520435388&amp;usg=AOvVaw3LYG6axABp-MG4qOMPJCVe">39.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gardner, A. F. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520435632&amp;usg=AOvVaw1uLEWm6rmalexKeDABLcKs">et al.</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520435893&amp;usg=AOvVaw2dghCiyF3ZCGt7G-CqzBYX">&nbsp;Rapid incorporation kinetics and improved fidelity of a novel class of 3&prime;-OH unblocked reversible terminators. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520436234&amp;usg=AOvVaw09EHPn6kklGhDDqx8O67aM">Nucleic Acids Res. </a></span><span class="c39 c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520436586&amp;usg=AOvVaw1rV3qWudXJoQYpLmi8eXyt">40</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520436871&amp;usg=AOvVaw29NP2ElmIBGvWTOApL1Rb1">, 7404&ndash;7415 (2012).</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520437257&amp;usg=AOvVaw1tIevu-nXCJuXCqYTF10_s">40.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Scanning Capacitance Microscopy (SCM) for Cypher and Jupiter XR AFMs. https://afm.oxinst.com/assets/uploads/products/asylum/documents/Scanning-Capacitance-SCM-Datasheet-6MAY2020.pdf.</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520437615&amp;usg=AOvVaw3-h6HL-ak1bFx4vd2KpLf7">41.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Toni, L. S. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520437878&amp;usg=AOvVaw06u05GJmpsMiZxaf7saWjZ">et al.</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520438121&amp;usg=AOvVaw278hAu2zb6qb_cHH9ejkFC">&nbsp;Optimization of phenol-chloroform RNA extraction. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520438361&amp;usg=AOvVaw1vC1rnRnUxgbf19KmhK_up">MethodsX </a></span><span class="c39 c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520438625&amp;usg=AOvVaw1NsxTz-Lu6eIKvkA5-FqV7">5</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520438891&amp;usg=AOvVaw0OGlPMS03CMPwZhIKUFD5U">, 599&ndash;608 (2018).</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520439325&amp;usg=AOvVaw3XbYy43kQWcL8sKxIbCnlS">42.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Coupland, P., Chandra, T., Quail, M., Reik, W. &amp; Swerdlow, H. Direct sequencing of small genomes on the Pacific Biosciences RS without library preparation. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520439590&amp;usg=AOvVaw14NVMClSMtycSxTdDx6MAx">BioTechniques </a></span><span class="c39 c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520439840&amp;usg=AOvVaw11degRGQqYJI247ig0CCrY">53</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520440085&amp;usg=AOvVaw3Eff5NN3xdDn_-nTQWR1dR">, 10.2144/000113962 (2012).</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520440512&amp;usg=AOvVaw1jOh-bZxdGX93sxrd5uji7">43.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Poly(A) Tailing Kit. https://www.thermofisher.com/order/catalog/product/jp/ja/AM1350.</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520440925&amp;usg=AOvVaw2_KuVQIomgMqAjNIJpLvUm">44.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NEBNext&reg; rRNA Depletion Kit (Human/Mouse/Rat). https://international.neb.com/-/media/nebus/files/manuals/manuale6310.pdf.</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520441402&amp;usg=AOvVaw2t-j6LFY09zu74MhwSNwf3">45.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Library Prep Automation | Automated methods for our library prep kits. https://www.illumina.com/techniques/sequencing/ngs-library-prep/automation.html.</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520441863&amp;usg=AOvVaw0gDrOuEpj1UXq-RbMuGEHa">46.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;VolTRAX | Oxford Nanopore Technologies. https://nanoporetech.com/products/voltrax.</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520442250&amp;usg=AOvVaw0LGV24BOb8OZT7TdNpHJS2">47.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Volta Labs. https://www.voltalabs.com/.</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520442665&amp;usg=AOvVaw3U3uts5v6eykcbkgSmFiLF">48.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NeoPrep Library Prep System. https://jp.illumina.com/content/dam/illumina-marketing/documents/products/datasheets/neoprep-system-data-sheet-970-2014-004.pdf.</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520443177&amp;usg=AOvVaw0vxzpz97fuJaA5g1P-jrMO">49.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Development Portfolio | DNAe. https://www.dnae.com/development-portfolio.</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520443641&amp;usg=AOvVaw0lrkwbZB5TIoylKsRfYjh1">50.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Clinical Evaluation of Three Sample-to-Answer Platforms for Detection of SARS-CoV-2 | Journal of Clinical Microbiology. https://journals.asm.org/doi/10.1128/JCM.00783-20.</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520444019&amp;usg=AOvVaw1P23Dhu4xkRvAM1BrbwANI">51.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;FDA Clearance for GenMark&rsquo;s ePlex Intensifies Competition in Highly Plexed MDx Test Market. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520444271&amp;usg=AOvVaw2jB_Ocz1RKMib-Niyb0yte">GenomeWeb </a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520444521&amp;usg=AOvVaw0vMpsYx1gpPh4tXQa8mbRH">https://www.genomeweb.com/regulatory-news/fda-clearance-genmarks-eplex-intensifies-competition-highly-plexed-mdx-test-market (2017).</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520444876&amp;usg=AOvVaw1csAMuXvxI3PNpkzND6LVT">52.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Time for $5 | M&eacute;decins Sans Fronti&egrave;res Access Campaign. https://msfaccess.org/time-for-5.</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520445250&amp;usg=AOvVaw2imqyzXW7OlJ3HzLSMSdwh">53.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Hall, A. R. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520445498&amp;usg=AOvVaw16_RzHb0YOTEqJyxeKNkNZ">et al.</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520445738&amp;usg=AOvVaw34lYt6vS-KmkRILXAVlTPO">&nbsp;Hybrid pore formation by directed insertion of &alpha;-haemolysin into solid-state nanopores. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520446015&amp;usg=AOvVaw2yycMPCfQ654iXXCQapaPT">Nat. Nanotechnol. </a></span><span class="c39 c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520446247&amp;usg=AOvVaw32DnyOMmvB-kba88lGkIQg">5</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520446587&amp;usg=AOvVaw1henYjFa9slDnsdv3trFef">, 874&ndash;877 (2010).</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520446953&amp;usg=AOvVaw2XDvWBZhmxqxRK7bnfNZPR">54.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Manteia Predictive Medicine.</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520447310&amp;usg=AOvVaw3VlvfXjwDOpah1h7c5UBRd">55.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Illumina Sequencing Technology.</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520447675&amp;usg=AOvVaw1mhQ0l4oZA0uAes11W84Cs">56.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cost per Gigabase. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520447925&amp;usg=AOvVaw2lFSaiIAzJZ9UgyK4FBqMG">41J Blog </a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520448155&amp;usg=AOvVaw3oHEMZxCwQ4eo_Tdhvo7jJ">https://41j.com/blog/2022/09/cost-per-gigabase/ (2022).</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520448504&amp;usg=AOvVaw1mYwdosfK3b47XW-rrAds3">57.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ion S5 S5XL Brochure. https://tools.thermofisher.com/content/sfs/brochures/Ion-S5-S5XL-Brochure.pdf.</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520448915&amp;usg=AOvVaw0zNjVyYrz9XZa_L2gABe5M">58.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Personal Genomics Inc./CrackerBio. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520449308&amp;usg=AOvVaw3zgwlZKoecHFBzSYPBvqPn">41J Blog </a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520449624&amp;usg=AOvVaw0pxQxTpWr8NOXK1e5zEsUf">https://41j.com/blog/2016/02/personal-genomics-inc-crackerbio/ (2016).</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520450033&amp;usg=AOvVaw3jVRfALv8tc1ctuH-4h-ly">59.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;InSilixa. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520450352&amp;usg=AOvVaw2QxGSmMTbbWd5HWQ-C3DJL">41J Blog </a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520450683&amp;usg=AOvVaw1_7LhYUA0QDS4dB4C2C3Id">https://41j.com/blog/2018/09/insilixa/ (2018).</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520451084&amp;usg=AOvVaw3s1bFkEtkr0Zl96I_EMdE2">60.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Derrington, I. M. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520451364&amp;usg=AOvVaw0bpTAPxydUsy7d1A1ofT3h">et al.</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520451658&amp;usg=AOvVaw2egQgNM61t9NdxBLMh9oKt">&nbsp;Nanopore DNA sequencing with MspA. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520451953&amp;usg=AOvVaw2bSg6BCVLjSZvSFY7GbNQQ">Proc. Natl. Acad. Sci. </a></span><span class="c39 c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520452227&amp;usg=AOvVaw0yI3thpHpEIXCZIVWMhNrd">107</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520452527&amp;usg=AOvVaw136N0tK8Q_FSexJ0HRD1-q">, 16060&ndash;16065 (2010).</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520452929&amp;usg=AOvVaw0UsVaZtHtk6-nNbaf3G_ZB">61.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Continuous development and improvement. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520453227&amp;usg=AOvVaw0kRjWEmJjKClUq23d2hG5n">Oxford Nanopore Technologies </a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520453516&amp;usg=AOvVaw22-eqQPiKUeJQyLkw6r0fd">https://nanoporetech.com/about-us/continuous-development-and-improvement (2022).</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520453889&amp;usg=AOvVaw2Lpioyn4nrfMz6kms22mmn">62.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Wang, Y., Zhao, Y., Bollas, A., Wang, Y. &amp; Au, K. F. Nanopore sequencing technology, bioinformatics and applications. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520454193&amp;usg=AOvVaw0RAsAPJIyLoqkG5Sicr1Kq">Nat. Biotechnol. </a></span><span class="c39 c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520454476&amp;usg=AOvVaw1R3ghfI9nnuJbhdTMoMX6-">39</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520454734&amp;usg=AOvVaw3c_DEqcYy0B8eaEGILviOS">, 1348&ndash;1365 (2021).</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520455102&amp;usg=AOvVaw2aUYqLCoxyU_kKX4psLxxh">63.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;41J Blog&#8239;&raquo; Blog Archive&#8239;&raquo; Single Technologies. https://41j.com/blog/2020/05/single-technologies/.</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520455577&amp;usg=AOvVaw2uNSHSlSe7NcRUlp1FjQN8">64.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;published, A. S. TSMC&rsquo;s Estimated Wafer Prices Revealed: 300mm Wafer at 5nm Is Nearly $17,000. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520455946&amp;usg=AOvVaw0KRwEwtHf4Oxg_H7PstmM6">Tom&rsquo;s Hardware </a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520456263&amp;usg=AOvVaw3SuqvXGajmKyXUfJRfKQ22">https://www.tomshardware.com/news/tsmcs-wafer-prices-revealed-300mm-wafer-at-5nm-is-nearly-dollar17000 (2020).</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520456673&amp;usg=AOvVaw0O4vDUANHvj0tb-uRQao50">65.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Oxford Nanopore [@nanopore]. JC: on voltage sensing chip - if these channels are engineered at a 40um pitch, this has the potential to deliver ~100,000 nanopore channels on a piece of silicon 16x30mm =&gt; 3.9Tb / day #nanoporeconf https://t.co/cMAZKZUTGu. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520456987&amp;usg=AOvVaw20W6WX36tITirXfOGCN_k7">Twitter </a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520457305&amp;usg=AOvVaw35BZbZJUlqh-CRI_rjeh9N">https://twitter.com/nanopore/status/1334232052472877065 (2020).</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520457843&amp;usg=AOvVaw1C5UvMdJJoRFVYDmJ2m6Kf">66.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Oxford Nanopore MinION: delivery of nanopore sequencing to the genomics community | Genome Biology | Full Text. https://genomebiology.biomedcentral.com/articles/10.1186/s13059-016-1103-0.</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520458332&amp;usg=AOvVaw0dwkU5mfYlxvxP9nv1jCvj">67.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Lieberman, K. R. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520458708&amp;usg=AOvVaw26t6UMg_OjF_l5A_2wTeX3">et al.</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520459044&amp;usg=AOvVaw1tsU7pna3d22GduLkhiNxc">&nbsp;Processive Replication of Single DNA Molecules in a Nanopore Catalyzed by phi29 DNA Polymerase. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520459332&amp;usg=AOvVaw1kcToxeX1ZwCA0X-Ar_La1">J. Am. Chem. Soc. </a></span><span class="c39 c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520459591&amp;usg=AOvVaw3c_yCCZjZr5YcWeQ1hedG0">132</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520459902&amp;usg=AOvVaw1rr-Au_gg8SQHkZXNhX5NT">, 17961&ndash;17972 (2010).</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520460407&amp;usg=AOvVaw0-FElQsPB2QhfHv5q8gVM8">68.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;AxBio - Nanopore Sequencing Startup - by Nava Whiteford. https://aseq.substack.com/p/axbio-nanopore-sequencing-startup.</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520460856&amp;usg=AOvVaw2TO2JmDbXn6-Qhidg36qGz">69.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Qitan Technology - by Nava Whiteford - ASeq Newsletter. https://aseq.substack.com/p/qitan-technology.</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520461289&amp;usg=AOvVaw05UV-gg86oqCRtvDUtaX_1">70.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Coulter counter. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520461556&amp;usg=AOvVaw27rLTwwFlrMHLh_9HXC_Vz">Wikipedia</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520461792&amp;usg=AOvVaw2623fG9oW__8kaXsaTgncR">&nbsp;(2023).</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520462143&amp;usg=AOvVaw1j_a2fjCz8tYGbErk3IrtZ">71.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;41J Blog&#8239;&raquo; Blog Archive&#8239;&raquo; Coulter counter/nanopore demonstrator. https://41j.com/blog/2021/03/coulter-counter-nanopore-demonstrator/.</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520462485&amp;usg=AOvVaw1ra5abopkKGJSQFj-vmLoz">72.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Z1 Coulter Particle Counter Teardown. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520462739&amp;usg=AOvVaw09XLYz3-tKwLf_0qN3zjP7">41J Blog </a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520463008&amp;usg=AOvVaw3aOnVy4l2Q_aWZZzX1IzKN">https://41j.com/blog/2021/04/z1-coulter-particle-counter-teardown/ (2021).</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520463416&amp;usg=AOvVaw09pO2UsgQ3pqxMqzO4-eWa">73.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Kowalczyk, S. W., Blosser, T. R. &amp; Dekker, C. Biomimetic nanopores: learning from and about nature. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520463697&amp;usg=AOvVaw2-9pvMFVta8E6oOez1MgWT">Trends Biotechnol. </a></span><span class="c39 c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520463987&amp;usg=AOvVaw0ehqr5Ezy_hCChiEx6_poO">29</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520464225&amp;usg=AOvVaw3eESgdea1VLWm5if5qFcUw">, 607&ndash;614 (2011).</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520464644&amp;usg=AOvVaw3TUZsf7yeMDJgiVpjFzcHU">74.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Solid-state nanopore systems: from materials to applications | NPG Asia Materials. https://www.nature.com/articles/s41427-021-00313-z.</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520465043&amp;usg=AOvVaw0wH0ilAGz5PhuE7KJcxKwf">75.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Venta, K. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520465318&amp;usg=AOvVaw275cBKQyPZDknfz6GCOo-z">et al.</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520465571&amp;usg=AOvVaw2A3mh8TwVdsLHpMv8y2obL">&nbsp;Differentiation of Short, Single-Stranded DNA Homopolymers in Solid-State Nanopores. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520465807&amp;usg=AOvVaw0wPsqmM_xFWx3UoKXmTmuC">ACS Nano </a></span><span class="c39 c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520466043&amp;usg=AOvVaw2i7E1VE1EfQM6BPkiu2gaC">7</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520466319&amp;usg=AOvVaw3T-1CtZMsomCk4iP77yXv9">, 4629&ndash;4636 (2013).</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520466788&amp;usg=AOvVaw0lozMnjmvXI6QY3XG2YEKj">76.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Nanopore-Based DNA Hard Drives for Rewritable and Secure Data Storage | Nano Letters. https://pubs.acs.org/doi/abs/10.1021/acs.nanolett.0c00755.</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520467168&amp;usg=AOvVaw3O1wjIHDKOeHp9FGJksBIf">77.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Drndic, M. DNA Sequencing with novel 2D FET-nanopore devices.</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520467580&amp;usg=AOvVaw1KQXJZl3Yfws9cKucGue2c">78.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Docking and Activity of DNA Polymerase on Solid-State Nanopores | ACS Sensors. https://pubs.acs.org/doi/10.1021/acssensors.2c00216.</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520468047&amp;usg=AOvVaw3ca_Xq-i3Zb8OXLpfQuDyg">79.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;41J Blog&#8239;&raquo; Blog Archive&#8239;&raquo; Armonica Technologies LLC (now Inc). https://41j.com/blog/2018/07/armonica-technologies-llc/.</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520468401&amp;usg=AOvVaw1X-Zhc39B3HlzsMG_QvQUP">80.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Whiteford, N. Nooma Bio. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520468647&amp;usg=AOvVaw1_x9ljnvH4CRX2DfDb3V_S">ASeq Newsletter </a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520468901&amp;usg=AOvVaw0XF0EUF-nUz7yonNbMxr_n">https://aseq.substack.com/p/nooma-bio (2021).</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520469235&amp;usg=AOvVaw0tWOpgEdRK5TrLjProg4eJ">81.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Universal Sequencing Technology. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520469471&amp;usg=AOvVaw2KlsF18Kpb_j_-kaw5a948">41J Blog </a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520469698&amp;usg=AOvVaw2sRWvnR7ggHppy83COcfcR">https://41j.com/blog/2018/09/universal-sequencing-technology/ (2018).</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520470058&amp;usg=AOvVaw2lz_V72JU6gRrbx3oO_WsY">82.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Spatially Multiplexed Single-molecule Translocations through a Nanopore at Controlled Speeds | bioRxiv. https://www.biorxiv.org/content/10.1101/2022.10.08.511427v1.abstract.</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520470394&amp;usg=AOvVaw21bOSc3bODnjt22O3Jw7Jo">83.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Feng, J. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520470805&amp;usg=AOvVaw0XTs3m6vYN0eX-NRzaetIG">et al.</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520471105&amp;usg=AOvVaw2h49w2kOx95LD2QICBbo1K">&nbsp;Identification of single nucleotides in MoS2 nanopores. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520471352&amp;usg=AOvVaw3NOeReeIaZbBE9UOr3lfbY">Nat. Nanotechnol. </a></span><span class="c39 c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520471621&amp;usg=AOvVaw3L4zF67rAXkjCvpul5arPL">10</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520471895&amp;usg=AOvVaw0YMKf7DiiRkaQRTmVWqtBp">, 1070&ndash;1076 (2015).</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520472368&amp;usg=AOvVaw0nMlpBRqYJ-xjfBGudsNOY">84.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Whiteford, N. RH Genetech. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520472646&amp;usg=AOvVaw3KvQakdyapa1yyrXAyOIn1">ASeq Newsletter </a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520472906&amp;usg=AOvVaw2QllJgqtMh-Zb9kmDLRuqv">https://aseq.substack.com/p/rh-genetech (2022).</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520473300&amp;usg=AOvVaw3K6eBE3vaccvx1DgIquZg3">85.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Northshore Biosciences. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520473545&amp;usg=AOvVaw3bNCEloKbYgbdUJL3DC69Z">41J Blog </a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520473821&amp;usg=AOvVaw2SQuM7lUVdBrOqmh3ggkk9">https://41j.com/blog/2018/08/northshore-biosciences/ (2018).</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520474199&amp;usg=AOvVaw1YP-OKsCdcdZlbyXoVz6-4">86.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A Low-Noise Solid-State Nanopore Platform Based on a Highly Insulating Substrate | Scientific Reports. https://www.nature.com/articles/srep07448.</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520474673&amp;usg=AOvVaw1MvATgO8Spjq-itQ8afVEE">87.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Genvida - Solidstate nanogap sequencing - by Nava Whiteford. https://aseq.substack.com/p/genvida-solidstate-nanogap-sequencing.</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520475090&amp;usg=AOvVaw1KU7MOgL7AME_mOroiAfVV">88.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tanaka, H. &amp; Kawai, T. Partial sequencing of a single DNA molecule with a scanning tunnelling microscope. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520475337&amp;usg=AOvVaw2LPZPNCoG4KuG8NiDVv17v">Nat. Nanotechnol. </a></span><span class="c39 c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520475563&amp;usg=AOvVaw224GqdjNSS0YaMWj7-TWJV">4</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520475797&amp;usg=AOvVaw3U8GAOl4QkKubf0uFvcaad">, 518&ndash;522 (2009).</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520476169&amp;usg=AOvVaw3DVi1Bk-WS7uH2QxCXNfBw">89.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ivanov, A. P. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520476433&amp;usg=AOvVaw2J5uaexHyYUloc6SzW9arC">et al.</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520476669&amp;usg=AOvVaw0EEfg8rbzya_JVoOhYPgM4">&nbsp;DNA Tunneling Detector Embedded in a Nanopore. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520476903&amp;usg=AOvVaw2jFdpdICnadR8uoiMAnL25">Nano Lett. </a></span><span class="c39 c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520477126&amp;usg=AOvVaw1_x1je42DiaHIMaEG_4VIf">11</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520477353&amp;usg=AOvVaw01r8x8dzQUGRkAlFKx-rfH">, 279&ndash;285 (2011).</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520477702&amp;usg=AOvVaw1Z0b5Eotz-CcjS00fmipkS">90.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;High Electronic Conductance through Double-Helix DNA Molecules with Fullerene Anchoring Groups | The Journal of Physical Chemistry A. https://pubs.acs.org/doi/10.1021/acs.jpca.7b00348.</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520478174&amp;usg=AOvVaw0Q0ccz8-hNJwV8cXp0Lk1m">91.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;41J Blog&#8239;&raquo; Blog Archive&#8239;&raquo; Roswell Biotechnologies. https://41j.com/blog/2018/09/roswell-biotechnologies/.</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520478636&amp;usg=AOvVaw1F_klk_OgxKRgVS7LuyU3m">92.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;F&ouml;rster resonance energy transfer - Wikipedia. https://en.wikipedia.org/wiki/F%C3%B6rster_resonance_energy_transfer.</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520479169&amp;usg=AOvVaw3TEp-8qi66kqFkLhQoQ4ye">93.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Lee, J., Park, S. &amp; Hohng, S. Accelerated FRET-PAINT microscopy. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520479453&amp;usg=AOvVaw1XOUaGVHiX--uqtrA2DZYi">Mol. Brain </a></span><span class="c39 c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520479686&amp;usg=AOvVaw2qGzQc_hgqVRK2ZrtKaJh0">11</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520479966&amp;usg=AOvVaw1BR-YrqdByJ_go8kfH2iCa">, 70 (2018).</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520480396&amp;usg=AOvVaw1eg840BW29dLabbckG2R9Q">94.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Rhoads, A. &amp; Au, K. F. PacBio Sequencing and Its Applications. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520480653&amp;usg=AOvVaw3EpNP7i9YeJhLLDnIiiS2T">Genomics Proteomics Bioinformatics </a></span><span class="c39 c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520480890&amp;usg=AOvVaw1oxYkFrHHegHbgYBaAysCP">13</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520481210&amp;usg=AOvVaw0z-14H4ro-fO63nyzEROXa">, 278&ndash;289 (2015).</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520481713&amp;usg=AOvVaw2ZdCPMw3qQbJi1dI_6r2eF">95.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ARRAYS OF INTEGRATED ANALYTICAL DEVICES. https://www.freepatentsonline.com/20180180548.pdf.</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520482188&amp;usg=AOvVaw1cZv0WyREbGHDW28vosT8W">96.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;University of Washington PacBio Sequencing Services. https://pacbio.gs.washington.edu/.</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520482594&amp;usg=AOvVaw0KPhWiJF3esZA4R7lfI1IP">97.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;454.bio LinkedIn Post. https://www.linkedin.com/posts/pablos08_this-is-a-99-dna-sequencer-thats-the-price-activity-7004468076989603840-vbyl/?utm_source=share&amp;utm_medium=member_ios.</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520482965&amp;usg=AOvVaw2zbNQXbjERxpixwg0q196f">98.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Fapon Biotech takes over DNA sequencing firm Sequlite ahead of planned IPO | BioWorld. https://www.bioworld.com/articles/513043-fapon-biotech-takes-over-dna-sequencing-firm-sequlite-ahead-of-planned-ipo, .</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520483379&amp;usg=AOvVaw2_RArKkHs3iHzeLOdMyj_i">99.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Illumina - 40th Annual J.P. Morgan Healthcare Conference. https://s24.q4cdn.com/526396163/files/doc_downloads/2022/jpm-presentation-optimized-draft-01-10-22-final-clean.pdf.</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520483774&amp;usg=AOvVaw2IvVf1_f0clWOhBjLQxK47">100.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;PacBio Announces Record Orders, Including Orders for 76 Revio Systems Received in the Fourth Quarter of 2022 - PacBio. https://www.pacb.com/press_releases/pacbio-announces-record-orders-including-orders-for-76-revio-systems-received-in-the-fourth-quarter-of-2022/.</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520484215&amp;usg=AOvVaw35dRowG8db1DKp6fPuZtLP">101.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;MGI Announces Milestone of 1,000 Sequencers Installed and Opens Early Access Program for Groundbreaking Ultra-High-Throughput Sequencer, MGISEQ-T7. https://www.prnewswire.com/news-releases/mgi-announces-milestone-of-1-000-sequencers-installed-and-opens-early-access-program-for-groundbreaking-ultra-high-throughput-sequencer-mgiseq-t7--300773694.html.</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520484639&amp;usg=AOvVaw27dcSNLNMymM2XCl69vSmR">102.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Narayanasamy, S. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520484984&amp;usg=AOvVaw0kOyACfbaUNsTFxsgV3xyb">et al.</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520485323&amp;usg=AOvVaw0dTesC1YQT1MkGVYYFKS5b">&nbsp;Genomic Sequencing Capacity, Data Retention, and Personal Access to Raw Data in Europe. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520485627&amp;usg=AOvVaw1YZP8pnqI53hI8Jih4xIW_">Front. Genet. </a></span><span class="c39 c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520485898&amp;usg=AOvVaw17FF6p-t6fBaF2AbOehAY3">11</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520486141&amp;usg=AOvVaw2-jNioxZ3UV6AhTg4rMvOj">, (2020).</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520486613&amp;usg=AOvVaw3VgReXhaKfNjL9O1UQfRZf">103.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pandemic puts a Gulf AI company on the cutting edge of genome research. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520486984&amp;usg=AOvVaw2vrPeP8enutnFlHE4rnDdw">Arab News Japan </a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520487340&amp;usg=AOvVaw3CFLnL8cuXUdEIjuCLmYlg">https://www.arabnews.jp/en/middle-east/article_45151/.</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520487810&amp;usg=AOvVaw0TPGCnFzO9qWt7ZDSLM0Z9">104.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;UW Nanopore Sequencing Core. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520488082&amp;usg=AOvVaw0vdDQ5Pm1SYHK8dC8E6vxR">UW Research </a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520488404&amp;usg=AOvVaw0qZmS0_RwNR9aO_M_AzdeF">https://www.washington.edu/research/shared-research-facilities-resources/uw-nanopore-sequencing-core/.</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520488862&amp;usg=AOvVaw1bOuBqoKyPTdYHBZCVpgEv">105.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;PromethION 24&#65288;Nanopore&#65289;. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520489124&amp;usg=AOvVaw0DgK0Mf94uVxrnsLiUoMjW">Core Facility </a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520489369&amp;usg=AOvVaw1pbuwiJGV7PJ23_IszFPTN">https://ashbi.kyoto-u.ac.jp/core-facility/equipment/promethion-24/.</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520489867&amp;usg=AOvVaw1gcfwqL9xoOsj8ZJsH1nOz">106.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Genome Center: New technology at the center - Oxford Nanopore PromethION 24. https://genomecenter.tu-dresden.de/research-highlights-news/news?tx_news_pi1%5Baction%5D=detail&amp;tx_news_pi1%5Bcontroller%5D=News&amp;tx_news_pi1%5Bnews%5D=11&amp;cHash=32dc756f99cf31f7ffc1a118ed6aa32f.</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520490416&amp;usg=AOvVaw3-wYyBh3hX-2vT_X-dbW-2">107.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;BCM-HGSC Long Read Sequencing Laboratory | BCM-HGSC. https://www.hgsc.bcm.edu/longreadsequencing.</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520490920&amp;usg=AOvVaw11Vq5axPFQHxAmF4eYC7GU">108.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Nanopore sequencing. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520491302&amp;usg=AOvVaw2ak_Q63eJ4sAnnlPrGbmSU">Garvan Institute of Medical Research </a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520491684&amp;usg=AOvVaw3QFniLUlMQdJrjauKvJeae">https://www.garvan.org.au/research/capabilities/nanopore.</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520492253&amp;usg=AOvVaw3UXL4ZtEa1NX0HdeeY-vvX">109.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Illumina, Inc. - Events &amp; Presentations. https://investor.illumina.com/events-and-presentations/default.aspx.</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520492889&amp;usg=AOvVaw38nTer0vt02HvwJFX8awWR">110.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pacific Biosciences of California, Inc. Announces Fourth Quarter and Fiscal Year 2020 Financial Results | PacBio. https://investor.pacificbiosciences.com/news-releases/news-release-details/pacific-biosciences-california-inc-announces-fourth-quarter-and.</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520493493&amp;usg=AOvVaw1_p6oClC4pPEoxTA9L8qM4">111.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;MGI Announces Commercial Availability of HotMPS Sequencing Chemistry*and Instrument**in the United Kingdom - PR Newswire APAC. https://en.prnasia.com/story/370823-0.shtml.</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520494021&amp;usg=AOvVaw3lPXhJNIYZ5937JrDOOsX9">112.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Saravia-Butler, A. M. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520494405&amp;usg=AOvVaw3jx2JTNqQIcKJpGmqkzH6C">et al.</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520494797&amp;usg=AOvVaw1BytVcCe6L3-1nt0kFaXBA">&nbsp;Host transcriptional responses in nasal swabs identify potential SARS-CoV-2 infection in PCR negative patients. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520495226&amp;usg=AOvVaw1akH-QPS4Y0GEMnQ4hOdpF">iScience </a></span><span class="c39 c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520495608&amp;usg=AOvVaw33e4m-t5biRaDbJRrHQQBc">25</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520495986&amp;usg=AOvVaw3PbXNvp1wCxmKOBptMQoeA">, 105310 (2022).</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520496584&amp;usg=AOvVaw0gbdHF6IHFVa4vCBoEYSyU">113.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Rajagopala, S. V. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520497141&amp;usg=AOvVaw3tbDz4OkW_39_tW5GfhcdO">et al.</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520497669&amp;usg=AOvVaw2izEMG8dDRXhcanojYWolY">&nbsp;Metatranscriptomics to characterize respiratory virome, microbiome, and host response directly from clinical samples. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520498187&amp;usg=AOvVaw0gfWL70lfSoCHMNggq6553">Cell Rep. Methods </a></span><span class="c39 c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520498691&amp;usg=AOvVaw2whKis4XcJvMGfpOHSzjO7">1</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520499157&amp;usg=AOvVaw1C7tHOoihBfS34AzZTT8kO">, 100091 (2021).</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520499718&amp;usg=AOvVaw396FAu1bPycUvwDkQTb5tc">114.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Chan, A. P. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520500135&amp;usg=AOvVaw208RKyA2UrrRTgUQDXC3DJ">et al. A Universal Day Zero Infectious Disease Testing Strategy Leveraging CRISPR-based Sample Depletion and Metagenomic Sequencing</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520500560&amp;usg=AOvVaw2bFUh18kSavsqAo-hjxXnT">. http://medrxiv.org/lookup/doi/10.1101/2022.05.12.22274799 (2022) doi:10.1101/2022.05.12.22274799.</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520501157&amp;usg=AOvVaw0wm7jz_rPowL57Nuaowg2X">115.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Nakamura, S. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520501559&amp;usg=AOvVaw1PFTW_NJKHAF1OHQy9a_Y5">et al.</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520501979&amp;usg=AOvVaw0oM6oXSTjkiPjcCmr1NU0t">&nbsp;Direct Metagenomic Detection of Viral Pathogens in Nasal and Fecal Specimens Using an Unbiased High-Throughput Sequencing Approach. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520502405&amp;usg=AOvVaw0WgL5ZGJRPW1bEYuKeEdiL">PLOS ONE </a></span><span class="c39 c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520502718&amp;usg=AOvVaw2rbr6Bq_Bv_rjzWgkGs3Z2">4</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520502998&amp;usg=AOvVaw0XJIAfKy8q5vexJ04kGFsj">, e4219 (2009).</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520503494&amp;usg=AOvVaw0JrUH7LNHyn7jrdU3xWaeb">116.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Piralla, A. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520503775&amp;usg=AOvVaw336-7MAzPbvVvAWGEjEM19">et al.</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520504118&amp;usg=AOvVaw2LmkSmPKfk7mzfFSfEhmqA">&nbsp;Residual SARS-CoV-2 RNA in nasal swabs of convalescent COVID-19 patients: Is prolonged quarantine always justified? </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520504530&amp;usg=AOvVaw0Tdf3V_06lMzMQ9LfvZtkD">Int. J. Infect. Dis. </a></span><span class="c39 c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520504889&amp;usg=AOvVaw2Tbrt0joS6wfB8sfvjcmMp">102</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520505191&amp;usg=AOvVaw0d41cMGLIg5N0C8vXMbae7">, 299&ndash;302 (2021).</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520506053&amp;usg=AOvVaw0KyaOqAQRo3l26Nh89zgsS">117.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Mostafa, H. H. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520506565&amp;usg=AOvVaw0H5keTRxYOWshmV_AkNAM-">et al.</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520507123&amp;usg=AOvVaw3uGlyEtxl3_M8cm7PSJZ5D">&nbsp;Metagenomic Next-Generation Sequencing of Nasopharyngeal Specimens Collected from Confirmed and Suspect COVID-19 Patients. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520507637&amp;usg=AOvVaw3SDXchdN_hBk4NMt2_NIa4">mBio </a></span><span class="c39 c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520508160&amp;usg=AOvVaw23UDk48VAOUx3y9a81PbWS">11</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520508684&amp;usg=AOvVaw2TOtFs3pyMNmlhXWBH9OO4">, e01969-20 (2020).</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520509438&amp;usg=AOvVaw1oMb5lia9leun_aDo_3Ny7">118.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Faridl, M. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520509952&amp;usg=AOvVaw121nchAVX1uDPu15sc73nL">et al.</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520510469&amp;usg=AOvVaw3dA-TRNjtCzTvFdddTF9Hj">&nbsp;RNA sequence analysis of nasopharyngeal swabs from asymptomatic and mildly symptomatic patients with COVID-19. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520510985&amp;usg=AOvVaw0DB8ER9AkVODtpTgp0KIdc">Int. J. Infect. Dis. </a></span><span class="c39 c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520511491&amp;usg=AOvVaw1IyzwiO7aHlGIAhhhZxVkx">122</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520511912&amp;usg=AOvVaw1QD0LsnelaCblWa3-vTEU8">, 449&ndash;460 (2022).</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520512467&amp;usg=AOvVaw2E8TuZXUfh_7gpqiJ26066">119.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Rodriguez, C. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520512834&amp;usg=AOvVaw0UTiVdrmU0gczKIudES880">et al.</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520513179&amp;usg=AOvVaw3efWnKOG9ZgytWG5LF07Vy">&nbsp;Viral genomic, metagenomic and human transcriptomic characterization and prediction of the clinical forms of COVID-19. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520513477&amp;usg=AOvVaw2rSMfVG99ouoBZqcxNMKEB">PLOS Pathog. </a></span><span class="c39 c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520513720&amp;usg=AOvVaw2JZcLtzMEqQJXVT4Vv19O3">17</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520513959&amp;usg=AOvVaw3nWOjI9VAHa9KOZp8B0J8b">, e1009416 (2021).</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520514454&amp;usg=AOvVaw0FzP_0DkziAuYRml5Mzr6y">120.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Schlaberg, R. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520514743&amp;usg=AOvVaw2LZ81K5kDs-_UNDp93TtnE">et al.</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520515327&amp;usg=AOvVaw0KesZxWcMSyaTyVYG8GKYt">&nbsp;Viral Pathogen Detection by Metagenomics and Pan-Viral Group Polymerase Chain Reaction in Children With Pneumonia Lacking Identifiable Etiology. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520515857&amp;usg=AOvVaw3j1LkgeKrqXFkQF0QuEH81">J. Infect. Dis. </a></span><span class="c39 c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520516360&amp;usg=AOvVaw3ZODccHW2fC5oUxtrPycuk">215</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520516920&amp;usg=AOvVaw0NxlVMnRmZukzocw2huyjr">, 1407&ndash;1415 (2017).</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520517798&amp;usg=AOvVaw2_kwjSeJ3rM1XirK20Zh4N">121.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Huang, B. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520518340&amp;usg=AOvVaw2xTxcPz4V4h3J3gP0tFnJ6">et al.</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520518782&amp;usg=AOvVaw3IlB9ZWDrIQdMpCNwFn28_">&nbsp;Illumina sequencing of clinical samples for virus detection in a public health laboratory. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520519100&amp;usg=AOvVaw1oerOGjno6n9HHe2XbeCN6">Sci. Rep. </a></span><span class="c12 c39"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520519532&amp;usg=AOvVaw1hdVEtTqmwAj9UM4N8nq92">9</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520519971&amp;usg=AOvVaw0zMD9kFoJyhsC49MMy0Yn1">, 5409 (2019).</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520520619&amp;usg=AOvVaw3dBFD5HehhqbStRqRUnFAw">122.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Babiker, A. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520521053&amp;usg=AOvVaw3yt3yCNeBIoAA5uEc-vh3r">et al.</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520521439&amp;usg=AOvVaw1xkJ-6n0gfa-JtPQMZTdaz">&nbsp;Metagenomic Sequencing To Detect Respiratory Viruses in Persons under Investigation for COVID-19. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520521720&amp;usg=AOvVaw2E80BVCpxFVC1UaBw3UDQD">J. Clin. Microbiol. </a></span><span class="c39 c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520522022&amp;usg=AOvVaw3iDzxuNSgoVX2TOwhB_1uq">59</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520522354&amp;usg=AOvVaw06XE1cirzat5TMrzp7fvdl">, e02142-20 (2020).</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520522917&amp;usg=AOvVaw1Q02_I7-5vkyLOeN9CiL_t">123.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Aljabr, W. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520523244&amp;usg=AOvVaw35MUcuF_KLA6qtn_VQ3GHh">et al.</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520523511&amp;usg=AOvVaw2eIu5OddbB0luY7c5m8548">&nbsp;High Resolution Analysis of Respiratory Syncytial Virus Infection In Vivo. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520523746&amp;usg=AOvVaw37a-Tnxdg7nxxZFipMIk_E">Viruses </a></span><span class="c39 c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520524097&amp;usg=AOvVaw1apNAf2bANSyim1s_qzisy">11</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520524400&amp;usg=AOvVaw3sXm3UGW2OTbTc6mExiS0H">, 926 (2019).</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520524871&amp;usg=AOvVaw3ye3ck2xfosWxL0apwfxmi">124.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Bal, A. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520525221&amp;usg=AOvVaw1VI4k-Wczij_oy4icwMQjN">et al.</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520525506&amp;usg=AOvVaw3Y0YStAJDXnizN21Si4R1W">&nbsp;Quality control implementation for universal characterization of DNA and RNA viruses in clinical respiratory samples using single metagenomic next-generation sequencing workflow. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520525744&amp;usg=AOvVaw2Qs5G0l0U4D7MB1Xi970hg">BMC Infect. Dis. </a></span><span class="c39 c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520526014&amp;usg=AOvVaw0VeRr0x-BnqmPooXVBBSSU">18</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520526314&amp;usg=AOvVaw3OHISzZv3lINsqrukHMgCG">, 537 (2018).</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520526799&amp;usg=AOvVaw2CNEyNv4A9X6OblITidInU">125.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Thorburn, F. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520527108&amp;usg=AOvVaw1hjlXPzrTXsLAh7KimaRZy">et al.</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520527440&amp;usg=AOvVaw3Og52lnpqErOtoWKYh5zPG">&nbsp;The use of next generation sequencing in the diagnosis and typing of respiratory infections. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520527792&amp;usg=AOvVaw1oVKWmr8Un8jgaoKlAsiBh">J. Clin. Virol. </a></span><span class="c39 c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520528175&amp;usg=AOvVaw3cDmMtTnG2yXQ6YxltiG2w">69</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520528478&amp;usg=AOvVaw3b2uGUVBCKE8aYKzYVnUSL">, 96&ndash;100 (2015).</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520529017&amp;usg=AOvVaw20IoOjeMn6q4SQGx83nTtb">126.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prachayangprecha, S. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520529373&amp;usg=AOvVaw31hIgHAYPm50WW72n1LOsV">et al.</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520529729&amp;usg=AOvVaw0oxn-GdoxwitiJAF2r9yQE">&nbsp;Exploring the Potential of Next-Generation Sequencing in Detection of Respiratory Viruses. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520530080&amp;usg=AOvVaw0j_M8_QA13fB2eXJTKO54r">J. Clin. Microbiol. </a></span><span class="c39 c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520530400&amp;usg=AOvVaw3J5OwXrIkxYjCDbSW0fRFX">52</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520530740&amp;usg=AOvVaw1GlaiFaztB9MgdNPfjoSTq">, 3722&ndash;3730 (2014).</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520531153&amp;usg=AOvVaw3WOGkOZ_KdGTblfx-U7_OR">127.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Carbo, E. C. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520531408&amp;usg=AOvVaw3fVsBfG6GjMPYRZa67Opr4">et al.</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520531645&amp;usg=AOvVaw2FOW1eVjNQ4uk2RiguViG8">&nbsp;Coronavirus discovery by metagenomic sequencing: a tool for pandemic preparedness. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520531923&amp;usg=AOvVaw2i2t037xn0WLVhsTkMa4e0">J. Clin. Virol. </a></span><span class="c39 c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520532157&amp;usg=AOvVaw1Qcl0QfFjob9Wwys4S5jTN">131</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520532436&amp;usg=AOvVaw1r1-X6s63GQFdRqEACjUZw">, 104594 (2020).</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520532931&amp;usg=AOvVaw0Jlv-XLoSrVfH2hOkRhC2-">128.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Lewandowski, K. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520533316&amp;usg=AOvVaw26OR2IxOqqEB6NmmoCqR2L">et al.</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520533792&amp;usg=AOvVaw3agN3bmDxdPQThyrVt7Z6r">&nbsp;Metagenomic Nanopore Sequencing of Influenza Virus Direct from Clinical Respiratory Samples. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520534225&amp;usg=AOvVaw0IdaOxBhANQ8LEKwehmwCm">J. Clin. Microbiol. </a></span><span class="c39 c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520534650&amp;usg=AOvVaw2H-Tl7SzV08G9dlbGt1XPe">58</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520535064&amp;usg=AOvVaw3upsCO4ET98MJlN6Vu41VY">, e00963-19 (2019).</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520535604&amp;usg=AOvVaw2X7FLvoTF5WAz05DTujyRL">129.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Madi, N., Al-Nakib, W., Mustafa, A. S. &amp; Habibi, N. Metagenomic analysis of viral diversity in respiratory samples from patients with respiratory tract infections in Kuwait. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520535971&amp;usg=AOvVaw2sHYoGUE7VCxsz1HdIYikW">J. Med. Virol. </a></span><span class="c39 c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520536297&amp;usg=AOvVaw2mJUXH3PZAlAWg7orYap1Q">90</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520536563&amp;usg=AOvVaw153avLl813Sr1-lpMWB7MF">, 412&ndash;420 (2018).</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520536943&amp;usg=AOvVaw2_hfwRaJBDJYt35a4CvXpb">130.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;O&rsquo;Flaherty, B. M. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520537233&amp;usg=AOvVaw2smZ8Icpkkk7L0ls4eoxsW">et al.</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520537489&amp;usg=AOvVaw3k2tfTALHrfFMw-tMNLf98">&nbsp;Comprehensive viral enrichment enables sensitive respiratory virus genomic identification and analysis by next generation sequencing. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520537720&amp;usg=AOvVaw0vNjo1I29zZk-T1DNF8XRx">Genome Res. </a></span><span class="c39 c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520538021&amp;usg=AOvVaw0WeRjolCDgUW2lAlEMPuYt">28</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520538441&amp;usg=AOvVaw0n1RJPivh_vL0VK-BPGubA">, 869&ndash;877 (2018).</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520539087&amp;usg=AOvVaw0VIjheboz_KgBj9h-1e2Wx">131.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Parker, J. &amp; Chen, J. Application of next generation sequencing for the detection of human viral pathogens in clinical specimens. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520539530&amp;usg=AOvVaw0aRZsOHdgubOMQ9lutgqr3">J. Clin. Virol. </a></span><span class="c39 c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520539934&amp;usg=AOvVaw21rPddCvGuuQKJIIT6wsPw">86</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520540225&amp;usg=AOvVaw1a-IO6bfSfG2ecKMS2bfiF">, 20&ndash;26 (2017).</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520540628&amp;usg=AOvVaw16jg8zOiSDSLVAHhSiiTEH">132.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ren, X. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520540953&amp;usg=AOvVaw3v15Kn8EN9Da4Xe_SUydZB">et al.</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520541259&amp;usg=AOvVaw3mMQ8sS1cSK3tWFZCHkREl">&nbsp;Clinical utility comparison of two benchtop deep sequencing instruments for rapid diagnosis of newly emergent influenza infections. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520541542&amp;usg=AOvVaw1q070ml3V9wYMULqFdFfs2">Clin. Microbiol. Infect. Off. Publ. Eur. Soc. Clin. Microbiol. Infect. Dis. </a></span><span class="c39 c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520541795&amp;usg=AOvVaw1OXnMd_YccPppKU3N_dcVB">21</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520542113&amp;usg=AOvVaw1SH0McnsVSaBkvJ_vVShVA">, 290.e1&ndash;4 (2015).</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520542655&amp;usg=AOvVaw2KzuCDJe9ex4JNUeA5SjDT">133.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shah, S. J. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520543041&amp;usg=AOvVaw0nYcX4YReKFLmRlhhWXhrh">et al.</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520543451&amp;usg=AOvVaw2ymKk0iD1Kak2IhiOdX2c0">&nbsp;Clinical features, diagnostics, and outcomes of patients presenting with acute respiratory illness: A retrospective cohort study of patients with and without COVID-19. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520543743&amp;usg=AOvVaw1hiHVoyeHZ_2sHkZlAZyxN">EClinicalMedicine </a></span><span class="c39 c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520544028&amp;usg=AOvVaw3is5eKRLhMP47wGX0XVvuX">27</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520544262&amp;usg=AOvVaw0ol7TyEkZwiDaisBmyS4pm">, 100518 (2020).</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520544655&amp;usg=AOvVaw08zuizhyD3jSC4Vq2AgSJo">134.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Thi Kha Tu, N. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520544925&amp;usg=AOvVaw3-TnA9ZNXfZjAgjKjA5Ndd">et al.</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520545169&amp;usg=AOvVaw3-CZlB87XXAjA_gGVD1qGI">&nbsp;The Virome of Acute Respiratory Diseases in Individuals at Risk of Zoonotic Infections. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520545524&amp;usg=AOvVaw2Wvgah8-xp4zcRw92TtZQ7">Viruses </a></span><span class="c39 c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520545844&amp;usg=AOvVaw3gxnYaRlKs3RhVUbLppuEE">12</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520546095&amp;usg=AOvVaw0rbVQLoSuIvcBmImuJlPPP">, 960 (2020).</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520546578&amp;usg=AOvVaw1L27fkKlxZcelI-6N47Rbu">135.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Yang, J. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520546979&amp;usg=AOvVaw1L_L5gq_hp38K22Na7dyzU">et al.</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520547383&amp;usg=AOvVaw2jpeFu81ywoTjYB7SPlk5s">&nbsp;Unbiased Parallel Detection of Viral Pathogens in Clinical Samples by Use of a Metagenomic Approach&#9663;. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520547778&amp;usg=AOvVaw2Y-eWI8InIU97DrxgjUTiQ">J. Clin. Microbiol. </a></span><span class="c39 c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520548160&amp;usg=AOvVaw1eGzKMDem03ckKdpUdcwNl">49</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520548543&amp;usg=AOvVaw1MVhTlLvJXbbijo5deNREq">, 3463&ndash;3469 (2011).</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520549127&amp;usg=AOvVaw3mbUONJ_q_0m8np8l_UhCh">136.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Zoll, J. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520549532&amp;usg=AOvVaw3f-6JCsin9kMNObyz_xf2J">et al.</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520549941&amp;usg=AOvVaw1c8RYLgMtdDovbcDet0OzM">&nbsp;Direct multiplexed whole genome sequencing of respiratory tract samples reveals full viral genomic information. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520550321&amp;usg=AOvVaw26jcD5ETIghHHTp-wsN_ES">J. Clin. Virol. </a></span><span class="c39 c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520550707&amp;usg=AOvVaw3GQbizM9gFTD7aQfmUCaBp">66</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520551080&amp;usg=AOvVaw0srvGDK5Rgzt7FOPnL5HEx">, 6&ndash;11 (2015).</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520551663&amp;usg=AOvVaw3li1Wxxp9bUPngUbgqX1Xu">137.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Charalampous, T. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520552071&amp;usg=AOvVaw1UpkD7vxTeIZ_daB8dlUAy">et al.</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520552479&amp;usg=AOvVaw0_cSRBKffFY2t3PjqNahLt">&nbsp;Nanopore metagenomics enables rapid clinical diagnosis of bacterial lower respiratory infection. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520552879&amp;usg=AOvVaw3OiVAzTe52lTbldVB5WTl1">Nat. Biotechnol. </a></span><span class="c39 c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520553232&amp;usg=AOvVaw0BPr9pFVghB_qowABUeWG4">37</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520553515&amp;usg=AOvVaw0-t4gRlSfB8EQ8kJoIgEnT">, 783&ndash;792 (2019).</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520553918&amp;usg=AOvVaw1onOi7dhZMS40hvibBaj9O">138.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Manning, J. E. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520554236&amp;usg=AOvVaw168FWwOGb4t6DNrFSqrJx5">et al.</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520554577&amp;usg=AOvVaw1b2xhe-NVf-ZwbQkNsC5cm">&nbsp;Rapid metagenomic characterization of a case of imported COVID-19 in Cambodia. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520554899&amp;usg=AOvVaw3XBEg4qnTDf5PD37udjRi9">BioRxiv Prepr. Serv. Biol.</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520555148&amp;usg=AOvVaw3df0AOqjbzNzk7zPBhbh1T">&nbsp;2020.03.02.968818 (2020) doi:10.1101/2020.03.02.968818.</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520555543&amp;usg=AOvVaw366aCat7LfGK1VLrJv_YnU">139.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tulloch, R. L. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520555825&amp;usg=AOvVaw0G9oyfNc54wgGGUBVf-I7e">et al.</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520556188&amp;usg=AOvVaw2O9OlKGoH1tQLlpIARGkzO">&nbsp;RAPIDprep: A Simple, Fast Protocol for RNA Metagenomic Sequencing of Clinical Samples. Preprint at https://doi.org/10.20944/preprints202212.0417.v1 (2022).</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520556667&amp;usg=AOvVaw0t2V3xh72FcdFyh3fUTlZ0">140.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Willner, D. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520557069&amp;usg=AOvVaw3VuNrDmFzzWUxsgP-x1GUL">et al.</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520557437&amp;usg=AOvVaw0GaTMwD4xFHSMazMwtSImU">&nbsp;Metagenomic Analysis of Respiratory Tract DNA Viral Communities in Cystic Fibrosis and Non-Cystic Fibrosis Individuals. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520557821&amp;usg=AOvVaw0p6rob4bpzksk3d4VyfUJM">PLOS ONE </a></span><span class="c39 c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520558204&amp;usg=AOvVaw1VpjiM_dGaUNVHDYoeAoms">4</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520558577&amp;usg=AOvVaw00jYqb4mS0Kdz4J3ve81L2">, e7370 (2009).</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520559024&amp;usg=AOvVaw1rBUrfwLSFT_NskAeqtrte">141.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ogunbayo, A. E., Sabiu, S. &amp; Nyaga, M. M. Evaluation of Extraction and Enrichment Methods for Recovery of Respiratory RNA Viruses in a Metagenomics Approach. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520559347&amp;usg=AOvVaw0nvK69Q_XlKAowrhE3K8w2">J. Virol. Methods</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520559685&amp;usg=AOvVaw1nd65oF8qapJkQhwKdvzM-">&nbsp;114677 (2023) doi:10.1016/j.jviromet.2023.114677.</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520560211&amp;usg=AOvVaw2W5bd4Y7T3_DlF9t_VJq_S">142.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Liu, B. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520560545&amp;usg=AOvVaw3IO2YkZk8HlBS-GJpKNG3L">et al.</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520560938&amp;usg=AOvVaw1E6rQ2rd-j9RzIxXxf-uyy">&nbsp;An Optimized Metagenomic Approach for Virome Detection of Clinical Pharyngeal Samples With Respiratory Infection. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520561313&amp;usg=AOvVaw3e3sOdvsY88CzI401YNIDl">Front. Microbiol. </a></span><span class="c39 c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520561672&amp;usg=AOvVaw3arUGcrcAW8JoCHBjZxQsk">11</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520562019&amp;usg=AOvVaw0K9s0Iywbo_NwOzH3Uh6OS">, (2020).</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520562504&amp;usg=AOvVaw0imyVHBKo5oxHoyFAJZNVq">143.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ogunbayo, A. E. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520562869&amp;usg=AOvVaw2vVKQ79ZBuNde64YOYGFMC">et al.</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520563222&amp;usg=AOvVaw3aRwSk0qJ6DkGYvSjlg0bQ">&nbsp;Metagenomic Analysis of Respiratory RNA Virome of Children with and without Severe Acute Respiratory Infection from the Free State, South Africa during COVID-19 Pandemic Reveals Higher Diversity and Abundance in Summer Compared with Winter Period. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520563540&amp;usg=AOvVaw1bwYvTBdsvY6O_YZctb9iy">Viruses </a></span><span class="c39 c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520563799&amp;usg=AOvVaw2r9p41RHr_ANY5MTW8k1Pf">14</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520564034&amp;usg=AOvVaw0qmrdP3d4vkzf8QbEpbNEc">, 2516 (2022).</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520564449&amp;usg=AOvVaw0LYnexQMT3EweivvhNNjLT">144.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cheemarla, N. R. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520564735&amp;usg=AOvVaw2CQLtAuymG6HOm4nMnHLuS">et al.</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520564994&amp;usg=AOvVaw3pdHZU4GIgco0feDaogQFn">&nbsp;Nasal host response-based screening for undiagnosed respiratory viruses: a pathogen surveillance and detection study. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520565264&amp;usg=AOvVaw089QhbvW5y17Ek4wRN19SB">Lancet Microbe </a></span><span class="c39 c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520565541&amp;usg=AOvVaw2UMCRMotWUJCeesCCXyGPy">4</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520565907&amp;usg=AOvVaw3xLBIA8u6xOMXfgSZW19qC">, e38&ndash;e46 (2023).</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520566370&amp;usg=AOvVaw138prkHBT2pyr5kQE3cuvQ">145.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Genomic surveillance reveals multiple introductions of SARS-CoV-2 into Northern California | Science. https://www.science.org/doi/10.1126/science.abb9263.</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520566767&amp;usg=AOvVaw0_W9TYEz8rE8mulFLbCFWv">146.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Saha, S. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520567027&amp;usg=AOvVaw2o2pUsHSrhuiNq0xwwszdj">et al.</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520567272&amp;usg=AOvVaw1LaU7bZKLSGtFDReo4AJGN">&nbsp;Complete Genome Sequence of a Novel Coronavirus (SARS-CoV-2) Isolate from Bangladesh. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520567518&amp;usg=AOvVaw2Q58_cawTwhe2yzs6ueZO6">Microbiol. Resour. Announc. </a></span><span class="c39 c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520567749&amp;usg=AOvVaw3itgWNaLQbHCJZb_CML7g1">9</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520568078&amp;usg=AOvVaw0_0oFpM10Dmymfd3F-UvEc">, e00568-20 (2020).</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520568744&amp;usg=AOvVaw0-PUxb4LPr5rqyloSQNOk8">147.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Bacci, G. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520569135&amp;usg=AOvVaw1pxxpYg3x9R90ykVYxFh8N">et al.</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520569603&amp;usg=AOvVaw3kjUwJxrYHzWFt0Svr8fCZ">&nbsp;Untargeted Metagenomic Investigation of the Airway Microbiome of Cystic Fibrosis Patients with Moderate-Severe Lung Disease. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520569935&amp;usg=AOvVaw2xU2L-Gpc48_mCOWsvEjpP">Microorganisms </a></span><span class="c39 c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520570207&amp;usg=AOvVaw0xg8eTp0Wm44CiTc-GhSsW">8</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520570467&amp;usg=AOvVaw16bVx9B_e70qQbPRn-Ywjz">, 1003 (2020).</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520571014&amp;usg=AOvVaw3_cUXR5ITREyEYodnSh62d">148.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deschamps, O. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520571480&amp;usg=AOvVaw06n5IECsk6bRQf0emV575L">et al.</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520571872&amp;usg=AOvVaw1zvhc2_mNnF9SRAs18DkHR">&nbsp;Acute exanthemas: a prospective study of 98 adult patients with an emphasis on cytokinic and metagenomic investigation. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520572156&amp;usg=AOvVaw290XBXXiJuYYzKYj5DYkQI">Br. J. Dermatol. </a></span><span class="c39 c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520572470&amp;usg=AOvVaw3pChQSvbFasdiMmJV7xYOZ">182</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520572839&amp;usg=AOvVaw0z9NIrtFCJxxwWzVsAjiOe">, 355&ndash;363 (2020).</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520573281&amp;usg=AOvVaw0aaKG0UEb09i9B4xG3DjZk">149.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Whiteford, N. Sequencing: More sensitive than qPCR. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520573540&amp;usg=AOvVaw249XYztVuIzTwFkLmH5n0Q">ASeq Newsletter </a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520573836&amp;usg=AOvVaw0s9-qfGJ8Gihm02uyFB0CQ">https://aseq.substack.com/p/sequencing-more-sensitive-than-qpcr (2022).</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520574213&amp;usg=AOvVaw2Bnci6FmAEMcVFRwE6bDPn">150.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Muller, M. S. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520574461&amp;usg=AOvVaw2JokmNqlzDkSW8aw8vsjjP">et al.</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520574698&amp;usg=AOvVaw2ezWlE1rNl6QZTBKH0wAqD">&nbsp;Practical strategies for SARS-CoV-2 RT-PCR testing in resource-constrained settings. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520574950&amp;usg=AOvVaw1fWE4QW2j-F6e3ggLvjwz9">medRxiv</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520575236&amp;usg=AOvVaw1Zq4aQLbOVS8wqNVUfkCAG">&nbsp;2021.02.18.21251999 (2021) doi:10.1101/2021.02.18.21251999.</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520575671&amp;usg=AOvVaw1RQoZ9GtmqurDpkahk1R7J">151.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Savela, E. S. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520575954&amp;usg=AOvVaw0UWInGTDAFN1U1bOL4fyiW">et al.</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520576204&amp;usg=AOvVaw0Qtv1WY5VR3G0kvBIbFFXk">&nbsp;Quantitative SARS-CoV-2 Viral-Load Curves in Paired Saliva Samples and Nasal Swabs Inform Appropriate Respiratory Sampling Site and Analytical Test Sensitivity Required for Earliest Viral Detection. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520576531&amp;usg=AOvVaw0xNmE8Qgc_gvn5q9rsavCX">J. Clin. Microbiol. </a></span><span class="c39 c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520576809&amp;usg=AOvVaw2u_f5zbicgFhrit7c_Lp_J">60</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520577046&amp;usg=AOvVaw3iCB7d-FNozDWUINHc8N_Z">, e01785-21 (2022).</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520577422&amp;usg=AOvVaw35JZJjUz6AP2FGz39KYGUw">152.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Casta&ntilde;eda-Mogoll&oacute;n, D. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520577694&amp;usg=AOvVaw2A61oaA_DWYaN0KcQYefMg">et al.</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520578028&amp;usg=AOvVaw1TMHQX9H4wJQ2uczMr58iM">&nbsp;A metagenomics workflow for SARS-CoV-2 identification, co-pathogen detection, and overall diversity. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520578302&amp;usg=AOvVaw1mEIKeJmJv0Oo_OdrWU55a">J. Clin. Virol. </a></span><span class="c39 c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520578558&amp;usg=AOvVaw3IdGbyzX5edZAYW1wXLQaw">145</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520578808&amp;usg=AOvVaw2x6VYoCUuM7BsI2Etf4Vhy">, 105025 (2021).</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520579238&amp;usg=AOvVaw2wZILLMh1Fhy2Xtd6wAqkA">153.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ur&scaron;i&#269;, T. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520579579&amp;usg=AOvVaw0QVw02rIaOZBGi651P0tDq">et al.</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520579899&amp;usg=AOvVaw3PK_9vRQRbv4uG5GqFW64U">&nbsp;Performance of nasopharyngeal swab and saliva in detecting Delta and Omicron SARS-CoV-2 variants. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520580169&amp;usg=AOvVaw2j5G66WGNuyjRd9JCBDcTm">J. Med. Virol. </a></span><span class="c39 c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520580434&amp;usg=AOvVaw3yHrwLwB92Db-AVzTsG66h">94</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520580703&amp;usg=AOvVaw090-3fjaBpa7xCJEaHio5l">, 4704&ndash;4711 (2022).</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520581171&amp;usg=AOvVaw34xdtpGt6UyrQicVJ-6tyW">154.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Han, M. S. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520581492&amp;usg=AOvVaw0CoddgIDj3-KRjqwm6OyZT">et al.</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520581838&amp;usg=AOvVaw3mTVBMAhunOIVHilIxAw8O">&nbsp;Viral RNA Load in Mildly Symptomatic and Asymptomatic Children with COVID-19, Seoul, South Korea - Volume 26, Number 10&mdash;October 2020 - Emerging Infectious Diseases journal - CDC. doi:10.3201/eid2610.202449.</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520582298&amp;usg=AOvVaw0a3Xzxu0Sioulpn8QRIH_S">155.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Choudhury, Y. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520582585&amp;usg=AOvVaw0wRtcEIPnu2r-zlwHc9UlA">et al.</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520582912&amp;usg=AOvVaw01CHdEJDI567Cq2ipPYPJo">&nbsp;A Viral Fragmentation Signature for SARS-CoV-2 in Clinical Samples Correlating with Contagiousness. 2021.01.11.21249265 Preprint at https://doi.org/10.1101/2021.01.11.21249265 (2021).</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520583337&amp;usg=AOvVaw12LfaqKEvs3NwrKZEAz_cy">156.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pan, Y., Zhang, D., Yang, P., Poon, L. L. M. &amp; Wang, Q. Viral load of SARS-CoV-2 in clinical samples. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520583671&amp;usg=AOvVaw2_fglG0LHdEZxKNcq7htux">Lancet Infect. Dis. </a></span><span class="c39 c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520583956&amp;usg=AOvVaw27m8VJTMHFbwC6pjsyhxVx">20</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520584229&amp;usg=AOvVaw25PqPv5e2L1pIiScs3jyve">, 411&ndash;412 (2020).</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520584655&amp;usg=AOvVaw083ogjR18jLwubfv_mMeN7">157.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Virological assessment of hospitalized patients with COVID-2019 | Nature. https://www.nature.com/articles/s41586-020-2196-x.</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520585152&amp;usg=AOvVaw0VjWXQx8w9PS2eVg8W4Hyr">158.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gauthier, N. P. G. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520585452&amp;usg=AOvVaw3L2VJ4SUL093QLyibN8l2n">et al.</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520585723&amp;usg=AOvVaw2mOhXz8D3o-SLB0OEuWEgj">&nbsp;Nanopore metagenomic sequencing for detection and characterization of SARS-CoV-2 in clinical samples. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520586013&amp;usg=AOvVaw2bYioIYVL7LUEqfcSViCWX">PLOS ONE </a></span><span class="c39 c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520586314&amp;usg=AOvVaw2JbLjpTER8foMrjDchahVA">16</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520586575&amp;usg=AOvVaw0Gtx9X4qEeHVU0V-W2oIl_">, e0259712 (2021).</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520586940&amp;usg=AOvVaw3VZgINJGjIDAhkf2ynNCKx">159.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Drosten, C. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520587206&amp;usg=AOvVaw00WYctcOJN_rhCr57Kj-T3">et al.</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520587471&amp;usg=AOvVaw0KhGGfHaG9jey5m6yE5_Sn">&nbsp;Evaluation of Advanced Reverse Transcription-PCR Assays and an Alternative PCR Target Region for Detection of Severe Acute Respiratory Syndrome-Associated Coronavirus. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520587703&amp;usg=AOvVaw0VpiHAGFmZakbJ4wKPWoUt">J. Clin. Microbiol. </a></span><span class="c39 c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520587946&amp;usg=AOvVaw09YthgRjygqGVE-g_PXX8c">42</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520588212&amp;usg=AOvVaw01KuOf5v6QCsSDAKaozEQI">, 2043&ndash;2047 (2004).</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520588809&amp;usg=AOvVaw19GAzpy1Dsigi8LD8Kc7fE">160.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Zhu, J., Guo, J., Xu, Y. &amp; Chen, X. Viral dynamics of SARS-CoV-2 in saliva from infected patients. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520589257&amp;usg=AOvVaw3SEstaBf-a2gaIP5sAJZmk">J. Infect. </a></span><span class="c39 c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520589607&amp;usg=AOvVaw3AZvwsOrPQ_o86z_wEjBiv">81</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520589973&amp;usg=AOvVaw3yBWBbyVabrMupKxSqs8qp">, e48&ndash;e50 (2020).</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520590408&amp;usg=AOvVaw0F0xxwxiiCZUs0i6NGxIPd">161.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Carrouel, F. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520590718&amp;usg=AOvVaw29F66BPR0qXFI8LpX5pN1u">et al.</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520591067&amp;usg=AOvVaw27tywNZYIp6anon3TD7gc3">&nbsp;Saliva Quantification of SARS-CoV-2 in Real-Time PCR From Asymptomatic or Mild COVID-19 Adults. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520591476&amp;usg=AOvVaw3BQGch8fcZfdfB5YBV0SBA">Front. Microbiol. </a></span><span class="c39 c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520591885&amp;usg=AOvVaw29qpB9nqU3BZQ63hxuHD5Z">12</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520592273&amp;usg=AOvVaw0s446ST5ol1sUh1LQ8p7Mz">, (2022).</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520592840&amp;usg=AOvVaw3CzRgkYa6Yk-5bBlUZRE9D">162.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To, K. K.-W. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520593262&amp;usg=AOvVaw3dnVBuLoGtvabm_2Yz1ClX">et al.</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520593676&amp;usg=AOvVaw1Gx2_INxKdDD83r2L2cs-3">&nbsp;Consistent Detection of 2019 Novel Coronavirus in Saliva. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520594094&amp;usg=AOvVaw37vikUaCrkOLyo8w3sxVWy">Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am.</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520594489&amp;usg=AOvVaw28o6Bk1mOFlOtaIikQAN0k">&nbsp;ciaa149 (2020) doi:10.1093/cid/ciaa149.</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520595081&amp;usg=AOvVaw2MdSOiW7tywKvW0GwfWJjW">163.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Savela, E. S. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520595461&amp;usg=AOvVaw2tshiEhGwoayU0Y5cu65yv">et al.</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520595861&amp;usg=AOvVaw28_FR37lLM5ydHTp1y28Uw">&nbsp;SARS-CoV-2 is detectable using sensitive RNA saliva testing days before viral load reaches detection range of low-sensitivity nasal swab tests.</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520596470&amp;usg=AOvVaw2Ui8yq-itUWFxw8bXYA9b6">164.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Anjos, D. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520596835&amp;usg=AOvVaw1qyr585oeGh-AkP0VLupVl">et al.</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520597215&amp;usg=AOvVaw1ihSxPp8BW3M4Lc3ZomzPj">&nbsp;SARS-CoV-2 loads in urine, sera and stool specimens in association with clinical features of COVID-19 patients. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520597587&amp;usg=AOvVaw36djPpLIniL0p6v9luO9uq">J. Clin. Virol. Plus </a></span><span class="c39 c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520597970&amp;usg=AOvVaw0gmK5SDP9_eyjB6LX5j6PB">2</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520598286&amp;usg=AOvVaw0DRIK6UbjJLaMpYWF6tG24">, 100059 (2022).</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520598877&amp;usg=AOvVaw1n3Ciax3P4fXZw1Nj-4H7H">165.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Direct RNA Sequencing Kit. https://store.nanoporetech.com/direct-rna-sequencing-kit.html.</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520599435&amp;usg=AOvVaw2f0BlH7icpX4SgJt46q04D">166.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Nextera</a></span><span class="c41"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520599821&amp;usg=AOvVaw38L73fwX84q7fKu1zDNyjN">TM</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520600185&amp;usg=AOvVaw0vtJZsodv3zA2NnYz7bR-j">&nbsp;DNA Flex Library Preparation Kit. https://static.llnw.on24.com/event/19/23/63/6/rt/1/documents/resourceList1546559077710/nexteradnaflexdatasheet77020170111546559150893.pdf.</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520600674&amp;usg=AOvVaw3EsCa2yUmttM7BWBbVaz9H">167.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ion XpressTM Plus gDNA Fragment Library Preparation. https://assets.thermofisher.com/TFS-Assets/LSG/manuals/MAN0009847_IonXpressPlus_gDNA_FragLibraryPrep_UG.pdf.</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520601098&amp;usg=AOvVaw2RDplVb025HKFCTKCviVVA">168.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;MGIEasy Fast FS DNA Library Prep Set.</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520601597&amp;usg=AOvVaw1sum0Hm_dgFnhW7cvvYilI">169.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Oxford Nanopore Develops Direct RNA Sequencing Protocol. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520601969&amp;usg=AOvVaw11ivnSIaXlwausqW99eD3J">GenomeWeb </a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520602320&amp;usg=AOvVaw0Ll-ISeqb0C4AKyfbu5f16">https://www.genomeweb.com/sequencing/oxford-nanopore-develops-direct-rna-sequencing-protocol (2016).</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520602819&amp;usg=AOvVaw25sXyygFQz7zB9rvbwdnv1">170.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Template Preparation.</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520603358&amp;usg=AOvVaw2VT-1TfrQ1sO4QeK8uR1iH">171.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Preparing whole genome and metagenome libraries using SMRTbell&reg; prep kit 3.0.</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520603823&amp;usg=AOvVaw2gurhqofUIfKCsDKvvk7qq">172.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Template Preparation and Sequencing Guide. https://www.pacb.com/wp-content/uploads/2015/09/Guide-Pacific-Biosciences-Template-Preparation-and-Sequencing.pdf.</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520604337&amp;usg=AOvVaw3gAAXx5-yJXeK27NMdoca3">173.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stadhouders, R. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520604656&amp;usg=AOvVaw1R6y-RGtzyFUvoc8FzNElr">et al.</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520605004&amp;usg=AOvVaw0utqqLBkj_-V9v7F67eMeQ">&nbsp;The Effect of Primer-Template Mismatches on the Detection and Quantification of Nucleic Acids Using the 5&prime; Nuclease Assay. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520605380&amp;usg=AOvVaw0c3w-GHTIPFPpUagh-xXn1">J. Mol. Diagn. JMD </a></span><span class="c39 c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520605768&amp;usg=AOvVaw1kkT6mVEl4CGVI8N_R61Oa">12</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520606148&amp;usg=AOvVaw3wYAITvvmnUqAeF_btvb_T">, 109&ndash;117 (2010).</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520606703&amp;usg=AOvVaw0Gffe30AY5eC_IcLJU6Lp0">174.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ziegler, K. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520607081&amp;usg=AOvVaw1gLan5Uo7renNxJyelFJcr">et al.</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520607423&amp;usg=AOvVaw2yygq9AV_kOZ4bb8N09d-W">&nbsp;SARS-CoV-2 samples may escape detection because of a single point mutation in the N gene. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520607821&amp;usg=AOvVaw1recBMSr-kY_DNqg29U1Ry">Euro Surveill. Bull. Eur. Sur Mal. Transm. Eur. Commun. Dis. Bull. </a></span><span class="c39 c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520608107&amp;usg=AOvVaw1WAR1HqDI8i0fM4REmXnuQ">25</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520608373&amp;usg=AOvVaw0pVI0QViGQa794stShSWdH">, 2001650 (2020).</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520608793&amp;usg=AOvVaw0l05oX1n3QL49uQ8dFyYec">175.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CDC. CDC&rsquo;s Influenza SARS-CoV-2 Multiplex Assay. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520609161&amp;usg=AOvVaw14jRBKlhkCdWpQdkOA_8Ll">Centers for Disease Control and Prevention </a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520609476&amp;usg=AOvVaw1mp02Vg946neb4Dh3qA-Nn">https://www.cdc.gov/coronavirus/2019-ncov/lab/multiplex.html (2020).</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520609880&amp;usg=AOvVaw1rgni5dmhsk9lPI3ZYQRWq">176.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Webinar - Using ultra-long reads to fully characterise genomes. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520610175&amp;usg=AOvVaw2X6KxwfPf9JKos3biDSR2T">Oxford Nanopore Technologies </a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520610491&amp;usg=AOvVaw2nyYr44tMMGYyn1qgCsei-">https://nanoporetech.com/resource-centre/using-ultra-long-reads-fully-characterise-genomes (2021).</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520610970&amp;usg=AOvVaw3pYssFJ2-TMelO5GhtNtJE">177.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Whiteford, N. Are long reads useful for infectious disease testing? </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520611345&amp;usg=AOvVaw3kB15rFDV-F0o9jHbEzTvv">ASeq Newsletter </a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520611710&amp;usg=AOvVaw166vxOnCmC7nofDVKfpapN">https://aseq.substack.com/p/are-long-reads-useful-for-infectious (2022).</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520612129&amp;usg=AOvVaw2Swx6tSWwST73MlH9LpJAm">178.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Baek, Y. H. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520612390&amp;usg=AOvVaw1HmUeJ19GHPRC2T5aUYNoN">et al.</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520612652&amp;usg=AOvVaw0bkZv9pha4XwfCLx6rHMHx">&nbsp;Evaluation of Alternative Transport Media for RT-qPCR-Based SARS-CoV-2 Testing. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520613005&amp;usg=AOvVaw3UL_8KDf-c34NsiW32-aOY">Int. J. Anal. Chem. </a></span><span class="c39 c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520613411&amp;usg=AOvVaw2kg75X87MTwBQoQnA5t50N">2022</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520613804&amp;usg=AOvVaw3m-ELpCQzmlk6XRJUd-OLQ">, 5020255 (2022).</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520614213&amp;usg=AOvVaw3LVFyyfWpsFQOnoRrY4YBP">179.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Santos Bravo, M. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520614475&amp;usg=AOvVaw1lMpIcG8eLzoN_FT9TVrQT">et al.</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520614787&amp;usg=AOvVaw3bzMCyXzYfaUme4zZk3QI_">&nbsp;Viral Culture Confirmed SARS-CoV-2 Subgenomic RNA Value as a Good Surrogate Marker of Infectivity. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520615176&amp;usg=AOvVaw1EYjRQRqWsEgEyWPngVHnF">J. Clin. Microbiol. </a></span><span class="c39 c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520615552&amp;usg=AOvVaw1cblF8AfJFtR_ctFHlLw0X">60</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520615952&amp;usg=AOvVaw1JRGAHb1AzUSJZfu8Vj2v_">, e01609-21 (2022).</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520616535&amp;usg=AOvVaw0yYZycV973yFrffDtRJRHi">180.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Mitchell, S. L. &amp; Loeffelholz, M. J. Considerations regarding Interpretation of Positive SARS-CoV-2 Molecular Results with Late Cycle Threshold Values. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520616932&amp;usg=AOvVaw2nUyfwduXzZBE9qE-p1luT">J. Clin. Microbiol. </a></span><span class="c39 c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520617304&amp;usg=AOvVaw1wM3yl7J19zJnTv2MKRCpS">60</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520617685&amp;usg=AOvVaw2dK6bLRVKB8XnB8Gyxv-Yl">, e00501-22 (2022).</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520618269&amp;usg=AOvVaw01r6mEahQYwkLtUfsWGYll">181.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Widders, A., Broom, A. &amp; Broom, J. SARS-CoV-2: The viral shedding vs infectivity dilemma. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520618676&amp;usg=AOvVaw1FAUhuNsCVZkOBM3Rh02DQ">Infect. Dis. Health </a></span><span class="c39 c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520619070&amp;usg=AOvVaw3EGD5tHym3AGFeFvFugACe">25</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520619470&amp;usg=AOvVaw18b44lNbKI7vc2XNTyWzWb">, 210&ndash;215 (2020).</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520620102&amp;usg=AOvVaw139iT0fK5Rn_WLDizZsMi8">182.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Perera, R. A. P. M. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520620499&amp;usg=AOvVaw1aJCP_7ehbXByPJdc6idNV">et al.</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520620902&amp;usg=AOvVaw1qd94tlRFVBryAykj4G5_F">&nbsp;SARS-CoV-2 Virus Culture and Subgenomic RNA for Respiratory Specimens from Patients with Mild Coronavirus Disease. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520621312&amp;usg=AOvVaw0KHNiqKbFTT_lm0_VL36qg">Emerg. Infect. Dis. </a></span><span class="c39 c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520621708&amp;usg=AOvVaw1MnZs1oTUCc-WYBrwSRFhy">26</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520622130&amp;usg=AOvVaw3qzDSry_vsxI-TP-qnb0wP">, 2701&ndash;2704 (2020).</a></span></p><p class="c23"><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520622710&amp;usg=AOvVaw3uxiOslx5wbyFnCmceTkTP">183.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Kim, D. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520623122&amp;usg=AOvVaw1s2LjxLzotPnx3Vu2S_xvD">et al.</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520623542&amp;usg=AOvVaw1HvmY-LtrJ4mD_Ah2xWvDz">&nbsp;The Architecture of SARS-CoV-2 Transcriptome. </a></span><span class="c12 c35"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520623992&amp;usg=AOvVaw2LAdNElcREvUOTqKA0P8Xd">Cell </a></span><span class="c39 c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520624423&amp;usg=AOvVaw2aEcQi3rCsb1vjNij4tKAo">181</a></span><span class="c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Rg9fMR&amp;sa=D&amp;source=editors&amp;ust=1679054520624842&amp;usg=AOvVaw2ZGVR1U-7X6XZyTX8yAeRR">, 914-921.e10 (2020).</a></span></p><p class="c1"><span class="c20 c12"></span></p><p class="c1"><span class="c20 c12"></span></p><hr style="page-break-before:always;display:none;"><h1 class="c75" id="h.edteeniy06s9"><span class="c33 c12"></span></h1><h1 class="c84" id="h.c3m6yl89hdok"><span class="c33 c12">Appendix X - Sample Prep Approaches</span></h1><p class="c7"><span class="c20 c12">[outdated]</span></p><h2 class="c72" id="h.5kiz63kkmh0l"><span class="c94 c12">Selection of Whole Cells and Capsids </span></h2><h3 class="c58" id="h.g7ws1kl5alqj"><span class="c34 c12">Size Selection </span></h3><p class="c7"><span class="c20 c12">Size selection of whole cells and capsids leverages the size differences of eukaryotic cells (5-100 microns), prokaryotic cells (0.1-5 microns), and viral capsids (0.1-0.3 microns) to separate them. </span></p><p class="c1"><span class="c20 c12"></span></p><p class="c7"><span class="c97"><a class="c2" href="https://www.google.com/url?q=https://journals.asm.org/doi/10.1128/JCM.00963-19&amp;sa=D&amp;source=editors&amp;ust=1679054520626334&amp;usg=AOvVaw03Rw4QnbDlSnSTJ8hTqb_V">This study</a></span><span class="c20 c12">&nbsp;used size selection by filtration to boost influenza read count by ~2 OOM in throat swab samples:</span></p><p class="c11"><span style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 503.50px; height: 521.76px;"><img alt="" src="images/image36.png" style="width: 503.50px; height: 521.76px; margin-left: 0.00px; margin-top: 0.00px; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px);" title=""></span></p><p class="c7"><span class="c20 c12">The 0.4-micron filter removed whole human and bacterial cells from the sample, drastically depleting host and bacterial RNA from the resultant sequencing library. They found centrifugation to be similarly effective. This suggests that in the case of throat swab samples, the majority of RNA is encapsulated in cells. </span></p><p class="c1"><span class="c20 c12"></span></p><p class="c7"><span>However, </span><span class="c97"><a class="c2" href="https://www.google.com/url?q=https://microbiomejournal.biomedcentral.com/articles/10.1186/s40168-018-0426-3&amp;sa=D&amp;source=editors&amp;ust=1679054520627467&amp;usg=AOvVaw265H4Wg4R3dl_sIxzL2eYI">a different study</a></span><span class="c20 c12">&nbsp;on saliva samples found size selection ineffective at depleting human DNA. They hypothesized that this is due to a significant amount of extracellular human DNA in the sample that they could not remove with 5-micron filtration, centrifugation, or flow cytometry.</span></p><p class="c1"><span class="c20 c12"></span></p><h3 class="c107 c112" id="h.sw4i4m3gni83"><span>Immunomagnetic Beads</span></h3><h3 class="c103" id="h.ibczj6drrqpy"><span class="c123">From the</span><span class="c123"><a class="c2" href="https://www.google.com/url?q=https://www.dnae.com/technology&amp;sa=D&amp;source=editors&amp;ust=1679054520628372&amp;usg=AOvVaw19SrGgFRH2VZuq6OKtrlC-">&nbsp;</a></span><span class="c97 c145"><a class="c2" href="https://www.google.com/url?q=https://www.dnae.com/technology&amp;sa=D&amp;source=editors&amp;ust=1679054520628748&amp;usg=AOvVaw0PLbDqTHKNgJdn7oEh8po3">DNAe website</a></span><span class="c20 c12">&nbsp;(links added):</span></h3><p class="c43"><span class="c39 c35">Sample Preparation System</span><span class="c123 c12 c125 c35 c140">&zwj;</span></p><ul class="c31 lst-kix_mnhl5qv63e85-0 start"><li class="c43 c82 li-bullet-0"><span class="c35">A standard 10 mL green-top</span><span class="c35"><a class="c2" href="https://www.google.com/url?q=https://www.fishersci.com/shop/products/bd-vacutainer-venous-blood-collection-tubes-vacutainer-plus-plastic-serum-tubes-silicone-coated-conventional-stopper-4/02685112&amp;sa=D&amp;source=editors&amp;ust=1679054520629538&amp;usg=AOvVaw0AAgTr-PJxflfojc0V3CI6">&nbsp;</a></span><span class="c97 c35"><a class="c2" href="https://www.google.com/url?q=https://www.fishersci.com/shop/products/bd-vacutainer-venous-blood-collection-tubes-vacutainer-plus-plastic-serum-tubes-silicone-coated-conventional-stopper-4/02685112&amp;sa=D&amp;source=editors&amp;ust=1679054520630065&amp;usg=AOvVaw0XVel9iZWlkq4sswzYsL6a">Vacutainer&trade;</a></span><span class="c123 c140 c12 c125 c35">&nbsp;containing whole blood is loaded into a single-use cartridge.</span></li><li class="c43 c82 li-bullet-0"><span class="c123 c140 c12 c125 c35">The cartridge is inserted into the instrument.</span></li><li class="c43 c82 li-bullet-0"><span class="c35">The clinical specimen is processed using a proprietary mixture of</span><span class="c35"><a class="c2" href="https://www.google.com/url?q=https://en.wikipedia.org/wiki/Immunomagnetic_separation&amp;sa=D&amp;source=editors&amp;ust=1679054520630782&amp;usg=AOvVaw2mFjYnu1XREHwb_YkXkSvN">&nbsp;</a></span><span class="c97 c35"><a class="c2" href="https://www.google.com/url?q=https://en.wikipedia.org/wiki/Immunomagnetic_separation&amp;sa=D&amp;source=editors&amp;ust=1679054520631213&amp;usg=AOvVaw2VrtQrVLbwsbZSbAskSOYZ">immunomagnetic</a></span><span class="c123 c140 c12 c125 c35">&nbsp;beads that specifically and rapidly extract bacterial and fungal pathogens at concentrations as low as 1 CFU/mL.</span></li></ul><p class="c43"><span class="c123 c140 c12 c125 c35">This ability to capture and concentrate low concentration pathogens in a complex matrix eliminates the need for blood culture, which significantly reduces the time to diagnosis. The system is being developed alongside our first test, a groundbreaking test which detects and identifies pathogens that lead to sepsis from whole blood specimens.&rdquo;</span></p><p class="c1"><span class="c20 c12"></span></p><h1 class="c84" id="h.fs7hms7l4v1l"><span class="c33 c12">Appendix X - Understanding the Target, publication details</span></h1><p class="c1"><span class="c20 c12"></span></p><p class="c1"><span class="c20 c12"></span></p><p class="c17 c32"><span class="c20 c12"></span></p><p class="c17 c32"><span class="c0"></span></p><p class="c17"><span style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 267.26px; height: 307.47px;"><img alt="Group" src="images/image44.png" style="width: 267.26px; height: 307.47px; margin-left: 0.00px; margin-top: 0.00px; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px);" title=""></span></p><p class="c53 c32"><span class="c100 c12 c70 c152"></span></p><p class="c17"><span class="c36">Two additional patients (early pandemic) from </span><span class="c97 c36"><a class="c2" href="https://www.google.com/url?q=https://www.thelancet.com/action/showPdf?pii%3DS1473-3099%252820%252930113-4&amp;sa=D&amp;source=editors&amp;ust=1679054520633048&amp;usg=AOvVaw0anB0SDF02hehR3MBTzKHJ">here</a></span><span class="c36">: </span></p><p class="c17"><span style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 624.00px; height: 296.00px;"><img alt="Image" src="images/image5.png" style="width: 624.00px; height: 296.00px; margin-left: 0.00px; margin-top: 0.00px; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px);" title=""></span></p><p class="c17"><span class="c0">Lowest early values here are ~10000 copies/mL, 10 copies/uL (see below for Saliva). </span></p><p class="c17 c32"><span class="c0"></span></p><p class="c17"><span class="c0">200/uL (total 5uL, Low viral input) sequence of total RNA (ribosomal depleted) is shown below (nasopharyngeal swab). This suggests an average of ~1% of total reads. For 10/uL (Saliva) this would be 0.05%. </span></p><p class="c17 c32"><span class="c0"></span></p><p class="c17"><span class="c36">Another metagenomic publication provides further support for this and suggests that SARS-CoV-2 is present at ~0.02% when ribosomal RNA is present: </span></p><p class="c17"><span class="c36">&ldquo;Amongst the SARS-CoV-2 infected individuals, an average of 0.02% of reads were mapped to the SARS-CoV-2 genome from the original number of raw cDNA reads.&ldquo; </span></p><p class="c17"><span class="c36">&ldquo;No poly-A enrichment step nor ribosomal depletion was carried out during the pipeline.&rdquo; </span></p><p class="c17"><span class="c36">0.05% would be 500 in 1M reads. </span></p><p class="c17"><span class="c36">10x coverage with 100bp reads would require 6M reads. </span></p><p class="c17"><span class="c36">From Saliva viral load appears to be ~1000/mL. 1/uL. Which would give ~ 50 reads in 1M. Require 60M 100bp reads for 10x coverage. </span></p><h5 class="c107 c126" id="h.wcytbzsszz2a"><span class="c28 c12">Before symptoms </span></h5><p class="c17"><span style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 624.00px; height: 197.33px;"><img alt="Image" src="images/image11.png" style="width: 624.00px; height: 197.33px; margin-left: 0.00px; margin-top: 0.00px; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px);" title=""></span></p><p class="c17"><span style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 303.33px; height: 237.52px;"><img alt="Image" src="images/image42.png" style="width: 303.33px; height: 237.52px; margin-left: 0.00px; margin-top: 0.00px; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px);" title=""></span></p><p class="c17"><span class="c36">Mostly this appears to be based on modeling. For example the above from here. Indicates that ~5 days before symptom onset we are looking at ~100 copies/mL (0.1 copies/uL). </span></p><p class="c17"><span class="c36">Typically will collect ~3mL. So have a total of 300 copies. This likely goes down a factor of 10 for Saliva. So 30 copies, 10 copies/mL, 0.01/uL. Using the rationale above, this means 0.05 reads in 1M, or 1 read in 20M. So, 6G reads (100bp) to get 10x coverage. </span></p><p class="c17"><span class="c0">A more realistic approach may be to deplete human material. Total RNA (excluding human ribosomal) appears to roughly break down as 90% human, 5% SARS-CoV-2, 5% Bacterial in low viral load individuals (1000K in 5uL from study). But we are still likely looking at needing ~600M reads against a bacterial background. </span></p><p class="c17 c32"><span class="c86 c36 c12"></span></p><h5 class="c126 c107" id="h.2wdybxqmyt2y"><span class="c28 c12">Other publications </span></h5><p class="c17 c32"><span class="c86 c36 c12"></span></p><p class="c17"><span class="c36">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7771462/pdf/JCM.02142-20.pdf </span></p><p class="c17"><span class="c36">All reads (cleaned of human reads) are available in the Sequence Read Archive under BioProject PRJNA634356. </span></p><p class="c17"><span class="c36">Has a nice plot which shows relationship between RPM and CT values: </span></p><p class="c17"><span style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 301.16px; height: 344.29px;"><img alt="Image" src="images/image40.png" style="width: 301.16px; height: 344.29px; margin-left: 0.00px; margin-top: 0.00px; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px);" title=""></span></p><p class="c17"><span class="c36">More than 50% of these have RPMs of &gt;100 (0.01%). Almost all individuals with a Ct value &gt;25 seem to have an RPM &gt;100. Supplementary Information suggests that nearly all individuals within 5 days of having symptoms are within this range: </span></p><p class="c17"><span style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 282.40px; height: 257.06px;"><img alt="Image" src="images/image14.png" style="width: 282.40px; height: 257.06px; margin-left: 0.00px; margin-top: 0.00px; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px);" title=""></span></p><p class="c17"><span class="c36">Other useful quotes: </span></p><p class="c17"><span class="c36">&ldquo;Interestingly, 60% of PUIs who were negative for SARS-CoV-2 had no alternative infection identified on either routine testing or mNGS&rdquo; </span></p><p class="c17"><span class="c0">&ldquo;3% rate of viral coinfection&rdquo; </span></p><p class="c17 c32"><span class="c0"></span></p><h4 class="c54" id="h.1ksv4uv"><span class="c68 c12">Viral Fragmentation</span></h4><p class="c17 c32"><span class="c0"></span></p><p class="c17"><span class="c36">Total RNA seems to be mostly &lt;1000nt, from https://pubmed.ncbi.nlm.nih.gov/23564756/: </span><span style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 501.03px; height: 167.53px;"><img alt="Image" src="images/image29.png" style="width: 501.03px; height: 167.53px; margin-left: 0.00px; margin-top: 0.00px; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px);" title=""></span><span style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 306.67px; height: 1.33px;"><img alt="Image" src="images/image20.png" style="width: 306.67px; height: 1.33px; margin-left: 0.00px; margin-top: 0.00px; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px);" title=""></span><span class="c51 c12 c70">&nbsp; </span></p><p class="c17 c32"><span class="c0"></span></p><p class="c17"><span class="c0">Seems similar: [https://exrna.org/salivary-exrna-towards-validated-methods-rna-isolation-quality-control-ngs-library-construction/](https://exrna.org/salivary-exrna-towards-validated-methods-rna-isolation-quality-control-ngs-library-construction/)</span></p><p class="c17 c32"><span class="c0"></span></p><p class="c17"><span class="c0">This seems similar to the fragment size for SARS-CoV-2 in Saliva: </span></p><p class="c17"><span class="c0">[https://www.medrxiv.org/content/10.1101/2021.01.11.21249265v1.full]. Here they state that VFS (long (220-350 bp insert) to short (70-150 bp insert) fragment count ratio)&hellip;ranged from 0.0433 to 184.9 in saliva. Graphs show (see figure 5, replicated below) that the majority of VFSs are below 1, this indicate that more material is short (70 to 150bp) than long (220 to 350bp insert). The paper does not fully investigate complete viral genomes, only making a distinction between these short and long fragments. But this indicates that the majority of material is likely in the 100bp and suggests that fully intact viral genomes may be rare in saliva. </span></p><p class="c17"><span style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 593.64px; height: 326.15px;"><img alt="Image" src="images/image16.png" style="width: 593.64px; height: 326.15px; margin-left: 0.00px; margin-top: 0.00px; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px);" title=""></span></p><p class="c17"><span class="c0">To fully understand how effective RNA size selection might be, it would be useful to investigate viral fragment size more deeply.</span></p><p class="c1"><span class="c20 c12"></span></p><h1 class="c84" id="h.3qlinufam2ea"><span class="c33 c12">Appendix Z - Further &nbsp;Sequencing Notes</span></h1><p class="c1"><span class="c20 c12"></span></p><p class="c7"><span class="c20 c12">Based on the work presented here, we have identified a number of critical factors required for the widespread adoption of sequencing:</span></p><p class="c1"><span class="c20 c12"></span></p><ul class="c31 lst-kix_reytss2l8ssc-0 start"><li class="c7 c82 li-bullet-0"><span class="c20 c12">Throughput: Sufficient throughput is required to allow sensitive detection against background material.</span></li><li class="c7 c82 li-bullet-0"><span class="c20 c12">Accuracy: Accuracy should be sufficient to allow known viruses to be identified, and novel viral material to be classified.</span></li><li class="c7 c82 li-bullet-0"><span class="c20 c12">Read length: Reads should be sufficiently long to allow known viruses to be identified, and novel viral material to be classified</span></li><li class="c7 c82 li-bullet-0"><span class="c20 c12">Ease of use: Simple, automated sample prep. A platform that does not have unique installation requirements or dedicated lab space.</span></li><li class="c7 c82 li-bullet-0"><span class="c20 c12">Short run time: Quick runs will allow immediate diagnostic feedback.</span></li><li class="c7 c82 li-bullet-0"><span class="c20 c12">Cost: The platform should be sufficiently cheap to allow widespread adoption.</span></li></ul><p class="c1"><span class="c20 c12"></span></p><p class="c7"><span class="c20 c12">Ideally, we would have a sequencing instrument that excels in all characteristics. For example, we could envisage an instrument that costs $50s, has a infinitely reusable consumable, provides a continuous readout of &gt;1M bases/second, reads that fully reflect the material in a sample (100Mbase+), and has an error rate near zero. We can (and have below) proposed potential routes to such an &ldquo;ideal platform&rdquo;. However even the most promising approaches have extremely high technical risk, have been in development for &gt;10 years and may require decades of further focused development.</span></p><p class="c1"><span class="c20 c12"></span></p><p class="c7"><span class="c20 c12">As such we need to rank our requirements in order to maintain a balance between ambition and practicality. In the terms stated above, our throughput, accuracy and read length requirements are fairly modest as compared to the state of the art. </span></p><p class="c1"><span class="c20 c12"></span></p><p class="c7"><span class="c20 c12">Throughput: We have shown that Viral RNA in symptomatic individuals is present at ~0.01% against a typical background. As such, as a lower bound, sequencer that generates 10,000 reads would provide sufficient throughput. These requirements could be relaxed further by targeting or by depleting background material.</span></p><p class="c1"><span class="c20 c12"></span></p><p class="c7"><span class="c20 c12">Accuracy, Read Length and Error rate: It is critical that our diagnostic platform does not produce false positives. Luckily, using a sequencing based readout analysis has shown that even short reads and high error rates are unlikely to result in mis-classification. False negatives can potentially be compensated for by increased throughput. Analysis has also shown that relatively high error rates can be tolerated (5% error rate, using short &lt;25bp reads). Overall our requirements here are well within the capabilities of existing platforms.</span></p><p class="c1"><span class="c20 c12"></span></p><p class="c7"><span class="c20 c12">We therefore come to our final two specifications: run time and cost.</span></p><p class="c1"><span class="c20 c12"></span></p><p class="c7"><span class="c20 c12">The majority of sequencers could not meet our time time requirements, only Oxford Nanopore, Qitan&rsquo;s and Pacific Biosciences instruments (ONT: ~1Kb fragments, 100,000 reads in ~10mins (verify). Pacific Biosciences 30m run) would allow quick diagnostic feedback. All other platforms require several hours to complete single runs.</span></p><p class="c1"><span class="c20 c12"></span></p><p class="c7"><span class="c20 c12">Cost is perhaps the most problematic specification for currently available platforms. Multiplexing (running multiple samples on the same instrument at the same time) can help reduce costs, but increases the effective run time (as users need to wait and batch samples), complexity (and additional sample preparation steps are required), and can increase costs (labor and reagent costs associated with the multiplexing process).</span></p><p class="c1"><span class="c20 c12"></span></p><p class="c7"><span class="c20 c12">The cheapest available runs are on the order of $100 (Oxford Nanopore Flongle). The COGS of these runs is not known, but is likely ~$50 (based on Oxford Nanopore&rsquo;s reported margins of ~50%). Illumina&rsquo;s cheapest runs are ~$500, but are sold at higher margin. The COGS is likely &lt;$100. In either case, these costs are too high for routine use in diagnostics.</span></p><p class="c1"><span class="c20 c12"></span></p><p class="c7"><span class="c20 c12">qPCR tests (commonly used in COVID19) have a COGS of ~$1. To be competitive and help sequencing based diagnostic approaches gain wide adoption we should aim to provide a platform with comparable COGS. That is a sequencing based platform with a COGS of ~$1.</span></p><p class="c1"><span class="c20 c12"></span></p><p class="c7"><span class="c20 c12">We would therefore recommend investigating approaches which have a clear route to a low COGS. </span></p><p class="c1"><span class="c20 c12"></span></p><p class="c7"><span class="c20 c12">The lowest risk route to a low COGS approach is likely to be an evolution of existing techniques focusing on cost optimisation. Sequencing-by-Synthesis is the market dominating sequencing approach and one company (Reticula, disclosure!) is working on optimizing this approach toward a $1 COGS run, with a focus on sequencing for viral diagnostics. Oxford Nanopore have also proposed a cost reduction approach using sputtered flowcells, this could potentially enable cheaper runs. Similarly Qitan Technology appears to be developing a platform using a cheaper flowcell as non-disposable ASIC.</span></p><p class="c1"><span class="c20 c12"></span></p><p class="c7"><span class="c20 c12">In academia, most work has not focused on low cost per sample. Existing grants have funded $1000 genomes (ref, $1000 SBIR/NIH grants). This has promoted projects which focus on a low cost per base with a view to sequencing whole human genomes. Academic work has therefore focused on longer read lengths, higher accuracy, detection of novel base modifications, and high throughput.</span></p><p class="c7"><span class="c20 c12">However as we have shown, for viral diagnostics we are primarily interested in low cost per sample. While academics have developed multiplexing strategies work has not focused on optimizing the single run cost itself. We would therefore recommend that such novel sequencing strategies receive funding.</span></p><p class="c1"><span class="c20 c12"></span></p><hr style="page-break-before:always;display:none;"><h1 class="c75" id="h.g49hlnolkqtm"><span class="c33 c12"></span></h1><h1 class="c84" id="h.5k6mlm70a3pm"><span class="c33 c12">Appendix X - Process flows</span></h1><p class="c1"><span class="c20 c12"></span></p><p class="c7"><span style="overflow: hidden; display: inline-block; margin: 241.33px -241.33px; border: 0.00px solid #000000; transform: rotate(1.57rad) translateZ(0px); -webkit-transform: rotate(1.57rad) translateZ(0px); width: 624.00px; height: 141.33px;"><img alt="" src="images/image41.png" style="width: 624.00px; height: 141.33px; margin-left: 0.00px; margin-top: 0.00px; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px);" title=""></span></p><p class="c1"><span class="c20 c12"></span></p><p class="c1"><span class="c20 c12"></span></p><h1 class="c84" id="h.h1aok5vmm5a0"><span class="c12 c33">Appendix X - Sample baselines</span></h1><p class="c1"><span class="c20 c12"></span></p><p class="c1"><span class="c20 c12"></span></p><a id="t.a28f2675c69623270980cf4c13cbfd683ac7117b"></a><a id="t.6"></a><table class="c127"><tr class="c25"><td class="c179" colspan="1" rowspan="1"><p class="c26"><span class="c18 c12">Sample Type</span></p></td><td class="c139" colspan="1" rowspan="1"><p class="c26"><span class="c18 c12">ng/uL RNA</span></p></td><td class="c3" colspan="1" rowspan="1"><p class="c26"><span class="c18 c12">Total Yield (ng)</span></p></td><td class="c3" colspan="1" rowspan="1"><p class="c26 c32"><span class="c18 c12"></span></p></td><td class="c3" colspan="1" rowspan="1"><p class="c26 c32"><span class="c18 c12"></span></p></td><td class="c3" colspan="1" rowspan="1"><p class="c26 c32"><span class="c18 c12"></span></p></td><td class="c3" colspan="1" rowspan="1"><p class="c26 c32"><span class="c18 c12"></span></p></td><td class="c3" colspan="1" rowspan="1"><p class="c26"><span class="c18 c12">References</span></p></td></tr><tr class="c25"><td class="c179" colspan="1" rowspan="1"><p class="c26"><span class="c18 c12">Saliva</span></p></td><td class="c139" colspan="1" rowspan="1"><p class="c26"><span class="c18 c12">71 (min 4.3 ng/&mu;L max 392.9 ng/&mu;L - &nbsp;1)</span></p></td><td class="c3" colspan="1" rowspan="1"><p class="c26 c32"><span class="c18 c12"></span></p></td><td class="c3" colspan="1" rowspan="1"><p class="c26 c32"><span class="c18 c12"></span></p></td><td class="c3" colspan="1" rowspan="1"><p class="c26 c32"><span class="c18 c12"></span></p></td><td class="c3" colspan="1" rowspan="1"><p class="c26 c32"><span class="c18 c12"></span></p></td><td class="c3" colspan="1" rowspan="1"><p class="c26 c32"><span class="c18 c12"></span></p></td><td class="c3" colspan="1" rowspan="1"><p class="c26"><span class="c97 c170"><a class="c2" href="https://www.google.com/url?q=https://www.sciencedirect.com/science/article/pii/S1870199X18300144&amp;sa=D&amp;source=editors&amp;ust=1679054520648713&amp;usg=AOvVaw2gPtt23FTREL0k5aHDMWQf">1</a></span><span class="c18 c12">&nbsp; </span></p></td></tr><tr class="c25"><td class="c179" colspan="1" rowspan="1"><p class="c26"><span class="c18 c12">Anterior Nasal </span></p></td><td class="c139" colspan="1" rowspan="1"><p class="c26"><span class="c18 c12">0.052 (1)</span></p></td><td class="c3" colspan="1" rowspan="1"><p class="c26"><span class="c18 c12">156 (1)</span></p></td><td class="c3" colspan="1" rowspan="1"><p class="c26 c32"><span class="c18 c12"></span></p></td><td class="c3" colspan="1" rowspan="1"><p class="c26 c32"><span class="c18 c12"></span></p></td><td class="c3" colspan="1" rowspan="1"><p class="c26 c32"><span class="c18 c12"></span></p></td><td class="c3" colspan="1" rowspan="1"><p class="c26 c32"><span class="c12 c18"></span></p></td><td class="c3" colspan="1" rowspan="1"><p class="c26"><span class="c97 c170"><a class="c2" href="https://www.google.com/url?q=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4600430/&amp;sa=D&amp;source=editors&amp;ust=1679054520651784&amp;usg=AOvVaw1L7Jxld6CuPwmRQ-snRnqx">1</a></span></p></td></tr><tr class="c25"><td class="c179" colspan="1" rowspan="1"><p class="c26"><span class="c18 c12">Nasopharyngeal</span></p></td><td class="c139" colspan="1" rowspan="1"><p class="c26"><span class="c18 c12">41.7 (1)</span></p></td><td class="c3" colspan="1" rowspan="1"><p class="c26 c32"><span class="c18 c12"></span></p></td><td class="c3" colspan="1" rowspan="1"><p class="c26 c32"><span class="c18 c12"></span></p></td><td class="c3" colspan="1" rowspan="1"><p class="c26 c32"><span class="c18 c12"></span></p></td><td class="c3" colspan="1" rowspan="1"><p class="c26 c32"><span class="c18 c12"></span></p></td><td class="c3" colspan="1" rowspan="1"><p class="c26 c32"><span class="c18 c12"></span></p></td><td class="c3" colspan="1" rowspan="1"><p class="c26"><span class="c97 c170"><a class="c2" href="https://www.google.com/url?q=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6851467/&amp;sa=D&amp;source=editors&amp;ust=1679054520654403&amp;usg=AOvVaw0Y9HaN3GL-45jrM9muTE2_">1</a></span></p></td></tr></table><p class="c1"><span class="c18 c12"></span></p><h1 class="c84" id="h.dqjrvxtlmac5"><span class="c33 c12">Appendix X - What factors determine sequencing sensitivity?</span></h1><p class="c7"><span>Metagenomic sequencing (MGS) produces data in the form of &ldquo;reads,&rdquo; which can then be classified and analyzed in various ways to identify threats. Reads are snippets of the genomes from the various organisms in a sample that has been sequenced.</span><sup><a href="#ftnt2" id="ftnt_ref2">[2]</a></sup><span class="c20 c12">&nbsp;To detect a virus (or any other pathogen) with MGS, we must see a sufficient number of snippets from its genetic code in our reads (i.e., its &ldquo;read count&rdquo;). Typically, only a single read from a pathogen&rsquo;s genome is required to identify it. </span></p><p class="c1"><span class="c20 c12"></span></p><p class="c7"><span class="c20 c12">Four factors determine the read count of a particular genome:</span></p><ol class="c31 lst-kix_x4qr3m7alqzt-0 start" start="1"><li class="c59 li-bullet-0"><span class="c39">The total number of sequencing reads obtained</span><span>. If we have more sequencing reads, on average we&rsquo;ll get proportionally more reads from every genome present.</span></li><li class="c59 li-bullet-0"><span class="c39">The genome&rsquo;s relative abundance in the sample.</span><span>&nbsp;If there is a species with 10</span><span class="c41">4</span><span class="c185">&nbsp;</span><span>genome copies among 10</span><span class="c41">5</span><span>&nbsp;genomes, its relative abundance is 10%. If that species was present in just 10</span><span class="c41">3</span><span>&nbsp;copies, or if there were 10</span><span class="c41">6</span><span>&nbsp;total genomes, its relative abundance would be 1%, in which case we&rsquo;d expect to get 10 times fewer reads for the same amount of sequencing. </span></li><li class="c59 li-bullet-0"><span class="c39">Taxonomic</span><sup class="c39"><a href="#ftnt3" id="ftnt_ref3">[3]</a></sup><span class="c39">&nbsp;bias</span><span>. To quote Mike McClaren&rsquo;s recent preprint</span><sup><a href="#ftnt4" id="ftnt_ref4">[4]</a></sup><span>: </span><span class="c35">&ldquo;Microbial species vary dramatically in how efficiently they are measured&mdash;that is, converted from cells [or capsids] into [...] sequencing reads&mdash;by a given MGS protocol</span><sup class="c35"><a href="#ftnt5" id="ftnt_ref5">[5]</a></sup><span class="c35">. This bias arises from variation in how species respond to each step in an MGS protocol, from sample collection to bioinformatic classification.&rdquo;</span><span class="c20 c12">&nbsp;Species with lower-than-average measurement efficiencies will tend to have a lower relative abundance in the sequencing reads than in the original sample.</span></li><li class="c59 li-bullet-0"><span class="c39">Random chance. </span><span>We can model the reads obtained by the sequencer as a random sampling of the genome fragments present (after accounting for taxonomic bias). If we were to sequence the same NA input many times, our model would expect a Poisson distribution</span><sup><a href="#ftnt6" id="ftnt_ref6">[6]</a></sup><span>&nbsp;of read counts for each species. For a species with a biased relative abundance of 0.01% and 10</span><span class="c41">4</span><span>&nbsp;total reads, we&rsquo;d expect to see 1 read. But there is a 37% chance we&rsquo;d happen to see 0 reads. Increase the total read count from 10</span><span class="c41">4</span><span>&nbsp;to 10</span><span class="c41">5</span><span>&nbsp;and the chance we&rsquo;d see 0 reads plummets to 5*10</span><span class="c41">-5</span><span class="c20 c12">.</span></li></ol><p class="c1"><span class="c20 c12"></span></p><p class="c7"><span class="c20 c12">The best way to mitigate the negative effects of random chance is to increase the expected read count, which reduces the variability in the observed count and the chance that the genome is missed entirely. The expected read count of a genome is determined by the remaining three factors: the total sequencing reads, the genome&rsquo;s relative abundance, and the taxonomic bias of the MGS protocol. </span></p><p class="c1"><span class="c20 c12"></span></p><p class="c7"><span class="c20 c12">We can understand how these factors jointly determine the expected read count through a single equation. </span></p><p class="c83"><span style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 540.00px; height: 40.00px;"><img alt="" src="images/image46.png" style="width: 540.00px; height: 40.00px; margin-left: 0.00px; margin-top: 0.00px; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px);" title=""></span></p><p class="c7"><span>The reads we get of a pathogen genome </span><span class="c35">i</span><span>&nbsp;equals the total reads (factor 1) multiplied by the relative abundance (factor 2) of species</span><span class="c35">&nbsp;i, </span><span class="c20 c12">followed by a term adjusting for taxonomic bias (factor 3). We&rsquo;re limited to a total number of reads, which all genomes compete for. Taxonomic bias increases or decreases the fraction of reads each genome receives in proportion to its efficiency relative to the average efficiency of all genomes (sum in the denominator of factor 3).</span></p><p class="c1"><span class="c20 c12"></span></p><p class="c7"><span class="c20 c12">This equation tells us that we can increase the expected read count (and thus the probability of detection) of a genome either by increasing the total amount of sequencing or by modifying the taxonomic bias of the MGS protocol to favor that genome over the genomes of other organisms in the sample. The total amount of sequencing is determined by time and cost constraints.</span></p><p class="c1"><span class="c20 c12"></span></p><div><p class="c1"><span class="c20 c12"></span></p></div><hr class="c192"><div><p class="c17"><a href="#ftnt_ref1" id="ftnt1">[1]</a><span class="c73">&nbsp;We justify this in &ldquo;</span><span class="c97 c73"><a class="c2" href="#h.m6p2op3667yp">Sensitivity</a></span><span class="c71 c12">&rdquo;</span></p></div><div><p class="c17"><a href="#ftnt_ref2" id="ftnt2">[2]</a><span class="c71 c12">&nbsp;In the case of RNA sequencing, there can also be reads from transcripts and ribosomal RNA.</span></p></div><div><p class="c17"><a href="#ftnt_ref3" id="ftnt3">[3]</a><span class="c71 c12">&nbsp;A taxon is a group of organisms that has been identified by taxonomists as forming a cohesive unit. Examples include SARS-CoV-2 (a species) and Bacteria (a domain).</span></p></div><div><p class="c17"><a href="#ftnt_ref4" id="ftnt4">[4]</a><span class="c73">&nbsp;(</span><span class="c97 c73"><a class="c2" href="https://www.google.com/url?q=https://www.biorxiv.org/content/10.1101/2022.08.19.504330v1.full.pdf&amp;sa=D&amp;source=editors&amp;ust=1679054520658987&amp;usg=AOvVaw0CxciCj94LEdM-7MwB1xYm">https://www.biorxiv.org/content/10.1101/2022.08.19.504330v1.full.pdf</a></span><span class="c71 c12">) </span></p></div><div><p class="c17"><a href="#ftnt_ref5" id="ftnt5">[5]</a><span class="c73">&nbsp;(</span><span class="c97 c73"><a class="c2" href="https://www.google.com/url?q=https://elifesciences.org/articles/46923&amp;sa=D&amp;source=editors&amp;ust=1679054520659710&amp;usg=AOvVaw1GdE1YWVk8LM_rIx1KIwh8">https://elifesciences.org/articles/46923</a></span><span class="c71 c12">)</span></p></div><div><p class="c17"><a href="#ftnt_ref6" id="ftnt6">[6]</a><span class="c73">&nbsp;See </span><span class="c97 c73"><a class="c2" href="https://www.google.com/url?q=https://athowes.github.io/exp-growth/all-hands&amp;sa=D&amp;source=editors&amp;ust=1679054520660295&amp;usg=AOvVaw2cwRbYMbVr2YEO2jVzjABS">Adam Howes&rsquo;s memo</a></span><span class="c71 c12">&nbsp;for an in-depth explanation </span></p></div><div class="c48"><p class="c26"><a href="#cmnt_ref1" id="cmnt1">[a]</a><span class="c20 c12">My argument would be that you need to make it as cheap as something&nbsp;like the GeneXpert. Providing a full panel at the same cost as a GeneXpert (or other qPCR) run.</span></p><p class="c26 c32"><span class="c20 c12"></span></p><p class="c26"><span class="c20 c12">If you don&#39;t, you wont displace that instrument and the metagenomic test will need up being a second stage diagnostics (first do Flu/RSV/COVID then something else). And this will entirely fail to meet our goals in terms of providing early detection.</span></p><p class="c26 c32"><span class="c20 c12"></span></p><p class="c26"><span class="c20 c12">Probably worth having a discussion about this and nailing down exactly what we believe/want to say in the report.</span></p></div><div class="c48"><p class="c26"><a href="#cmnt_ref2" id="cmnt2">[b]</a><span class="c20 c12">Assuming our goal is to displace PCR and not just to give MGS a toehold in the ID diagnostics market (probably a good assumption), I agree.</span></p><p class="c26 c32"><span class="c20 c12"></span></p><p class="c26"><span class="c20 c12">I also think this might be better phrased as &quot;COGS per run&quot; instead of Cost per sample</span></p></div><div class="c48"><p class="c26"><a href="#cmnt_ref3" id="cmnt3">[c]</a><span class="c20 c12">Overall comment:</span></p><p class="c26 c32"><span class="c20 c12"></span></p><p class="c26"><span class="c20 c12">Generally missing tonal and formality agreement between sections. Can the paid editor&nbsp;fix that?</span></p></div><div class="c48"><p class="c26"><a href="#cmnt_ref4" id="cmnt4">[d]</a><span class="c20 c12">This section could be more compelling... it doesn&#39;t read like a tight story yet</span></p></div><div class="c48"><p class="c26"><a href="#cmnt_ref5" id="cmnt5">[e]</a><span class="c20 c12">These sections (phase 1, phase 2&amp;3) currently feel rather disjointed, but the content in this section is good</span></p></div><div class="c48"><p class="c26"><a href="#cmnt_ref6" id="cmnt6">[f]</a><span class="c20 c12">@new@sgenomics.org a few more citations here would be very helpful</span></p></div><div class="c48"><p class="c26"><a href="#cmnt_ref7" id="cmnt7">[g]</a><span class="c20 c12">there are good reviews showing the viral load range - let&#39;s find one</span></p></div><div class="c48"><p class="c26"><a href="#cmnt_ref8" id="cmnt8">[h]</a><span class="c20 c12">A summary of the main findings here would be very helpful.</span></p></div><div class="c48"><p class="c26"><a href="#cmnt_ref9" id="cmnt9">[i]</a><span class="c20 c12">Do we want a summary or an introduction? Right now, this reads like an introduction</span></p></div><div class="c48"><p class="c26"><a href="#cmnt_ref10" id="cmnt10">[j]</a><span class="c20 c12">Is Genapsys gone gone?</span></p><p class="c26 c32"><span class="c20 c12"></span></p><p class="c26"><span class="c20 c12">https://www.genomeweb.com/business-news/court-approves-genapsys-sale-sequencing-health#.Y5ElonbMLgc</span></p></div><div class="c48"><p class="c26"><a href="#cmnt_ref11" id="cmnt11">[k]</a><span class="c20 c12">Can we add Flongle here, given that adapting it is going to be an important rec? We discuss the COGS but none of the other variables.</span></p></div><div class="c48"><p class="c26"><a href="#cmnt_ref12" id="cmnt12">[l]</a><span class="c20 c12">Could we add estimated number of sequencers?</span></p></div><div class="c48"><p class="c26"><a href="#cmnt_ref13" id="cmnt13">[m]</a><span class="c20 c12">these specs are probably out of date, RNA and DNA input requirements should&nbsp;be similar</span></p></div><div class="c48"><p class="c26"><a href="#cmnt_ref14" id="cmnt14">[n]</a><span class="c20 c12">see comment above - no reason that ONT can&#39;t do 1ng input for RNA</span></p></div><div class="c48"><p class="c26"><a href="#cmnt_ref15" id="cmnt15">[o]</a><span class="c20 c12">Would be good to get corroboration of this and make sure there isn&#39;t anything out there we&#39;re missing, since if this true then I think it is the strongest case against this approach.</span></p></div><div class="c48"><p class="c26"><a href="#cmnt_ref16" id="cmnt16">[p]</a><span class="c20 c12">Could we elaborate on this more?</span></p></div><div class="c48"><p class="c26"><a href="#cmnt_ref17" id="cmnt17">[q]</a><span class="c20 c12">@new@sgenomics.org is this up-to-date with your most recent analysis?</span></p></div><div class="c48"><p class="c26"><a href="#cmnt_ref18" id="cmnt18">[r]</a><span class="c20 c12">Wouldn&#39;t it depend on concentration?</span></p><p class="c26 c32"><span class="c20 c12"></span></p><p class="c26"><span class="c20 c12">Do we mean assuming there is an active infection?</span></p></div><div class="c48"><p class="c26"><a href="#cmnt_ref19" id="cmnt19">[s]</a><span class="c20 c12">perhaps, but unproven. RNA RTs not nearly as developed at polymerases. Some early data and grants in progress though:&nbsp;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3623877/. Also see new grant with Wanunu team https://www.genomeweb.com/sequencing/northeastern-university-researchers-develop-new-type-zero-mode-waveguide-sequencing</span></p></div><div class="c48"><p class="c26"><a href="#cmnt_ref20" id="cmnt20">[t]</a><span class="c20 c12">I think it would be good to expand this section.</span></p></div><div class="c48"><p class="c26"><a href="#cmnt_ref21" id="cmnt21">[u]</a><span class="c20 c12">I began a potential re-write (or appendix) to this section in this doc. I have finals week and then three weeks of traveling ahead of me, but I should be able to finish it during the first week of January.&nbsp;https://docs.google.com/document/d/1SdlxWj4CJFqt5ziKw1iZQoyO3PBoWzux9PTdA-ml6Jo/edit#</span></p></div><div class="c48"><p class="c26"><a href="#cmnt_ref22" id="cmnt22">[v]</a><span class="c20 c12">Flagging that &quot;sample preparation&quot; usually includes&nbsp;library preparation as a step within it.</span></p></div><div class="c48"><p class="c26"><a href="#cmnt_ref23" id="cmnt23">[w]</a><span class="c20 c12">which parts of sample preparation&nbsp;are necessary no matter the sequencing technology that is ultimately used? (are there any that are likely to need to be used even if sequencing radically changes?) how do we streamline these?</span></p></div><div class="c48"><p class="c26"><a href="#cmnt_ref24" id="cmnt24">[x]</a><span class="c20 c12">I like this question</span></p></div><div class="c48"><p class="c26"><a href="#cmnt_ref25" id="cmnt25">[y]</a><span class="c20 c12">We might want to explore potential avenues for detecting viruses, bacteria, and parasites in a single run, given that genomes can be RNA or DNA-based</span></p></div><div class="c48"><p class="c26"><a href="#cmnt_ref26" id="cmnt26">[z]</a><span class="c20 c12">Additionally, how sample prep requirements&nbsp;might change based on different sample types and what sorts of automated sample prep systems can handle such variation</span></p></div><div class="c48"><p class="c26"><a href="#cmnt_ref27" id="cmnt27">[aa]</a><span class="c20 c12">Write a section (initially in a separate doc) on how to address sensitivity issues with sample prep while maintaining pathogen agnosticism</span></p></div><div class="c48"><p class="c26"><a href="#cmnt_ref28" id="cmnt28">[ab]</a><span class="c20 c12">@new@sgenomics.org Here&#39;s the doc&nbsp;https://docs.google.com/document/d/1WemJaGCq-JEm4tGOLhnOsQNb1BiizzpreH6KHVfOUs8/edit#</span></p><p class="c26 c32"><span class="c20 c12"></span></p><p class="c26"><span class="c20 c12">And here&#39;s the spreadsheet</span></p><p class="c26"><span class="c20 c12">https://personalmicrosoftsoftware0-my.sharepoint.com/:x:/g/personal/lmccline4_personalmicrosoftsoftware_ucla_edu/ETDKyEgT4OVLll9k9HpRBhABH13hrkfLP616nqNajoWadA?rtime=ic7pPq_R2kg</span></p></div><div class="c48"><p class="c26"><a href="#cmnt_ref29" id="cmnt29">[ac]</a><span class="c20 c12">I feel like this section could be expanded.</span></p></div><div class="c48"><p class="c26"><a href="#cmnt_ref30" id="cmnt30">[ad]</a><span class="c20 c12">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3623877/. Also see new grant with Wanunu team&nbsp;https://www.genomeweb.com/sequencing/northeastern-university-researchers-develop-new-type-zero-mode-waveguide-sequencing</span></p></div><div class="c48"><p class="c26"><a href="#cmnt_ref31" id="cmnt31">[ae]</a><span class="c20 c12">Interesting stuff, lots of fun things about that paper. I should have a careful read. I do wonder if the PacBio stuff should be mentioned (perhaps as part of single molecule optical approaches)...</span></p></div><div class="c48"><p class="c26"><a href="#cmnt_ref32" id="cmnt32">[af]</a><span class="c20 c12">there isn&#39;t a rapid&nbsp;kit for RNA, and I&#39;m not sure about the requirements to find suitable enzymes for RNA -needs further investigation</span></p></div><div class="c48"><p class="c26"><a href="#cmnt_ref33" id="cmnt33">[ag]</a><span class="c20 c12">Could we make it a little clearer what we mean here?</span></p></div><div class="c48"><p class="c26"><a href="#cmnt_ref34" id="cmnt34">[ah]</a><span class="c20 c12">@lennymccline@gmail.com Flag to update this section with new research</span></p><p class="c26"><span class="c20 c12">_Assigned to Lenny McCline_</span></p></div><div class="c48"><p class="c26"><a href="#cmnt_ref35" id="cmnt35">[ai]</a><span class="c20 c12">particularly&nbsp;to improve sensitivity</span></p></div><div class="c48"><p class="c26"><a href="#cmnt_ref36" id="cmnt36">[aj]</a><span class="c20 c12">Disagree with this, and discussions with experts involved in testing at CDC states that most viral material probably protected in viral package or cell</span></p></div><div class="c48"><p class="c26"><a href="#cmnt_ref37" id="cmnt37">[ak]</a><span class="c20 c12">It would be useful to have a solid reference for this, or ideally a referenced paragraph supporting this.</span></p><p class="c26 c32"><span class="c20 c12"></span></p><p class="c26"><span class="c20 c12">I&#39;m kind of at a dead end, but most of the work I&#39;ve seen suggests that viruses are not viable (and the capid is not intact) within minutes to hours. I wrote this up here:</span></p><p class="c26 c32"><span class="c20 c12"></span></p><p class="c26"><span class="c20 c12">https://aseq.substack.com/p/are-long-reads-useful-for-infectious</span></p><p class="c26 c32"><span class="c20 c12"></span></p><p class="c26"><span class="c20 c12">And there&#39;s other work on viral viability on surfaces showing half lives in hours.</span></p><p class="c26 c32"><span class="c20 c12"></span></p><p class="c26"><span class="c20 c12">I think you mentioned work that suggests that it&#39;s fully intact as collected without using a&nbsp;stabilization buffer. I wouldn&#39;t dispute this, but if you can reference this it would help support our arguments in the report I think.</span></p></div><div class="c48"><p class="c26"><a href="#cmnt_ref38" id="cmnt38">[al]</a><span class="c20 c12">I think the significant technical risk here is developing the direct RNA seq optical chemistry. I would like to see refs to it working in principle and roadmap to develop. PacBio have not progressed their direct RNA seq tech since initially publishing 9 years ago</span></p></div><div class="c48"><p class="c26"><a href="#cmnt_ref39" id="cmnt39">[am]</a><span class="c20 c12">Helicos published on direct RNA sequencing e.g.&nbsp;https://www.nature.com/articles/nature08390</span></p><p class="c26 c32"><span class="c20 c12"></span></p><p class="c26"><span class="c20 c12">SeqLL also provide direct RNA sequencing services using the approach: http://seqll.com/technology-information/</span></p></div><div class="c48"><p class="c26"><a href="#cmnt_ref40" id="cmnt40">[an]</a><span class="c20 c12">Agreed, but just want to clarify that this is only demonstrated for cyclic washing chemistries, which significantly increases the cost and complexity of the system. Development of a free-running or UV-cleavable method that avoids wash cycles is unproven AFAIK and carries risk</span></p></div><div class="c48"><p class="c26"><a href="#cmnt_ref41" id="cmnt41">[ao]</a><span class="c20 c12">Confused by this. Didn&#39;t Nanopore recently release&nbsp;direct RNA sequencing (https://store.nanoporetech.com/us/direct-rna-sequencing-kit.html)? Although, it seems to have a lower accuracy and throughput at the moment</span></p></div><div class="c48"><p class="c26"><a href="#cmnt_ref42" id="cmnt42">[ap]</a><span class="c20 c12">agreed, we need to qualify that the direct RNA is relatively less mature and requires a more complex sample prep, but conversion to cDNA is another option</span></p></div><div class="c48"><p class="c26"><a href="#cmnt_ref43" id="cmnt43">[aq]</a><span class="c20 c12">We should discuss, but based on my reading it didn&#39;t seem like either the prep approaches, or the sample requirements for direct RNA sequencing using ONT were viable a present meaning that the most likely route here would be via cDNA conversion.</span></p></div><div class="c48"><p class="c26"><a href="#cmnt_ref44" id="cmnt44">[ar]</a><span class="c20 c12">Sample input requirements should be approx the same for both.&nbsp;The sample prep and speed at which the enzyme runs (5x slower than DNA) are the primary issues. In principle it should be possible to find a faster motor - coincidentally, the Nsp13 motor from SARS-CoV-2 is reported to run up to 280 bp/s&nbsp;https://www.sciencedirect.com/science/article/pii/S0006349520332100</span></p></div><div class="c48"><p class="c26"><a href="#cmnt_ref45" id="cmnt45">[as]</a><span class="c20 c12">How confident are we that this is true for well-off countries?</span></p></div><div class="c48"><p class="c26"><a href="#cmnt_ref46" id="cmnt46">[at]</a><span class="c20 c12">+1, I wasn&#39;t able to find where this was argued. </span></p><p class="c26 c32"><span class="c20 c12"></span></p><p class="c26"><span class="c20 c12">Taking the other side: The US healthcare system is f*cked and price insensitive. At least in the case of drugs, which I&#39;m more familiar, small improvements in standard of care get exclusivity and payers are forced to pay insane prices because the prescriber wants the slightly-better-thing.&nbsp;</span></p><p class="c26 c32"><span class="c20 c12"></span></p><p class="c26"><span class="c20 c12">If you made something which doctors reliably preferred&nbsp;over standard of care, which you had exclusivity on, do you expect them to avoid prescribing it as the diagnostic because it costs $200?</span></p></div><div class="c48"><p class="c26"><a href="#cmnt_ref47" id="cmnt47">[au]</a><span class="c20 c12">The sell is making a full respiratory&nbsp;panel as cheap as qPCR essentially. You could (certainly during COVID, but hopefully at other times now?) get a doctor to run a Flu/RSV/COVID test on the 120M people who come in with respiratory infections. GenXpert sell a ton of these. If you make a metagenomic test which effectively provides a full respiratory&nbsp;panel at qPCR cost you displace qPCR while also providing pandemic preparedness (detection, kits that work for new viruses).</span></p><p class="c26 c32"><span class="c20 c12"></span></p><p class="c26"><span class="c20 c12">This is a hard sell. It&#39;s saying we need to make it so cheap that they have the option to do a metagenomic test for everyone they see as a replacement for qPCR. But of course, they also need to /want/ to do it. And consumers will also need to expect it do be done (no longer acceptable to walk in with a cold and out without a clear diagnosis and random antibiotics / anti-inflammatories)</span></p><p class="c26 c32"><span class="c20 c12"></span></p><p class="c26"><span class="c20 c12">But a $1000 test (which is what it will be at $100 COGS) will only ever be used as a last resort. They might do qPCR first. Then a $120 BioFire panel. Then the metagenomic test. I find it unlikely that this would buy you much in terms of pandemic preparedness&nbsp;(which is the focus of this report). This is somewhat discussed in the background.</span></p></div><div class="c48"><p class="c26"><a href="#cmnt_ref48" id="cmnt48">[av]</a><span class="c20 c12">Expounding on these use cases may be helpful, i.e. variant identification, AMR stuff, and spotting genetic engineering. But maybe that should be in the section where the case for short reads is made.</span></p></div><div class="c48"><p class="c26"><a href="#cmnt_ref49" id="cmnt49">[aw]</a><span class="c20 c12">no, most channels have 1 pore, not poisson limited due to control of insertion</span></p></div><div class="c48"><p class="c26"><a href="#cmnt_ref50" id="cmnt50">[ax]</a><span class="c20 c12">Is there a good public reference for this? I thought Minions still had multiple wells/channel. I&#39;ve seen Genia&#39;s controlled pore insertion stuff, but it would be useful to have a reference for ONT.</span></p></div><div class="c48"><p class="c26"><a href="#cmnt_ref51" id="cmnt51">[ay]</a><span class="c20 c12">possibly here&nbsp;https://www.amazon.co.uk/Nanopore-Sequencing-Introduction-Daniel-Branton/dp/9813270608</span></p></div><div class="c48"><p class="c26"><a href="#cmnt_ref52" id="cmnt52">[az]</a><span class="c20 c12">Hm, given that some tech we&#39;re considerinf is 1-3M in the runtime we propose, why 10M+?</span></p></div><div class="c48"><p class="c26"><a href="#cmnt_ref53" id="cmnt53">[ba]</a><span class="c20 c12">Main reason is that there is significant sample-to-sample variance in multiplexed runs. If you set the average reads per sample at 1M you will likely get many runs with 100K or less. This would better be a threshold on the minimum read count for a sample perhaps, but often that information is not available.</span></p><p class="c26 c32"><span class="c20 c12"></span></p><p class="c26"><span class="c20 c12">The ideal actually would be to perform a meta analysis of all available public datasets. This however would be outside the scope of this report.</span></p></div><div class="c48"><p class="c26"><a href="#cmnt_ref54" id="cmnt54">[bb]</a><span class="c20 c12">I found this column to be somewhat misleading, as it lists fragmentation after using a specific RNA extraction method storage in a lysing VTM. The fragmentation post-extraction may not accurately measure the fragmentation pre-extraction. Additionally, the fragmentation pre-storage may not accurately measure the fragmentation post-storage.</span></p><p class="c26 c32"><span class="c20 c12"></span></p><p class="c26"><span class="c20 c12">SISPA numbers are useful, but we should be clear that these post-amplification figures generally don&#39;t match the original sample fragmentation</span></p></div><div class="c48"><p class="c26"><a href="#cmnt_ref55" id="cmnt55">[bc]</a><span class="c20 c12">I&#39;d like to fill this out with other studies if we have them. Agree that current studies&nbsp;are less than ideal, but I&#39;d hope we&#39;d be able to come to some broad conclusion on the level of fragmentation in different sample types.</span></p></div><div class="c48"><p class="c26"><a href="#cmnt_ref56" id="cmnt56">[bd]</a><span class="c20 c12">From paper: &quot;Archived [frozen] extracted RNA from anonymized samples were used for this study.&quot;</span></p></div></body></html>
